{"8fbf7243172d9230678e4a1eab1d7ae5a4a25cd8": [["IntroductionThe 2019 coronavirus (COVID-19) pandemic has had a major effect on the National Health Service (NHS) and everyday clinical practice.", [["COVID-19", "CHEMICAL", 34, 42], ["2019 coronavirus", "ORGANISM", 16, 32], ["COVID-19", "ORGANISM", 34, 42], ["COVID", "TEST", 34, 39], ["pandemic", "PROBLEM", 44, 52]]], ["Efforts to increase hospital capacity for patients with COVID-19 and reduce the spread of the virus, both in community and hospital settings, has led to widespread changes to surgical practice.IntroductionThe World Health Organisation (WHO) recommend droplet and contact precautions with the use of personal protective equipment (PPE) as well as rigorous adherence to doffing and hand hygiene to reduce spread.", [["hand", "ANATOMY", 380, 384], ["patients", "ORGANISM", 42, 50], ["hand", "ORGANISM_SUBDIVISION", 380, 384], ["patients", "SPECIES", 42, 50], ["COVID", "TEST", 56, 61], ["the virus", "PROBLEM", 90, 99], ["surgical practice", "TREATMENT", 175, 192], ["droplet", "TREATMENT", 251, 258], ["contact precautions", "TREATMENT", 263, 282], ["personal protective equipment (PPE)", "TREATMENT", 299, 334], ["doffing and hand hygiene", "TREATMENT", 368, 392]]], ["1 Studies have differing estimates on the infectivity of COVID-19 with the Centre for Disease Control and Prevention (CDC) calculating an estimated R 0 of 5.7.", [["1 Studies", "TEST", 0, 9], ["COVID", "TEST", 57, 62], ["Disease Control", "TREATMENT", 86, 101]]], ["2 One case report documented a surgical patient in Wuhan who was found to infect 14 healthcare workers before he became pyrexic and developed symptoms himself.", [["pyrexic", "DISEASE", 120, 127], ["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["pyrexic", "PROBLEM", 120, 127], ["symptoms", "PROBLEM", 142, 150]]], ["3 To date COVID-19 has also been detected in blood, peritoneal fluid and faeces.", [["blood", "ANATOMY", 45, 50], ["peritoneal fluid", "ANATOMY", 52, 68], ["faeces", "ANATOMY", 73, 79], ["COVID-19", "CHEMICAL", 10, 18], ["COVID-19", "GENE_OR_GENE_PRODUCT", 10, 18], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["peritoneal fluid", "ORGANISM_SUBSTANCE", 52, 68], ["faeces", "ORGANISM_SUBSTANCE", 73, 79], ["COVID-19", "DNA", 10, 18], ["COVID", "TEST", 10, 15], ["blood, peritoneal fluid", "TEST", 45, 68], ["blood", "ANATOMY", 45, 50], ["peritoneal", "ANATOMY", 52, 62], ["fluid", "OBSERVATION", 63, 68]]], ["4 Although no transmission by any means other than respiratory droplets has been reported, live viral particles have been isolated from stool raising the potential of faeco-oral transmission too.", [["respiratory droplets", "ANATOMY", 51, 71], ["stool", "ANATOMY", 136, 141], ["oral", "ANATOMY", 173, 177], ["stool", "ORGANISM_SUBSTANCE", 136, 141], ["oral", "ORGANISM_SUBDIVISION", 173, 177], ["respiratory droplets", "PROBLEM", 51, 71], ["live viral particles", "PROBLEM", 91, 111], ["faeco", "TEST", 167, 172], ["no", "UNCERTAINTY", 11, 13], ["stool", "OBSERVATION", 136, 141]]], ["5, 6 The previous outbreak of SARS (2002) led to changes in PPE worn during surgery.", [["SARS", "DISEASE", 30, 34], ["SARS", "PROBLEM", 30, 34], ["changes in PPE", "TREATMENT", 49, 63], ["surgery", "TREATMENT", 76, 83], ["PPE worn", "OBSERVATION", 60, 68]]], ["However, comparatively SARS only had 8096 confirmed cases and 774 deaths as opposed to over 6.4 million confirmed cases of COVID-19 and 382,867 deaths to date.", [["SARS", "DISEASE", 23, 27], ["deaths", "DISEASE", 66, 72], ["COVID", "DISEASE", 123, 128], ["deaths", "DISEASE", 144, 150], ["COVID", "TEST", 123, 128]]], ["7 Other examples of precautions taken to limit viral transmission during surgery include those with blood borne viruses such as HIV and Hepatitis B. With regard to blood bourne transmission, laparoscopy may be beneficial as it reduces exposure to blood and body fluids, whilst reducing the risk of surgeon and assistant injury.", [["blood", "ANATOMY", 100, 105], ["blood", "ANATOMY", 164, 169], ["blood", "ANATOMY", 247, 252], ["body fluids", "ANATOMY", 257, 268], ["blood borne viruses", "DISEASE", 100, 119], ["HIV and Hepatitis B.", "DISEASE", 128, 148], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["HIV", "ORGANISM", 128, 131], ["Hepatitis B.", "ORGANISM", 136, 148], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["blood", "ORGANISM_SUBSTANCE", 247, 252], ["body", "ORGANISM_SUBDIVISION", 257, 261], ["fluids", "ORGANISM_SUBSTANCE", 262, 268], ["HIV", "SPECIES", 128, 131], ["HIV", "SPECIES", 128, 131], ["Hepatitis B.", "SPECIES", 136, 148], ["precautions", "TREATMENT", 20, 31], ["surgery", "TREATMENT", 73, 80], ["blood borne viruses", "PROBLEM", 100, 119], ["HIV", "PROBLEM", 128, 131], ["Hepatitis B.", "PROBLEM", 136, 148], ["blood bourne transmission", "TREATMENT", 164, 189], ["laparoscopy", "TREATMENT", 191, 202], ["blood and body fluids", "TREATMENT", 247, 268], ["assistant injury", "PROBLEM", 310, 326]]], ["8 However, Kwak et al. were able to identify hepatitis B in the surgical smoke produced during laparoscopy and therefore recommended evacuation of pneumoperitoneum into a closed system in a controlled manner.", [["hepatitis B", "DISEASE", 45, 56], ["hepatitis B", "PROBLEM", 45, 56], ["laparoscopy", "TEST", 95, 106], ["evacuation", "TREATMENT", 133, 143], ["pneumoperitoneum", "PROBLEM", 147, 163], ["a closed system", "TREATMENT", 169, 184], ["pneumoperitoneum", "OBSERVATION", 147, 163], ["closed", "OBSERVATION", 171, 177]]], ["9 Specific concerns have been raised around aerosol generating procedures in particular and protecting staff, many of which occur commonly in theatre.", [["aerosol generating procedures", "TREATMENT", 44, 73]]], ["Use of laparoscopy is also felt to carry risk of aerosol formation and is a concern to the surgical team and healthcare professionals in the theatre environment.", [["laparoscopy", "TREATMENT", 7, 18], ["aerosol formation", "PROBLEM", 49, 66], ["laparoscopy", "OBSERVATION", 7, 18], ["aerosol", "OBSERVATION", 49, 56]]], ["The Royal Colleges of Surgeons have released guidance regarding the use of PPE during surgery and have specifically suggested that laparoscopic surgery should only be performed where the clinical benefit to patient substantially outweighs the risk of potential viral transmission to healthcare workers during the COVID-19 pandemic.", [["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["PPE", "TREATMENT", 75, 78], ["surgery", "TREATMENT", 86, 93], ["laparoscopic surgery", "TREATMENT", 131, 151], ["the COVID", "TEST", 309, 318], ["pandemic", "PROBLEM", 322, 330]]], ["10 Whilst other countries and societies recognise the risk laparoscopy may pose to theatre staff, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) highlight the importance of considering the benefits to patients of minimally invasive surgery, such as enhanced recovery and reduced length of hospital stay.", [["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["minimally invasive surgery", "TREATMENT", 239, 265]]], ["They also suggest that filtration of aerosolised particles may be even more difficult during open as opposed to laparoscopic surgery.", [["filtration of aerosolised particles", "TREATMENT", 23, 58], ["laparoscopic surgery", "TREATMENT", 112, 132]]], ["11AimTo date there has not been a systematic review of viral transmission risk comparing laparoscopic with open surgery.", [["laparoscopic", "TREATMENT", 89, 101], ["open surgery", "TREATMENT", 107, 119], ["surgery", "OBSERVATION", 112, 119]]], ["The aim of this study is to conduct an objective, systematic review of studies reporting on viral transmission risk comparing laparoscopic and open surgery.MethodsThis systematic review was conducted in accordance to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.", [["this study", "TEST", 11, 21], ["studies", "TEST", 71, 78], ["viral transmission risk", "TREATMENT", 92, 115], ["laparoscopic", "TREATMENT", 126, 138], ["open surgery", "TREATMENT", 143, 155], ["Systematic Reviews", "TEST", 259, 277], ["surgery", "OBSERVATION", 148, 155]]], ["5Study eligibility criteriaAny original study examining airborne viral transmission secondary to incisional surgical procedure.", [["Any original study", "TEST", 27, 45], ["airborne viral transmission", "PROBLEM", 56, 83], ["incisional surgical procedure", "TREATMENT", 97, 126], ["incisional surgical", "OBSERVATION", 97, 116]]], ["Operative interventions were either laparoscopic or open procedures, irrespective of site, presentation (elective or emergency), duration, or hospital setting (inpatient or outpatient).Study eligibility criteriaPrimary data to be extracted were risk of particle aerosolisation and risk of viral transmission.", [["Operative interventions", "TREATMENT", 0, 23], ["laparoscopic", "TREATMENT", 36, 48], ["open procedures", "TREATMENT", 52, 67], ["particle aerosolisation", "PROBLEM", 253, 276], ["viral transmission", "PROBLEM", 289, 307], ["laparoscopic", "OBSERVATION", 36, 48], ["particle aerosolisation", "OBSERVATION", 253, 276], ["viral transmission", "OBSERVATION", 289, 307]]], ["Age of publication was restricted to the last four decades (1st January 1980e27 th April 2020) as this would encompass research during the HIV/AIDS and SARS emergence eras.", [["HIV/AIDS", "DISEASE", 139, 147], ["SARS", "DISEASE", 152, 156], ["HIV", "SPECIES", 139, 142], ["the HIV/AIDS", "TREATMENT", 135, 147], ["SARS emergence eras", "TREATMENT", 152, 171], ["publication", "OBSERVATION", 7, 18]]], ["There were no geographical limitations.Information sources and searchFour databases: PubMed MeSH, Ovid Embase, SCOPUS, and Cochrane Library were searched.", [["no", "UNCERTAINTY", 11, 13], ["geographical", "OBSERVATION_MODIFIER", 14, 26], ["limitations", "OBSERVATION", 27, 38]]], ["The search strategy for these has been outlined in Table 1 .Study selection and data collection processTwo independent authors reviewed all titles, placing any screened citations into an Excel database.", [["Study selection", "TEST", 60, 75], ["data collection process", "TEST", 80, 103]]], ["If a study had been reported by more than one publication, the last publication which reported the trial was used as the reference publication in this review.", [["a study", "TEST", 3, 10]]], ["Once each author had completed data extraction, the data files were electronically compared and discrepancies in data entry were investigated and resolved.Data itemsThe following variables were recorded in an Excel spreadsheet: Basic information -First author, publication year, and country of origin.", [["data extraction", "TREATMENT", 31, 46], ["the data files", "TEST", 48, 62], ["Data items", "TEST", 155, 165]]], ["Treatment information: Type of open or laparoscopic procedure, timing, instrumentation, and protective equipment used were also recorded.", [["open or laparoscopic procedure", "TREATMENT", 31, 61], ["instrumentation", "TREATMENT", 71, 86], ["protective equipment", "TREATMENT", 92, 112], ["laparoscopic", "OBSERVATION", 39, 51]]], ["Pathogen type, detection method, and quantitative data resulting from this were recorded.", [["detection method", "TEST", 15, 31], ["quantitative data", "TEST", 37, 54]]], ["The authors synthesised the results into prose and tabular form.Risk of bias in individual studies and across studiesTwo authors independently assessed the potential bias using the ROBINS-I tool.", [["individual studies", "TEST", 80, 98], ["across studies", "TEST", 103, 117], ["bias", "OBSERVATION", 72, 76]]], ["12Summary measures and synthesis of resultsThe rates of patient reported outcomes were shown as crude rates and if appropriate, mean scores.Study characteristicsThree studies with unique populations met inclusion criteria.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["crude rates", "TEST", 96, 107], ["Study characteristics", "TEST", 140, 161], ["Three studies", "TEST", 161, 174]]], ["The PRISMA flow diagram of search results is presented in Fig. 1 .Study characteristicsThere were 9 unique studies containing 389 study participants, with one study not including sample size and one study depicting sample size as the number of operations.", [["participants", "SPECIES", 136, 148], ["The PRISMA flow diagram", "TEST", 0, 23], ["Study characteristics", "TEST", 66, 87], ["unique studies", "TEST", 100, 114], ["one study", "TEST", 155, 164], ["one study", "TEST", 195, 204], ["size", "OBSERVATION_MODIFIER", 222, 226], ["operations", "OBSERVATION", 244, 254]]], ["Of the 389 study participants described, 324 were tested or presumed infected for the viral pathogen in question.", [["participants", "SPECIES", 17, 29], ["the viral pathogen", "PROBLEM", 82, 100]]], ["Eight studies examined Human Papilloma Virus (HPV) aerosolisation and one studied Hepatitis B Virus (HBV) aerosolisation.", [["Human Papilloma Virus (HPV) aerosolisation", "DISEASE", 23, 65], ["Hepatitis B", "DISEASE", 82, 93], ["Human Papilloma Virus", "ORGANISM", 23, 44], ["HPV", "ORGANISM", 46, 49], ["Hepatitis B Virus", "ORGANISM", 82, 99], ["HBV", "ORGANISM", 101, 104], ["Human", "SPECIES", 23, 28], ["Hepatitis B Virus", "SPECIES", 82, 99], ["Human Papilloma Virus", "SPECIES", 23, 44], ["HPV", "SPECIES", 46, 49], ["Hepatitis B Virus", "SPECIES", 82, 99], ["HBV", "SPECIES", 101, 104], ["Eight studies", "TEST", 0, 13], ["Human Papilloma Virus (HPV) aerosolisation", "PROBLEM", 23, 65], ["Hepatitis B Virus (HBV) aerosolisation", "PROBLEM", 82, 120], ["Papilloma Virus", "OBSERVATION", 29, 44]]], ["One study examined virus aerosolisation during laparoscopic procedures, with the other eight studies examining open procedures.", [["One study", "TEST", 0, 9], ["laparoscopic procedures", "TREATMENT", 47, 70], ["the other eight studies", "TEST", 77, 100], ["open procedures", "TREATMENT", 111, 126]]], ["Four studies examined aerosolisation by electrosurgery and three by CO 2 laser ablation.", [["CO 2", "CHEMICAL", 68, 72], ["Four studies", "TEST", 0, 12], ["CO 2 laser ablation", "TREATMENT", 68, 87], ["ablation", "OBSERVATION", 79, 87]]], ["One study compared aerosolisation by CO 2 laser ablation with electrosurgery and one study compared CO 2 laser ablation with that of multi-layered argon plasma coagulation.", [["plasma", "ANATOMY", 153, 159], ["CO 2", "CHEMICAL", 37, 41], ["CO 2", "CHEMICAL", 100, 104], ["argon", "CHEMICAL", 147, 152], ["plasma", "ORGANISM_SUBSTANCE", 153, 159], ["One study", "TEST", 0, 9], ["CO 2 laser ablation", "TREATMENT", 37, 56], ["electrosurgery", "TREATMENT", 62, 76], ["one study", "TEST", 81, 90], ["CO 2 laser ablation", "TREATMENT", 100, 119], ["multi-layered argon plasma coagulation", "TREATMENT", 133, 171], ["argon plasma coagulation", "OBSERVATION", 147, 171]]], ["A table (Table 2) of techniques, devices and results of each individual study is presented below.Patient characteristicsAnalysis of patient characteristics of these studies is limited.", [["patient", "ORGANISM", 132, 139], ["Patient", "SPECIES", 97, 104], ["patient", "SPECIES", 132, 139], ["techniques, devices", "TREATMENT", 21, 40], ["each individual study", "TEST", 56, 77], ["these studies", "TEST", 159, 172]]], ["Of the 4 studies which reported the sex of their population, 3 were female only and 1 comprised male and female study participants.", [["participants", "SPECIES", 118, 130], ["the 4 studies", "TEST", 3, 16]]], ["Study specific patient characteristics are included in Table 3 .Risk of bias within studiesRisk of bias was assessed using the ROBINS-I risk of bias tool.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["bias within studies", "TEST", 72, 91], ["bias tool", "PROBLEM", 144, 153], ["bias", "OBSERVATION", 72, 76], ["bias", "OBSERVATION", 99, 103]]], ["A low risk of bias overall was found in 6 studies, with none having a critical risk.", [["A low risk of bias", "PROBLEM", 0, 18], ["low", "OBSERVATION_MODIFIER", 2, 5]]], ["12,16,18e21 Due to access restrictions or information not being specified in the original manuscript, there were 3 studies that overall risk of bias could not be described.", [["12,16,18e21", "CHEMICAL", 0, 11], ["3 studies", "TEST", 113, 122], ["bias", "PROBLEM", 144, 148], ["bias", "OBSERVATION", 144, 148]]], ["12, 14, 17 Risk of bias in the measurement of outcomes was recorded in two studies, which had not specified the testing method for viral quantification.", [["two studies", "TEST", 71, 82], ["the testing method", "TEST", 108, 126], ["viral quantification", "PROBLEM", 131, 151]]], ["12, 17 The risk of bias assessment is presented in Table 4 .DiscussionTo date this is the first systematic review assessing the risk of viral transmission during laparoscopic or open surgery.", [["bias assessment", "TEST", 19, 34], ["viral transmission", "PROBLEM", 136, 154], ["laparoscopic", "TREATMENT", 162, 174], ["open surgery", "TREATMENT", 178, 190], ["surgery", "OBSERVATION", 183, 190]]], ["The results in this study demonstrate that aerosol generated during procedures may contain viral DNA.", [["DNA", "CELLULAR_COMPONENT", 97, 100], ["viral DNA", "DNA", 91, 100], ["this study", "TEST", 15, 25], ["aerosol", "TREATMENT", 43, 50], ["viral DNA", "PROBLEM", 91, 100], ["viral DNA", "OBSERVATION", 91, 100]]], ["They demonstrated that HPV and HBV viral DNA was detectable following CO 2 laser ablation and electrosurgery (both open and laparoscopic).DiscussionWhen healthcare staff risk was investigated, Weyandt and Zhou have shown that samples taken from the operating surgeons were positive for viral DNA from HPV.", [["samples", "ANATOMY", 226, 233], ["CO 2", "CHEMICAL", 70, 74], ["HPV", "ORGANISM", 23, 26], ["HBV", "ORGANISM", 31, 34], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["DNA", "CELLULAR_COMPONENT", 292, 295], ["HPV", "ORGANISM", 301, 304], ["HPV and HBV viral DNA", "DNA", 23, 44], ["viral DNA", "DNA", 286, 295], ["HPV", "SPECIES", 23, 26], ["HBV", "SPECIES", 31, 34], ["HPV", "SPECIES", 301, 304], ["HPV", "PROBLEM", 23, 26], ["HBV viral DNA", "PROBLEM", 31, 44], ["CO 2 laser ablation", "TREATMENT", 70, 89], ["electrosurgery", "TREATMENT", 94, 108], ["laparoscopic", "TREATMENT", 124, 136], ["viral DNA from HPV", "PROBLEM", 286, 304]]], ["18, 21 However, there were differences shown within these studies as Weyandt found that viral DNA obtained from operators was not consistent with that of the patients they were operating on.", [["DNA", "CELLULAR_COMPONENT", 94, 97], ["patients", "ORGANISM", 158, 166], ["viral DNA", "DNA", 88, 97], ["patients", "SPECIES", 158, 166], ["these studies", "TEST", 52, 65], ["viral DNA", "PROBLEM", 88, 97], ["not consistent with", "UNCERTAINTY", 126, 145]]], ["18 In contrast to this, Zhou demonstrated consistency between operator and patient viral DNA subtypes.", [["patient", "ORGANISM", 75, 82], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["patient", "SPECIES", 75, 82], ["patient viral DNA subtypes", "PROBLEM", 75, 101], ["viral DNA subtypes", "OBSERVATION", 83, 101]]], ["21 Only a single study investigated the aerosolisation of viral DNA during laparoscopy with HBV DNA being detected in 10 of 11 (90.9%) cases.", [["DNA", "CELLULAR_COMPONENT", 64, 67], ["HBV", "ORGANISM", 92, 95], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["viral DNA", "DNA", 58, 67], ["HBV DNA", "DNA", 92, 99], ["HBV", "SPECIES", 92, 95], ["a single study", "TEST", 8, 22], ["viral DNA", "PROBLEM", 58, 67], ["laparoscopy", "TEST", 75, 86], ["HBV DNA", "PROBLEM", 92, 99], ["viral DNA", "OBSERVATION", 58, 67], ["HBV", "OBSERVATION", 92, 95]]], ["19 Fig. 1 e PRISMA study selection process flow diagram.", [["flow diagram", "TEST", 43, 55], ["flow diagram", "OBSERVATION", 43, 55]]], ["The implication of this is that minimisation of exposure via limited use of energy devices, the use of PPE by theatre staff, and smoke extraction mechanisms should be used whenever practically possible.", [["energy devices", "TREATMENT", 76, 90], ["PPE", "TREATMENT", 103, 106], ["smoke extraction mechanisms", "TREATMENT", 129, 156]]], ["Quantification of the viral load between open and laparoscopic approaches in comparable settings has not yet been studied.", [["the viral load", "PROBLEM", 18, 32], ["laparoscopic approaches", "TREATMENT", 50, 73], ["viral load", "OBSERVATION", 22, 32], ["laparoscopic", "OBSERVATION", 50, 62]]], ["Additionally, no studies to date have investigated the viral load of respiratory viruses or the risk of transmission to healthcare staff e so these recommendations remain theoretical.DiscussionWhen the authors further consider the implication of these data to the current COVID-19 pandemic, we note that aerosolisation of detectable viral DNA occurs with both open and laparoscopic surgery.", [["respiratory viruses", "DISEASE", 69, 88], ["DNA", "CELLULAR_COMPONENT", 339, 342], ["viral DNA", "DNA", 333, 342], ["studies", "TEST", 17, 24], ["respiratory viruses", "PROBLEM", 69, 88], ["detectable viral DNA", "PROBLEM", 322, 342], ["laparoscopic surgery", "TREATMENT", 369, 389], ["respiratory viruses", "OBSERVATION", 69, 88], ["viral DNA", "OBSERVATION", 333, 342], ["laparoscopic surgery", "OBSERVATION", 369, 389]]], ["The reason for the initiation of this review was to objectively gather data regarding viral transmission and assess if there was a difference between open or laparoscopic surgery.", [["viral transmission", "TEST", 86, 104], ["laparoscopic surgery", "TREATMENT", 158, 178], ["laparoscopic", "OBSERVATION", 158, 170]]], ["If such a difference had been found this would have had major implications for the practice of visceral surgery going forward in the COVID-19 era.DiscussionWith such limited data available, the authors believe that a pragmatic approach must be taken with regard to whether or not open or minimally invasive surgery is appropriate.DiscussionWhere laparoscopic surgery has been demonstrated to have a clear benefit for patients, it would seem prudent to continue with such an approach, as long as theatre staff are adequately protected with the use of appropriate PPE and effective smoke extraction systems.", [["visceral", "ANATOMY", 95, 103], ["visceral", "ORGANISM_SUBDIVISION", 95, 103], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 417, 425], ["visceral surgery", "TREATMENT", 95, 111], ["a pragmatic approach", "TREATMENT", 215, 235], ["minimally invasive surgery", "TREATMENT", 288, 314], ["laparoscopic surgery", "TREATMENT", 346, 366], ["appropriate PPE", "TREATMENT", 550, 565], ["effective smoke extraction systems", "TREATMENT", 570, 604], ["visceral", "ANATOMY", 95, 103], ["surgery", "OBSERVATION", 104, 111]]], ["Additionally, both preoperative testing for the presence of SARS-CoV-2 and perioperative self-isolation of the surgical patient in the elective setting can also further enhance the safety of the theatre environment.DiscussionAdopting a pragmatic approach however does not mean that further investigation into the risk of viral transmission during surgical procedures should be abandoned.", [["SARS", "DISEASE", 60, 64], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["SARS-CoV", "SPECIES", 60, 68], ["both preoperative testing", "TEST", 14, 39], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["perioperative self-isolation", "TREATMENT", 75, 103], ["further investigation", "TEST", 282, 303], ["viral transmission", "PROBLEM", 321, 339], ["surgical procedures", "TREATMENT", 347, 366]]], ["Ongoing surveillance and screening efforts should be continued at local level to enhance staff safety.", [["Ongoing surveillance", "TEST", 0, 20], ["screening efforts", "TEST", 25, 42]]], ["Clinical studies looking specifically at risk of SARS-CoV-2 transmission in the theatre arena should be pursued to better quantify whether or not the risk to theatre staff of contracting COVID-19 is influenced by the surgical approach.DiscussionOverall, the limited studies and heterogenous data available in the world literature currently does not allow for meaningful comparison between laparoscopic and open techniques.ConclusionThis systematic review has demonstrated that viral transmission during surgical procedures remains a potential source of risk for theatre teams in the healthcare setting.", [["SARS", "DISEASE", 49, 53], ["COVID-19", "CHEMICAL", 187, 195], ["CoV-2", "ORGANISM", 54, 59], ["Clinical studies", "TEST", 0, 16], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["contracting COVID", "TREATMENT", 175, 192], ["the limited studies", "TEST", 254, 273], ["heterogenous data", "TEST", 278, 295], ["laparoscopic", "TREATMENT", 389, 401], ["open techniques", "TREATMENT", 406, 421], ["viral transmission", "PROBLEM", 477, 495], ["surgical procedures", "TREATMENT", 503, 522], ["surgical", "OBSERVATION", 217, 225]]], ["In particular, with the current COVID-19 pandemic, the use of aerosol generating procedures in theatre could lead to transmission of viral DNA.", [["DNA", "CELLULAR_COMPONENT", 139, 142], ["viral DNA", "DNA", 133, 142], ["the current COVID", "TEST", 20, 37], ["aerosol generating procedures", "TREATMENT", 62, 91], ["viral DNA", "PROBLEM", 133, 142], ["viral DNA", "OBSERVATION", 133, 142]]], ["This systematic review has demonstrated that viral DNA is able to be aerosolised during both open and laparoscopic surgical procedures and this has been quantified by several studies.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["This systematic review", "TEST", 0, 22], ["viral DNA", "PROBLEM", 45, 54], ["laparoscopic surgical procedures", "TREATMENT", 102, 134], ["several studies", "TEST", 167, 182], ["viral DNA", "OBSERVATION", 45, 54]]], ["There is currently no high quality evidence that the risk is worse with a minimally invasive approach in comparison to open surgery.", [["a minimally invasive approach", "TREATMENT", 72, 101], ["open surgery", "TREATMENT", 119, 131], ["no", "UNCERTAINTY", 19, 21], ["high quality", "OBSERVATION_MODIFIER", 22, 34], ["worse", "OBSERVATION_MODIFIER", 61, 66], ["minimally", "OBSERVATION_MODIFIER", 74, 83], ["invasive", "OBSERVATION", 84, 92], ["surgery", "OBSERVATION", 124, 131]]], ["There is a need for further investigation regarding aerosolised viral load and the effect of different operative techniques.FundingThis study received no funding sources. r e f e r e n c e s", [["further investigation", "TEST", 20, 41], ["aerosolised viral load", "PROBLEM", 52, 74], ["different operative techniques", "TREATMENT", 93, 123], ["This study", "TEST", 131, 141], ["e r e n c e s", "TREATMENT", 177, 190]]]], "6d69b0029d456f566d24b4b2083d3def32888d2d": [], "73bdd3b33b1bc51679e21db9efcb02b7722b06a7": [["vector, while L. infantum causes VL due to parasite dissemination into internal organs.", [["organs", "ANATOMY", 80, 86], ["VL", "DISEASE", 33, 35], ["L. infantum", "ORGANISM", 14, 25], ["organs", "ORGAN", 80, 86], ["L. infantum", "SPECIES", 14, 25], ["L. infantum", "SPECIES", 14, 25], ["L. infantum", "PROBLEM", 14, 25], ["VL", "PROBLEM", 33, 35], ["parasite dissemination into internal organs", "PROBLEM", 43, 86], ["parasite", "OBSERVATION", 43, 51], ["internal organs", "ANATOMY", 71, 86]]], ["Leishmania parasites exist in two developmental stages.", [["Leishmania parasites", "DISEASE", 0, 20], ["Leishmania parasites", "ORGANISM", 0, 20], ["Leishmania parasites", "PROBLEM", 0, 20], ["parasites", "OBSERVATION", 11, 20], ["two developmental", "OBSERVATION_MODIFIER", 30, 47], ["stages", "OBSERVATION_MODIFIER", 48, 54]]], ["The flagellated promastigote is transmitted with the bite of the sand fly (insect vector) to the mammalian host, where it transforms into the amastigote stage.", [["promastigote", "ANATOMY", 16, 28], ["promastigote", "CELL", 16, 28], ["sand fly", "ORGANISM", 65, 73], ["sand fly", "SPECIES", 65, 73], ["flagellated", "OBSERVATION_MODIFIER", 4, 15], ["promastigote", "OBSERVATION", 16, 28], ["amastigote stage", "OBSERVATION", 142, 158]]], ["Leishmania amastigotes infect mononuclear phagocytes, where their intracellular location allows them to subvert the effector and regulatory functions of these cells (Duclos and Desjardins, 2000) .", [["mononuclear phagocytes", "ANATOMY", 30, 52], ["intracellular", "ANATOMY", 66, 79], ["cells", "ANATOMY", 159, 164], ["Leishmania amastigotes", "ORGANISM", 0, 22], ["mononuclear phagocytes", "CELL", 30, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["cells", "CELL", 159, 164], ["mononuclear phagocytes", "CELL_TYPE", 30, 52], ["Leishmania amastigotes infect mononuclear phagocytes", "PROBLEM", 0, 52], ["mononuclear phagocytes", "OBSERVATION", 30, 52]]], ["Since epidermal Langerhans cells and dermal dendritic cells (DCs) contribute to immunosurveillance of the skin (Banchereau and Steinman, 1998; Mellman and Steinman, 2001) and are located in proximity to the site of parasite delivery, their role in the initiation of Leishmania-specific immune responses is an active area of research.Leishmania host cellsTo attain a successful infection, Leishmania needs to subvert the host immune response from the early steps after its inoculation.", [["epidermal Langerhans cells", "ANATOMY", 6, 32], ["dermal dendritic cells", "ANATOMY", 37, 59], ["DCs", "ANATOMY", 61, 64], ["skin", "ANATOMY", 106, 110], ["cells", "ANATOMY", 349, 354], ["infection", "DISEASE", 377, 386], ["epidermal Langerhans cells", "CELL", 6, 32], ["dermal dendritic cells", "CELL", 37, 59], ["DCs", "CELL", 61, 64], ["skin", "ORGAN", 106, 110], ["Leishmania", "ORGANISM", 266, 276], ["Leishmania host cells", "CELL", 333, 354], ["Leishmania", "ORGANISM", 388, 398], ["epidermal Langerhans cells", "CELL_TYPE", 6, 32], ["dermal dendritic cells", "CELL_TYPE", 37, 59], ["DCs", "CELL_TYPE", 61, 64], ["Leishmania host cells", "CELL_TYPE", 333, 354], ["epidermal Langerhans cells", "PROBLEM", 6, 32], ["dermal dendritic cells", "PROBLEM", 37, 59], ["parasite delivery", "TREATMENT", 215, 232], ["Leishmania", "PROBLEM", 266, 276], ["Leishmania host cells", "PROBLEM", 333, 354], ["a successful infection", "PROBLEM", 364, 386], ["Leishmania", "PROBLEM", 388, 398], ["Langerhans cells", "OBSERVATION", 16, 32], ["dermal", "OBSERVATION_MODIFIER", 37, 43], ["dendritic cells", "OBSERVATION", 44, 59], ["skin", "ANATOMY", 106, 110], ["parasite", "OBSERVATION", 215, 223], ["Leishmania", "OBSERVATION", 266, 276], ["active", "OBSERVATION_MODIFIER", 309, 315], ["area", "OBSERVATION_MODIFIER", 316, 320], ["host cells", "OBSERVATION", 344, 354], ["infection", "OBSERVATION", 377, 386], ["Leishmania", "OBSERVATION", 388, 398]]], ["In the natural course of infection, these events occur in the dermis, where DCs may act as host cells for Leishmania, independently of the pathological outcome of the infection (McDowell et al., 2002) .", [["dermis", "ANATOMY", 62, 68], ["DCs", "ANATOMY", 76, 79], ["cells", "ANATOMY", 96, 101], ["infection", "DISEASE", 25, 34], ["infection", "DISEASE", 167, 176], ["dermis", "TISSUE", 62, 68], ["DCs", "CELL", 76, 79], ["host cells", "CELL", 91, 101], ["Leishmania", "ORGANISM", 106, 116], ["DCs", "CELL_TYPE", 76, 79], ["host cells", "CELL_TYPE", 91, 101], ["infection", "PROBLEM", 25, 34], ["these events", "PROBLEM", 36, 48], ["DCs", "TREATMENT", 76, 79], ["Leishmania", "PROBLEM", 106, 116], ["the infection", "PROBLEM", 163, 176], ["infection", "OBSERVATION", 25, 34], ["dermis", "ANATOMY", 62, 68], ["infection", "OBSERVATION", 167, 176]]], ["In this regard, Langerhans cells within cutaneous lesions are parasitized by Leishmania in vivo in both human and experimental murine CL (Blank et al., 1993; Moll, 1993) .", [["Langerhans cells", "ANATOMY", 16, 32], ["cutaneous lesions", "ANATOMY", 40, 57], ["CL", "ANATOMY", 134, 136], ["Langerhans cells", "CELL", 16, 32], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 40, 57], ["Leishmania", "ORGANISM", 77, 87], ["human", "ORGANISM", 104, 109], ["murine", "ORGANISM", 127, 133], ["CL", "MULTI-TISSUE_STRUCTURE", 134, 136], ["Langerhans cells", "CELL_TYPE", 16, 32], ["human", "SPECIES", 104, 109], ["murine", "SPECIES", 127, 133], ["human", "SPECIES", 104, 109], ["Langerhans cells", "PROBLEM", 16, 32], ["cutaneous lesions", "PROBLEM", 40, 57], ["Leishmania", "PROBLEM", 77, 87], ["Langerhans cells", "OBSERVATION", 16, 32], ["cutaneous", "ANATOMY", 40, 49], ["lesions", "OBSERVATION", 50, 57], ["Leishmania", "OBSERVATION", 77, 87]]], ["Studies on the interactions of Leishmania with murine or human DC have not yet clearly determined the range of parasite forms that these cells can internalize (Amprey et al., 2004; Bennett et al., 2001; Blank et al., 1993; Konecny et al., 1999; Marovich et al., 2000; Moll, 2000; Moll and Flohe, 1997; Qi et al., 2001; Sacks and Sher, 2002; Udey et al., 2001; von Stebut et al., 1998 von Stebut et al., , 2000 or their influence on parasite survival.Leishmania host cellsAlthough Leishmania species might differentially subvert DC effector function (Antoine et al., 2004; Brandonisio et al., 2004; Chaussabel et al., 2003; Ghosh and Bandyopadhyay, 2004; Jebbari et al., 2002; Konecny, et al., 1999; Ponte-Sucre et al., 2001; Scott and Hunter, 2002; von Stebut et al., 1998) , the receptors involved in the Leishmania-DC interaction remain largely undefined and could be critical for this process.", [["DC", "ANATOMY", 63, 65], ["cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 466, 471], ["DC", "ANATOMY", 528, 530], ["DC", "ANATOMY", 817, 819], ["Leishmania", "ORGANISM", 31, 41], ["murine", "ORGANISM", 47, 53], ["human", "ORGANISM", 57, 62], ["DC", "CELL", 63, 65], ["cells", "CELL", 137, 142], ["Leishmania host cells", "CELL", 450, 471], ["Leishmania species", "ORGANISM", 480, 498], ["DC", "CELL", 817, 819], ["murine or human DC", "CELL_TYPE", 47, 65], ["Leishmania host cells", "CELL_TYPE", 450, 471], ["DC", "CELL_TYPE", 528, 530], ["DC", "CELL_TYPE", 817, 819], ["murine", "SPECIES", 47, 53], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["Leishmania", "PROBLEM", 31, 41], ["parasite survival", "TREATMENT", 432, 449], ["Leishmania host cells", "PROBLEM", 450, 471], ["Leishmania species", "PROBLEM", 480, 498], ["host cells", "OBSERVATION", 461, 471], ["Leishmania", "OBSERVATION", 480, 490], ["Leishmania", "OBSERVATION", 806, 816]]], ["In contrast, several macrophage receptors have been identified which mediate binding and subsequent uptake of Leishmania promastigotes (Blackwell, 1985; Russell and Talamas-Rohana, 1989) .", [["macrophage", "ANATOMY", 21, 31], ["macrophage", "CELL", 21, 31], ["Leishmania promastigotes", "ORGANISM", 110, 134], ["macrophage receptors", "PROTEIN", 21, 41], ["several macrophage receptors", "PROBLEM", 13, 41], ["subsequent uptake of Leishmania promastigotes", "PROBLEM", 89, 134], ["macrophage receptors", "OBSERVATION", 21, 41], ["uptake", "OBSERVATION_MODIFIER", 100, 106], ["Leishmania promastigotes", "OBSERVATION", 110, 134]]], ["In this regard, lipophosphoglycan (LPG) and the metalloproteinase gp63 bind to complement receptor type 3 (CR3), mannose-fucose, and fibronectin receptors on macrophages (Blackwell, 1985; Da Silva et al., 1989; Guy and Belosevic, 1993; Mosser, 1994; Talamas-Rohana et al., 1990; Wilson and Pearson, 1988) .", [["macrophages", "ANATOMY", 158, 169], ["mannose-fucose", "CHEMICAL", 113, 127], ["mannose", "CHEMICAL", 113, 120], ["fucose", "CHEMICAL", 121, 127], ["lipophosphoglycan", "GENE_OR_GENE_PRODUCT", 16, 33], ["LPG", "SIMPLE_CHEMICAL", 35, 38], ["gp63", "GENE_OR_GENE_PRODUCT", 66, 70], ["complement receptor type 3", "GENE_OR_GENE_PRODUCT", 79, 105], ["CR3", "GENE_OR_GENE_PRODUCT", 107, 110], ["mannose-fucose", "SIMPLE_CHEMICAL", 113, 127], ["fibronectin", "GENE_OR_GENE_PRODUCT", 133, 144], ["macrophages", "CELL", 158, 169], ["lipophosphoglycan", "PROTEIN", 16, 33], ["LPG", "PROTEIN", 35, 38], ["metalloproteinase gp63", "PROTEIN", 48, 70], ["complement receptor type 3", "PROTEIN", 79, 105], ["CR3", "PROTEIN", 107, 110], ["fibronectin receptors", "PROTEIN", 133, 154], ["macrophages", "CELL_TYPE", 158, 169], ["lipophosphoglycan (LPG", "TREATMENT", 16, 38], ["the metalloproteinase gp63 bind", "TREATMENT", 44, 75], ["mannose", "TEST", 113, 120]]], ["However, the receptors implicated in amastigote uptake by DC and macrophages are poorly characterized, mainly due to the fact that isolation or in vitro culture of this intracellular form is difficult.", [["DC", "ANATOMY", 58, 60], ["macrophages", "ANATOMY", 65, 76], ["intracellular", "ANATOMY", 169, 182], ["amastigote", "CELL", 37, 47], ["DC", "CELL", 58, 60], ["macrophages", "CELL", 65, 76], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 169, 182], ["DC", "CELL_TYPE", 58, 60], ["macrophages", "CELL_TYPE", 65, 76], ["vitro culture", "TEST", 147, 160], ["amastigote uptake", "OBSERVATION", 37, 54], ["macrophages", "ANATOMY", 65, 76], ["poorly characterized", "OBSERVATION_MODIFIER", 81, 101], ["isolation", "OBSERVATION", 131, 140]]], ["The availability of axenic cultures has now opened the possibility of addressing the identification of Leishmania amastigotes receptors on macrophages and DCs (Armson et al., 1999; Bates et al., 1992; Debrabant et al., 2004; Doyle et al., 1991; Gupta et al., 2001; Hodgkinson et al., 1996) .Leishmania interaction with dendritic cells: exploiting DC-SIGNMacrophages and DCs express a wide variety of pathogen-associated molecular pattern receptors, including numerous C-type lectin and lectin-like receptors (Engering et al., 2002; Figdor et al., 2002; McGreal et al., 2004) .", [["macrophages", "ANATOMY", 139, 150], ["DCs", "ANATOMY", 155, 158], ["dendritic cells", "ANATOMY", 319, 334], ["DC-SIGNMacrophages", "ANATOMY", 347, 365], ["DCs", "ANATOMY", 370, 373], ["Leishmania", "ORGANISM", 103, 113], ["macrophages", "CELL", 139, 150], ["DCs", "CELL", 155, 158], ["Leishmania", "ORGANISM", 291, 301], ["dendritic cells", "CELL", 319, 334], ["DC-SIGNMacrophages", "CELL", 347, 365], ["DCs", "CELL", 370, 373], ["pathogen-associated molecular pattern receptors", "GENE_OR_GENE_PRODUCT", 400, 447], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 468, 481], ["lectin-like receptors", "GENE_OR_GENE_PRODUCT", 486, 507], ["axenic cultures", "CELL_LINE", 20, 35], ["Leishmania amastigotes receptors", "PROTEIN", 103, 135], ["macrophages", "CELL_TYPE", 139, 150], ["DCs", "CELL_TYPE", 155, 158], ["dendritic cells", "CELL_TYPE", 319, 334], ["DC", "CELL_TYPE", 347, 349], ["SIGNMacrophages", "CELL_TYPE", 350, 365], ["DCs", "CELL_TYPE", 370, 373], ["pathogen-associated molecular pattern receptors", "PROTEIN", 400, 447], ["C-type lectin and lectin-like receptors", "PROTEIN", 468, 507], ["axenic cultures", "TEST", 20, 35], ["Leishmania amastigotes receptors", "PROBLEM", 103, 135], ["Leishmania", "PROBLEM", 291, 301], ["dendritic cells", "PROBLEM", 319, 334], ["Leishmania amastigotes", "OBSERVATION", 103, 125], ["dendritic cells", "OBSERVATION", 319, 334]]], ["Since Leishmania spp. display an abundance of mannose-rich glycoconjugates on their surface that are important for parasite virulence (Ilgoutz and McConville, 2001; Garami and Ilg, 2001) , a reasonable hypothesis is that lectin-oligosaccharide interactions are involved in parasite recognition by mononuclear phagocytes.", [["surface", "ANATOMY", 84, 91], ["mononuclear phagocytes", "ANATOMY", 297, 319], ["mannose", "CHEMICAL", 46, 53], ["Leishmania spp", "ORGANISM", 6, 20], ["mannose", "SIMPLE_CHEMICAL", 46, 53], ["surface", "CELLULAR_COMPONENT", 84, 91], ["lectin", "GENE_OR_GENE_PRODUCT", 221, 227], ["parasite", "CELL", 273, 281], ["mononuclear phagocytes", "CELL", 297, 319], ["lectin", "PROTEIN", 221, 227], ["mononuclear phagocytes", "CELL_TYPE", 297, 319], ["Leishmania spp", "PROBLEM", 6, 20], ["parasite virulence", "PROBLEM", 115, 133], ["Leishmania spp", "OBSERVATION", 6, 20], ["abundance", "OBSERVATION_MODIFIER", 33, 42], ["mononuclear phagocytes", "OBSERVATION", 297, 319]]], ["DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN, CD209) is a type II transmembrane C-type lectin expressed on DCs and macrophages, and was initially described as involved in cell-cell interactions through its capacity to bind ICAM-3 and ICAM-2 (Geijtenbeek et al., 2000a, b; van Kooyk and Geijtenbeek, 2002) .", [["DC", "ANATOMY", 0, 2], ["DCs", "ANATOMY", 111, 114], ["macrophages", "ANATOMY", 119, 130], ["cell", "ANATOMY", 175, 179], ["cell", "ANATOMY", 180, 184], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 12, 18], ["nonintegrin", "GENE_OR_GENE_PRODUCT", 28, 39], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 41, 48], ["CD209", "GENE_OR_GENE_PRODUCT", 50, 55], ["type II transmembrane C-type lectin", "GENE_OR_GENE_PRODUCT", 62, 97], ["DCs", "CELL", 111, 114], ["macrophages", "CELL", 119, 130], ["cell", "CELL", 175, 179], ["cell", "CELL", 180, 184], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 227, 233], ["ICAM-2", "GENE_OR_GENE_PRODUCT", 238, 244], ["DC", "CELL_TYPE", 0, 2], ["ICAM-3", "PROTEIN", 12, 18], ["grabbing nonintegrin", "PROTEIN", 19, 39], ["DC", "PROTEIN", 41, 43], ["SIGN", "PROTEIN", 44, 48], ["CD209", "PROTEIN", 50, 55], ["type II transmembrane C-type lectin", "PROTEIN", 62, 97], ["DCs", "CELL_TYPE", 111, 114], ["macrophages", "CELL_TYPE", 119, 130], ["ICAM", "PROTEIN", 227, 231], ["ICAM", "PROTEIN", 238, 242], ["specific ICAM", "TEST", 3, 16], ["a type II transmembrane C-type lectin", "PROBLEM", 60, 97], ["ICAM", "TEST", 227, 231], ["ICAM", "TEST", 238, 242]]], ["The DC-SIGN extracellular domain comprises eight 23-residue tandem repeats and a Cterminal carbohydrate-recognition domain (Mitchell et al., 2001) .", [["DC", "ANATOMY", 4, 6], ["extracellular", "ANATOMY", 12, 25], ["carbohydrate", "CHEMICAL", 91, 103], ["DC", "CELL_TYPE", 4, 6], ["SIGN extracellular domain", "PROTEIN", 7, 32], ["23-residue tandem repeats", "PROTEIN", 49, 74], ["Cterminal carbohydrate-recognition domain", "PROTEIN", 81, 122]]], ["DC-SIGN is now known to be a receptor for HIV (Geijtenbeek et al., 2000c; Pohlmann et al., 2001) , Ebola virus (Alvarez et al., 2002) , Schistosoma mansoni , Sindbis virus (Klimstra et al., 2003) Candida albicans (Cambi et al., 2003) Mycobacterium tuberculosis , Hepatitis C (Wang et al., 2004) , Helicobacter pylori (Bergman et al., 2004) and the fungal pathogen Aspergillus fumigatus .Leishmania interaction with dendritic cells: exploiting DC-SIGNMost Leishmania amastigote-DC studies have been carried out with tissue-derived opsonized parasites, which might be bound via Fc and complement receptors, thus precluding the identification of opsonization-independent binding mechanisms.", [["dendritic cells", "ANATOMY", 415, 430], ["DC", "ANATOMY", 443, 445], ["DC", "ANATOMY", 477, 479], ["tissue", "ANATOMY", 515, 521], ["Ebola virus", "DISEASE", 99, 110], ["Schistosoma mansoni", "DISEASE", 136, 155], ["Sindbis virus", "DISEASE", 158, 171], ["Candida albicans", "DISEASE", 196, 212], ["Mycobacterium tuberculosis", "DISEASE", 234, 260], ["Hepatitis C", "DISEASE", 263, 274], ["Helicobacter pylori", "DISEASE", 297, 316], ["Aspergillus fumigatus", "DISEASE", 364, 385], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 0, 7], ["HIV", "ORGANISM", 42, 45], ["Ebola virus", "ORGANISM", 99, 110], ["Schistosoma mansoni", "ORGANISM", 136, 155], ["Sindbis virus", "ORGANISM", 158, 171], ["Candida albicans", "ORGANISM", 196, 212], ["Mycobacterium tuberculosis", "ORGANISM", 234, 260], ["Hepatitis C", "ORGANISM", 263, 274], ["Helicobacter pylori", "ORGANISM", 297, 316], ["fungal pathogen", "ORGANISM", 348, 363], ["Aspergillus fumigatus", "ORGANISM", 364, 385], ["Leishmania", "ORGANISM", 387, 397], ["dendritic cells", "CELL", 415, 430], ["tissue", "TISSUE", 515, 521], ["parasites", "CELL", 540, 549], ["Fc", "GENE_OR_GENE_PRODUCT", 576, 578], ["complement receptors", "GENE_OR_GENE_PRODUCT", 583, 603], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7], ["dendritic cells", "CELL_TYPE", 415, 430], ["DC", "CELL_TYPE", 443, 445], ["DC", "CELL_TYPE", 477, 479], ["Fc", "PROTEIN", 576, 578], ["complement receptors", "PROTEIN", 583, 603], ["Ebola virus", "SPECIES", 99, 110], ["Schistosoma mansoni", "SPECIES", 136, 155], ["Sindbis virus", "SPECIES", 158, 171], ["Candida albicans", "SPECIES", 196, 212], ["Mycobacterium tuberculosis", "SPECIES", 234, 260], ["Helicobacter pylori", "SPECIES", 297, 316], ["Aspergillus fumigatus", "SPECIES", 364, 385], ["HIV", "SPECIES", 42, 45], ["Ebola virus", "SPECIES", 99, 110], ["Schistosoma mansoni", "SPECIES", 136, 155], ["Sindbis virus", "SPECIES", 158, 171], ["Candida albicans", "SPECIES", 196, 212], ["Mycobacterium tuberculosis", "SPECIES", 234, 260], ["Helicobacter pylori", "SPECIES", 297, 316], ["Aspergillus fumigatus", "SPECIES", 364, 385], ["HIV", "PROBLEM", 42, 45], ["Ebola virus", "PROBLEM", 99, 110], ["Schistosoma mansoni", "PROBLEM", 136, 155], ["Sindbis virus", "TREATMENT", 158, 171], ["Candida albicans", "PROBLEM", 196, 212], ["Mycobacterium tuberculosis", "PROBLEM", 234, 260], ["Hepatitis C", "PROBLEM", 263, 274], ["Helicobacter pylori", "PROBLEM", 297, 316], ["the fungal pathogen Aspergillus fumigatus", "PROBLEM", 344, 385], ["Leishmania interaction", "PROBLEM", 387, 409], ["dendritic cells", "PROBLEM", 415, 430], ["SIGNMost Leishmania amastigote", "PROBLEM", 446, 476], ["DC studies", "TEST", 477, 487], ["opsonized parasites", "PROBLEM", 530, 549], ["Schistosoma mansoni", "ANATOMY", 136, 155], ["Sindbis virus", "OBSERVATION", 158, 171], ["Mycobacterium tuberculosis", "OBSERVATION", 234, 260], ["Hepatitis", "ANATOMY", 263, 272], ["Helicobacter pylori", "ANATOMY", 297, 316], ["fungal pathogen", "OBSERVATION", 348, 363], ["Aspergillus fumigatus", "OBSERVATION", 364, 385], ["dendritic cells", "OBSERVATION", 415, 430], ["opsonized parasites", "OBSERVATION", 530, 549]]], ["To analyze the participation of the receptor DC-SIGN in binding and internalization of Leishmania, we used axenic amastigotes (Armson et al., 1999; Pan and McMahon-Pratt, 1988) , which are devoid of opsonizing antibodies.", [["DC-SIGN", "GENE_OR_GENE_PRODUCT", 45, 52], ["Leishmania", "ORGANISM", 87, 97], ["DC", "PROTEIN", 45, 47], ["SIGN", "PROTEIN", 48, 52], ["opsonizing antibodies", "PROTEIN", 199, 220], ["SIGN in binding", "PROBLEM", 48, 63], ["Leishmania", "PROBLEM", 87, 97], ["opsonizing antibodies", "PROBLEM", 199, 220], ["Leishmania", "OBSERVATION", 87, 97]]], ["We first analyzed the interaction of L. pifanoi (that causes CL) axenic amastigote with K562-DC-SIGN transfectants and demonstrated that they are specifically recognized by DC-SIGN (Colmenares et al., 2002) .Leishmania interaction with dendritic cells: exploiting DC-SIGNSubsequently, L. pifanoi amastigotes were found to bind DC-SIGN on the surface of immature monocytederived dendritic cells (IMDDCs), an interaction that was dramatically reduced in the presence of anti-DC-SIGN blocking antibodies (Colmenares et al., 2002) .", [["K562-DC-SIGN transfectants", "ANATOMY", 88, 114], ["DC", "ANATOMY", 173, 175], ["dendritic cells", "ANATOMY", 236, 251], ["DC", "ANATOMY", 264, 266], ["DC", "ANATOMY", 327, 329], ["surface", "ANATOMY", 342, 349], ["monocytederived dendritic cells", "ANATOMY", 362, 393], ["IMDDCs", "ANATOMY", 395, 401], ["L. pifanoi", "ORGANISM", 37, 47], ["K562-DC-SIGN transfectants", "CELL", 88, 114], ["Leishmania", "ORGANISM", 208, 218], ["dendritic cells", "CELL", 236, 251], ["DC", "CELL", 264, 266], ["L. pifanoi amastigotes", "ORGANISM", 285, 307], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 327, 334], ["surface", "CELLULAR_COMPONENT", 342, 349], ["monocytederived dendritic cells", "CELL", 362, 393], ["IMDDCs", "CELL", 395, 401], ["anti-DC-SIGN", "GENE_OR_GENE_PRODUCT", 468, 480], ["K562-DC-SIGN transfectants", "CELL_LINE", 88, 114], ["DC", "CELL_TYPE", 173, 175], ["dendritic cells", "CELL_TYPE", 236, 251], ["DC", "CELL_TYPE", 264, 266], ["DC", "CELL_TYPE", 327, 329], ["SIGN", "PROTEIN", 330, 334], ["immature monocytederived dendritic cells", "CELL_TYPE", 353, 393], ["IMDDCs", "CELL_TYPE", 395, 401], ["anti-DC-SIGN blocking antibodies", "PROTEIN", 468, 500], ["L. pifanoi", "SPECIES", 37, 47], ["L. pifanoi", "SPECIES", 285, 295], ["L. pifanoi", "SPECIES", 37, 47], ["L. pifanoi", "SPECIES", 285, 295], ["L. pifanoi", "TREATMENT", 37, 47], ["Leishmania", "PROBLEM", 208, 218], ["dendritic cells", "PROBLEM", 236, 251], ["L. pifanoi amastigotes", "TREATMENT", 285, 307], ["immature monocytederived dendritic cells", "PROBLEM", 353, 393], ["SIGN blocking antibodies", "PROBLEM", 476, 500], ["dendritic cells", "OBSERVATION", 236, 251], ["immature", "OBSERVATION_MODIFIER", 353, 361], ["monocytederived dendritic cells", "OBSERVATION", 362, 393], ["dramatically", "OBSERVATION_MODIFIER", 428, 440], ["reduced", "OBSERVATION_MODIFIER", 441, 448]]], ["This set of results suggested an important role for DC-SIGN in the early stages of infection of DCs by Leishmania.Leishmania interaction with dendritic cells: exploiting DC-SIGNSince infection of immature dermal DCs is a common step shared by all Leishmania species, we next analyzed the capacity of IMDDCs to bind other Leishmania life cycle forms and species.", [["DC", "ANATOMY", 52, 54], ["DCs", "ANATOMY", 96, 99], ["dendritic cells", "ANATOMY", 142, 157], ["DC", "ANATOMY", 170, 172], ["dermal DCs", "ANATOMY", 205, 215], ["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 183, 192], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 52, 59], ["DCs", "CELL", 96, 99], ["Leishmania", "ORGANISM", 103, 113], ["Leishmania", "ORGANISM", 114, 124], ["dendritic cells", "CELL", 142, 157], ["DC-SIGNSince", "CELL", 170, 182], ["dermal DCs", "CELL", 205, 215], ["Leishmania species", "ORGANISM", 247, 265], ["IMDDCs", "GENE_OR_GENE_PRODUCT", 300, 306], ["DC", "CELL_TYPE", 52, 54], ["SIGN", "PROTEIN", 55, 59], ["DCs", "CELL_TYPE", 96, 99], ["dendritic cells", "CELL_TYPE", 142, 157], ["DC", "CELL_TYPE", 170, 172], ["immature dermal DCs", "CELL_TYPE", 196, 215], ["infection of DCs", "PROBLEM", 83, 99], ["Leishmania", "PROBLEM", 103, 113], ["Leishmania", "PROBLEM", 114, 124], ["dendritic cells", "PROBLEM", 142, 157], ["SIGNSince infection", "PROBLEM", 173, 192], ["immature dermal DCs", "PROBLEM", 196, 215], ["all Leishmania species", "PROBLEM", 243, 265], ["IMDDCs", "TREATMENT", 300, 306], ["early stages", "OBSERVATION_MODIFIER", 67, 79], ["infection", "OBSERVATION", 83, 92], ["Leishmania", "OBSERVATION", 103, 113], ["dendritic cells", "OBSERVATION", 142, 157], ["immature", "OBSERVATION_MODIFIER", 196, 204], ["dermal DCs", "OBSERVATION", 205, 215], ["Leishmania species", "OBSERVATION", 247, 265]]], ["Our results underscored the relevance of the DC-SIGN-Leishmania interaction in both VL (L. infantum) and CL (L. pifanoi), as amastigotes and promastigotes from both species exhibited DC-SIGN-interaction capacity.", [["DC", "ANATOMY", 45, 47], ["DC", "ANATOMY", 183, 185], ["SIGN", "GENE_OR_GENE_PRODUCT", 48, 52], ["Leishmania", "ORGANISM", 53, 63], ["VL", "ORGANISM", 84, 86], ["L. infantum", "ORGANISM", 88, 99], ["CL", "ORGANISM", 105, 107], ["L. pifanoi", "ORGANISM", 109, 119], ["promastigotes", "CELL", 141, 154], ["SIGN", "GENE_OR_GENE_PRODUCT", 186, 190], ["DC", "CELL_TYPE", 45, 47], ["DC", "CELL_TYPE", 183, 185], ["SIGN", "PROTEIN", 186, 190], ["L. infantum", "SPECIES", 88, 99], ["L. pifanoi", "SPECIES", 109, 119], ["L. infantum", "SPECIES", 88, 99], ["L. pifanoi", "SPECIES", 109, 119], ["the DC", "TEST", 41, 47], ["Leishmania interaction", "PROBLEM", 53, 75], ["CL (L. pifanoi)", "PROBLEM", 105, 120], ["promastigotes", "PROBLEM", 141, 154], ["Leishmania", "OBSERVATION", 53, 63], ["both", "ANATOMY_MODIFIER", 79, 83], ["VL", "ANATOMY", 84, 86]]], ["Since the membrane composition of the parasite changes throughout its life cycle (Bahr et al., 1993; Wright and el Amin, 1989) , we tested the ability of DC-SIGN to bind the three main life cycle forms of the parasite (amastigotes, procyclic promastigotes and metacyclic promastigotes).", [["membrane", "ANATOMY", 10, 18], ["DC", "ANATOMY", 154, 156], ["promastigotes", "ANATOMY", 271, 284], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 154, 161], ["amastigotes", "CELL", 219, 230], ["procyclic promastigotes", "ORGANISM", 232, 255], ["promastigotes", "CELL", 271, 284], ["DC", "CELL_TYPE", 154, 156], ["SIGN", "PROTEIN", 157, 161], ["the parasite changes", "PROBLEM", 34, 54], ["procyclic promastigotes", "TREATMENT", 232, 255], ["metacyclic promastigotes", "TREATMENT", 260, 284], ["membrane", "OBSERVATION_MODIFIER", 10, 18], ["composition", "OBSERVATION_MODIFIER", 19, 30], ["parasite", "OBSERVATION", 38, 46]]], ["Amastigotes and metacyclic promastigotes showed the strongest DC-SIGN-dependent interaction with IMDDC ( Fig. 1) .", [["DC", "ANATOMY", 62, 64], ["metacyclic promastigotes", "CELL", 16, 40], ["SIGN", "SIMPLE_CHEMICAL", 65, 69], ["IMDDC", "SIMPLE_CHEMICAL", 97, 102], ["DC", "CELL_TYPE", 62, 64], ["SIGN", "PROTEIN", 65, 69], ["IMDDC", "PROTEIN", 97, 102], ["Amastigotes", "TEST", 0, 11], ["metacyclic promastigotes", "TEST", 16, 40]]], ["Moreover, the avidity for DC-SIGN increased in the transition from procyclic (non-infective) to metacyclic (infective) promastigotes (i.e., procyclic and metacyclic promastigotes, respectively) (Fig. 1) .", [["DC", "ANATOMY", 26, 28], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 26, 33], ["promastigotes", "CELL", 165, 178], ["DC", "CELL_TYPE", 26, 28], ["SIGN", "PROTEIN", 29, 33], ["the transition from procyclic (non-infective)", "PROBLEM", 47, 92], ["metacyclic (infective) promastigotes", "PROBLEM", 96, 132], ["procyclic and metacyclic promastigotes", "TREATMENT", 140, 178], ["increased", "OBSERVATION_MODIFIER", 34, 43]]], ["Hence, the avidity of the different forms of the parasite for DC-SIGN appears to correlate with their virulence.", [["DC", "ANATOMY", 62, 64], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 62, 69], ["DC", "CELL_TYPE", 62, 64], ["SIGN", "PROTEIN", 65, 69]]], ["On the other hand, a much lower ability for DC-SIGN recognition was observed in Leishmania major promastigotes (Fig. 1) .DC-SIGN ligands on Leishmania:LPG is one of the most abundant glycoconjugates exposed on the cell surface of promastigotes, but scarcely expressed on amastigotes, and plays a pleiotropic role through the life cycle of Leishmania (Aebischer et al., 2005; Cunningham, 2002; Kamhawi et al., 2000; Naderer et al., 2004; Sacks et al., 2000; Turco and Descoteaux, 1992; Turco et al., 2001) .", [["DC", "ANATOMY", 44, 46], ["cell surface", "ANATOMY", 214, 226], ["promastigotes", "ANATOMY", 230, 243], ["SIGN", "GENE_OR_GENE_PRODUCT", 47, 51], ["Leishmania major promastigotes", "ORGANISM", 80, 110], [".DC-SIGN", "SIMPLE_CHEMICAL", 120, 128], ["Leishmania", "ORGANISM", 140, 150], ["LPG", "SIMPLE_CHEMICAL", 151, 154], ["cell surface", "CELLULAR_COMPONENT", 214, 226], ["promastigotes", "CELL", 230, 243], ["Leishmania", "ORGANISM", 339, 349], ["DC", "CELL_TYPE", 44, 46], ["SIGN", "PROTEIN", 47, 51], ["Leishmania major promastigotes", "SPECIES", 80, 110], ["Leishmania", "PROBLEM", 140, 150], ["Leishmania", "OBSERVATION", 140, 150], ["cell surface", "OBSERVATION_MODIFIER", 214, 226], ["Leishmania", "OBSERVATION", 339, 349]]], ["This molecule is characterized by a high mannose content, and has been proposed to mediate promastigote interaction with DCs via DC-SIGN .", [["DCs", "ANATOMY", 121, 124], ["DC", "ANATOMY", 129, 131], ["mannose", "CHEMICAL", 41, 48], ["mannose", "SIMPLE_CHEMICAL", 41, 48], ["DCs", "CELL", 121, 124], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 129, 136], ["DCs", "CELL_TYPE", 121, 124], ["DC", "CELL_TYPE", 129, 131], ["SIGN", "PROTEIN", 132, 136], ["a high mannose content", "PROBLEM", 34, 56], ["high", "OBSERVATION_MODIFIER", 36, 40], ["mannose content", "OBSERVATION", 41, 56]]], ["However, our results indicate that LPG is not an important Leishmania ligand for DC-SIGN because: (1) LPG is strongly down-regulated in amastigotes (Ilg et al., 1999; Ilgoutz and McConville, 2001; Turco and Descoteaux, 1992) , which exhibit the highest DC-SIGN-binding ability; (2) LPG was unable to block Leishmania binding to DC-SIGN for all species and parasite developmental stages assayed; and (3) the LPG-defective L. donovani promastigotes (R2D2) bind to DC-SIGN-expressing cells.", [["DC", "ANATOMY", 81, 83], ["DC", "ANATOMY", 253, 255], ["DC", "ANATOMY", 328, 330], ["DC-SIGN-expressing cells", "ANATOMY", 462, 486], ["LPG", "SIMPLE_CHEMICAL", 35, 38], ["LPG", "GENE_OR_GENE_PRODUCT", 102, 105], ["amastigotes", "CELL", 136, 147], ["SIGN", "GENE_OR_GENE_PRODUCT", 256, 260], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 328, 335], ["LPG", "GENE_OR_GENE_PRODUCT", 407, 410], ["L. donovani promastigotes", "ORGANISM", 421, 446], ["R2D2", "ORGANISM", 448, 452], ["SIGN", "GENE_OR_GENE_PRODUCT", 465, 469], ["cells", "CELL", 481, 486], ["LPG", "PROTEIN", 35, 38], ["DC", "CELL_TYPE", 81, 83], ["LPG", "PROTEIN", 102, 105], ["DC", "CELL_TYPE", 253, 255], ["SIGN", "PROTEIN", 256, 260], ["LPG", "PROTEIN", 282, 285], ["DC", "CELL_TYPE", 328, 330], ["SIGN", "PROTEIN", 331, 335], ["LPG", "PROTEIN", 407, 410], ["DC", "CELL_TYPE", 462, 464], ["SIGN-expressing cells", "CELL_LINE", 465, 486], ["L. donovani", "SPECIES", 421, 432], ["L. donovani", "SPECIES", 421, 432], ["LPG", "TEST", 102, 105], ["LPG", "PROBLEM", 282, 285], ["unable to block Leishmania binding", "PROBLEM", 290, 324], ["all species", "PROBLEM", 340, 351], ["parasite developmental stages", "PROBLEM", 356, 385], ["the LPG", "TEST", 403, 410], ["defective L. donovani promastigotes", "TREATMENT", 411, 446], ["expressing cells", "PROBLEM", 470, 486], ["donovani promastigotes", "OBSERVATION", 424, 446], ["expressing cells", "OBSERVATION", 470, 486]]], ["Furthermore, since LPG-defective promastigotes bound DC-SIGN with higher avidity than their wild-type counterparts, LPG might in fact mask other promastigote membrane ligands with affinity for DC-SIGN .DC-SIGN ligands on Leishmania:Leishmania ability to modulate the DC maturation state: Conflicting results have been obtained on the ability of various Leishmania species to induce DC maturation (Antoine et al., 2004) .", [["DC", "ANATOMY", 53, 55], ["membrane", "ANATOMY", 158, 166], ["DC", "ANATOMY", 193, 195], ["DC", "ANATOMY", 267, 269], ["DC", "ANATOMY", 382, 384], ["LPG", "GENE_OR_GENE_PRODUCT", 19, 22], ["promastigotes", "CELL", 33, 46], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 53, 60], ["LPG", "SIMPLE_CHEMICAL", 116, 119], ["Leishmania", "ORGANISM", 221, 231], ["Leishmania", "ORGANISM", 232, 242], ["Leishmania", "ORGANISM", 353, 363], ["DC", "CELL", 382, 384], ["LPG", "PROTEIN", 19, 22], ["DC", "CELL_TYPE", 53, 55], ["SIGN", "PROTEIN", 56, 60], ["LPG", "PROTEIN", 116, 119], ["DC", "CELL_TYPE", 193, 195], ["SIGN", "PROTEIN", 196, 200], ["DC", "CELL_TYPE", 267, 269], ["DC", "CELL_TYPE", 382, 384], ["LPG", "TEST", 19, 22], ["defective promastigotes", "PROBLEM", 23, 46], ["higher avidity", "PROBLEM", 66, 80], ["Leishmania", "PROBLEM", 221, 231], ["Leishmania", "PROBLEM", 232, 242], ["various Leishmania species", "PROBLEM", 345, 371]]], ["It is currently unknown whether this variability is due to variations in the experimental conditions or truly reflects speciesspecific or strain-specific interactions between Leishmania and DC.", [["DC", "ANATOMY", 190, 192], ["Leishmania", "ORGANISM", 175, 185], ["DC", "CELL", 190, 192], ["DC", "CELL_TYPE", 190, 192], ["the experimental conditions", "PROBLEM", 73, 100], ["strain", "PROBLEM", 138, 144]]], ["Since Leishmania spp. express highly polymorphic cell surface molecules, the DC response might vary according to the Leishmania species examined (Bennett et al., 2001; Flohe et al., 1998; Henri et al., 2002; Konecny et al., 1999; McDowell et al., 2002; von Stebut et al., 1998 von Stebut et al., , 2000 .", [["cell surface", "ANATOMY", 49, 61], ["DC", "ANATOMY", 77, 79], ["Leishmania spp", "ORGANISM", 6, 20], ["cell", "CELL", 49, 53], ["highly polymorphic cell surface molecules", "PROTEIN", 30, 71], ["DC", "CELL_TYPE", 77, 79], ["Leishmania spp", "PROBLEM", 6, 20], ["highly polymorphic cell surface molecules", "PROBLEM", 30, 71], ["Leishmania spp", "OBSERVATION", 6, 20], ["polymorphic cell", "OBSERVATION", 37, 53], ["surface molecules", "OBSERVATION", 54, 71]]], ["We have evaluated the ability of L. infantum to alter the maturation state of IMDDC.", [["L. infantum", "ORGANISM", 33, 44], ["IMDDC", "CANCER", 78, 83], ["L. infantum", "SPECIES", 33, 44], ["L. infantum", "SPECIES", 33, 44]]], ["Unlike LPS, L. infantum amastigotes, which bind to IMDDC via DC-SIGN, did not affect the cell surface expression of CD83, CD86 or MHC II, commonly considered as DC maturation parameters.", [["cell surface", "ANATOMY", 89, 101], ["DC", "ANATOMY", 161, 163], ["LPS", "CHEMICAL", 7, 10], ["LPS", "SIMPLE_CHEMICAL", 7, 10], ["L. infantum amastigotes", "ORGANISM", 12, 35], ["IMDDC", "GENE_OR_GENE_PRODUCT", 51, 56], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 61, 68], ["cell", "CELL", 89, 93], ["CD83", "GENE_OR_GENE_PRODUCT", 116, 120], ["CD86", "GENE_OR_GENE_PRODUCT", 122, 126], ["MHC II", "GENE_OR_GENE_PRODUCT", 130, 136], ["IMDDC", "PROTEIN", 51, 56], ["DC", "CELL_TYPE", 61, 63], ["SIGN", "PROTEIN", 64, 68], ["CD83", "PROTEIN", 116, 120], ["CD86", "PROTEIN", 122, 126], ["MHC II", "PROTEIN", 130, 136], ["DC", "CELL_TYPE", 161, 163], ["L. infantum", "SPECIES", 12, 23], ["L. infantum", "SPECIES", 12, 23], ["LPS", "PROBLEM", 7, 10], ["L. infantum amastigotes", "PROBLEM", 12, 35], ["CD83", "TEST", 116, 120]]], ["Therefore, our results suggest that non-opsonized L. infantum amastigotes are unable to induce IMDDC maturation, at least during a 48-hour period ( Fig. 2A) .", [["L. infantum amastigotes", "ORGANISM", 50, 73], ["IMDDC", "GENE_OR_GENE_PRODUCT", 95, 100], ["L. infantum", "SPECIES", 50, 61], ["L. infantum", "SPECIES", 50, 61], ["non-opsonized L. infantum amastigotes", "PROBLEM", 36, 73]]], ["Moreover, LPS induced maturation of IMDDCs infected with L. infantum amastigotes ( Fig. 2A) , indicating that the parasites do not inhibit the capacity of DCs to be matured by other pathogen-derived products.", [["IMDDCs", "ANATOMY", 36, 42], ["DCs", "ANATOMY", 155, 158], ["LPS", "CHEMICAL", 10, 13], ["LPS", "SIMPLE_CHEMICAL", 10, 13], ["IMDDCs", "PATHOLOGICAL_FORMATION", 36, 42], ["L. infantum amastigotes", "ORGANISM", 57, 80], ["Fig. 2A", "ORGANISM", 83, 90], ["DCs", "CELL", 155, 158], ["IMDDCs", "CELL_TYPE", 36, 42], ["DCs", "CELL_TYPE", 155, 158], ["L. infantum", "SPECIES", 57, 68], ["L. infantum", "SPECIES", 57, 68], ["IMDDCs infected", "PROBLEM", 36, 51], ["L. infantum amastigotes", "PROBLEM", 57, 80], ["the parasites", "PROBLEM", 110, 123], ["parasites", "OBSERVATION", 114, 123]]], ["The failure of IMDDC to mature in response to Leishmania capture and entry might represent a parasite strategy to avoid immunosurveillance and to allow their establishment and multiplication before the onset of immune responses.", [["IMDDC", "GENE_OR_GENE_PRODUCT", 15, 20], ["Leishmania", "ORGANISM", 46, 56], ["IMDDC", "PROTEIN", 15, 20], ["The failure of IMDDC", "PROBLEM", 0, 20], ["Leishmania capture", "PROBLEM", 46, 64], ["a parasite strategy", "TREATMENT", 91, 110], ["immunosurveillance", "TREATMENT", 120, 138], ["immune responses", "PROBLEM", 211, 227], ["failure", "OBSERVATION", 4, 11], ["Leishmania capture", "OBSERVATION", 46, 64]]], ["On the other hand, L. infantum amastigotes did not induce CCR7-directed IMDDC migration but Immature monocyte-derived DCs were prepared as previously described, left untreated or pre-treated 10 min at 25 1C with the blocking anti-DC-SIGN monoclonal antibody (Relloso et al., 2002) and incubated with CFSE-labeled parasites at a 1:5 ratio for 1 h at 35 1C.", [["IMDDC", "ANATOMY", 72, 77], ["monocyte", "ANATOMY", 101, 109], ["DCs", "ANATOMY", 118, 121], ["CFSE", "CHEMICAL", 300, 304], ["CFSE", "CHEMICAL", 300, 304], ["L. infantum", "ORGANISM", 19, 30], ["amastigotes", "ORGANISM", 31, 42], ["CCR7", "GENE_OR_GENE_PRODUCT", 58, 62], ["IMDDC", "CELL", 72, 77], ["monocyte", "CELL", 101, 109], ["DCs", "CELL", 118, 121], ["anti-DC-SIGN", "GENE_OR_GENE_PRODUCT", 225, 237], ["CFSE", "SIMPLE_CHEMICAL", 300, 304], ["parasites", "CELL", 313, 322], ["CCR7", "PROTEIN", 58, 62], ["Immature monocyte", "CELL_TYPE", 92, 109], ["DCs", "CELL_TYPE", 118, 121], ["anti-DC", "PROTEIN", 225, 232], ["SIGN monoclonal antibody", "PROTEIN", 233, 257], ["L. infantum", "SPECIES", 19, 30], ["L. infantum", "SPECIES", 19, 30], ["L. infantum amastigotes", "TEST", 19, 42], ["CCR7", "TEST", 58, 62], ["the blocking anti-DC", "TEST", 212, 232]]], ["Afterward, the percentage of cells with bound parasites was quantified by flow cytometry and the contribution of DC-SIGN (%) was calculated as: 100\u00c0((% MR-1treated cells with bound parasites \u00c2 100)/% untreated cell with bound parasites).DC-SIGN ligands on Leishmania:inhibited the CCR7-dependent migration induced upon LPS maturation (Fig. 2B) .", [["cells", "ANATOMY", 29, 34], ["DC", "ANATOMY", 113, 115], ["cells", "ANATOMY", 164, 169], ["cell", "ANATOMY", 210, 214], ["LPS", "CHEMICAL", 319, 322], ["cells", "CELL", 29, 34], ["parasites", "CELL", 46, 55], ["cells", "CELL", 164, 169], ["cell", "CELL", 210, 214], ["Leishmania", "ORGANISM", 256, 266], ["CCR7", "GENE_OR_GENE_PRODUCT", 281, 285], ["LPS", "SIMPLE_CHEMICAL", 319, 322], ["DC", "CELL_TYPE", 113, 115], ["SIGN", "PROTEIN", 116, 120], ["MR", "PROTEIN", 152, 154], ["DC", "CELL_TYPE", 237, 239], ["CCR7", "PROTEIN", 281, 285], ["bound parasites", "PROBLEM", 40, 55], ["flow cytometry", "TEST", 74, 88], ["MR", "TEST", 152, 154], ["bound parasites", "TEST", 175, 190], ["bound parasites", "PROBLEM", 220, 235], ["Leishmania", "PROBLEM", 256, 266], ["the CCR7", "PROBLEM", 277, 285], ["dependent migration", "PROBLEM", 286, 305], ["LPS maturation", "TREATMENT", 319, 333], ["bound parasites", "OBSERVATION", 40, 55], ["Leishmania", "OBSERVATION", 256, 266], ["CCR7", "ANATOMY", 281, 285], ["dependent", "OBSERVATION_MODIFIER", 286, 295], ["migration", "OBSERVATION", 296, 305]]], ["These data are in agreement with previous results demonstrating that cytokines abundantly produced during Leishmania infection (e.g., IL-10) down-regulate CCR7 expression (Antoine et al., 2004) .", [["Leishmania infection", "DISEASE", 106, 126], ["Leishmania", "ORGANISM", 106, 116], ["IL-10", "GENE_OR_GENE_PRODUCT", 134, 139], ["CCR7", "GENE_OR_GENE_PRODUCT", 155, 159], ["cytokines", "PROTEIN", 69, 78], ["CCR7", "PROTEIN", 155, 159], ["cytokines", "PROBLEM", 69, 78], ["Leishmania infection", "PROBLEM", 106, 126], ["IL", "TEST", 134, 136], ["Leishmania infection", "OBSERVATION", 106, 126], ["CCR7", "ANATOMY", 155, 159]]], ["Therefore, Leishmania might prevent the establishment of T cell-mediated immunity by interfering with the migratory properties of DCs.", [["T cell", "ANATOMY", 57, 63], ["DCs", "ANATOMY", 130, 133], ["Leishmania", "ORGANISM", 11, 21], ["T cell", "CELL", 57, 63], ["DCs", "CELL", 130, 133], ["DCs", "CELL_TYPE", 130, 133], ["Leishmania", "PROBLEM", 11, 21], ["T cell-mediated immunity", "TREATMENT", 57, 81], ["Leishmania", "OBSERVATION", 11, 21]]], ["L-SIGN: a receptor implicated in VL: L-SIGN is a close homologue of DC-SIGN (77% amino acid sequence identity) that is expressed on human liver and lymph node sinusoidal endothelial cells (Soilleux et al., 2000) .", [["DC", "ANATOMY", 68, 70], ["liver", "ANATOMY", 138, 143], ["lymph node sinusoidal endothelial cells", "ANATOMY", 148, 187], ["amino acid", "CHEMICAL", 81, 91], ["amino acid", "CHEMICAL", 81, 91], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 0, 6], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 37, 43], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 68, 75], ["amino acid", "AMINO_ACID", 81, 91], ["human", "ORGANISM", 132, 137], ["liver", "ORGAN", 138, 143], ["lymph node sinusoidal endothelial cells", "CELL", 148, 187], ["SIGN", "PROTEIN", 2, 6], ["VL: L-SIGN", "PROTEIN", 33, 43], ["DC", "CELL_TYPE", 68, 70], ["SIGN", "PROTEIN", 71, 75], ["human liver and lymph node sinusoidal endothelial cells", "CELL_TYPE", 132, 187], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["amino acid sequence identity", "TEST", 81, 109], ["VL", "ANATOMY", 33, 35], ["liver", "ANATOMY", 138, 143], ["lymph node", "OBSERVATION", 148, 158], ["sinusoidal endothelial cells", "OBSERVATION", 159, 187]]], ["Like DC-SIGN, L-SIGN recognizes and binds high-mannose glycans, binds to ICAM-3 (Bashirova et al., 2001) , and recognizes carbohydrate structures on pathogens such as ManLAM on M. tuberculosis (Koppel et al., 2004) and high-mannose moieties on HIV-1, HCV and Ebola.", [["DC", "ANATOMY", 5, 7], ["HIV-1, HCV and Ebola", "DISEASE", 244, 264], ["mannose", "CHEMICAL", 47, 54], ["carbohydrate", "CHEMICAL", 122, 134], ["mannose", "CHEMICAL", 224, 231], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 5, 12], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 14, 20], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 73, 79], ["ManLAM", "SIMPLE_CHEMICAL", 167, 173], ["M. tuberculosis", "ORGANISM", 177, 192], ["high-mannose moieties", "SIMPLE_CHEMICAL", 219, 240], ["HIV-1", "ORGANISM", 244, 249], ["HCV", "ORGANISM", 251, 254], ["Ebola", "ORGANISM", 259, 264], ["DC", "CELL_TYPE", 5, 7], ["SIGN", "PROTEIN", 8, 12], ["L", "PROTEIN", 14, 15], ["SIGN", "PROTEIN", 16, 20], ["ICAM", "PROTEIN", 73, 77], ["M. tuberculosis", "SPECIES", 177, 192], ["HIV-1", "SPECIES", 244, 249], ["Ebola", "SPECIES", 259, 264], ["M. tuberculosis", "SPECIES", 177, 192], ["HIV-1", "SPECIES", 244, 249], ["HCV", "SPECIES", 251, 254], ["ICAM", "TEST", 73, 77], ["pathogens", "PROBLEM", 149, 158], ["high-mannose moieties", "PROBLEM", 219, 240], ["HCV", "PROBLEM", 251, 254], ["Ebola", "PROBLEM", 259, 264], ["Ebola", "OBSERVATION", 259, 264]]], ["Besides, L-SIGN has been described as a receptor for severe acute respiratory syndrome coronavirus (Jeffers et al., 2004) .", [["L-SIGN", "CHEMICAL", 9, 15], ["acute respiratory syndrome coronavirus", "DISEASE", 60, 98], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 9, 15], ["L-SIGN", "PROTEIN", 9, 15], ["severe acute respiratory syndrome coronavirus", "SPECIES", 53, 98], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 53, 98], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86]]], ["Unlike DC-SIGN, L-SIGN does not bind to the fucose-containing Lewis x antigens, suggesting that L-SIGN-expressing liver endothelial cells and lymph node are not involved in capture and internalization of Lewis x -containing pathogens such as H. pylori and S. mansoni (Van Liempt et al., 2004) .", [["DC", "ANATOMY", 7, 9], ["liver endothelial cells", "ANATOMY", 114, 137], ["lymph node", "ANATOMY", 142, 152], ["L-SIGN", "CHEMICAL", 16, 22], ["fucose", "CHEMICAL", 44, 50], ["DC-SIGN", "SIMPLE_CHEMICAL", 7, 14], ["L-SIGN", "SIMPLE_CHEMICAL", 16, 22], ["fucose", "SIMPLE_CHEMICAL", 44, 50], ["Lewis x antigens", "GENE_OR_GENE_PRODUCT", 62, 78], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 96, 102], ["liver endothelial cells", "CELL", 114, 137], ["lymph node", "MULTI-TISSUE_STRUCTURE", 142, 152], ["H. pylori", "ORGANISM", 242, 251], ["S. mansoni", "ORGANISM", 256, 266], ["DC", "CELL_TYPE", 7, 9], ["SIGN", "PROTEIN", 10, 14], ["SIGN", "PROTEIN", 18, 22], ["fucose-containing Lewis x antigens", "PROTEIN", 44, 78], ["L-SIGN", "PROTEIN", 96, 102], ["liver endothelial cells", "CELL_TYPE", 114, 137], ["H. pylori", "SPECIES", 242, 251], ["S. mansoni", "SPECIES", 256, 266], ["H. pylori", "SPECIES", 242, 251], ["S. mansoni", "SPECIES", 256, 266], ["L-SIGN", "TEST", 96, 102], ["liver endothelial cells", "PROBLEM", 114, 137], ["lymph node", "PROBLEM", 142, 152], ["pathogens", "PROBLEM", 224, 233], ["H. pylori", "PROBLEM", 242, 251], ["liver", "ANATOMY", 114, 119], ["endothelial cells", "OBSERVATION", 120, 137], ["lymph node", "OBSERVATION", 142, 152]]], ["Besides, binding to L-SIGN is not reversible at low pH, suggesting that L-SIGN does not release internalized ligand in low-pH vesicles and that L-SIGN is degraded upon internalization (Guo et al., 2004) .", [["L-SIGN", "CHEMICAL", 20, 26], ["L-SIGN", "CHEMICAL", 72, 78], ["L-SIGN", "SIMPLE_CHEMICAL", 20, 26], ["L-SIGN", "SIMPLE_CHEMICAL", 72, 78], ["vesicles", "CELLULAR_COMPONENT", 126, 134], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 144, 150], ["L-SIGN", "PROTEIN", 20, 26], ["SIGN", "PROTEIN", 74, 78], ["L-SIGN", "PROTEIN", 144, 150], ["reversible at low pH", "PROBLEM", 34, 54], ["pH vesicles", "OBSERVATION", 123, 134]]], ["Because of their similar ligand specificity but differential tissue location, we have compared the capacity of DC-SIGN and L-SIGN to bind axenic amastigotes from L. pifanoi (responsible for CL), and L. infantum (responsible for VL).", [["tissue", "ANATOMY", 61, 67], ["DC", "ANATOMY", 111, 113], ["CL", "ANATOMY", 190, 192], ["tissue", "TISSUE", 61, 67], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 111, 118], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 123, 129], ["L. pifanoi", "ORGANISM", 162, 172], ["CL", "MULTI-TISSUE_STRUCTURE", 190, 192], ["L. infantum", "ORGANISM", 199, 210], ["DC", "CELL_TYPE", 111, 113], ["SIGN", "PROTEIN", 114, 118], ["SIGN", "PROTEIN", 125, 129], ["L. pifanoi", "SPECIES", 162, 172], ["L. infantum", "SPECIES", 199, 210], ["L. pifanoi", "SPECIES", 162, 172], ["L. infantum", "SPECIES", 199, 210], ["bind axenic amastigotes", "PROBLEM", 133, 156], ["L. pifanoi", "PROBLEM", 162, 172], ["L. infantum", "PROBLEM", 199, 210]]], ["Binding experiments with Jurkat cells stably transfected with DC-SIGN or L-SIGN indicated that L. infantum amastigotes specifically bound to both DC-SIGN and L-SIGN, whereas L. pifanoi amastigotes were unable to bind to L-SIGN (Fig. 3) .", [["Jurkat cells", "ANATOMY", 25, 37], ["DC", "ANATOMY", 62, 64], ["DC", "ANATOMY", 146, 148], ["L-SIGN", "CHEMICAL", 220, 226], ["Jurkat cells", "CELL", 25, 37], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 62, 69], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 73, 79], ["L. infantum amastigotes", "ORGANISM", 95, 118], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 146, 153], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 158, 164], ["L. pifanoi amastigotes", "ORGANISM", 174, 196], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 220, 226], ["Jurkat cells", "CELL_LINE", 25, 37], ["DC", "CELL_TYPE", 62, 64], ["SIGN", "PROTEIN", 65, 69], ["L-SIGN", "PROTEIN", 73, 79], ["DC", "CELL_TYPE", 146, 148], ["SIGN", "DNA", 222, 226], ["L. infantum", "SPECIES", 95, 106], ["L. pifanoi", "SPECIES", 174, 184], ["L. infantum", "SPECIES", 95, 106], ["L. pifanoi", "SPECIES", 174, 184], ["Jurkat cells", "PROBLEM", 25, 37], ["L-SIGN", "TEST", 73, 79], ["L. infantum amastigotes", "PROBLEM", 95, 118]]], ["Therefore, only VL-causing parasites (L. infantum) appear to be recognized by L-SIGN.", [["VL-causing parasites", "ORGANISM", 16, 36], ["L. infantum", "ORGANISM", 38, 49], ["L-SIGN", "PROTEIN", 78, 84], ["L. infantum", "SPECIES", 38, 49], ["L. infantum", "SPECIES", 38, 49], ["VL", "TEST", 16, 18], ["parasites", "PROBLEM", 27, 36], ["VL", "ANATOMY", 16, 18], ["parasites", "OBSERVATION", 27, 36]]], ["These results suggest that L-SIGN recognition of the distinct Leishmania species might play a role in the outcome of the parasite infection (CL vs. VL).ARTICLE IN PRESSTo further evaluate the relevance of L-SIGN in binding of Leishmania species causing VL, human hepatic sinusoidal endothelial cells (HSEC) were isolated from hepatic surgery donors, using a modification (In\u02dcigo Martinez and Fernando Vidal-Vanaclocha, unpublished information) of previously described isolation procedures (Daneker et al., 1998; Heuff et al., 1994) .", [["hepatic sinusoidal endothelial cells", "ANATOMY", 263, 299], ["HSEC", "ANATOMY", 301, 305], ["hepatic", "ANATOMY", 326, 333], ["parasite infection", "DISEASE", 121, 139], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 27, 33], ["Leishmania species", "ORGANISM", 62, 80], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 205, 211], ["Leishmania species", "ORGANISM", 226, 244], ["human", "ORGANISM", 257, 262], ["hepatic sinusoidal endothelial cells", "CELL", 263, 299], ["HSEC", "CELL", 301, 305], ["hepatic", "ORGAN", 326, 333], ["donors", "ORGANISM", 342, 348], ["L-SIGN", "PROTEIN", 27, 33], ["L-SIGN", "PROTEIN", 205, 211], ["human hepatic sinusoidal endothelial cells", "CELL_TYPE", 257, 299], ["HSEC", "CELL_TYPE", 301, 305], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 257, 262], ["the distinct Leishmania species", "PROBLEM", 49, 80], ["the parasite infection", "PROBLEM", 117, 139], ["Leishmania species", "PROBLEM", 226, 244], ["VL", "PROBLEM", 253, 255], ["human hepatic sinusoidal endothelial cells", "PROBLEM", 257, 299], ["hepatic surgery donors", "TREATMENT", 326, 348], ["a modification (In\u02dcigo Martinez", "TREATMENT", 356, 387], ["distinct", "OBSERVATION_MODIFIER", 53, 61], ["Leishmania species", "OBSERVATION", 62, 80], ["parasite", "OBSERVATION_MODIFIER", 121, 129], ["infection", "OBSERVATION", 130, 139], ["Leishmania species", "OBSERVATION", 226, 244], ["hepatic", "ANATOMY", 263, 270], ["sinusoidal", "ANATOMY_MODIFIER", 271, 281], ["endothelial cells", "OBSERVATION", 282, 299], ["hepatic", "ANATOMY", 326, 333], ["surgery", "OBSERVATION", 334, 341]]], ["Incubation of HSEC with axenic amastigotes showed that L. infantum amastigotes bound strongly to HSEC, whereas no binding was observed with L. pifanoi amastigotes (Fig. 4) .", [["HSEC", "ANATOMY", 14, 18], ["HSEC", "ANATOMY", 97, 101], ["HSEC", "CELL", 14, 18], ["L. infantum", "ORGANISM", 55, 66], ["amastigotes", "ORGANISM", 67, 78], ["HSEC", "GENE_OR_GENE_PRODUCT", 97, 101], ["L. pifanoi amastigotes", "ORGANISM", 140, 162], ["HSEC", "CELL_TYPE", 14, 18], ["HSEC", "PROTEIN", 97, 101], ["L. infantum", "SPECIES", 55, 66], ["L. pifanoi", "SPECIES", 140, 150], ["L. infantum", "SPECIES", 55, 66], ["L. pifanoi", "SPECIES", 140, 150], ["axenic amastigotes", "TEST", 24, 42], ["L. infantum amastigotes bound", "PROBLEM", 55, 84]]], ["In addition, the HSEC-L. infantum (Alvarez et al., 2002) were left untreated or pretreated with receptor-specific blocking antibodies, and then incubated at 35 1C with the indicated CFSE-labeled parasites (1:5 cell:parasite ratio), or left uninfected (Colmenares et al., 2002) .", [["cell", "ANATOMY", 210, 214], ["CFSE", "CHEMICAL", 182, 186], ["CFSE", "CHEMICAL", 182, 186], ["HSEC-L. infantum", "ORGANISM", 17, 33], ["CFSE", "SIMPLE_CHEMICAL", 182, 186], ["parasites", "CELL", 195, 204], ["cell", "CELL", 210, 214], ["receptor-specific blocking antibodies", "PROTEIN", 96, 133], ["L. infantum", "SPECIES", 22, 33], ["L. infantum", "SPECIES", 22, 33], ["the HSEC", "TEST", 13, 21], ["receptor-specific blocking antibodies", "TREATMENT", 96, 133], ["parasite ratio", "TEST", 215, 229], ["left", "ANATOMY_MODIFIER", 62, 66], ["left", "ANATOMY_MODIFIER", 235, 239]]], ["The percentage of cells with bound parasites was quantified by flow cytometry.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["parasites", "CELL", 35, 44], ["bound parasites", "PROBLEM", 29, 44], ["flow cytometry", "TEST", 63, 77], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["bound parasites", "OBSERVATION", 29, 44], ["flow cytometry", "OBSERVATION", 63, 77]]], ["Three independent experiments were performed with similar results, and a representative experiment is shown. amastigote interaction was reduced in the presence of a blocking monoclonal antibody against L-SIGN (Fig. 4) .", [["L-SIGN", "GENE_OR_GENE_PRODUCT", 202, 208], ["monoclonal antibody", "PROTEIN", 174, 193], ["SIGN", "PROTEIN", 204, 208], ["amastigote interaction", "PROBLEM", 109, 131], ["a blocking monoclonal antibody", "TEST", 163, 193]]], ["These results confirmed the ability of VL-causing amastigotes to interact with L-SIGN.", [["VL", "ORGANISM", 39, 41], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 79, 85], ["L-SIGN", "PROTEIN", 79, 85], ["amastigotes", "PROBLEM", 50, 61]]], ["Given the mechanism described for the hepatitis C virus (Cormier et al., 2004) , it is tempting to speculate that L-SIGNmediated capture of L. infantum by HSEC could result in transinfection of Kupffer cells, which are the final targets of VL-causing Leishmania parasites (el Hag et al., 1994; Murray, 2001) .Concluding remarksTaken together, the present work demonstrates that the C-type lectins DC-SIGN and L-SIGN are broad Leishmania receptors that differentially bind the distinct infective forms and species of the parasite.", [["Kupffer cells", "ANATOMY", 194, 207], ["hepatitis C", "DISEASE", 38, 49], ["HSEC", "CHEMICAL", 155, 159], ["Leishmania parasites", "DISEASE", 251, 271], ["hepatitis C virus", "ORGANISM", 38, 55], ["L. infantum", "ORGANISM", 140, 151], ["HSEC", "GENE_OR_GENE_PRODUCT", 155, 159], ["Kupffer cells", "CELL", 194, 207], ["VL", "ORGANISM", 240, 242], ["Leishmania", "ORGANISM", 251, 261], ["parasites", "ORGANISM", 262, 271], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 397, 404], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 409, 415], ["Kupffer cells", "CELL_TYPE", 194, 207], ["C-type lectins", "PROTEIN", 382, 396], ["DC", "PROTEIN", 397, 399], ["SIGN", "PROTEIN", 400, 404], ["L", "PROTEIN", 409, 410], ["SIGN", "PROTEIN", 411, 415], ["Leishmania receptors", "PROTEIN", 426, 446], ["hepatitis C virus", "SPECIES", 38, 55], ["L. infantum", "SPECIES", 140, 151], ["hepatitis C virus", "SPECIES", 38, 55], ["L. infantum", "SPECIES", 140, 151], ["the hepatitis C virus", "PROBLEM", 34, 55], ["L. infantum", "PROBLEM", 140, 151], ["transinfection of Kupffer cells", "PROBLEM", 176, 207], ["VL", "TEST", 240, 242], ["Leishmania parasites", "PROBLEM", 251, 271], ["broad Leishmania receptors", "PROBLEM", 420, 446], ["the distinct infective forms", "PROBLEM", 472, 500], ["Kupffer cells", "OBSERVATION", 194, 207], ["Leishmania parasites", "OBSERVATION", 251, 271], ["broad", "OBSERVATION_MODIFIER", 420, 425], ["Leishmania", "OBSERVATION", 426, 436], ["distinct", "OBSERVATION_MODIFIER", 476, 484], ["infective", "OBSERVATION", 485, 494]]], ["A deeper knowledge of the Leishmania-DC/L-SIGN interactions, and the subsequent immune consequences, may pave the way for the design of new therapeutic approaches against leishmaniasis.", [["DC", "ANATOMY", 37, 39], ["leishmaniasis", "DISEASE", 171, 184], ["Leishmania", "ORGANISM", 26, 36], ["DC", "CELL", 37, 39], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 40, 46], ["the Leishmania", "TEST", 22, 36], ["leishmaniasis", "PROBLEM", 171, 184], ["Leishmania", "OBSERVATION", 26, 36]]], ["The recent description that macrophage treated with IL-4 (alternatively activated macrophages) also express DC-SIGN (Puig-Kroger et al., 2004) could be of major importance, due to the fact that the expression of this cytokine correlates with the pathology of the disease, and hence increases the potential relevance of these C-type lectins in leishmaniasis.", [["macrophage", "ANATOMY", 28, 38], ["macrophages", "ANATOMY", 82, 93], ["DC", "ANATOMY", 108, 110], ["leishmaniasis", "DISEASE", 343, 356], ["macrophage", "CELL", 28, 38], ["IL-4", "GENE_OR_GENE_PRODUCT", 52, 56], ["macrophages", "CELL", 82, 93], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 325, 339], ["IL-4", "PROTEIN", 52, 56], ["activated macrophages", "CELL_TYPE", 72, 93], ["DC", "CELL_TYPE", 108, 110], ["cytokine", "PROTEIN", 217, 225], ["C-type lectins", "PROTEIN", 325, 339], ["IL", "TREATMENT", 52, 54], ["the disease", "PROBLEM", 259, 270], ["these C-type lectins in leishmaniasis", "PROBLEM", 319, 356], ["disease", "OBSERVATION", 263, 270], ["leishmaniasis", "OBSERVATION", 343, 356]]], ["L. infantum binding to hepatic sinusoidal endothelial cells (HSEC) is partially mediated by L-SIGN.", [["hepatic sinusoidal endothelial cells", "ANATOMY", 23, 59], ["HSEC", "ANATOMY", 61, 65], ["L.", "CHEMICAL", 0, 2], ["infantum", "ORGANISM", 3, 11], ["hepatic sinusoidal endothelial cells", "CELL", 23, 59], ["HSEC", "CELL", 61, 65], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 92, 98], ["hepatic sinusoidal endothelial cells", "CELL_TYPE", 23, 59], ["HSEC", "CELL_TYPE", 61, 65], ["L-SIGN", "PROTEIN", 92, 98], ["L.", "SPECIES", 0, 2], ["infantum", "SPECIES", 3, 11], ["L.", "SPECIES", 0, 2], ["infantum", "SPECIES", 3, 11], ["infantum binding", "PROBLEM", 3, 19], ["hepatic sinusoidal endothelial cells", "TEST", 23, 59], ["hepatic", "ANATOMY", 23, 30], ["sinusoidal endothelial cells", "OBSERVATION", 31, 59]]], ["Human HSEC were isolated from liver biopsies, and subjected to binding assays with L. pifanoi or L. infantum axenic amastigotes, as described (Colmenares et al., 2002) .", [["HSEC", "ANATOMY", 6, 10], ["liver biopsies", "ANATOMY", 30, 44], ["Human", "ORGANISM", 0, 5], ["HSEC", "CELL", 6, 10], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 30, 44], ["L. pifanoi", "ORGANISM", 83, 93], ["L. infantum", "ORGANISM", 97, 108], ["Human HSEC", "CELL_TYPE", 0, 10], ["Human", "SPECIES", 0, 5], ["L. pifanoi", "SPECIES", 83, 93], ["L. infantum", "SPECIES", 97, 108], ["Human", "SPECIES", 0, 5], ["L. pifanoi", "SPECIES", 83, 93], ["L. infantum", "SPECIES", 97, 108], ["Human HSEC", "TEST", 0, 10], ["liver biopsies", "TEST", 30, 44], ["L. infantum axenic amastigotes", "PROBLEM", 97, 127], ["liver", "ANATOMY", 30, 35], ["biopsies", "OBSERVATION", 36, 44], ["axenic amastigotes", "OBSERVATION", 109, 127]]], ["After incubation and washing, cells were photographed (HSEC, hepatic sinusoidal endothelial cells; K, Kupffer cells).", [["cells", "ANATOMY", 30, 35], ["HSEC", "ANATOMY", 55, 59], ["hepatic sinusoidal endothelial cells", "ANATOMY", 61, 97], ["Kupffer cells", "ANATOMY", 102, 115], ["cells", "CELL", 30, 35], ["HSEC", "CELL", 55, 59], ["hepatic sinusoidal endothelial cells", "CELL", 61, 97], ["K", "CELL", 99, 100], ["Kupffer cells", "CELL", 102, 115], ["HSEC", "CELL_TYPE", 55, 59], ["hepatic sinusoidal endothelial cells", "CELL_TYPE", 61, 97], ["Kupffer cells", "CELL_TYPE", 102, 115], ["washing", "TREATMENT", 21, 28], ["cells", "TEST", 30, 35], ["HSEC", "TEST", 55, 59], ["K", "TEST", 99, 100], ["hepatic", "ANATOMY", 61, 68], ["sinusoidal", "ANATOMY_MODIFIER", 69, 79], ["endothelial cells", "ANATOMY", 80, 97]]]], "PMC7392413": [["The StudyWe searched 3 major databases\u2014MEDLINE/PubMed, EMBASE, and CENTRAL (Cochrane Central Register of Controlled Trials)\u2014for clinical studies published December 1, 2019, through March 28, 2020.", [["clinical studies", "TEST", 128, 144]]], ["To broadly identify studies detailing lymphocyte and leukocyte testing among patients with COVID-19, we used the following search criteria: \u201c(COVID-19 OR SARS-CoV-2 OR 2019-NCoV OR HCov-19 OR novel coronavirus) AND (laboratory OR WBC OR lymphocyte).\u201d", [["lymphocyte", "ANATOMY", 38, 48], ["leukocyte", "ANATOMY", 53, 62], ["lymphocyte", "ANATOMY", 237, 247], ["lymphocyte", "CELL", 38, 48], ["leukocyte", "CELL", 53, 62], ["patients", "ORGANISM", 77, 85], ["lymphocyte", "CELL", 237, 247], ["patients", "SPECIES", 77, 85], ["lymphocyte", "TEST", 38, 48], ["leukocyte testing", "TEST", 53, 70], ["COVID", "TEST", 91, 96], ["COVID", "TEST", 142, 147], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["HCov", "TEST", 181, 185], ["WBC", "TEST", 230, 233]]], ["We prioritized studies that measured lymphocyte and leukocyte counts among patients who had severe or critical cases versus those with mild cases.", [["lymphocyte", "ANATOMY", 37, 47], ["leukocyte", "ANATOMY", 52, 61], ["lymphocyte", "CELL", 37, 47], ["leukocyte", "CELL", 52, 61], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["prioritized studies", "TEST", 3, 22], ["lymphocyte", "TEST", 37, 47], ["leukocyte counts", "TEST", 52, 68], ["mild cases", "PROBLEM", 135, 145], ["mild", "OBSERVATION_MODIFIER", 135, 139]]], ["Severe cases were defined as significant respiratory distress (acute hypoxic respiratory failure, acute respiratory distress syndrome, need for mechanical ventilation, or intensive care unit admission) caused by COVID-19.The StudyOur meta-analysis included articles about studies and clinical trials that met the following 4 inclusion criteria: 1) involved adult, human patients; 2) written in English; 3) reported lymphocyte and leukocyte counts for patients; and 4) compared patients with severe versus mild illness.", [["respiratory", "ANATOMY", 41, 52], ["respiratory", "ANATOMY", 77, 88], ["respiratory", "ANATOMY", 104, 115], ["lymphocyte", "ANATOMY", 415, 425], ["leukocyte", "ANATOMY", 430, 439], ["respiratory distress", "DISEASE", 41, 61], ["hypoxic respiratory failure", "DISEASE", 69, 96], ["acute respiratory distress syndrome", "DISEASE", 98, 133], ["COVID-19", "CHEMICAL", 212, 220], ["COVID-19", "CHEMICAL", 212, 220], ["human", "ORGANISM", 364, 369], ["patients", "ORGANISM", 370, 378], ["lymphocyte", "CELL", 415, 425], ["leukocyte", "CELL", 430, 439], ["patients", "ORGANISM", 451, 459], ["patients", "ORGANISM", 477, 485], ["human", "SPECIES", 364, 369], ["patients", "SPECIES", 370, 378], ["patients", "SPECIES", 451, 459], ["patients", "SPECIES", 477, 485], ["human", "SPECIES", 364, 369], ["Severe cases", "PROBLEM", 0, 12], ["significant respiratory distress", "PROBLEM", 29, 61], ["acute hypoxic respiratory failure", "PROBLEM", 63, 96], ["acute respiratory distress syndrome", "PROBLEM", 98, 133], ["mechanical ventilation", "TREATMENT", 144, 166], ["COVID", "TEST", 212, 217], ["studies", "TEST", 272, 279], ["clinical trials", "TEST", 284, 299], ["lymphocyte", "TEST", 415, 425], ["leukocyte counts", "TEST", 430, 446], ["severe versus mild illness", "PROBLEM", 491, 517], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["respiratory distress", "OBSERVATION", 41, 61], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["hypoxic", "OBSERVATION_MODIFIER", 69, 76], ["respiratory failure", "OBSERVATION", 77, 96], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["respiratory distress", "OBSERVATION", 104, 124], ["mild", "OBSERVATION_MODIFIER", 505, 509], ["illness", "OBSERVATION", 510, 517]]], ["Our meta-analysis excluded articles about studies with the following 9 characteristics: 1) involved nonhuman subjects; 2) written in a language other than English; 3) were not a clinical trial, such as a review paper or letter; 4) were out of the scope of the study question detailed above; 5) did not provide raw data to perform quantitative meta-analysis; 6) involved pediatric patients; 7) did not have the full article available; 8) were duplicates; and 9) were ongoing or not completed.The StudyWe performed the meta-analysis by using Review Manager software version 5.3 (The Cochrane Collaboration, https://training.cochrane.org).", [["patients", "ORGANISM", 380, 388], ["patients", "SPECIES", 380, 388], ["Our meta-analysis", "TEST", 0, 17], ["the study", "TEST", 256, 265]]], ["We calculated mean differences (MDs) between groups for continuous variables and reported 95% CIs for both severe and nonsevere cases.", [["both severe and nonsevere cases", "PROBLEM", 102, 133], ["mean", "OBSERVATION_MODIFIER", 14, 18]]], ["If the included studies provided medians and interquartile ranges instead of MDs and SDs, we imputed the MDs and SDs as described previously (4\u20136) and additionally described in the Cochrane Handbook for Systematic Reviews (7).", [["MDs", "PROBLEM", 77, 80], ["SDs", "PROBLEM", 85, 88], ["the MDs", "PROBLEM", 101, 108], ["SDs", "PROBLEM", 113, 116], ["MDs", "OBSERVATION", 105, 108]]], ["We assessed statistical heterogeneity by using the I2 statistic and awarded the following values: 0%\u201324%, homogeneity; 25%\u201349%, mild heterogeneity; 50%\u201374%, moderate heterogeneity; and >75%, high heterogeneity.", [["homogeneity", "TEST", 106, 117], ["mild heterogeneity", "PROBLEM", 128, 146], ["\u2013", "TEST", 151, 152], ["moderate heterogeneity", "PROBLEM", 157, 179], ["high heterogeneity", "PROBLEM", 191, 209], ["mild", "OBSERVATION_MODIFIER", 128, 132], ["heterogeneity", "OBSERVATION", 133, 146], ["moderate", "OBSERVATION_MODIFIER", 157, 165], ["heterogeneity", "OBSERVATION", 166, 179], ["high heterogeneity", "OBSERVATION", 191, 209]]], ["If moderate to high heterogeneity was present (I2>50%), then we used the random effects model to pool the effect sizes of included studies and subgroup analyses.The StudyWe identified 959 articles; among them, 318 were duplicates.", [["moderate to high heterogeneity", "PROBLEM", 3, 33], ["I2", "TEST", 47, 49], ["studies", "TEST", 131, 138], ["subgroup analyses", "TEST", 143, 160], ["The StudyWe", "TEST", 161, 172], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["high", "OBSERVATION_MODIFIER", 15, 19], ["heterogeneity", "OBSERVATION", 20, 33]]], ["We assessed 59 articles as eligible (included patient-level clinical data) and identified 8 studies (included lymphocyte counts and stratification of illness severity) for the quantitative synthesis (Appendix Table).", [["lymphocyte", "ANATOMY", 110, 120], ["illness", "DISEASE", 150, 157], ["patient", "ORGANISM", 46, 53], ["lymphocyte", "CELL", 110, 120], ["patient", "SPECIES", 46, 53], ["8 studies", "TEST", 90, 99], ["lymphocyte counts", "TEST", 110, 127], ["illness severity", "PROBLEM", 150, 166]]], ["These studies described 1,289 cases of COVID-19, of which 592 (45.9%) were classified as severe.The StudyWe compared lymphocyte and leukocyte counts in patients with severe/critical versus mild cases of COIVD-19 (Appendix Figure).", [["lymphocyte", "ANATOMY", 117, 127], ["leukocyte", "ANATOMY", 132, 141], ["lymphocyte", "CELL", 117, 127], ["leukocyte", "CELL", 132, 141], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["These studies", "TEST", 0, 13], ["COVID", "TEST", 39, 44], ["The StudyWe", "TEST", 96, 107], ["lymphocyte", "TEST", 117, 127], ["leukocyte counts", "TEST", 132, 148], ["severe/critical versus mild cases of COIVD", "PROBLEM", 166, 208], ["severe", "OBSERVATION_MODIFIER", 89, 95]]], ["All laboratory data were captured at the time of patient admission.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["All laboratory data", "TEST", 0, 19]]], ["Overall, patients categorized as having severe illness tended to have lower lymphocyte counts (pooled MD \u22120.36, 95% CI \u22120.50 to \u22120.22; p<0.00001) and higher leukocyte counts (pooled MD 1.32, 95% CI 0.62 to 2.02; p<0.00001).", [["lymphocyte", "ANATOMY", 76, 86], ["leukocyte", "ANATOMY", 157, 166], ["patients", "ORGANISM", 9, 17], ["lymphocyte", "CELL", 76, 86], ["leukocyte", "CELL", 157, 166], ["patients", "SPECIES", 9, 17], ["severe illness", "PROBLEM", 40, 54], ["lower lymphocyte counts", "PROBLEM", 70, 93], ["CI", "TEST", 116, 118], ["higher leukocyte counts", "PROBLEM", 150, 173], ["CI", "TEST", 195, 197], ["p", "TEST", 212, 213], ["lower lymphocyte", "ANATOMY", 70, 86]]], ["Fan et al. reported an absolute lymphocyte count of >1.0 \u00d7 109 cells/L for 39/58 (69.6%) patients in the nonsevere group and 2/9 (22.2%) patients in the severe group (8).", [["lymphocyte", "ANATOMY", 32, 42], ["cells", "ANATOMY", 63, 68], ["lymphocyte", "CELL", 32, 42], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 137, 145], ["an absolute lymphocyte count", "TEST", 20, 48], ["cells", "TEST", 63, 68], ["absolute lymphocyte count", "OBSERVATION", 23, 48], ["severe", "OBSERVATION_MODIFIER", 153, 159]]], ["Huang et al. reported an absolute lymphocyte count of <1 \u00d7 109 cells/L in 15/28 (54%) patients in the nonsevere group and 11/13 (83%) in the severe group (9).", [["lymphocyte", "ANATOMY", 34, 44], ["cells", "ANATOMY", 63, 68], ["lymphocyte", "CELL", 34, 44], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["an absolute lymphocyte count", "TEST", 22, 50], ["cells/L", "TEST", 63, 70], ["absolute lymphocyte count", "OBSERVATION", 25, 50], ["severe", "OBSERVATION_MODIFIER", 141, 147]]], ["Wan et al. reported an absolute lymphocyte count of <1.0 \u00d7 109 cells/L for 36/95 (38%) patients in the nonsevere group and 32/40 (80%) in the severe group (10).", [["lymphocyte", "ANATOMY", 32, 42], ["cells", "ANATOMY", 63, 68], ["lymphocyte", "CELL", 32, 42], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["an absolute lymphocyte count", "TEST", 20, 48], ["cells", "TEST", 63, 68], ["absolute lymphocyte count", "OBSERVATION", 23, 48], ["severe", "OBSERVATION_MODIFIER", 142, 148]]], ["Zhang et al. reported a decreased lymphocyte count for 28/82 (70.7%) patients in the nonsevere group and 46/56 (82.1%) in the severe group (11).ConclusionsPooled data across early studies validate a significant correlation between elevated leukocyte count and decreased lymphocyte count among patients with severe cases of COVID-19 compared with those with mild cases.", [["lymphocyte", "ANATOMY", 34, 44], ["leukocyte", "ANATOMY", 240, 249], ["lymphocyte", "ANATOMY", 270, 280], ["lymphocyte", "CELL", 34, 44], ["patients", "ORGANISM", 69, 77], ["leukocyte", "CELL", 240, 249], ["lymphocyte", "CELL", 270, 280], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 293, 301], ["a decreased lymphocyte count", "PROBLEM", 22, 50], ["early studies", "TEST", 174, 187], ["elevated leukocyte count", "PROBLEM", 231, 255], ["decreased lymphocyte count", "PROBLEM", 260, 286], ["COVID", "TEST", 323, 328], ["mild cases", "PROBLEM", 357, 367], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["lymphocyte count", "OBSERVATION", 34, 50], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["elevated", "OBSERVATION_MODIFIER", 231, 239], ["leukocyte count", "OBSERVATION", 240, 255], ["decreased", "OBSERVATION_MODIFIER", 260, 269], ["lymphocyte count", "OBSERVATION", 270, 286], ["severe", "OBSERVATION_MODIFIER", 307, 313], ["mild", "OBSERVATION_MODIFIER", 357, 361], ["cases", "OBSERVATION", 362, 367]]], ["Why lymphopenia is associated with severe illness remains unclear.", [["lymphopenia", "DISEASE", 4, 15], ["lymphopenia", "PROBLEM", 4, 15], ["severe illness", "PROBLEM", 35, 49], ["lymphopenia", "OBSERVATION", 4, 15], ["associated with", "UNCERTAINTY", 19, 34], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["illness", "OBSERVATION", 42, 49]]], ["It has been hypothesized that this association could result from direct lymphocyte infection, destruction of lymphatic tissue, inflammation leading to lymphocyte apoptosis, or inhibition of lymphocytes by metabolic disorders such as lactic acidosis (12).", [["lymphocyte", "ANATOMY", 72, 82], ["lymphatic tissue", "ANATOMY", 109, 125], ["lymphocyte", "ANATOMY", 151, 161], ["lymphocytes", "ANATOMY", 190, 201], ["infection", "DISEASE", 83, 92], ["inflammation", "DISEASE", 127, 139], ["metabolic disorders", "DISEASE", 205, 224], ["lactic acidosis", "DISEASE", 233, 248], ["lymphocyte", "CELL", 72, 82], ["lymphatic tissue", "TISSUE", 109, 125], ["lymphocyte", "CELL", 151, 161], ["lymphocytes", "CELL", 190, 201], ["lymphocytes", "CELL_TYPE", 190, 201], ["direct lymphocyte infection", "PROBLEM", 65, 92], ["destruction of lymphatic tissue", "PROBLEM", 94, 125], ["inflammation", "PROBLEM", 127, 139], ["lymphocyte apoptosis", "PROBLEM", 151, 171], ["inhibition of lymphocytes", "PROBLEM", 176, 201], ["metabolic disorders", "PROBLEM", 205, 224], ["lactic acidosis", "PROBLEM", 233, 248], ["lymphocyte infection", "OBSERVATION", 72, 92], ["lymphatic tissue", "OBSERVATION", 109, 125], ["inflammation", "OBSERVATION", 127, 139], ["lymphocyte apoptosis", "OBSERVATION", 151, 171], ["lactic acidosis", "OBSERVATION", 233, 248]]], ["Lymphopenia as a marker of severity does not seem to be specific to COVID-19; it has been used to prognosticate other viral pneumonias such as influenza (13).", [["Lymphopenia", "DISEASE", 0, 11], ["COVID-19", "CHEMICAL", 68, 76], ["pneumonias", "DISEASE", 124, 134], ["influenza", "DISEASE", 143, 152], ["Lymphopenia", "PROBLEM", 0, 11], ["COVID", "TEST", 68, 73], ["viral pneumonias", "PROBLEM", 118, 134], ["influenza", "PROBLEM", 143, 152], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["pneumonias", "OBSERVATION", 124, 134]]], ["Neutrophilia may be more specific to severe disease than leukocytosis, but neutrophil count was not uniformly reported across the studies included in our analysis.ConclusionsDespite our findings regarding clinical characteristics of severe COVID-19, our study had several limitations.", [["neutrophil", "ANATOMY", 75, 85], ["Neutrophilia", "DISEASE", 0, 12], ["leukocytosis", "DISEASE", 57, 69], ["COVID", "DISEASE", 240, 245], ["COVID-19", "CHEMICAL", 240, 248], ["neutrophil", "CELL", 75, 85], ["neutrophil", "CELL_TYPE", 75, 85], ["Neutrophilia", "PROBLEM", 0, 12], ["severe disease", "PROBLEM", 37, 51], ["leukocytosis", "PROBLEM", 57, 69], ["neutrophil count", "TEST", 75, 91], ["the studies", "TEST", 126, 137], ["our analysis", "TEST", 150, 162], ["severe COVID", "PROBLEM", 233, 245], ["our study", "TEST", 250, 259], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 44, 51], ["leukocytosis", "OBSERVATION", 57, 69], ["severe", "OBSERVATION_MODIFIER", 233, 239]]], ["First, our literature search found an expected paucity of data surrounding this topic because published characterizations of patients with COVID-19 remain minimal.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["our literature search", "TEST", 7, 28], ["COVID", "TEST", 139, 144], ["minimal", "OBSERVATION_MODIFIER", 155, 162]]], ["More COVID-19 data from other nations and patient populations will aid in the comparison and validation of our clinical findings.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["More COVID", "TEST", 0, 10], ["our clinical findings", "TEST", 107, 128]]], ["Second, we noted significant heterogeneity in both the leukocyte and lymphocyte analyses.", [["leukocyte", "ANATOMY", 55, 64], ["lymphocyte", "ANATOMY", 69, 79], ["leukocyte", "CELL", 55, 64], ["lymphocyte", "CELL", 69, 79], ["significant heterogeneity in both the leukocyte and lymphocyte analyses", "PROBLEM", 17, 88], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["heterogeneity", "OBSERVATION", 29, 42], ["both", "ANATOMY_MODIFIER", 46, 50], ["leukocyte", "ANATOMY", 55, 64], ["lymphocyte", "ANATOMY", 69, 79]]], ["This phenomenon probably resulted from the small sample size, limited and early data, and skewed representation of the patient population.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["the small sample size", "PROBLEM", 39, 60], ["the patient population", "PROBLEM", 115, 137], ["probably resulted", "UNCERTAINTY", 16, 33], ["small", "OBSERVATION_MODIFIER", 43, 48], ["sample", "OBSERVATION_MODIFIER", 49, 55], ["size", "OBSERVATION_MODIFIER", 56, 60]]], ["Third, the definitions of severe cases were somewhat inconsistent across these studies, varying from acute hypoxic respiratory failure to requiring mechanical ventilation.", [["respiratory", "ANATOMY", 115, 126], ["respiratory failure", "DISEASE", 115, 134], ["severe cases", "PROBLEM", 26, 38], ["these studies", "TEST", 73, 86], ["acute hypoxic respiratory failure", "PROBLEM", 101, 134], ["mechanical ventilation", "TREATMENT", 148, 170], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["hypoxic", "OBSERVATION_MODIFIER", 107, 114], ["respiratory failure", "OBSERVATION", 115, 134], ["mechanical ventilation", "OBSERVATION", 148, 170]]], ["This variability could further compound the heterogeneity found across these studies.", [["the heterogeneity", "PROBLEM", 40, 57], ["these studies", "TEST", 71, 84]]], ["Last, only a minority of the manuscripts reported the proportion of patients with lymphopenia, and variable cutoffs based on the articles\u2019 reference ranges made it difficult to ascertain a cutoff for severe disease.ConclusionsWith the rising cases of COVID-19 and limited resources (14), being able to prioritize patients with severe disease is crucial.", [["lymphopenia", "DISEASE", 82, 93], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 313, 321], ["lymphopenia", "PROBLEM", 82, 93], ["variable cutoffs", "PROBLEM", 99, 115], ["severe disease", "PROBLEM", 200, 214], ["COVID", "TEST", 251, 256], ["severe disease", "PROBLEM", 327, 341], ["lymphopenia", "OBSERVATION", 82, 93], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["disease", "OBSERVATION", 207, 214], ["rising", "OBSERVATION_MODIFIER", 235, 241], ["severe", "OBSERVATION_MODIFIER", 327, 333], ["disease", "OBSERVATION", 334, 341]]], ["Some therapeutic agents are being investigated (15); however, supplies are often low and procurement may be delayed.", [["Some therapeutic agents", "TREATMENT", 0, 23]]], ["The sooner patients with severe disease can be identified, the sooner the process of obtaining therapy can be initiated.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["severe disease", "PROBLEM", 25, 39], ["therapy", "TREATMENT", 95, 102], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["disease", "OBSERVATION", 32, 39]]]], "PMC7094159": [["IntroductionThe timing of infectiousness relative to symptom onset has been identified as a key factor in ability to control an outbreak (Fraser et al., 2004).", [["infectiousness", "PROBLEM", 26, 40], ["symptom onset", "PROBLEM", 53, 66]]], ["The explanation is intuitive: if symptoms appear before infectiousness, then contact tracing and isolation strategies will be effective, whereas for post-infectiousness symptom presentation, broader, non-symptom based strategies must be adopted.", [["symptoms", "PROBLEM", 33, 41], ["infectiousness", "PROBLEM", 56, 70], ["contact tracing", "TEST", 77, 92], ["isolation strategies", "TREATMENT", 97, 117], ["post-infectiousness symptom", "PROBLEM", 149, 176]]], ["Consequently, identifying the relative timing as early as possible in an outbreak is imperative to assessing potential for control and selecting a measured response.IntroductionSevere acute respiratory syndrome (SARS) is a prime example of a disease in which symptoms foreshadow significant levels of infectiousness (Anderson et al., 2004).", [["acute respiratory syndrome", "DISEASE", 184, 210], ["SARS", "DISEASE", 212, 216], ["acute respiratory syndrome", "PROBLEM", 184, 210], ["a disease in which symptoms", "PROBLEM", 240, 267], ["infectiousness", "PROBLEM", 301, 315], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["respiratory syndrome", "OBSERVATION", 190, 210], ["disease", "OBSERVATION", 242, 249]]], ["This played a critical role in limiting mortality and morbidity in outbreaks during 2003, via simple public health measures such as isolation and quarantining (Ksiazek, Erdman, Goldsmith, Zaki, Peret, Emery, Tong, Urbani, Comer, Lim, et al., 2003, Lee, Hui, Wu, Chan, Cameron, Joynt, Ahuja, Yung, Leung, To, et al., 2003, Fraser, Riley, Anderson, Ferguson, 2004, Anderson, Fraser, Ghani, Donnelly, Riley, Ferguson, Leung, Lam, Hedley, 2004, Hsieh, King, Chen, Ho, Lee, Liu, Wu, et al., 2005, Day, Park, Madras, Gumel, Wu, 2006).", [["Ahuja", "CHEMICAL", 284, 289], ["Yung", "CHEMICAL", 291, 295], ["Ahuja", "SIMPLE_CHEMICAL", 284, 289], ["Lam", "ANATOMY", 422, 425]]], ["Smallpox is most similar to SARS in this respect, but must be contrasted with HIV, where a large proportion of secondary infections occur before symptoms (Fraser et al., 2004).", [["SARS", "DISEASE", 28, 32], ["infections", "DISEASE", 121, 131], ["HIV", "ORGANISM", 78, 81], ["HIV", "SPECIES", 78, 81], ["Smallpox", "PROBLEM", 0, 8], ["SARS", "PROBLEM", 28, 32], ["HIV", "PROBLEM", 78, 81], ["secondary infections", "PROBLEM", 111, 131], ["symptoms", "PROBLEM", 145, 153], ["most similar", "OBSERVATION_MODIFIER", 12, 24], ["SARS", "OBSERVATION", 28, 32], ["large", "OBSERVATION_MODIFIER", 91, 96], ["secondary", "OBSERVATION_MODIFIER", 111, 120], ["infections", "OBSERVATION", 121, 131]]], ["For influenza, the relationship is less clear, with symptoms and infectiousness likely coinciding closely, with some transmission possible before symptom onset (Patrozou, Mermel, 2009, Lau, Cowling, Fang, Chan, Lau, et al., 2010).", [["influenza", "DISEASE", 4, 13], ["influenza", "PROBLEM", 4, 13], ["symptoms", "PROBLEM", 52, 60], ["infectiousness", "PROBLEM", 65, 79], ["influenza", "OBSERVATION", 4, 13]]], ["For established diseases, experimental evidence (Charleston et al., 2011) or large-scale detailed case information (International Ebola Response Team et al., 2016) can provide insight into the relative timing of symptom onset and infectiousness; however, this relationship will not be known in an outbreak of an emerging pathogen.", [["Ebola", "DISEASE", 130, 135], ["established diseases", "PROBLEM", 4, 24], ["symptom onset", "PROBLEM", 212, 225], ["infectiousness", "PROBLEM", 230, 244], ["an emerging pathogen", "PROBLEM", 309, 329], ["diseases", "OBSERVATION", 16, 24]]], ["Therefore, one must turn to early outbreak surveillance data for insights.IntroductionMany jurisdictions organize their emerging disease monitoring policies around households.", [["surveillance data", "TEST", 43, 60]]], ["As an example, First Few Hundred studies are proposed as a first response surveillance scheme following the identification of a novel disease and/or strain as part of national pandemic plans (McLean, Pebody, Campbell, Champerland, et al., 2010, van Gageldonk-Lafeber, van der Sande, Meijer, Friesema, Donker, Reimerink, et al., 2012, AHMPPI, 2014).", [["a novel disease", "PROBLEM", 126, 141]]], ["Studies of this form were developed for pandemic influenza in 2009 in both the United Kingdom (McLean et al., 2010) and the Netherlands (van Gageldonk-Lafeber et al., 2012); and have been instituted in response to a lack of methods for determining disease epidemiology as required for determining a proportionate response to novel outbreaks.", [["influenza", "DISEASE", 49, 58], ["pandemic influenza", "PROBLEM", 40, 58], ["determining disease epidemiology", "PROBLEM", 236, 268]]], ["In the Australian Health Management Plan for Pandemic Influenza (AHMPPI), First Few Hundred studies are proposed to be implemented following the first case of a novel influenza strain, with households being tracked nationally (but managed at the state/territory level) (AHMPPI, 2014).", [["Pandemic Influenza", "DISEASE", 45, 63], ["influenza", "DISEASE", 167, 176], ["Pandemic Influenza", "PROBLEM", 45, 63], ["a novel influenza strain", "PROBLEM", 159, 183], ["influenza", "OBSERVATION", 167, 176]]], ["Methods have recently been developed to characterise transmissibility and severity of a novel pathogen \u2013 other factors influencing ability to control an outbreak (Fraser et al., 2004) \u2013 based on such data (Black, Geard, Caw, Vernon, Ross, 2017, Walker, Ross, Black, 2017).", [["Methods", "TREATMENT", 0, 7], ["a novel pathogen", "PROBLEM", 86, 102]]], ["Currently lacking is a method for accurate determination of relative timing of infectiousness and symptom onset using this data.IntroductionHere we introduce, and demonstrate through a simulation study, a method for identifying with high accuracy the timing of infectiousness relative to symptom onset from household-stratified symptom surveillance data (generated via simulation).", [["a method", "TREATMENT", 21, 29], ["infectiousness", "PROBLEM", 79, 93], ["symptom onset", "PROBLEM", 98, 111], ["this data", "TEST", 118, 127], ["a simulation study", "TEST", 183, 201], ["infectiousness", "PROBLEM", 261, 275], ["surveillance data", "TEST", 336, 353]]], ["This heuristic provides a general, computationally-efficient approach to optimal design for Bayesian model discrimination.Bayesian model discrimination for outbreak controlWe model disease dynamics within each household as a continuous-time Markov chain (Keeling and Ross, 2008), that counts the number of household members that are susceptible (S), exposed (E1 and E2), infectious (I1 and I2), or recovered (and immune; R).", [["Bayesian model discrimination", "TEST", 92, 121], ["infectious (I1 and I2)", "PROBLEM", 371, 393], ["infectious", "OBSERVATION", 371, 381]]], ["Two compartments for exposed and infectious individuals allows for a broad range outbreak observation dynamics, and allows Erlang-distributed exposed and infectious periods.", [["infectious", "OBSERVATION", 33, 43], ["infectious", "OBSERVATION_MODIFIER", 154, 164]]], ["Under this model, the timing of symptom onset relative to infectiousness is mapped to which transition is observed: symptoms appear either upon infection, between infection and infectiousness, coincident with infectiousness, between infectiousness and recovery, or upon recovery.", [["infection", "DISEASE", 144, 153], ["infection", "DISEASE", 163, 172], ["symptom", "PROBLEM", 32, 39], ["infectiousness", "PROBLEM", 58, 72], ["symptoms", "PROBLEM", 116, 124], ["infection", "PROBLEM", 144, 153], ["infection", "PROBLEM", 163, 172], ["infectiousness", "PROBLEM", 177, 191], ["infectiousness", "PROBLEM", 209, 223], ["infectiousness", "PROBLEM", 233, 247], ["infection", "OBSERVATION", 144, 153], ["infection", "OBSERVATION", 163, 172]]], ["The challenge is to determine which of these five (observation) models best describes the household-stratified symptom-onset data (Fig. 1a).Bayesian model discrimination for outbreak controlThere is a relatively rich literature on Bayesian model discrimination (Chopin, Jacob, Papaspiliopoulos, 2013, Drovandi, Cutchan, 2016, Alzahrani, Neal, Spencer, McKinley, Touloupou, 2018, Touloupou, Alzahrani, Neal, Spencer, Kinley, 2018), and optimal design for such (Chaloner, Verdinelli, 1995, Ryan, Drovandi, Gree, Pettitt, 2015), which are the most appropriate tools and framework to address this question.", [["outbreak control", "TREATMENT", 174, 190], ["relatively", "OBSERVATION_MODIFIER", 201, 211], ["rich", "OBSERVATION_MODIFIER", 212, 216]]], ["A general difficulty with this theory is that practical implementation is at best difficult, and often infeasible.", [["practical implementation", "TREATMENT", 46, 70]]], ["Unfortunately, there exists \u2018a fundamental difficulty\u2019 in establishing robust methods based upon summary statistics (Robert, Cornuet, Marin, Pillai, 2011, Robert, 2016); however, see the recent work of Dehideniya et al. (Dehideniya et al., 2018).Bayesian model discrimination for outbreak controlAnother approach to model discrimination in an ABC framework has been proposed by Pudlo et al. (Pudlo et al., 2015).", [["fundamental difficulty", "PROBLEM", 31, 53], ["outbreak control", "TREATMENT", 280, 296], ["fundamental", "OBSERVATION_MODIFIER", 31, 42], ["difficulty", "OBSERVATION", 43, 53]]], ["They treat model discrimination as a classification problem, for which machine learning methods are ideal, and in particular propose the use of random forests to perform this task.", [["random forests", "TREATMENT", 144, 158], ["this task", "TEST", 170, 179]]], ["Hainy et al. (Hainy et al., 2018) expand on this approach as specifically applied to optimal design for model discrimination.Bayesian model discrimination for outbreak controlWe apply random-forest based Bayesian model discrimination, first for accurate, robust characterisation of relative timing of symptoms and infectiousness, and second, for optimal design of early outbreak surveillance for accurate model discrimination.", [["this approach", "TREATMENT", 44, 57], ["model discrimination", "TEST", 104, 124], ["symptoms", "PROBLEM", 301, 309], ["infectiousness", "PROBLEM", 314, 328], ["early outbreak surveillance", "TEST", 364, 391], ["et al", "OBSERVATION", 6, 11]]], ["Specifically, the aim of the latter is to select an optimal surveillance scheme, consisting of a fixed number of observations, in order to discriminate five different timings of symptom onset relative to infectiousness, within a household-stratified epidemic model.", [["symptom onset", "PROBLEM", 178, 191], ["infectiousness", "PROBLEM", 204, 218]]], ["Additionally, we propose a new, computationally-efficient and highly-accurate heuristic for optimal design choice, which in this application determines the optimal days upon which to perform surveillance in households.Epidemic model ::: MethodsWe demonstrate using an example system of a novel infectious disease, spreading in a population structured into households.", [["infectious disease", "DISEASE", 294, 312], ["a novel infectious disease", "PROBLEM", 286, 312], ["new", "OBSERVATION_MODIFIER", 27, 30], ["infectious", "OBSERVATION", 294, 304], ["population", "OBSERVATION_MODIFIER", 329, 339]]], ["We assume that the population is large and mixing between households is random, such that after a household is initially infected, the remaining transmission within the household is independent of transmission outside the household (Ross, House, Keeling, 2010, Black, House, Keeling, Ross, 2013).", [["population", "OBSERVATION_MODIFIER", 19, 29], ["large", "OBSERVATION_MODIFIER", 33, 38], ["infected", "OBSERVATION", 121, 129]]], ["Therefore, transmission dynamics within households can be modelled independently (Black et al., 2017), i.e., with infection only occurring between individuals within a household, rather than between households.", [["infection", "DISEASE", 114, 123], ["infection", "PROBLEM", 114, 123], ["infection", "OBSERVATION", 114, 123]]], ["Given this novel etiological agent, we wish to determine if symptom onset occurs at the time of infection, between infection and infectiousness, coincident with infectiousness, after infectiousness, or coincident with recovery (i.e., these are the five candidate models we wish to discriminate).", [["infection", "DISEASE", 96, 105], ["infection", "DISEASE", 115, 124], ["symptom", "PROBLEM", 60, 67], ["infection", "PROBLEM", 96, 105], ["infection", "PROBLEM", 115, 124], ["infectiousness", "PROBLEM", 129, 143], ["infectiousness", "PROBLEM", 161, 175], ["infectiousness", "PROBLEM", 183, 197], ["infection", "OBSERVATION", 96, 105], ["infection", "OBSERVATION", 115, 124]]], ["To be emphatic, the underlying disease dynamics is identical in all five models, each differing only in when observations are made, corresponding to different timings of symptom onset (Fig. 1a).", [["the underlying disease dynamics", "PROBLEM", 16, 47], ["disease", "OBSERVATION", 31, 38]]], ["We focus on selecting between these observation models as the relative timing of infectiousness and symptom onset is critical to effective outbreak management: quarantine can be applied effectively if symptoms occur before (or possibly coincident to) infectiousness.Epidemic model ::: MethodsWe model the epidemic dynamics in households as a continuous-time Markov chain (Figure 1a) (Keeling and Ross, 2008).", [["these observation models", "TEST", 30, 54], ["infectiousness", "PROBLEM", 81, 95], ["symptom", "PROBLEM", 100, 107], ["effective outbreak management", "TREATMENT", 129, 158], ["quarantine", "TREATMENT", 160, 170], ["symptoms", "PROBLEM", 201, 209], ["infectiousness", "PROBLEM", 251, 265]]], ["Individuals transition from susceptible (S) to exposed (E1, and subsequently E2), then to infectious (I1, and subsequently I2), and finally to recovered (R), with rates as described in Table 1.", [["E2", "CHEMICAL", 77, 79], ["Individuals transition", "PROBLEM", 0, 22], ["infectious", "OBSERVATION", 90, 100]]], ["The model dynamics are general, but explicitly resemble the dynamics of a respiratory virus such as influenza, as potential future pandemic influenza is of substantial concern globally.", [["respiratory virus", "DISEASE", 74, 91], ["influenza", "DISEASE", 100, 109], ["influenza", "DISEASE", 140, 149], ["a respiratory virus", "PROBLEM", 72, 91], ["influenza", "PROBLEM", 100, 109], ["pandemic influenza", "PROBLEM", 131, 149], ["respiratory virus", "OBSERVATION", 74, 91]]], ["The collection of First Few Hundred data is included in the Australian Health Management Plan for Pandemic Influenza (AHMPPI, 2014), along with similar pandemic preparedness plans in other jurisdictions, so demonstrating the ability to discriminate models using these data for diseases resembling influenza is highly relevant.", [["Pandemic Influenza", "DISEASE", 98, 116], ["influenza", "DISEASE", 297, 306], ["Pandemic Influenza", "PROBLEM", 98, 116], ["AHMPPI", "TEST", 118, 124], ["these data", "TEST", 262, 272], ["diseases", "PROBLEM", 277, 285], ["influenza", "PROBLEM", 297, 306], ["collection", "OBSERVATION_MODIFIER", 4, 14], ["influenza", "OBSERVATION", 297, 306]]], ["As such, prior parameter choices and the overall duration of the observation process (i.e., 14 days) also reflect influenza dynamics.Epidemic model ::: MethodsWe assign a prior distribution to each parameter (Supplemental Figure S1), based on physical quantities to reflect the assumed prior knowledge of the etiological agent:\u20221\u03c3\u223cGamma(6,1/2), representing a mean exposed duration of 3 days (mode at approximately 2.5 days);\u20221\u03b3\u223cGamma(6,1/2), representing a mean infectious duration of 3 days (mode at approximately 2.5 days); and,\u2022R0\u223c1+Gamma(2,1/2), representing a mean R0 (the expected number of secondary cases caused by an infectious individual in a fully susceptible population) of 2 (mode at approximately 1.5).", [["prior parameter choices", "TREATMENT", 9, 32], ["the observation process", "TEST", 61, 84], ["influenza dynamics", "PROBLEM", 114, 132], ["Supplemental Figure S1)", "TREATMENT", 209, 232], ["a mean R0", "PROBLEM", 564, 573], ["secondary cases", "PROBLEM", 598, 613], ["an infectious individual", "PROBLEM", 624, 648], ["influenza", "OBSERVATION", 114, 123], ["+Gamma", "ANATOMY_MODIFIER", 536, 542], ["mean R0", "OBSERVATION", 566, 573], ["infectious", "OBSERVATION", 627, 637]]]], "PMC7115694": [["IntroductionThe increasing incidence of infection caused by the rapid development of microbial resistance to most of the known antibiotics is a serious health problem.", [["infection", "DISEASE", 40, 49], ["infection", "PROBLEM", 40, 49], ["microbial resistance", "PROBLEM", 85, 105], ["the known antibiotics", "TREATMENT", 117, 138], ["a serious health problem", "PROBLEM", 142, 166], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["incidence", "OBSERVATION_MODIFIER", 27, 36], ["infection", "OBSERVATION", 40, 49], ["rapid", "OBSERVATION_MODIFIER", 64, 69], ["microbial resistance", "OBSERVATION", 85, 105]]], ["There are a number of factors responsible for mutations in the microbial genomes.", [["microbial genomes", "DNA", 63, 80], ["mutations", "PROBLEM", 46, 55], ["microbial genomes", "OBSERVATION", 63, 80]]], ["As multidrug-resistant microbial strains proliferate, the necessity for effective therapy has stimulated research on the design and synthesis of novel antimicrobial molecules [1].IntroductionIn spite of nearly three decades of intensive research toward the treatment and eradication of HIV/AIDS, the disease remains a global health problem.", [["strains", "ANATOMY", 33, 40], ["HIV/AIDS", "DISEASE", 286, 294], ["HIV", "ORGANISM", 286, 289], ["HIV", "SPECIES", 286, 289], ["HIV", "SPECIES", 286, 289], ["multidrug-resistant microbial strains proliferate", "PROBLEM", 3, 52], ["effective therapy", "TREATMENT", 72, 89], ["synthesis of novel antimicrobial molecules", "TREATMENT", 132, 174], ["intensive research", "TREATMENT", 227, 245], ["the treatment", "TREATMENT", 253, 266], ["eradication", "TREATMENT", 271, 282], ["HIV", "PROBLEM", 286, 289], ["AIDS", "PROBLEM", 290, 294], ["the disease", "PROBLEM", 296, 307], ["a global health problem", "PROBLEM", 316, 339], ["resistant", "OBSERVATION_MODIFIER", 13, 22], ["microbial strains", "OBSERVATION", 23, 40]]], ["The advent of highly active antiretroviral therapy (HAART) in the mid 1990s, which employed various combinations of reverse transcriptase and protease inhibitors, led to marked improvements of clinical outcomes.", [["reverse transcriptase", "PROTEIN", 116, 137], ["highly active antiretroviral therapy", "TREATMENT", 14, 50], ["HAART", "TREATMENT", 52, 57], ["reverse transcriptase and protease inhibitors", "TREATMENT", 116, 161], ["active", "OBSERVATION_MODIFIER", 21, 27], ["antiretroviral therapy", "OBSERVATION", 28, 50], ["marked", "OBSERVATION_MODIFIER", 170, 176], ["improvements", "OBSERVATION_MODIFIER", 177, 189]]], ["While the diversity of drugs now available to the clinician has substantially improved HIV treatment, still significant challenges remain.", [["HIV", "SPECIES", 87, 90], ["drugs", "TREATMENT", 23, 28], ["HIV treatment", "TREATMENT", 87, 100], ["improved", "OBSERVATION_MODIFIER", 78, 86], ["HIV", "OBSERVATION", 87, 90], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["challenges", "OBSERVATION", 120, 130]]], ["Of particular concern are long-term treatment side effects and the emergence of drug-resistant viral strains [2].IntroductionThe heterocyclic molecule, benzimidazole, is isosteric with indole and purine nuclei, which are present in a number of fundamental cellular components and bioactive compounds which makes the benzimidazole molecule endowed with a variety of biological properties [3].", [["nuclei", "ANATOMY", 203, 209], ["cellular", "ANATOMY", 256, 264], ["benzimidazole", "CHEMICAL", 152, 165], ["indole", "CHEMICAL", 185, 191], ["purine", "CHEMICAL", 196, 202], ["benzimidazole", "CHEMICAL", 152, 165], ["indole", "CHEMICAL", 185, 191], ["purine", "CHEMICAL", 196, 202], ["benzimidazole", "CHEMICAL", 316, 329], ["benzimidazole", "SIMPLE_CHEMICAL", 152, 165], ["indole", "SIMPLE_CHEMICAL", 185, 191], ["purine nuclei", "SIMPLE_CHEMICAL", 196, 209], ["cellular", "CELL", 256, 264], ["long-term treatment side effects", "TREATMENT", 26, 58], ["resistant viral strains", "PROBLEM", 85, 108], ["The heterocyclic molecule", "TREATMENT", 125, 150], ["benzimidazole", "TREATMENT", 152, 165], ["isosteric with indole and purine nuclei", "TREATMENT", 170, 209], ["bioactive compounds", "TREATMENT", 280, 299], ["the benzimidazole molecule", "TREATMENT", 312, 338], ["long-term", "OBSERVATION_MODIFIER", 26, 35], ["heterocyclic molecule", "OBSERVATION", 129, 150], ["purine nuclei", "OBSERVATION", 196, 209], ["fundamental", "OBSERVATION_MODIFIER", 244, 255], ["cellular components", "OBSERVATION", 256, 275], ["bioactive compounds", "OBSERVATION", 280, 299]]], ["The study of recent literature reveals that benzimidazole is reported to have number of biological activities viz. antiviral [4], antifungal [5], antihelmintic [6], antiprotozoal [7], psychotropic [8], anti-HIV [9], antitumor [10], antioxidant [11] and anticoagulant [12] activities.IntroductionIndeed, a number of important drugs used in different therapeutic areas contain the benzimidazole ring, as proton pump inhibitors (omeprazole), antihypertensives (candesartan, telmisartan), antihistaminics (astemizole), antihelmintics (albendazole, mebendazole), as well as several other kinds of still investigational therapeutic agents, including antitumorals and antivirals [1].IntroductionQSAR refers to a discipline in computational chemistry that addresses the modeling of biological activities or chemical reactivity based on the quantitative description for the chemical structure of molecules.", [["antitumor", "ANATOMY", 216, 225], ["benzimidazole", "CHEMICAL", 44, 57], ["omeprazole", "CHEMICAL", 426, 436], ["candesartan", "CHEMICAL", 458, 469], ["telmisartan", "CHEMICAL", 471, 482], ["astemizole", "CHEMICAL", 502, 512], ["antihelmintics", "CHEMICAL", 515, 529], ["albendazole", "CHEMICAL", 531, 542], ["mebendazole", "CHEMICAL", 544, 555], ["benzimidazole", "CHEMICAL", 44, 57], ["benzimidazole", "CHEMICAL", 379, 392], ["omeprazole", "CHEMICAL", 426, 436], ["candesartan", "CHEMICAL", 458, 469], ["telmisartan", "CHEMICAL", 471, 482], ["antihistaminics", "CHEMICAL", 485, 500], ["astemizole", "CHEMICAL", 502, 512], ["albendazole", "CHEMICAL", 531, 542], ["mebendazole", "CHEMICAL", 544, 555], ["benzimidazole", "SIMPLE_CHEMICAL", 44, 57], ["antifungal [5]", "SIMPLE_CHEMICAL", 130, 144], ["antihelmintic [6]", "SIMPLE_CHEMICAL", 146, 163], ["antiprotozoal [7]", "SIMPLE_CHEMICAL", 165, 182], ["psychotropic [8]", "SIMPLE_CHEMICAL", 184, 200], ["anti-", "SIMPLE_CHEMICAL", 202, 207], ["HIV", "ORGANISM", 207, 210], ["antitumor", "CANCER", 216, 225], ["[10]", "SIMPLE_CHEMICAL", 226, 230], ["antioxidant [11]", "SIMPLE_CHEMICAL", 232, 248], ["anticoagulant [12]", "SIMPLE_CHEMICAL", 253, 271], ["benzimidazole ring", "SIMPLE_CHEMICAL", 379, 397], ["proton pump inhibitors", "SIMPLE_CHEMICAL", 402, 424], ["omeprazole", "SIMPLE_CHEMICAL", 426, 436], ["antihypertensives", "SIMPLE_CHEMICAL", 439, 456], ["candesartan", "SIMPLE_CHEMICAL", 458, 469], ["telmisartan", "SIMPLE_CHEMICAL", 471, 482], ["antihistaminics", "SIMPLE_CHEMICAL", 485, 500], ["astemizole", "SIMPLE_CHEMICAL", 502, 512], ["antihelmintics", "SIMPLE_CHEMICAL", 515, 529], ["albendazole", "SIMPLE_CHEMICAL", 531, 542], ["mebendazole", "SIMPLE_CHEMICAL", 544, 555], ["antitumorals", "SIMPLE_CHEMICAL", 644, 656], ["HIV", "SPECIES", 207, 210], ["HIV", "SPECIES", 207, 210], ["The study", "TEST", 0, 9], ["benzimidazole", "TREATMENT", 44, 57], ["antiviral [", "TREATMENT", 115, 126], ["antifungal", "TREATMENT", 130, 140], ["antihelmintic", "TREATMENT", 146, 159], ["antiprotozoal", "TREATMENT", 165, 178], ["psychotropic", "TREATMENT", 184, 196], ["anti-HIV", "TREATMENT", 202, 210], ["antitumor", "TREATMENT", 216, 225], ["antioxidant", "TREATMENT", 232, 243], ["anticoagulant", "TREATMENT", 253, 266], ["important drugs", "TREATMENT", 315, 330], ["the benzimidazole ring", "TREATMENT", 375, 397], ["proton pump inhibitors", "TREATMENT", 402, 424], ["omeprazole)", "TREATMENT", 426, 437], ["antihypertensives", "TREATMENT", 439, 456], ["candesartan", "TREATMENT", 458, 469], ["telmisartan", "TREATMENT", 471, 482], ["antihistaminics (astemizole)", "TREATMENT", 485, 513], ["antihelmintics", "TREATMENT", 515, 529], ["albendazole", "TREATMENT", 531, 542], ["mebendazole", "TREATMENT", 544, 555], ["still investigational therapeutic agents", "TREATMENT", 592, 632], ["antitumorals", "TREATMENT", 644, 656], ["antivirals", "TREATMENT", 661, 671], ["benzimidazole ring", "OBSERVATION", 379, 397]]], ["Quantitative structure\u2013activity relationship (QSAR) is one of the most important areas in chemometrics, and is a valuable tool that is used extensively in drug design and medicinal chemistry.", [["medicinal chemistry", "TEST", 171, 190], ["chemometrics", "OBSERVATION", 90, 102]]], ["Once a reliable QSAR model is established, we can predict the activities of molecules, and know which structural features play an important role in biological processes [14].IntroductionBearing these results in mind and in continuation of our research efforts in searching novel antiviral agents [15], [16], we hereby present the synthesis, antimicrobial and antiviral activity and QSAR modeling of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids.ChemistryThe synthesis of compounds 1-20 followed the general pathway elicited in Scheme 1.", [["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 399, 479], ["compounds 1-20", "CHEMICAL", 506, 520], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 399, 479], ["[15]", "SIMPLE_CHEMICAL", 296, 300], ["[16]", "SIMPLE_CHEMICAL", 302, 306], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 399, 479], ["compounds 1-20", "SIMPLE_CHEMICAL", 506, 520], ["novel antiviral agents", "TREATMENT", 273, 295], ["the synthesis", "TREATMENT", 326, 339], ["antimicrobial", "TREATMENT", 341, 354], ["antiviral activity", "TREATMENT", 359, 377], ["QSAR modeling", "TEST", 382, 395], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 405, 437], ["benzoimidazol", "TREATMENT", 438, 451], ["benzenesulfonic acids", "TREATMENT", 458, 479], ["Chemistry", "TEST", 480, 489], ["The synthesis of compounds", "TEST", 489, 515]]], ["The key intermediate, 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid was prepared by the condensation of benzimidazole with aryldiazonium chloride of 4-amino-benzenesulfonic acid, which in turn prepared by the diazotization of 4-amino-benzenesulfonic acid [17].", [["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 22, 68], ["benzimidazole", "CHEMICAL", 105, 118], ["aryldiazonium chloride", "CHEMICAL", 124, 146], ["4-amino-benzenesulfonic acid", "CHEMICAL", 150, 178], ["4-amino-benzenesulfonic acid", "CHEMICAL", 227, 255], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 22, 68], ["benzimidazole", "CHEMICAL", 105, 118], ["aryldiazonium chloride", "CHEMICAL", 124, 146], ["4-amino-benzenesulfonic acid", "CHEMICAL", 150, 178], ["4-amino-benzenesulfonic acid", "CHEMICAL", 227, 255], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 22, 68], ["benzimidazole", "SIMPLE_CHEMICAL", 105, 118], ["aryldiazonium chloride", "SIMPLE_CHEMICAL", 124, 146], ["4-amino-benzenesulfonic acid", "SIMPLE_CHEMICAL", 150, 178], ["4-amino-benzenesulfonic acid", "SIMPLE_CHEMICAL", 227, 255], ["benzoimidazol", "TREATMENT", 28, 41], ["benzenesulfonic acid", "TREATMENT", 48, 68], ["benzimidazole", "TREATMENT", 105, 118], ["aryldiazonium chloride", "TREATMENT", 124, 146], ["amino-benzenesulfonic acid", "TREATMENT", 152, 178], ["amino-benzenesulfonic acid", "TREATMENT", 229, 255]]], ["However, based on our experience, the application of the cupric chloride for the condensation of aryldiazonium chloride with benzimidazole as suggested by Dahiya and Pathak [18] resulted in resinous (sticky) products.", [["cupric chloride", "CHEMICAL", 57, 72], ["aryldiazonium chloride", "CHEMICAL", 97, 119], ["benzimidazole", "CHEMICAL", 125, 138], ["Dahiya", "CHEMICAL", 155, 161], ["cupric chloride", "CHEMICAL", 57, 72], ["aryldiazonium chloride", "CHEMICAL", 97, 119], ["benzimidazole", "CHEMICAL", 125, 138], ["cupric chloride", "SIMPLE_CHEMICAL", 57, 72], ["aryldiazonium chloride", "SIMPLE_CHEMICAL", 97, 119], ["benzimidazole", "SIMPLE_CHEMICAL", 125, 138], ["Dahiya", "SIMPLE_CHEMICAL", 155, 161], ["Pathak [18]", "SIMPLE_CHEMICAL", 166, 177], ["the cupric chloride", "TREATMENT", 53, 72], ["the condensation of aryldiazonium chloride", "TREATMENT", 77, 119], ["benzimidazole", "TREATMENT", 125, 138], ["resinous (sticky) products", "TREATMENT", 190, 216]]], ["Therefore, the coupling was carried out by using sodium acetate along with stirring at cold conditions for the initial 3 h followed by 48 h stirring at room temperature which resulted in a solid product.", [["sodium acetate", "CHEMICAL", 49, 63], ["sodium acetate", "CHEMICAL", 49, 63], ["sodium acetate", "SIMPLE_CHEMICAL", 49, 63], ["sodium acetate", "TREATMENT", 49, 63]]], ["For the synthesis of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids, the key intermediates 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid has been reacted with corresponding aryl/alkyl acid chlorides which were formed by the reaction of corresponding aryl/alkyl acids with thionyl chloride.", [["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 21, 101], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 125, 171], ["aryl/alkyl acid chlorides", "CHEMICAL", 208, 233], ["aryl/alkyl acids", "CHEMICAL", 285, 301], ["thionyl chloride", "CHEMICAL", 307, 323], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 21, 101], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 125, 171], ["aryl/alkyl acid chlorides", "CHEMICAL", 208, 233], ["aryl/alkyl acids", "CHEMICAL", 285, 301], ["thionyl chloride", "CHEMICAL", 307, 323], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 21, 101], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 125, 171], ["aryl/alkyl acid chlorides", "SIMPLE_CHEMICAL", 208, 233], ["aryl/alkyl acids", "SIMPLE_CHEMICAL", 285, 301], ["thionyl chloride", "SIMPLE_CHEMICAL", 307, 323], ["the synthesis", "TEST", 4, 17], ["substituted aryl/alkyl carbonyl)", "TREATMENT", 27, 59], ["benzoimidazol", "TREATMENT", 60, 73], ["benzenesulfonic acids", "TREATMENT", 80, 101], ["the key intermediates", "TREATMENT", 103, 124], ["benzoimidazol", "TREATMENT", 131, 144], ["benzenesulfonic acid", "TREATMENT", 151, 171], ["corresponding aryl/alkyl acid chlorides", "TREATMENT", 194, 233], ["corresponding aryl/alkyl acids", "TREATMENT", 271, 301], ["thionyl chloride", "TREATMENT", 307, 323]]], ["It is important to note here that the yield of most of the synthesized benzimidazoles were below 50%.", [["benzimidazoles", "CHEMICAL", 71, 85], ["benzimidazoles", "CHEMICAL", 71, 85], ["benzimidazoles", "SIMPLE_CHEMICAL", 71, 85], ["the synthesized benzimidazoles", "TREATMENT", 55, 85]]], ["The low yield of synthetic compounds may be attributed to any one or more of the following reasons [17]: a).", [["synthetic compounds", "TREATMENT", 17, 36], ["low yield", "OBSERVATION_MODIFIER", 4, 13]]], ["The reaction may be reversible and position of equilibrium is unfavorable to the product; b).", [["The reaction", "PROBLEM", 0, 12], ["may be", "UNCERTAINTY", 13, 19], ["reversible", "OBSERVATION_MODIFIER", 20, 30]]], ["The incursion of side reactions leading to the formation of by-products; c).", [["side reactions", "PROBLEM", 17, 31]]], ["The premature work-up of the reaction before its completion; d).", [["the reaction", "PROBLEM", 25, 37]]], ["The volatilization of products during reaction or work-up; e).", [["The volatilization of products", "TREATMENT", 0, 30]]], ["The loss of product due to incomplete extraction, inefficient crystallization or other work-up procedures; f).", [["The loss of product", "PROBLEM", 0, 19], ["incomplete extraction", "TREATMENT", 27, 48], ["inefficient crystallization", "TREATMENT", 50, 77]]], ["The presence of contaminants in the reactants or reagents leading to a less efficient reaction.", [["contaminants in the reactants", "PROBLEM", 16, 45], ["a less efficient reaction", "PROBLEM", 69, 94], ["contaminants", "OBSERVATION", 16, 28]]], ["The physicochemical characteristics of the synthesized compounds are presented in Table 1.ChemistryThe structures of compounds 1-20 were assigned by IR and 1H NMR spectroscopic data, which are consistent with the proposed molecular structures.", [["compounds 1-20", "CHEMICAL", 117, 131], ["1H", "CHEMICAL", 156, 158], ["compounds 1-20", "SIMPLE_CHEMICAL", 117, 131], ["the synthesized compounds", "PROBLEM", 39, 64], ["Chemistry", "TEST", 90, 99], ["1H NMR spectroscopic data", "TEST", 156, 181], ["synthesized compounds", "OBSERVATION", 43, 64], ["consistent with", "UNCERTAINTY", 193, 208]]], ["The primary amino group in compound 1 is depicted by the presence of NH asymmetric stretch at 3481.81 cm\u22121.", [["NH", "CHEMICAL", 69, 71], ["amino", "CHEMICAL", 12, 17], ["NH", "CHEMICAL", 69, 71], ["amino", "AMINO_ACID", 12, 17], ["asymmetric", "OBSERVATION_MODIFIER", 72, 82], ["stretch", "OBSERVATION_MODIFIER", 83, 90]]], ["The IR bending vibration corresponding to OCH3 of compound 8 appeared at 1425.61 cm\u22121.", [["OCH3 of compound 8", "CHEMICAL", 42, 60], ["The IR bending vibration", "TREATMENT", 0, 24]]], ["The presence of heterocyclic pyridine moiety in compound 15 is demonstrated by the presence of CH out of plane bending at 829.04 cm\u22121.", [["heterocyclic pyridine", "CHEMICAL", 16, 37], ["pyridine", "CHEMICAL", 29, 37], ["CH", "CHEMICAL", 95, 97], ["heterocyclic pyridine moiety", "SIMPLE_CHEMICAL", 16, 44], ["heterocyclic pyridine moiety", "TREATMENT", 16, 44], ["heterocyclic", "OBSERVATION", 16, 28], ["pyridine moiety", "OBSERVATION", 29, 44]]], ["The presence of an additional S\u2013N stretch at 808.61 cm\u22121 apart from the SO3 asymmetric stretch in the region of 1260\u20131150 cm\u22121 indicated that compound 20 contains a link between SO2 and N1 of benzimidazole.", [["S\u2013N", "CHEMICAL", 30, 33], ["SO3", "CHEMICAL", 72, 75], ["SO2", "CHEMICAL", 178, 181], ["benzimidazole", "CHEMICAL", 192, 205], ["S\u2013N", "CHEMICAL", 30, 33], ["SO3", "CHEMICAL", 72, 75], ["SO2", "CHEMICAL", 178, 181], ["N1", "CHEMICAL", 186, 188], ["benzimidazole", "CHEMICAL", 192, 205], ["SO2", "SIMPLE_CHEMICAL", 178, 181], ["N1 of benzimidazole", "SIMPLE_CHEMICAL", 186, 205], ["an additional S\u2013N stretch", "PROBLEM", 16, 41], ["benzimidazole", "TREATMENT", 192, 205], ["stretch", "OBSERVATION_MODIFIER", 34, 41], ["SO3", "ANATOMY_MODIFIER", 72, 75], ["asymmetric", "OBSERVATION_MODIFIER", 76, 86], ["stretch", "OBSERVATION", 87, 94], ["region", "ANATOMY_MODIFIER", 102, 108]]], ["The appearance of CO stretch in the range of 1630\u20131600 cm\u22121 indicated the formation of tertiary amides (1-20) by the reaction of acid chlorides with the 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid.", [["1-20", "CHEMICAL", 104, 108], ["acid chlorides", "CHEMICAL", 129, 143], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 153, 199], ["CO", "CHEMICAL", 18, 20], ["tertiary amides", "CHEMICAL", 87, 102], ["acid chlorides", "CHEMICAL", 129, 143], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 153, 199], ["tertiary amides", "SIMPLE_CHEMICAL", 87, 102], ["1-20)", "SIMPLE_CHEMICAL", 104, 109], ["acid chlorides", "SIMPLE_CHEMICAL", 129, 143], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 153, 199], ["CO", "PROTEIN", 18, 20], ["CO stretch", "TEST", 18, 28], ["tertiary amides", "TEST", 87, 102], ["acid chlorides", "TREATMENT", 129, 143], ["benzoimidazol", "TREATMENT", 159, 172], ["benzenesulfonic acid", "TREATMENT", 179, 199], ["CO stretch", "OBSERVATION_MODIFIER", 18, 28]]], ["Formation of tertiary amide is further evidenced by the absence of IR bands at 1725\u20131700 cm\u22121 and 1700\u20131680 cm\u22121 corresponding to the alkyl and aryl acids, respectively.", [["alkyl", "CHEMICAL", 134, 139], ["aryl acids", "CHEMICAL", 144, 154], ["tertiary amide", "CHEMICAL", 13, 27], ["alkyl and aryl acids", "CHEMICAL", 134, 154], ["tertiary amide", "SIMPLE_CHEMICAL", 13, 27], ["alkyl", "SIMPLE_CHEMICAL", 134, 139], ["aryl acids", "SIMPLE_CHEMICAL", 144, 154], ["IR bands", "TEST", 67, 75], ["the alkyl and aryl acids", "TEST", 130, 154], ["tertiary amide", "OBSERVATION", 13, 27], ["alkyl", "ANATOMY_MODIFIER", 134, 139]]], ["The appearance of SO3 asymmetric stretch in the region of 1260\u20131150 cm\u22121 demonstrated the presence of SO3H group of benzenesulfonic acid attached to the 2nd position of benzimidazole.ChemistryThe appearance of singlet around 2.5 \u03b4 ppm corresponds to the proton of SO3H in the NMR of all the compounds indicated the presence of para sulfonyl phenyl nucleus to the 2nd position of synthesized benzimidazoles (11-20).", [["SO3", "CHEMICAL", 18, 21], ["SO3H", "CHEMICAL", 102, 106], ["benzenesulfonic acid", "CHEMICAL", 116, 136], ["benzimidazole", "CHEMICAL", 169, 182], ["SO3H", "CHEMICAL", 264, 268], ["para sulfonyl phenyl", "CHEMICAL", 327, 347], ["benzimidazoles", "CHEMICAL", 391, 405], ["SO3", "CHEMICAL", 18, 21], ["SO3H", "CHEMICAL", 102, 106], ["benzenesulfonic acid", "CHEMICAL", 116, 136], ["benzimidazole", "CHEMICAL", 169, 182], ["SO3H", "CHEMICAL", 264, 268], ["para sulfonyl phenyl", "CHEMICAL", 327, 347], ["benzimidazoles", "CHEMICAL", 391, 405], ["SO3", "SIMPLE_CHEMICAL", 18, 21], ["SO3H", "SIMPLE_CHEMICAL", 102, 106], ["benzenesulfonic acid", "SIMPLE_CHEMICAL", 116, 136], ["benzimidazole", "SIMPLE_CHEMICAL", 169, 182], ["SO3H", "SIMPLE_CHEMICAL", 264, 268], ["sulfonyl phenyl nucleus", "SIMPLE_CHEMICAL", 332, 355], ["benzimidazoles", "SIMPLE_CHEMICAL", 391, 405], ["SO3 asymmetric stretch", "PROBLEM", 18, 40], ["SO3H group of benzenesulfonic acid", "TREATMENT", 102, 136], ["the 2nd position of benzimidazole", "TREATMENT", 149, 182], ["Chemistry", "TEST", 183, 192], ["para sulfonyl phenyl nucleus", "PROBLEM", 327, 355], ["synthesized benzimidazoles", "TREATMENT", 379, 405], ["SO3", "OBSERVATION", 18, 21], ["asymmetric", "OBSERVATION_MODIFIER", 22, 32], ["stretch", "OBSERVATION_MODIFIER", 33, 40], ["region", "ANATOMY_MODIFIER", 48, 54], ["singlet", "OBSERVATION_MODIFIER", 210, 217]]], ["Further the multiplet corresponds to 6.9\u20138.6 \u03b4 ppm confirmed the presence of protons of benzimidazole and aryl nucleus.", [["benzimidazole", "CHEMICAL", 88, 101], ["benzimidazole", "CHEMICAL", 88, 101], ["aryl", "CHEMICAL", 106, 110], ["protons", "SIMPLE_CHEMICAL", 77, 84], ["benzimidazole", "SIMPLE_CHEMICAL", 88, 101], ["aryl nucleus", "SIMPLE_CHEMICAL", 106, 118], ["benzimidazole and aryl nucleus", "TREATMENT", 88, 118], ["aryl nucleus", "OBSERVATION", 106, 118]]], ["The appearance of \u03b4 at 8.46\u20139.66 confirmed the presence of the pyridine ring system in compound 15.", [["pyridine", "CHEMICAL", 63, 71], ["pyridine", "CHEMICAL", 63, 71], ["pyridine", "SIMPLE_CHEMICAL", 63, 71], ["the pyridine ring system", "TREATMENT", 59, 83], ["pyridine ring", "OBSERVATION", 63, 76]]], ["The appearance doublet at 3.66\u20133.72 \u03b4 ppm (CH2 of CHCH2) and 3.79\u20133.85 \u03b4 ppm (CH of CHCH2) indicated the formation of compound 14 by the reaction of 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid and acid chloride of methacrylic acid.", [["CHCH2", "CHEMICAL", 50, 55], ["CHCH2", "CHEMICAL", 84, 89], ["compound 14", "CHEMICAL", 118, 129], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 149, 195], ["acid chloride", "CHEMICAL", 200, 213], ["methacrylic acid", "CHEMICAL", 217, 233], ["CH2", "CHEMICAL", 43, 46], ["CHCH2", "CHEMICAL", 50, 55], ["CH", "CHEMICAL", 78, 80], ["CHCH2", "CHEMICAL", 84, 89], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 149, 195], ["acid chloride", "CHEMICAL", 200, 213], ["methacrylic acid", "CHEMICAL", 217, 233], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 149, 195], ["acid chloride of methacrylic acid", "SIMPLE_CHEMICAL", 200, 233], ["ppm", "TEST", 38, 41], ["CHCH2", "TEST", 50, 55], ["CHCH2", "TEST", 84, 89], ["the reaction", "TEST", 133, 145], ["benzoimidazol", "TEST", 155, 168], ["benzenesulfonic acid", "TREATMENT", 175, 195], ["acid chloride of methacrylic acid", "TREATMENT", 200, 233]]], ["Further the coupling constant value of 18 Hz in compound 14 indicated that the nature of the double bond in the synthesized compound 14 is of trans nature.", [["the coupling constant value", "TEST", 8, 35], ["double bond", "OBSERVATION", 93, 104]]], ["Compound 8 showed a singlet at \u03b4 3.78 ppm corresponding to a proton of the OCH3.", [["OCH3", "CHEMICAL", 75, 79], ["OCH3", "CHEMICAL", 75, 79], ["OCH3", "SIMPLE_CHEMICAL", 75, 79], ["OCH3", "PROTEIN", 75, 79], ["the OCH3", "TREATMENT", 71, 79]]], ["This confirmed the attachment of the para methoxy benzoyl group to the N1 position of benzimidazole.", [["methoxy benzoyl", "CHEMICAL", 42, 57], ["benzimidazole", "CHEMICAL", 86, 99], ["para methoxy benzoyl", "CHEMICAL", 37, 57], ["benzimidazole", "CHEMICAL", 86, 99], ["para methoxy benzoyl", "SIMPLE_CHEMICAL", 37, 57], ["benzimidazole", "SIMPLE_CHEMICAL", 86, 99], ["the para methoxy benzoyl", "TREATMENT", 33, 57], ["the N1 position of benzimidazole", "TREATMENT", 67, 99]]], ["The absence of a singlet at \u03b4 11 ppm in the NMR spectra of compounds 1-20 indicated the absence of the free COOH group.", [["compounds 1-20", "CHEMICAL", 59, 73], ["COOH", "CHEMICAL", 108, 112], ["COOH", "GENE_OR_GENE_PRODUCT", 108, 112], ["COOH group", "PROTEIN", 108, 118], ["a singlet at \u03b4 11 ppm", "TREATMENT", 15, 36], ["the NMR spectra of compounds", "TEST", 40, 68]]], ["This confirms that the compounds 1-20 are tertiary amides and not the physical mixture of aryl/alkyl acids and 4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid.", [["compounds 1-20", "CHEMICAL", 23, 37], ["aryl/alkyl acids", "CHEMICAL", 90, 106], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 111, 157], ["tertiary amides", "CHEMICAL", 42, 57], ["aryl/alkyl acids", "CHEMICAL", 90, 106], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "CHEMICAL", 111, 157], ["1-20", "SIMPLE_CHEMICAL", 33, 37], ["tertiary amides", "SIMPLE_CHEMICAL", 42, 57], ["aryl/alkyl acids", "SIMPLE_CHEMICAL", 90, 106], ["4-(1H-benzoimidazol-2-yl)-benzenesulfonic acid", "SIMPLE_CHEMICAL", 111, 157], ["the compounds", "TEST", 19, 32], ["tertiary amides", "TREATMENT", 42, 57], ["aryl/alkyl acids", "TREATMENT", 90, 106], ["benzoimidazol", "TEST", 117, 130], ["benzenesulfonic acid", "TREATMENT", 137, 157]]], ["Therefore, this assures the reaction of aryl/alkyl acid chlorides with the secondary nitrogen of the benzimidazole nucleus.Antimicrobial activity ::: Results and discussionThe synthesized compounds were evaluated for their in vitro antimicrobial activities against two Gram-positive bacteria \u2013 Staphylococcus aureus, Bacillus subtilis; the Gram-negative bacterium \u2013 Escherichia coli and the fungal strains \u2013 Aspergillus niger and Candida albicans by tube dilution method [19] using ciprofloxacin and fluconazole as control drugs for antibacterial and antifungal activity, respectively.", [["tube", "ANATOMY", 450, 454], ["aryl/alkyl acid chlorides", "CHEMICAL", 40, 65], ["Staphylococcus aureus", "DISEASE", 294, 315], ["ciprofloxacin", "CHEMICAL", 482, 495], ["fluconazole", "CHEMICAL", 500, 511], ["aryl/alkyl acid chlorides", "CHEMICAL", 40, 65], ["nitrogen", "CHEMICAL", 85, 93], ["benzimidazole", "CHEMICAL", 101, 114], ["ciprofloxacin", "CHEMICAL", 482, 495], ["fluconazole", "CHEMICAL", 500, 511], ["aryl/alkyl acid chlorides", "SIMPLE_CHEMICAL", 40, 65], ["Gram", "GENE_OR_GENE_PRODUCT", 269, 273], ["Staphylococcus aureus", "ORGANISM", 294, 315], ["Bacillus subtilis", "ORGANISM", 317, 334], ["Gram-negative bacterium \u2013", "ORGANISM", 340, 365], ["Escherichia coli", "ORGANISM", 366, 382], ["fungal strains \u2013", "ORGANISM", 391, 407], ["Aspergillus niger", "ORGANISM", 408, 425], ["Candida albicans", "ORGANISM", 430, 446], ["tube", "TISSUE", 450, 454], ["ciprofloxacin", "SIMPLE_CHEMICAL", 482, 495], ["fluconazole", "SIMPLE_CHEMICAL", 500, 511], ["Staphylococcus aureus", "SPECIES", 294, 315], ["Bacillus subtilis", "SPECIES", 317, 334], ["Escherichia coli", "SPECIES", 366, 382], ["Aspergillus niger", "SPECIES", 408, 425], ["Candida albicans", "SPECIES", 430, 446], ["Staphylococcus aureus", "SPECIES", 294, 315], ["Bacillus subtilis", "SPECIES", 317, 334], ["Escherichia coli", "SPECIES", 366, 382], ["Aspergillus niger", "SPECIES", 408, 425], ["Candida albicans", "SPECIES", 430, 446], ["aryl/alkyl acid chlorides", "TREATMENT", 40, 65], ["the secondary nitrogen of the benzimidazole nucleus", "TREATMENT", 71, 122], ["two Gram", "TEST", 265, 273], ["positive bacteria", "PROBLEM", 274, 291], ["Staphylococcus aureus", "PROBLEM", 294, 315], ["Bacillus subtilis", "PROBLEM", 317, 334], ["the Gram-negative bacterium", "PROBLEM", 336, 363], ["Escherichia coli", "PROBLEM", 366, 382], ["the fungal strains", "TEST", 387, 405], ["Aspergillus niger", "TREATMENT", 408, 425], ["Candida albicans", "TREATMENT", 430, 446], ["tube dilution method", "TREATMENT", 450, 470], ["ciprofloxacin", "TREATMENT", 482, 495], ["fluconazole", "TREATMENT", 500, 511], ["drugs", "TREATMENT", 523, 528], ["antibacterial and antifungal activity", "TREATMENT", 533, 570], ["benzimidazole nucleus", "OBSERVATION", 101, 122], ["positive bacteria", "OBSERVATION_MODIFIER", 274, 291], ["Staphylococcus aureus", "OBSERVATION", 294, 315], ["Escherichia coli", "OBSERVATION", 366, 382]]], ["The results of the antimicrobial studies are presented in Table 2.", [["the antimicrobial studies", "TEST", 15, 40]]], ["In general the compounds showed an improved antibacterial activity when compared to their antifungal activity.", [["improved", "OBSERVATION_MODIFIER", 35, 43], ["antibacterial activity", "OBSERVATION", 44, 66]]], ["The deduced patterns of antimicrobial activity of the synthesized benzimidazoles are in the following order: Antibacterial activity > antifungal activity.Antimicrobial activity ::: Results and discussionThe compound 9 is the most effective compound against S. aureus with pMICsa value of 2.43 (Table 2), respectively.", [["benzimidazoles", "CHEMICAL", 66, 80], ["compound 9", "CHEMICAL", 207, 217], ["benzimidazoles", "CHEMICAL", 66, 80], ["benzimidazoles", "SIMPLE_CHEMICAL", 66, 80], ["S. aureus", "ORGANISM", 257, 266], ["S. aureus", "SPECIES", 257, 266], ["S. aureus", "SPECIES", 257, 266], ["the synthesized benzimidazoles", "TREATMENT", 50, 80], ["Antibacterial activity", "TREATMENT", 109, 131], ["S. aureus", "PROBLEM", 257, 266], ["pMICsa value", "TEST", 272, 284], ["antimicrobial activity", "OBSERVATION", 24, 46], ["aureus", "OBSERVATION", 260, 266]]], ["For activity against B. subtilis the compounds 7 and 9 yielded better activity (Table 2) in comparison to other compounds synthesized.", [["B. subtilis", "ORGANISM", 21, 32], ["B. subtilis", "SPECIES", 21, 32], ["B. subtilis", "SPECIES", 21, 32]]], ["The antimicrobial spectrum of synthesized benzimidazoles against E. coli demonstrated that compounds 4, 5, 7 and 9 were the most active ones with pMICec values of 2.42, 2.42, 2.42 and 2.43 (Table 2) respectively.", [["benzimidazoles", "CHEMICAL", 42, 56], ["compounds 4, 5, 7 and 9", "CHEMICAL", 91, 114], ["benzimidazoles", "CHEMICAL", 42, 56], ["benzimidazoles", "SIMPLE_CHEMICAL", 42, 56], ["E. coli", "ORGANISM", 65, 72], ["5", "ORGANISM", 104, 105], ["pMICec", "SIMPLE_CHEMICAL", 146, 152], ["E. coli", "SPECIES", 65, 72], ["E. coli", "SPECIES", 65, 72], ["The antimicrobial spectrum of synthesized benzimidazoles", "TREATMENT", 0, 56], ["E. coli", "PROBLEM", 65, 72], ["pMICec values", "TEST", 146, 159]]], ["From the above discussion it is evident that compound 9 emerged as the most active antibacterial benzimidazole.", [["compound 9", "CHEMICAL", 45, 55], ["benzimidazole", "CHEMICAL", 97, 110], ["benzimidazole", "CHEMICAL", 97, 110], ["antibacterial benzimidazole", "SIMPLE_CHEMICAL", 83, 110], ["the most active antibacterial benzimidazole", "TREATMENT", 67, 110], ["antibacterial benzimidazole", "OBSERVATION", 83, 110]]], ["Compounds 9 and 18 emerged as the most effective antifungal agents against C. albicans whereas compound 18 was most active against A. niger (Table 2).", [["Compounds 9 and 18", "CHEMICAL", 0, 18], ["compound 18", "CHEMICAL", 95, 106], ["C. albicans", "ORGANISM", 75, 86], ["A. niger", "ORGANISM", 131, 139], ["C. albicans", "SPECIES", 75, 86], ["A. niger", "SPECIES", 131, 139], ["C. albicans", "SPECIES", 75, 86], ["A. niger", "SPECIES", 131, 139], ["antifungal agents", "TREATMENT", 49, 66], ["C. albicans", "PROBLEM", 75, 86]]], ["From the above discussion it is evident that compound 18 emerged as the most effective antifungal benzimidazole.Antimicrobial activity ::: Results and discussionThe minimum bactericidal concentration/minimum fungicidal concentration (MBC/MFC) (Table 3) determination results revealed that the synthesized compounds were fungistatic against both fungi and bacteriostatic against S. aureus, B. subtilis but bacteriocidal against E. coli.", [["benzimidazole", "CHEMICAL", 98, 111], ["MBC", "CHEMICAL", 234, 237], ["benzimidazole", "CHEMICAL", 98, 111], ["antifungal benzimidazole", "SIMPLE_CHEMICAL", 87, 111], ["S. aureus", "ORGANISM", 378, 387], ["B. subtilis", "ORGANISM", 389, 400], ["E. coli", "ORGANISM", 427, 434], ["S. aureus", "SPECIES", 378, 387], ["B. subtilis", "SPECIES", 389, 400], ["E. coli", "SPECIES", 427, 434], ["S. aureus", "SPECIES", 378, 387], ["B. subtilis", "SPECIES", 389, 400], ["E. coli", "SPECIES", 427, 434], ["the most effective antifungal benzimidazole", "TREATMENT", 68, 111], ["The minimum bactericidal concentration", "TREATMENT", 161, 199], ["minimum fungicidal concentration", "TEST", 200, 232], ["MBC/MFC", "TREATMENT", 234, 241], ["the synthesized compounds", "PROBLEM", 289, 314], ["fungistatic", "PROBLEM", 320, 331], ["both fungi", "PROBLEM", 340, 350], ["S. aureus", "PROBLEM", 378, 387], ["B. subtilis", "PROBLEM", 389, 400], ["bacteriocidal", "PROBLEM", 405, 418], ["E. coli", "PROBLEM", 427, 434], ["aureus", "OBSERVATION", 381, 387], ["coli", "OBSERVATION", 430, 434]]], ["In general, the MBC and MFC of synthesized benzimidazole derivatives were 3-fold higher than their MIC values, which indicated that they were bacteriostatic and fungistatic in action except for E. coli (a drug is considered to be bacteriosatic/fungistatic when its MBC and MFC values are 3-fold higher than its MIC values) [20].", [["MBC", "CHEMICAL", 16, 19], ["benzimidazole", "CHEMICAL", 43, 56], ["MBC", "CHEMICAL", 265, 268], ["benzimidazole", "CHEMICAL", 43, 56], ["MBC", "SIMPLE_CHEMICAL", 16, 19], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 43, 68], ["E. coli", "ORGANISM", 194, 201], ["MBC", "SIMPLE_CHEMICAL", 265, 268], ["E. coli", "SPECIES", 194, 201], ["E. coli", "SPECIES", 194, 201], ["the MBC", "TEST", 12, 19], ["synthesized benzimidazole derivatives", "TREATMENT", 31, 68], ["their MIC values", "TEST", 93, 109], ["bacteriostatic", "PROBLEM", 142, 156], ["fungistatic", "PROBLEM", 161, 172], ["E. coli", "PROBLEM", 194, 201], ["bacteriosatic", "PROBLEM", 230, 243], ["fungistatic", "PROBLEM", 244, 255], ["its MBC", "TEST", 261, 268], ["MFC values", "TEST", 273, 283], ["bacteriostatic", "OBSERVATION_MODIFIER", 142, 156]]], ["In the case of S. aureus compounds 10 and 17 and for Bacillus subtitlis compounds 11 and 17 were found to be active bacteriocidal agents.Development of one-target QSAR model ::: QSAR studies ::: Results and discussionIn order to understand the experimental antimicrobial data on a theoretical basis, we established a quantitative structure activity relationship (QSAR) between the in vitro antimicrobial activity of synthesized benzimidazole derivatives and descriptors coding for lipophilic, electronic, steric and topological properties of the molecules under consideration using the linear free energy relationship model (LFER) described by Hansch and Fujita [21].", [["benzimidazole", "CHEMICAL", 428, 441], ["benzimidazole", "CHEMICAL", 428, 441], ["S. aureus", "ORGANISM", 15, 24], ["Bacillus subtitlis", "ORGANISM", 53, 71], ["bacteriocidal agents", "SIMPLE_CHEMICAL", 116, 136], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 428, 453], ["S. aureus", "SPECIES", 15, 24], ["Bacillus subtitlis", "SPECIES", 53, 71], ["S. aureus", "SPECIES", 15, 24], ["Bacillus subtitlis", "SPECIES", 53, 71], ["S. aureus compounds", "PROBLEM", 15, 34], ["Bacillus subtitlis compounds", "TEST", 53, 81], ["active bacteriocidal agents", "TREATMENT", 109, 136], ["QSAR studies", "TEST", 178, 190], ["the in vitro antimicrobial activity", "TREATMENT", 377, 412], ["synthesized benzimidazole derivatives", "TREATMENT", 416, 453], ["lipophilic, electronic, steric and topological properties", "PROBLEM", 481, 538], ["aureus", "OBSERVATION", 18, 24], ["active", "OBSERVATION", 109, 115]]], ["Biological activity data determined as MIC values were first transformed into pMIC values and used as dependent variables in a QSAR study.", [["Biological activity data", "TEST", 0, 24], ["MIC values", "TEST", 39, 49], ["a QSAR study", "TEST", 125, 137]]], ["The different molecular descriptors (independent variables) like log of octanol-water partition coefficient (log P), molar refractivity (MR), Kier\u2019s molecular connectivity (0\u03c7, 0\u03c7v, 1\u03c7, 1\u03c7v, 2\u03c7, 2\u03c7v) and shape (\u03ba1, \u03ba\u03b11) topological indices, Randic topological index (R), Balaban topological index (J), Wiener topological index (W), Total energy (Te), energies of highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO), dipole moment (\u03bc), electronic energy (Ele.E), nuclear energy (Nu.E) and molecular surface area (SA) calculated for of 4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids are used as independent variables and are presented in Table 4[22], [23], [24], [25], [26], [27].Development of one-target QSAR model ::: QSAR studies ::: Results and discussionIn the present study, a data set of 20 benzimidazole derivatives was subjected to linear free energy regression analysis for model generation.", [["octanol", "CHEMICAL", 72, 79], ["benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 610, 651], ["benzimidazole", "CHEMICAL", 868, 881], ["octanol", "CHEMICAL", 72, 79], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "CHEMICAL", 571, 651], ["benzimidazole", "CHEMICAL", 868, 881], ["octanol", "SIMPLE_CHEMICAL", 72, 79], ["4-[1-(substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids", "SIMPLE_CHEMICAL", 571, 651], ["[23]", "SIMPLE_CHEMICAL", 720, 724], ["[24], [25], [26]", "SIMPLE_CHEMICAL", 726, 742], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 868, 893], ["MR", "PROTEIN", 137, 139], ["MR", "TEST", 137, 139], ["shape", "TEST", 204, 209], ["topological indices", "TEST", 220, 239], ["Randic topological index", "TEST", 241, 265], ["Balaban topological index", "TEST", 271, 296], ["Wiener topological index", "TEST", 302, 326], ["Total energy", "TEST", 332, 344], ["nuclear energy", "TEST", 499, 513], ["substituted aryl/alkyl carbonyl", "TREATMENT", 577, 608], ["benzoimidazol", "TREATMENT", 610, 623], ["benzenesulfonic acids", "TREATMENT", 630, 651], ["QSAR studies", "TEST", 790, 802], ["20 benzimidazole derivatives", "TREATMENT", 865, 893], ["model generation", "PROBLEM", 954, 970], ["molecular orbital", "ANATOMY", 380, 397], ["molecular orbital", "ANATOMY", 427, 444], ["surface", "ANATOMY_MODIFIER", 535, 542]]], ["The reference drugs were not included in model development as they belong to different structural series.", [["The reference drugs", "TREATMENT", 0, 19]]], ["Preliminary analysis was carried out in terms of correlation analysis.", [["Preliminary analysis", "TEST", 0, 20], ["correlation analysis", "TEST", 49, 69]]], ["A correlation matrix constructed for antibacterial activity against S. aureus is presented in Table 5.", [["S. aureus", "ORGANISM", 68, 77], ["S. aureus", "SPECIES", 68, 77], ["S. aureus", "SPECIES", 68, 77], ["A correlation matrix", "TREATMENT", 0, 20], ["antibacterial activity", "PROBLEM", 37, 59], ["S. aureus", "PROBLEM", 68, 77], ["aureus", "OBSERVATION", 71, 77]]], ["The correlations of different molecular descriptors with antimicrobial activity are presented in Table 6.", [["antimicrobial activity", "TREATMENT", 57, 79], ["antimicrobial activity", "OBSERVATION", 57, 79]]], ["In general, high colinearity (r > 0.8) was observed between different parameters.", [["high colinearity", "OBSERVATION", 12, 28]]], ["The high interrelationship was observed between Te and Nu.E (r = 0.990) and low interrelationship was observed between 2\u03c7v and LUMO (r = 0.001).Development of one-target QSAR model ::: QSAR studies ::: Results and discussionCorrelation matrix (Table 5) indicated the importance of the topological parameter, Balaban index (J) in describing antibacterial activity of synthesized benzimidazole derivatives against S. aureus [Eq.", [["benzimidazole", "CHEMICAL", 378, 391], ["benzimidazole", "CHEMICAL", 378, 391], ["benzimidazole derivatives", "SIMPLE_CHEMICAL", 378, 403], ["S. aureus", "ORGANISM", 412, 421], ["S. aureus", "SPECIES", 412, 421], ["S. aureus", "SPECIES", 412, 421], ["LUMO", "TEST", 127, 131], ["Balaban index (J)", "TREATMENT", 308, 325], ["antibacterial activity of synthesized benzimidazole derivatives", "TREATMENT", 340, 403], ["S. aureus", "PROBLEM", 412, 421], ["high", "OBSERVATION_MODIFIER", 4, 8], ["aureus", "OBSERVATION", 415, 421]]], ["(1)].Development of one-target QSAR model ::: QSAR studies ::: Results and discussion", [["QSAR studies", "TEST", 46, 58]]]], "PMC7337221": [["TRAINED INNATE IMMUNITY AND COVID-19When we get sick, our body\u2019s first line of defense, the immune cells, responds and stores a memory of the pathogen; this is called immunological memory (1).", [["body", "ANATOMY", 58, 62], ["immune cells", "ANATOMY", 92, 104], ["COVID-19When", "CELL", 28, 40], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["immune cells", "CELL", 92, 104], ["immune cells", "CELL_TYPE", 92, 104], ["COVID", "TEST", 28, 33], ["immune cells", "OBSERVATION", 92, 104]]], ["Two types of functionally distinct memories have been described, i.e., innate memory (non-specific) and acquired memory (specific).", [["distinct memories", "OBSERVATION", 26, 43]]], ["There are two ways by which T and B cells form an acquired immunological memory.", [["B cells", "ANATOMY", 34, 41], ["T", "CELL", 28, 29], ["B cells", "CELL", 34, 41], ["T and B cells", "CELL_TYPE", 28, 41]]], ["The first is based on genetic mechanisms that involve the recombination of membrane receptor genes (TCR) and selection of T cell clones capable of perfectly recognizing self and non-self antigens (e.g. proteins belonging to pathogens).", [["membrane", "ANATOMY", 75, 83], ["T cell clones", "ANATOMY", 122, 135], ["membrane receptor", "GENE_OR_GENE_PRODUCT", 75, 92], ["TCR", "GENE_OR_GENE_PRODUCT", 100, 103], ["T cell clones", "CELL", 122, 135], ["membrane receptor genes", "DNA", 75, 98], ["TCR", "PROTEIN", 100, 103], ["T cell clones", "CELL_LINE", 122, 135], ["non-self antigens", "PROTEIN", 178, 195], ["membrane receptor genes", "PROBLEM", 75, 98], ["T cell clones", "PROBLEM", 122, 135], ["cell clones", "OBSERVATION", 124, 135]]], ["The second, is based on the recombination of immunoglobulin genes (antibody genes) that recognize the proteins expressed by pathogens and the selection of memory B cell clones.", [["memory B cell clones", "ANATOMY", 155, 175], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 45, 59], ["memory B cell clones", "CELL", 155, 175], ["immunoglobulin genes", "DNA", 45, 65], ["antibody genes", "DNA", 67, 81], ["memory B cell clones", "CELL_LINE", 155, 175], ["immunoglobulin genes (antibody genes", "PROBLEM", 45, 81], ["the proteins", "PROBLEM", 98, 110], ["pathogens", "PROBLEM", 124, 133], ["memory B cell clones", "PROBLEM", 155, 175], ["memory B cell clones", "OBSERVATION", 155, 175]]], ["Memory B cells express membrane receptors (BCR)\u2014or bound antibody molecules with high affinity\u2014that recognize the pathogens in the event of a second infection.", [["Memory B cells", "ANATOMY", 0, 14], ["membrane", "ANATOMY", 23, 31], ["infection", "DISEASE", 149, 158], ["Memory B cells", "CELL", 0, 14], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["BCR", "GENE_OR_GENE_PRODUCT", 43, 46], ["Memory B cells", "CELL_TYPE", 0, 14], ["membrane receptors", "PROTEIN", 23, 41], ["BCR", "PROTEIN", 43, 46], ["antibody molecules", "PROTEIN", 57, 75], ["membrane receptors", "TEST", 23, 41], ["bound antibody molecules", "PROBLEM", 51, 75], ["high affinity", "PROBLEM", 81, 94], ["the pathogens", "PROBLEM", 110, 123], ["a second infection", "PROBLEM", 140, 158], ["infection", "OBSERVATION", 149, 158]]], ["However, the big question is, \u201chow are antibodies produced against an infectious pathogen or vaccine?\u201d", [["antibodies", "PROTEIN", 39, 49], ["an infectious pathogen", "PROBLEM", 67, 89], ["infectious", "OBSERVATION", 70, 80]]], ["First, dendritic cells phagocytize and degrade the pathogen and present its pieces in the form of epitopes (protein fragments) to CD4+ T lymphocytes.", [["dendritic cells", "ANATOMY", 7, 22], ["fragments", "ANATOMY", 116, 125], ["CD4+ T lymphocytes", "ANATOMY", 130, 148], ["dendritic cells", "CELL", 7, 22], ["CD4", "GENE_OR_GENE_PRODUCT", 130, 133], ["dendritic cells", "CELL_TYPE", 7, 22], ["epitopes", "PROTEIN", 98, 106], ["protein fragments", "PROTEIN", 108, 125], ["CD4", "PROTEIN", 130, 133], ["T lymphocytes", "CELL_TYPE", 135, 148], ["dendritic cells phagocytize", "PROBLEM", 7, 34], ["the pathogen", "PROBLEM", 47, 59], ["epitopes (protein fragments", "PROBLEM", 98, 125], ["CD4", "TEST", 130, 133], ["dendritic cells phagocytize", "OBSERVATION", 7, 34], ["lymphocytes", "ANATOMY", 137, 148]]], ["Then, helper CD4+ T cells communicate with lymphocytes B, which initiate the production of different classes of antibodies (humoral soluble response) against these epitopes.", [["helper CD4+ T cells", "ANATOMY", 6, 25], ["lymphocytes", "ANATOMY", 43, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 13, 16], ["lymphocytes B", "CELL", 43, 56], ["helper CD4+ T cells", "CELL_TYPE", 6, 25], ["lymphocytes B", "CELL_TYPE", 43, 56], ["antibodies", "PROTEIN", 112, 122], ["epitopes", "PROTEIN", 164, 172], ["lymphocytes B", "PROBLEM", 43, 56], ["antibodies (humoral soluble response", "TREATMENT", 112, 148], ["these epitopes", "PROBLEM", 158, 172]]], ["B lymphocyte clones die at the end of the infection and only few clones that contain the code (memory) for the synthesis of specific antibodies remain.", [["B lymphocyte clones", "ANATOMY", 0, 19], ["infection", "DISEASE", 42, 51], ["B lymphocyte clones", "CELL", 0, 19], ["B lymphocyte clones", "CELL_LINE", 0, 19], ["antibodies", "PROTEIN", 133, 143], ["B lymphocyte clones die", "PROBLEM", 0, 23], ["the infection", "PROBLEM", 38, 51], ["few clones", "PROBLEM", 61, 71], ["the synthesis of specific antibodies", "PROBLEM", 107, 143], ["lymphocyte clones", "OBSERVATION", 2, 19], ["infection", "OBSERVATION", 42, 51]]], ["Another population of lymphocytes, called effector CD8+ T lymphocytes (cellular response), also recognizes pathogen-related antigens in infected cells.", [["lymphocytes", "ANATOMY", 22, 33], ["effector CD8+ T lymphocytes", "ANATOMY", 42, 69], ["cellular", "ANATOMY", 71, 79], ["cells", "ANATOMY", 145, 150], ["lymphocytes", "CELL", 22, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["cellular", "CELL", 71, 79], ["cells", "CELL", 145, 150], ["lymphocytes", "CELL_TYPE", 22, 33], ["effector CD8+ T lymphocytes", "CELL_TYPE", 42, 69], ["pathogen-related antigens", "PROTEIN", 107, 132], ["infected cells", "CELL_TYPE", 136, 150], ["lymphocytes", "PROBLEM", 22, 33], ["cellular response", "TEST", 71, 88], ["pathogen", "PROBLEM", 107, 115], ["infected cells", "PROBLEM", 136, 150], ["lymphocytes", "ANATOMY", 22, 33], ["infected cells", "OBSERVATION", 136, 150]]], ["These cytotoxic lymphocytes attack the pathogens by releasing cytokines, toxins, and enzymes that lead to cell death via apoptosis and necroptosis.", [["lymphocytes", "ANATOMY", 16, 27], ["cell", "ANATOMY", 106, 110], ["death", "DISEASE", 111, 116], ["cytotoxic lymphocytes", "CELL", 6, 27], ["cell", "CELL", 106, 110], ["cytotoxic lymphocytes", "CELL_TYPE", 6, 27], ["cytokines", "PROTEIN", 62, 71], ["enzymes", "PROTEIN", 85, 92], ["These cytotoxic lymphocytes attack the pathogens", "PROBLEM", 0, 48], ["releasing cytokines", "TEST", 52, 71], ["toxins", "TEST", 73, 79], ["enzymes", "TEST", 85, 92], ["cell death", "PROBLEM", 106, 116], ["apoptosis", "PROBLEM", 121, 130], ["necroptosis", "PROBLEM", 135, 146], ["cytotoxic lymphocytes", "OBSERVATION", 6, 27], ["pathogens", "OBSERVATION_MODIFIER", 39, 48], ["apoptosis", "OBSERVATION", 121, 130], ["necroptosis", "OBSERVATION", 135, 146]]], ["These cytotoxic lymphocytes also die at the end, and only a few clones survive.", [["lymphocytes", "ANATOMY", 16, 27], ["cytotoxic lymphocytes", "CELL", 6, 27], ["clones", "CELL", 64, 70], ["cytotoxic lymphocytes", "CELL_TYPE", 6, 27], ["These cytotoxic lymphocytes", "PROBLEM", 0, 27], ["cytotoxic lymphocytes", "OBSERVATION", 6, 27], ["few", "OBSERVATION_MODIFIER", 60, 63], ["clones", "OBSERVATION", 64, 70]]], ["The survivors are programmed to become memory CD8+ T lymphocytes that would recognize the pathogen in the event of a second infection.TRAINED INNATE IMMUNITY AND COVID-19How is memory in CD8+ T cells formed chemically?", [["memory CD8+ T lymphocytes", "ANATOMY", 39, 64], ["CD8+", "ANATOMY", 187, 191], ["T cells", "ANATOMY", 192, 199], ["infection", "DISEASE", 124, 133], ["CD8", "GENE_OR_GENE_PRODUCT", 46, 49], ["COVID-19How", "CELL", 162, 173], ["CD8", "GENE_OR_GENE_PRODUCT", 187, 190], ["T cells", "CELL", 192, 199], ["memory CD8+ T lymphocytes", "CELL_TYPE", 39, 64], ["CD8", "PROTEIN", 187, 190], ["T cells", "CELL_TYPE", 192, 199], ["T lymphocytes", "PROBLEM", 51, 64], ["the pathogen", "PROBLEM", 86, 98], ["a second infection", "PROBLEM", 115, 133], ["COVID", "TEST", 162, 167], ["second", "OBSERVATION_MODIFIER", 117, 123], ["infection", "OBSERVATION", 124, 133]]], ["What we know is that cytosine and guanine (CpG)-rich regions in the promoters of genes encoding for various proteins, such as transcription factors, cytotoxic proteins, and cytokines involved in lymphocyte activation, undergo chemical modifications (methylation and demethylation, i.e., addition or removal of methyl groups).", [["lymphocyte", "ANATOMY", 195, 205], ["cytosine", "CHEMICAL", 21, 29], ["guanine", "CHEMICAL", 34, 41], ["CpG", "CHEMICAL", 43, 46], ["methyl", "CHEMICAL", 310, 316], ["cytosine", "CHEMICAL", 21, 29], ["guanine", "CHEMICAL", 34, 41], ["CpG", "CHEMICAL", 43, 46], ["methyl", "CHEMICAL", 310, 316], ["cytosine", "SIMPLE_CHEMICAL", 21, 29], ["guanine", "SIMPLE_CHEMICAL", 34, 41], ["lymphocyte", "CELL", 195, 205], ["cytosine and guanine (CpG)-rich regions", "DNA", 21, 60], ["promoters", "DNA", 68, 77], ["transcription factors", "PROTEIN", 126, 147], ["cytotoxic proteins", "PROTEIN", 149, 167], ["cytokines", "PROTEIN", 173, 182], ["cytosine and guanine (CpG)", "TREATMENT", 21, 47], ["various proteins", "PROBLEM", 100, 116], ["cytotoxic proteins", "PROBLEM", 149, 167], ["cytokines", "PROBLEM", 173, 182], ["lymphocyte activation", "TREATMENT", 195, 216], ["chemical modifications", "TREATMENT", 226, 248], ["methylation and demethylation", "TREATMENT", 250, 279], ["removal of methyl groups", "TREATMENT", 299, 323]]], ["Such modifications form a silencing or activating on/off switch for the transcription of immune response genes.", [["immune response genes", "DNA", 89, 110], ["immune response genes", "TREATMENT", 89, 110]]], ["Histone proteins that bind DNA molecules also undergo methylation and acetylation at their lysine and arginine residues.", [["lysine", "CHEMICAL", 91, 97], ["arginine", "CHEMICAL", 102, 110], ["lysine", "CHEMICAL", 91, 97], ["arginine", "CHEMICAL", 102, 110], ["Histone proteins", "GENE_OR_GENE_PRODUCT", 0, 16], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["lysine", "AMINO_ACID", 91, 97], ["arginine", "AMINO_ACID", 102, 110], ["Histone proteins", "PROTEIN", 0, 16], ["DNA molecules", "PROTEIN", 27, 40], ["Histone proteins", "PROBLEM", 0, 16], ["bind DNA molecules", "PROBLEM", 22, 40], ["methylation", "TREATMENT", 54, 65], ["acetylation", "TREATMENT", 70, 81], ["their lysine", "TREATMENT", 85, 97], ["arginine residues", "TREATMENT", 102, 119]]], ["These types of chemical changes are referred to epigenetic and non-genetic (non-hereditary) modifications, as they do not cause any changes (mutations) in the DNA molecule, nor are they transmitted to the next generation.", [["DNA", "CELLULAR_COMPONENT", 159, 162], ["chemical changes", "PROBLEM", 15, 31], ["any changes (mutations) in the DNA molecule", "PROBLEM", 128, 171], ["chemical changes", "OBSERVATION", 15, 31]]], ["Therefore, children need to receive vaccines that protected their parents from pathogen, for example, the measles vaccine, to develop their own immune responses.TRAINED INNATE IMMUNITY AND COVID-19Bone marrow progenitor myeloid cells that give rise to blood leukocytes, such as neutrophils, monocytes, and natural killer cells (NKs), are the innate cells participating in the non-specific innate response and trained immunity (2).", [["COVID-19Bone marrow progenitor myeloid cells", "ANATOMY", 189, 233], ["blood leukocytes", "ANATOMY", 252, 268], ["neutrophils", "ANATOMY", 278, 289], ["monocytes", "ANATOMY", 291, 300], ["natural killer cells", "ANATOMY", 306, 326], ["NKs", "ANATOMY", 328, 331], ["cells", "ANATOMY", 349, 354], ["children", "ORGANISM", 11, 19], ["COVID-19Bone marrow progenitor myeloid cells", "CELL", 189, 233], ["blood leukocytes", "CELL", 252, 268], ["neutrophils", "CELL", 278, 289], ["monocytes", "CELL", 291, 300], ["natural killer cells", "CELL", 306, 326], ["NKs", "CELL", 328, 331], ["cells", "CELL", 349, 354], ["COVID-19Bone marrow progenitor myeloid cells", "CELL_LINE", 189, 233], ["blood leukocytes", "CELL_TYPE", 252, 268], ["neutrophils", "CELL_TYPE", 278, 289], ["monocytes", "CELL_TYPE", 291, 300], ["natural killer cells", "CELL_TYPE", 306, 326], ["NKs", "CELL_TYPE", 328, 331], ["innate cells", "CELL_TYPE", 342, 354], ["children", "SPECIES", 11, 19], ["vaccines", "TREATMENT", 36, 44], ["the measles vaccine", "TREATMENT", 102, 121], ["COVID", "TEST", 189, 194], ["myeloid cells", "PROBLEM", 220, 233], ["blood leukocytes", "TEST", 252, 268], ["neutrophils", "TEST", 278, 289], ["monocytes", "TEST", 291, 300], ["natural killer cells", "TEST", 306, 326], ["NKs", "TEST", 328, 331], ["marrow", "ANATOMY", 202, 208], ["progenitor myeloid cells", "OBSERVATION", 209, 233], ["natural killer cells", "OBSERVATION", 306, 326]]], ["Studies have shown that monocytes and macrophages are \u201ceducated or trained\u201d during the first infection, and thus they acquire the ability to fight more effectively in subsequent infections.", [["monocytes", "ANATOMY", 24, 33], ["macrophages", "ANATOMY", 38, 49], ["infection", "DISEASE", 93, 102], ["infections", "DISEASE", 178, 188], ["monocytes", "CELL", 24, 33], ["macrophages", "CELL", 38, 49], ["monocytes", "CELL_TYPE", 24, 33], ["macrophages", "CELL_TYPE", 38, 49], ["Studies", "TEST", 0, 7], ["monocytes", "PROBLEM", 24, 33], ["the first infection", "PROBLEM", 83, 102], ["subsequent infections", "PROBLEM", 167, 188], ["monocytes", "OBSERVATION", 24, 33], ["macrophages", "OBSERVATION", 38, 49], ["infection", "OBSERVATION", 93, 102], ["infections", "OBSERVATION", 178, 188]]], ["Monocytes are trained through stimulation with lipopolysaccharide (LPS)\u2014a gram-negative bacterial membrane protein\u2014or beta-glucan, a component of the fungal cell wall.", [["Monocytes", "ANATOMY", 0, 9], ["membrane", "ANATOMY", 98, 106], ["cell wall", "ANATOMY", 157, 166], ["lipopolysaccharide", "CHEMICAL", 47, 65], ["LPS", "CHEMICAL", 67, 70], ["beta-glucan", "CHEMICAL", 118, 129], ["Monocytes", "CELL", 0, 9], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 47, 65], ["LPS", "SIMPLE_CHEMICAL", 67, 70], ["gram-", "GENE_OR_GENE_PRODUCT", 74, 79], ["beta-glucan", "SIMPLE_CHEMICAL", 118, 129], ["cell wall", "TISSUE", 157, 166], ["Monocytes", "CELL_TYPE", 0, 9], ["Monocytes", "TEST", 0, 9], ["lipopolysaccharide (LPS", "TEST", 47, 70], ["bacterial membrane protein\u2014or beta-glucan", "PROBLEM", 88, 129], ["the fungal cell wall", "PROBLEM", 146, 166], ["bacterial membrane protein\u2014or beta-glucan", "OBSERVATION", 88, 129], ["fungal cell", "OBSERVATION", 150, 161], ["wall", "ANATOMY_MODIFIER", 162, 166]]], ["For example, the bacillus Calmette-Gu\u00e9rin (BCG) vaccine can increase the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), and IL-6, up to 5 times on second contact with the pathogen.", [["bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 17, 41], ["BCG", "CHEMICAL", 43, 46], ["tumor necrosis", "DISEASE", 123, 137], ["bacillus Calmette-Gu\u00e9rin", "ORGANISM", 17, 41], ["BCG", "ORGANISM", 43, 46], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 123, 144], ["TNF", "GENE_OR_GENE_PRODUCT", 146, 149], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 152, 165], ["IL-1", "GENE_OR_GENE_PRODUCT", 167, 171], ["IL-6", "GENE_OR_GENE_PRODUCT", 178, 182], ["pro-inflammatory cytokines", "PROTEIN", 87, 113], ["tumor necrosis factor", "PROTEIN", 123, 144], ["TNF", "PROTEIN", 146, 149], ["interleukin-1 (IL-1", "PROTEIN", 152, 171], ["IL", "PROTEIN", 178, 180], ["bacillus Calmette-Gu\u00e9rin", "SPECIES", 17, 41], ["the bacillus Calmette", "TREATMENT", 13, 34], ["Gu\u00e9rin (BCG) vaccine", "TREATMENT", 35, 55], ["pro-inflammatory cytokines", "PROBLEM", 87, 113], ["tumor necrosis factor", "PROBLEM", 123, 144], ["TNF", "TEST", 146, 149], ["interleukin", "TEST", 152, 163], ["the pathogen", "PROBLEM", 221, 233], ["pro-inflammatory cytokines", "OBSERVATION", 87, 113]]], ["This type of immunological memory or epigenetic programming to a pre-activated state allows the generation of a sustained and more effective non-specific response, even after years, although in the protocols of these studies, the innate immunity was evaluated after 3 months (2).TRAINED INNATE IMMUNITY AND COVID-19Biochemical analyses on chromatin showed that trained monocytes are characterized by an increase in histone 3 acetylation, in particular H3K27Ac and H3K4me3 as well as by an increase in the metabolism of glucose (glycolysis) and glutamine (glutaminolysis), and by high levels of fumarate, a metabolite of the tricarboxylic acid cycle or Krebs cycle (2).", [["chromatin", "ANATOMY", 339, 348], ["monocytes", "ANATOMY", 369, 378], ["glucose", "CHEMICAL", 519, 526], ["glutamine", "CHEMICAL", 544, 553], ["glutaminolysis", "CHEMICAL", 555, 569], ["fumarate", "CHEMICAL", 594, 602], ["tricarboxylic acid", "CHEMICAL", 624, 642], ["glucose", "CHEMICAL", 519, 526], ["glutamine", "CHEMICAL", 544, 553], ["glutaminolysis", "CHEMICAL", 555, 569], ["fumarate", "CHEMICAL", 594, 602], ["tricarboxylic acid", "CHEMICAL", 624, 642], ["chromatin", "CELLULAR_COMPONENT", 339, 348], ["monocytes", "CELL", 369, 378], ["histone 3", "GENE_OR_GENE_PRODUCT", 415, 424], ["H3K27Ac", "GENE_OR_GENE_PRODUCT", 452, 459], ["H3K4me3", "GENE_OR_GENE_PRODUCT", 464, 471], ["glucose", "SIMPLE_CHEMICAL", 519, 526], ["glutamine", "AMINO_ACID", 544, 553], ["glutaminolysis", "SIMPLE_CHEMICAL", 555, 569], ["fumarate", "SIMPLE_CHEMICAL", 594, 602], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 624, 642], ["chromatin", "DNA", 339, 348], ["monocytes", "CELL_TYPE", 369, 378], ["histone 3", "PROTEIN", 415, 424], ["H3K27Ac", "PROTEIN", 452, 459], ["H3K4me3", "PROTEIN", 464, 471], ["immunological memory", "PROBLEM", 13, 33], ["epigenetic programming", "PROBLEM", 37, 59], ["these studies", "TEST", 211, 224], ["COVID", "TEST", 307, 312], ["19Biochemical analyses", "TEST", 313, 335], ["trained monocytes", "PROBLEM", 361, 378], ["histone 3 acetylation", "TREATMENT", 415, 436], ["glucose (glycolysis", "TREATMENT", 519, 538], ["glutamine (glutaminolysis", "TREATMENT", 544, 569], ["fumarate", "TREATMENT", 594, 602], ["the tricarboxylic acid cycle", "TREATMENT", 620, 648], ["Krebs cycle", "TREATMENT", 652, 663], ["increase", "OBSERVATION_MODIFIER", 403, 411], ["histone 3 acetylation", "OBSERVATION", 415, 436], ["increase", "OBSERVATION_MODIFIER", 489, 497]]], ["It has also been observed that after the training of human monocytes with Candida albicans (a human opportunistic pathogen) beta-glucan, the induced innate immunity protects not only against fungi, but also against bacteria, viruses, and parasites (2).", [["monocytes", "ANATOMY", 59, 68], ["beta-glucan", "CHEMICAL", 124, 135], ["human", "ORGANISM", 53, 58], ["monocytes", "CELL", 59, 68], ["Candida albicans", "ORGANISM", 74, 90], ["human", "ORGANISM", 94, 99], ["beta-glucan", "SIMPLE_CHEMICAL", 124, 135], ["human monocytes", "CELL_TYPE", 53, 68], ["human", "SPECIES", 53, 58], ["Candida albicans", "SPECIES", 74, 90], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 53, 58], ["Candida albicans", "SPECIES", 74, 90], ["human", "SPECIES", 94, 99], ["human monocytes", "PROBLEM", 53, 68], ["Candida albicans", "PROBLEM", 74, 90], ["a human opportunistic pathogen) beta-glucan", "TREATMENT", 92, 135], ["the induced innate immunity protects", "TREATMENT", 137, 173], ["fungi", "PROBLEM", 191, 196], ["bacteria", "PROBLEM", 215, 223], ["viruses", "PROBLEM", 225, 232], ["parasites", "PROBLEM", 238, 247]]], ["In addition, the training of human monocytes by Saccharomyces cerevisiae (another human opportunistic pathogen) chitin greatly increased their ability to eliminate microbes such as Candida albicans, Staphylococcus aureus (a gram-positive bacterium), and Escherichia coli (a gram-negative bacterium) in comparison with untrained human monocytes.", [["monocytes", "ANATOMY", 35, 44], ["monocytes", "ANATOMY", 334, 343], ["chitin", "CHEMICAL", 112, 118], ["human", "ORGANISM", 29, 34], ["monocytes", "CELL", 35, 44], ["Saccharomyces cerevisiae", "ORGANISM", 48, 72], ["human", "ORGANISM", 82, 87], ["chitin", "SIMPLE_CHEMICAL", 112, 118], ["Candida albicans", "ORGANISM", 181, 197], ["Staphylococcus aureus", "ORGANISM", 199, 220], ["gram-", "GENE_OR_GENE_PRODUCT", 224, 229], ["Escherichia coli", "ORGANISM", 254, 270], ["human", "ORGANISM", 328, 333], ["monocytes", "CELL", 334, 343], ["human monocytes", "CELL_TYPE", 29, 44], ["untrained human monocytes", "CELL_TYPE", 318, 343], ["human", "SPECIES", 29, 34], ["Saccharomyces cerevisiae", "SPECIES", 48, 72], ["human", "SPECIES", 82, 87], ["Candida albicans", "SPECIES", 181, 197], ["Staphylococcus aureus", "SPECIES", 199, 220], ["Escherichia coli", "SPECIES", 254, 270], ["human", "SPECIES", 328, 333], ["human", "SPECIES", 29, 34], ["Saccharomyces cerevisiae", "SPECIES", 48, 72], ["human", "SPECIES", 82, 87], ["Candida albicans", "SPECIES", 181, 197], ["Staphylococcus aureus", "SPECIES", 199, 220], ["Escherichia coli", "SPECIES", 254, 270], ["human", "SPECIES", 328, 333], ["human monocytes", "PROBLEM", 29, 44], ["Saccharomyces cerevisiae", "TREATMENT", 48, 72], ["Candida albicans", "PROBLEM", 181, 197], ["Staphylococcus aureus", "PROBLEM", 199, 220], ["a gram-positive bacterium", "PROBLEM", 222, 247], ["Escherichia coli", "PROBLEM", 254, 270], ["a gram-negative bacterium", "PROBLEM", 272, 297], ["untrained human monocytes", "PROBLEM", 318, 343], ["Escherichia coli", "OBSERVATION", 254, 270], ["human monocytes", "OBSERVATION", 328, 343]]], ["More interesting, the non-specific effects of BCG vaccination improved the effects of low-efficiency vaccines, such as the vaccine against typhus\u2014caused by Salmonella typhi (http://www.clinicaltrials.gov, number NCT02175420)\u2014or the influenza vaccine.", [["influenza", "DISEASE", 232, 241], ["Salmonella typhi", "ORGANISM", 156, 172], ["Salmonella typhi", "SPECIES", 156, 172], ["Salmonella typhi", "SPECIES", 156, 172], ["BCG vaccination", "TREATMENT", 46, 61], ["low-efficiency vaccines", "TREATMENT", 86, 109], ["the vaccine", "TREATMENT", 119, 130], ["Salmonella typhi", "PROBLEM", 156, 172], ["the influenza vaccine", "TREATMENT", 228, 249], ["low-efficiency", "OBSERVATION_MODIFIER", 86, 100]]], ["This protective effect has been known for decades in many countries (e.g. in Denmark and South Africa) where the BCG vaccine is administered to babies a few days after birth.", [["the BCG vaccine", "TREATMENT", 109, 124]]], ["In these countries, there was a 38-70% reduction in infant mortality associated with pneumonia and sepsis (3).", [["pneumonia", "DISEASE", 85, 94], ["sepsis", "DISEASE", 99, 105], ["infant mortality", "PROBLEM", 52, 68], ["pneumonia", "PROBLEM", 85, 94], ["sepsis", "PROBLEM", 99, 105], ["pneumonia", "OBSERVATION", 85, 94], ["sepsis", "OBSERVATION", 99, 105]]], ["However, to the best of our knowledge, none of the studies have determined if a similar phenomenon occurs in vaccinated babies in Brazil.TRAINED INNATE IMMUNITY AND COVID-19Various clinical trials are underway to evaluate trained immunity through BCG vaccination in healthy volunteers under the coordination of Dr. Mihail Netea (Radboud University Medical Center, Nijmegen, the Netherlands).", [["volunteers", "ORGANISM", 274, 284], ["the studies", "TEST", 47, 58], ["a similar phenomenon", "PROBLEM", 78, 98], ["COVID", "TEST", 165, 170], ["BCG vaccination", "TREATMENT", 247, 262]]], ["Clinical trials BRACE (http://www.clinicaltrialgov, number NCT04327206) and BCG-corona (http://www.clinicaltrial.gov, number NCT04328441) are employing large cohorts of health professionals in the Netherlands, Denmark, Germany, England, France, Tanzania, Uganda, Colombia, and Uruguay (3).", [["Clinical trials BRACE", "TREATMENT", 0, 21], ["BCG", "PROBLEM", 76, 79], ["corona", "ANATOMY_MODIFIER", 80, 86], ["large", "OBSERVATION_MODIFIER", 152, 157]]], ["The objective is to demonstrate whether immunization with BCG vaccines produced using different strains and titers of the bacillus Calmette-Gu\u00e9rin\u2014the vaccine against tuberculosis\u2014can protect these professionals against SARS-CoV-2 infection (3).", [["tuberculosis\u2014can", "CHEMICAL", 167, 183], ["SARS-CoV-2 infection", "DISEASE", 220, 240], ["bacillus Calmette-Gu\u00e9rin\u2014the vaccine", "ORGANISM", 122, 158], ["tuberculosis\u2014can", "SIMPLE_CHEMICAL", 167, 183], ["SARS-CoV-2", "ORGANISM", 220, 230], ["CoV-2", "SPECIES", 225, 230], ["SARS-CoV-2", "SPECIES", 220, 230], ["immunization", "TREATMENT", 40, 52], ["BCG vaccines", "TREATMENT", 58, 70], ["different strains", "TREATMENT", 86, 103], ["the bacillus Calmette", "TREATMENT", 118, 139], ["Gu\u00e9rin\u2014the vaccine", "TREATMENT", 140, 158], ["SARS", "PROBLEM", 220, 224], ["CoV-2 infection", "PROBLEM", 225, 240]]], ["A similar study will be carried out in Brazil (http://www.clinicaltrial.gov, number NCT04369794).", [["A similar study", "TEST", 0, 15]]], ["Dr. Netea said that preliminary results showed that in a large number of human volunteer cohorts, the BCG vaccine induced trained immunity (>50%; as stated in https://www.youtube.com/watch?v=3W36p40poLs).", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["human volunteer cohorts", "TREATMENT", 73, 96], ["the BCG vaccine", "TREATMENT", 98, 113], ["large", "OBSERVATION_MODIFIER", 57, 62]]], ["It is expected that the volunteers, if infected, will respond mildly or asymptomatically to the SARS-CoV-2 infection.", [["SARS", "DISEASE", 96, 100], ["infection", "DISEASE", 107, 116], ["volunteers", "ORGANISM", 24, 34], ["SARS-CoV-2", "ORGANISM", 96, 106], ["SARS-CoV-2", "SPECIES", 96, 106], ["infected", "PROBLEM", 39, 47], ["the SARS", "PROBLEM", 92, 100], ["CoV-2 infection", "PROBLEM", 101, 116], ["infection", "OBSERVATION", 107, 116]]], ["The scientific basis for this hypothesis comes from studies undertaken on human volunteers previously immunized with the live BCG vaccine and then with the vaccine for the yellow fever virus that causes a hemorrhagic disease (4).", [["yellow fever", "DISEASE", 172, 184], ["hemorrhagic disease", "DISEASE", 205, 224], ["human", "ORGANISM", 74, 79], ["volunteers", "ORGANISM", 80, 90], ["yellow fever virus", "ORGANISM", 172, 190], ["human", "SPECIES", 74, 79], ["yellow fever virus", "SPECIES", 172, 190], ["human", "SPECIES", 74, 79], ["yellow fever virus", "SPECIES", 172, 190], ["this hypothesis", "PROBLEM", 25, 40], ["human volunteers", "TREATMENT", 74, 90], ["the live BCG vaccine", "TREATMENT", 117, 137], ["the vaccine", "TREATMENT", 152, 163], ["the yellow fever virus", "PROBLEM", 168, 190], ["a hemorrhagic disease", "PROBLEM", 203, 224], ["hemorrhagic", "OBSERVATION_MODIFIER", 205, 216]]], ["It has also been verified through epidemiological and observational clinical studies that the number of deaths caused by coronaviruses in low-income countries, such as India and some countries in Africa and the Americas, are significantly lower than those in countries with medium and high levels of economic development, such as Italy, Belgium, Holland, and the United States of America (5).", [["deaths", "DISEASE", 104, 110], ["coronaviruses", "DISEASE", 121, 134], ["observational clinical studies", "TEST", 54, 84], ["coronaviruses", "PROBLEM", 121, 134]]], ["Despite the presence of evidences regarding the efficacy of BCG, the latter countries have not adopted the universal policy of mandatory immunization against tuberculosis (6).", [["tuberculosis", "DISEASE", 158, 170], ["BCG", "TREATMENT", 60, 63], ["mandatory immunization", "TREATMENT", 127, 149], ["tuberculosis", "PROBLEM", 158, 170]]], ["Live or attenuated vaccines against measles and smallpox as well as the oral polio vaccine are also effective in inducing innate cross-protection against other unrelated viral infections.", [["oral", "ANATOMY", 72, 76], ["measles and smallpox", "DISEASE", 36, 56], ["viral infections", "DISEASE", 170, 186], ["measles", "ORGANISM", 36, 43], ["oral", "ORGANISM_SUBDIVISION", 72, 76], ["polio", "ORGANISM", 77, 82], ["attenuated vaccines", "TREATMENT", 8, 27], ["measles", "PROBLEM", 36, 43], ["smallpox", "TREATMENT", 48, 56], ["the oral polio vaccine", "TREATMENT", 68, 90], ["other unrelated viral infections", "PROBLEM", 154, 186], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["infections", "OBSERVATION", 176, 186]]], ["The hypothesis that all vaccinated children are protected or are less likely to develop severe symptoms of the SARS-CoV-2 has been contested by many investigators (7,8).", [["SARS", "DISEASE", 111, 115], ["children", "ORGANISM", 35, 43], ["SARS-CoV-2", "ORGANISM", 111, 121], ["children", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 111, 119], ["severe symptoms", "PROBLEM", 88, 103], ["the SARS", "PROBLEM", 107, 115]]], ["Therefore, we need to wait for the results of the clinical trials that are currently underway.TRAINED INNATE IMMUNITY AND COVID-19In Brazil, epidemiological data on tuberculosis, published by the Ministry of Health on March 2019, indicates that the incidence of the disease (30-35 cases/100 thousand inhabitants) has not changed in the last 10 years (9).", [["tuberculosis", "DISEASE", 165, 177], ["the clinical trials", "TEST", 46, 65], ["tuberculosis", "PROBLEM", 165, 177], ["the disease", "PROBLEM", 262, 273], ["tuberculosis", "OBSERVATION", 165, 177]]], ["Rio de Janeiro, Amazonas, Par\u00e1, Roraima, and Acre are the states with a tuberculosis incidence higher than the national average.", [["tuberculosis", "DISEASE", 72, 84], ["a tuberculosis incidence", "PROBLEM", 70, 94], ["tuberculosis", "OBSERVATION", 72, 84]]], ["In addition, mortality is higher than the national average (2.2 deaths /100 thousand inhabitants) in Rio de Janeiro, Amazonas, Pernambuco, Rio Grande do Sul, Par\u00e1, Maranh\u00e3o, Rio Grande do Norte, Cear\u00e1, and Acre.", [["deaths", "DISEASE", 64, 70], ["higher", "OBSERVATION_MODIFIER", 26, 32]]], ["Vaccination, although recommended by the WHO (World Health organization) for vulnerable populations, is not routinely employed, and only newborns receive the vaccine in Brazil. since 2010, the Butantan Institute has stopped the production of oral BCG (live strain); now, it only produces the BCG vaccine formulated using the recombinant tuberculin protein.", [["oral", "ANATOMY", 242, 246], ["newborns", "ORGANISM", 137, 145], ["oral", "ORGANISM_SUBDIVISION", 242, 246], ["BCG", "ORGANISM", 247, 250], ["recombinant tuberculin protein", "PROTEIN", 325, 355], ["Vaccination", "TREATMENT", 0, 11], ["vulnerable populations", "PROBLEM", 77, 99], ["the vaccine", "TREATMENT", 154, 165], ["oral BCG", "TREATMENT", 242, 250], ["the BCG vaccine", "TREATMENT", 288, 303], ["the recombinant tuberculin protein", "TREATMENT", 321, 355]]], ["To our knowledge, there are no published articles or clinical evidences that show that BCG immunization protects against SARS-CoV-2 in Brazil.", [["SARS-CoV-2", "ORGANISM", 121, 131], ["SARS-CoV", "SPECIES", 121, 129], ["BCG immunization", "TREATMENT", 87, 103], ["SARS", "PROBLEM", 121, 125], ["CoV", "TEST", 126, 129], ["no", "UNCERTAINTY", 28, 30]]], ["Is innate memory more effective against SARS-CoV-2 than acquired memory?", [["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS", "PROBLEM", 40, 44]]], ["Could BCG vaccination be a more promising therapeutic alternative than chloroquine?", [["chloroquine", "CHEMICAL", 71, 82], ["chloroquine", "CHEMICAL", 71, 82], ["chloroquine", "SIMPLE_CHEMICAL", 71, 82], ["BCG vaccination", "TREATMENT", 6, 21], ["chloroquine", "TREATMENT", 71, 82]]], ["How evidence is transformed into scientific knowledge depends on statistical methods that define whether certain types of interferences (errors, biases, or confounding factors)\u2014that occur either randomly or systematically\u2014are leading to relevant clinical outcomes in patient cohorts (10).", [["patient", "ORGANISM", 267, 274], ["patient", "SPECIES", 267, 274], ["interferences (errors, biases", "PROBLEM", 122, 151]]], ["Chloroquine has been used in the prevention and treatment of malaria since 1947 (11).", [["Chloroquine", "CHEMICAL", 0, 11], ["malaria", "DISEASE", 61, 68], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Chloroquine", "TREATMENT", 0, 11], ["malaria", "PROBLEM", 61, 68], ["malaria", "OBSERVATION", 61, 68]]], ["Its clinical use in the treatment of rheumatoid arthritis and lupus erythematosus has been approved using pre-established protocols and doses based on the disease stage and the clinical conditions of the patient.", [["rheumatoid arthritis", "DISEASE", 37, 57], ["lupus erythematosus", "DISEASE", 62, 81], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["rheumatoid arthritis", "PROBLEM", 37, 57], ["lupus erythematosus", "PROBLEM", 62, 81], ["pre-established protocols", "TREATMENT", 106, 131], ["the disease stage", "PROBLEM", 151, 168], ["rheumatoid", "OBSERVATION_MODIFIER", 37, 47], ["arthritis", "OBSERVATION", 48, 57], ["lupus erythematosus", "OBSERVATION", 62, 81]]], ["The side effects of chloroquine, such as retinopathy and ventricular arrhythmia, are well-known, and are rarely reported by patients (11).", [["ventricular", "ANATOMY", 57, 68], ["chloroquine", "CHEMICAL", 20, 31], ["retinopathy", "DISEASE", 41, 52], ["ventricular arrhythmia", "DISEASE", 57, 79], ["chloroquine", "CHEMICAL", 20, 31], ["chloroquine", "SIMPLE_CHEMICAL", 20, 31], ["ventricular", "ORGAN", 57, 68], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["chloroquine", "TREATMENT", 20, 31], ["retinopathy", "PROBLEM", 41, 52], ["ventricular arrhythmia", "PROBLEM", 57, 79], ["side effects", "OBSERVATION_MODIFIER", 4, 16], ["ventricular", "ANATOMY", 57, 68], ["arrhythmia", "OBSERVATION", 69, 79]]], ["Chloroquine should not be used in the absence of any medical supervision in patients with diabetes and heart problems, neither in people over 65 who\u2014among other problems\u2014may have reduced kidney function.", [["heart", "ANATOMY", 103, 108], ["kidney", "ANATOMY", 187, 193], ["Chloroquine", "CHEMICAL", 0, 11], ["diabetes", "DISEASE", 90, 98], ["heart problems", "DISEASE", 103, 117], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 76, 84], ["heart", "ORGAN", 103, 108], ["people", "ORGANISM", 130, 136], ["problems\u2014may", "CANCER", 161, 173], ["kidney", "ORGAN", 187, 193], ["patients", "SPECIES", 76, 84], ["people", "SPECIES", 130, 136], ["Chloroquine", "TREATMENT", 0, 11], ["diabetes", "PROBLEM", 90, 98], ["heart problems", "PROBLEM", 103, 117], ["reduced kidney function", "PROBLEM", 179, 202], ["heart", "ANATOMY", 103, 108], ["kidney", "ANATOMY", 187, 193]]], ["Therefore, any clinical study aimed at assessing the therapeutic effects of chloroquine should not include volunteers or patients having such comorbidities; therefore, these caveats should be included as a part of the trial protocol when establishing the inclusion and exclusion criteria.", [["chloroquine", "CHEMICAL", 76, 87], ["chloroquine", "CHEMICAL", 76, 87], ["chloroquine", "SIMPLE_CHEMICAL", 76, 87], ["volunteers", "ORGANISM", 107, 117], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["any clinical study", "TEST", 11, 29], ["chloroquine", "TREATMENT", 76, 87], ["such comorbidities", "PROBLEM", 137, 155], ["the trial protocol", "TREATMENT", 214, 232]]], ["A previous study in a small patient cohort showed evidence that chloroquine could exhibit therapeutic effects in patients with COVID-19 (12).", [["chloroquine", "CHEMICAL", 64, 75], ["COVID-19", "CHEMICAL", 127, 135], ["chloroquine", "CHEMICAL", 64, 75], ["COVID-19", "CHEMICAL", 127, 135], ["patient", "ORGANISM", 28, 35], ["chloroquine", "SIMPLE_CHEMICAL", 64, 75], ["patients", "ORGANISM", 113, 121], ["patient", "SPECIES", 28, 35], ["patients", "SPECIES", 113, 121], ["A previous study", "TEST", 0, 16], ["chloroquine", "TREATMENT", 64, 75], ["COVID", "TEST", 127, 132]]], ["The journal The Lancet, in May 2020, published the results of an observational, longitudinal, and retrospective clinical study based on medical records of COVID-19 patient cohorts treated across 6 countries and 671 hospitals, with different technical capabilities and diverse drug protocols (13).", [["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["retrospective clinical study", "TEST", 98, 126], ["COVID", "TEST", 155, 160], ["diverse drug protocols", "TREATMENT", 268, 290]]], ["The results suggested that chloroquine and hydroxychloroquine\u2014and their combination with azithromycin\u2014did not result in any clinical benefit; on the contrary, they worsened the condition of the patients.", [["chloroquine", "CHEMICAL", 27, 38], ["hydroxychloroquine\u2014and", "CHEMICAL", 43, 65], ["chloroquine", "CHEMICAL", 27, 38], ["hydroxychloroquine\u2014and", "CHEMICAL", 43, 65], ["azithromycin\u2014did", "CHEMICAL", 89, 105], ["chloroquine", "SIMPLE_CHEMICAL", 27, 38], ["hydroxychloroquine\u2014and", "SIMPLE_CHEMICAL", 43, 65], ["azithromycin\u2014did", "SIMPLE_CHEMICAL", 89, 105], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["chloroquine", "TREATMENT", 27, 38], ["hydroxychloroquine\u2014and", "TREATMENT", 43, 65], ["azithromycin\u2014did", "TREATMENT", 89, 105]]], ["However, in these studies, patients with several comorbidities were evaluated, including those with cardiovascular disease (including congestive heart failure and history of heart failure arrhythmia), current or previous smoking history, history of hypertension, diabetes, or hyperlipidemia, or chronic obstructive pulmonary disease (COPD).", [["cardiovascular", "ANATOMY", 100, 114], ["heart", "ANATOMY", 145, 150], ["heart", "ANATOMY", 174, 179], ["pulmonary", "ANATOMY", 315, 324], ["cardiovascular disease", "DISEASE", 100, 122], ["congestive heart failure", "DISEASE", 134, 158], ["heart failure arrhythmia", "DISEASE", 174, 198], ["hypertension", "DISEASE", 249, 261], ["diabetes", "DISEASE", 263, 271], ["hyperlipidemia", "DISEASE", 276, 290], ["chronic obstructive pulmonary disease", "DISEASE", 295, 332], ["COPD", "DISEASE", 334, 338], ["patients", "ORGANISM", 27, 35], ["heart", "ORGAN", 145, 150], ["heart", "ORGAN", 174, 179], ["pulmonary", "ORGAN", 315, 324], ["patients", "SPECIES", 27, 35], ["these studies", "TEST", 12, 25], ["several comorbidities", "PROBLEM", 41, 62], ["cardiovascular disease", "PROBLEM", 100, 122], ["congestive heart failure", "PROBLEM", 134, 158], ["heart failure arrhythmia", "PROBLEM", 174, 198], ["hypertension", "PROBLEM", 249, 261], ["diabetes", "PROBLEM", 263, 271], ["hyperlipidemia", "PROBLEM", 276, 290], ["chronic obstructive pulmonary disease", "PROBLEM", 295, 332], ["COPD)", "PROBLEM", 334, 339], ["congestive", "OBSERVATION_MODIFIER", 134, 144], ["heart", "ANATOMY", 145, 150], ["failure", "OBSERVATION", 151, 158], ["heart", "ANATOMY", 174, 179], ["failure", "OBSERVATION", 180, 187], ["hypertension", "OBSERVATION", 249, 261], ["diabetes", "OBSERVATION", 263, 271], ["hyperlipidemia", "OBSERVATION", 276, 290], ["chronic", "OBSERVATION_MODIFIER", 295, 302], ["obstructive", "OBSERVATION_MODIFIER", 303, 314], ["pulmonary", "ANATOMY", 315, 324], ["disease", "OBSERVATION", 325, 332], ["COPD", "OBSERVATION", 334, 338]]], ["These trials also reported that 47% of the treated patients needed admission to an intensive care unit (ICU) and assisted ventilation (severe case of the disease) against only 5% in the control group.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["assisted ventilation", "TREATMENT", 113, 133], ["the disease", "PROBLEM", 150, 161]]], ["The authors concluded that all underlying diseases (comorbidities)\u2014considered as confounding factors\u2014influenced the mortality rate; this was the most relevant outcome of the study.", [["all underlying diseases (comorbidities", "PROBLEM", 27, 65], ["the study", "TEST", 170, 179], ["diseases", "OBSERVATION", 42, 50]]], ["The secondary outcome of interest was related to ventricular arrhythmia.", [["ventricular", "ANATOMY", 49, 60], ["ventricular arrhythmia", "DISEASE", 49, 71], ["ventricular", "ORGAN", 49, 60], ["ventricular arrhythmia", "PROBLEM", 49, 71], ["ventricular", "ANATOMY", 49, 60], ["arrhythmia", "OBSERVATION", 61, 71]]], ["It was mentioned that, among the 81 000 patients in the control group, a small population (16%, 14 300) had a history of heart disease, whereas 890 (1%) suffered from de novo ventricular arrhythmia, along with in-hospital treatment, and survived.", [["heart", "ANATOMY", 121, 126], ["ventricular", "ANATOMY", 175, 186], ["heart disease", "DISEASE", 121, 134], ["ventricular arrhythmia", "DISEASE", 175, 197], ["patients", "ORGANISM", 40, 48], ["heart", "ORGAN", 121, 126], ["ventricular", "ORGAN", 175, 186], ["patients", "SPECIES", 40, 48], ["a small population", "PROBLEM", 71, 89], ["heart disease", "PROBLEM", 121, 134], ["de novo ventricular arrhythmia", "PROBLEM", 167, 197], ["small", "OBSERVATION_MODIFIER", 73, 78], ["heart", "ANATOMY", 121, 126], ["disease", "OBSERVATION", 127, 134], ["ventricular", "ANATOMY", 175, 186], ["arrhythmia", "OBSERVATION", 187, 197]]], ["Of the 14 800 patients in the treatment group, 10 600 died.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["A large number of patients in the non-survival population (33%, 3 500 patients) had a history of cardiovascular disease.", [["cardiovascular", "ANATOMY", 97, 111], ["cardiovascular disease", "DISEASE", 97, 119], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 70, 78], ["cardiovascular", "ANATOMICAL_SYSTEM", 97, 111], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 70, 78], ["cardiovascular disease", "PROBLEM", 97, 119], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["cardiovascular", "ANATOMY", 97, 111], ["disease", "OBSERVATION", 112, 119]]], ["These were the patients for whom chloroquine treatment was not recommended because of the high risk of suffering from adverse effects, such as the prolonged QT interval and arrhythmia.", [["chloroquine", "CHEMICAL", 33, 44], ["arrhythmia", "DISEASE", 173, 183], ["chloroquine", "CHEMICAL", 33, 44], ["patients", "ORGANISM", 15, 23], ["chloroquine", "SIMPLE_CHEMICAL", 33, 44], ["patients", "SPECIES", 15, 23], ["chloroquine treatment", "TREATMENT", 33, 54], ["adverse effects", "PROBLEM", 118, 133], ["the prolonged QT interval", "PROBLEM", 143, 168], ["arrhythmia", "PROBLEM", 173, 183]]], ["In this group, as expected, 400 patients (3.7%) suffered from de novo ventricular arrhythmia (13).", [["ventricular", "ANATOMY", 70, 81], ["ventricular arrhythmia", "DISEASE", 70, 92], ["patients", "ORGANISM", 32, 40], ["ventricular", "ORGAN", 70, 81], ["patients", "SPECIES", 32, 40], ["de novo ventricular arrhythmia", "PROBLEM", 62, 92], ["ventricular", "ANATOMY", 70, 81], ["arrhythmia", "OBSERVATION", 82, 92]]], ["Whether this effect was observed before or during the treatment, was not specified by the authors.", [["the treatment", "TREATMENT", 50, 63]]], ["The episodes of de novo ventricular arrhythmia could be induced by several factors and clinical conditions; these include treatment with chloroquine, hydroxychloroquine, or a combination of chloroquine and azithromycin or that of hydroxychloroquine and azithromycin, and\u2014finally\u2014the pathology caused by SARS-CoV-2 (as it was observed in patients in the control group).", [["ventricular", "ANATOMY", 24, 35], ["ventricular arrhythmia", "DISEASE", 24, 46], ["chloroquine", "CHEMICAL", 137, 148], ["hydroxychloroquine", "CHEMICAL", 150, 168], ["chloroquine", "CHEMICAL", 190, 201], ["azithromycin", "CHEMICAL", 206, 218], ["hydroxychloroquine", "CHEMICAL", 230, 248], ["azithromycin", "CHEMICAL", 253, 265], ["SARS", "DISEASE", 303, 307], ["chloroquine", "CHEMICAL", 137, 148], ["hydroxychloroquine", "CHEMICAL", 150, 168], ["chloroquine", "CHEMICAL", 190, 201], ["azithromycin", "CHEMICAL", 206, 218], ["hydroxychloroquine", "CHEMICAL", 230, 248], ["azithromycin", "CHEMICAL", 253, 265], ["ventricular", "ORGAN", 24, 35], ["chloroquine", "SIMPLE_CHEMICAL", 137, 148], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 150, 168], ["chloroquine", "SIMPLE_CHEMICAL", 190, 201], ["azithromycin", "SIMPLE_CHEMICAL", 206, 218], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 230, 248], ["azithromycin", "SIMPLE_CHEMICAL", 253, 265], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 303, 313], ["patients", "ORGANISM", 337, 345], ["patients", "SPECIES", 337, 345], ["SARS-CoV", "SPECIES", 303, 311], ["de novo ventricular arrhythmia", "PROBLEM", 16, 46], ["clinical conditions", "PROBLEM", 87, 106], ["treatment", "TREATMENT", 122, 131], ["chloroquine", "TREATMENT", 137, 148], ["hydroxychloroquine", "TREATMENT", 150, 168], ["chloroquine", "TREATMENT", 190, 201], ["azithromycin", "TREATMENT", 206, 218], ["hydroxychloroquine", "TREATMENT", 230, 248], ["azithromycin", "TREATMENT", 253, 265], ["SARS", "PROBLEM", 303, 307], ["ventricular", "ANATOMY", 24, 35], ["arrhythmia", "OBSERVATION", 36, 46]]], ["I think that the study was not useful\u2014or was partially useful\u2014for assessing the cause and effect relationship of the medications because of the heterogeneity of the confounding factors.", [["the study", "TEST", 13, 22], ["the medications", "TREATMENT", 113, 128], ["the confounding factors", "PROBLEM", 161, 184]]], ["Therefore, further studies are required to assess the effect of the tested medicaments in patients only having COVID-19 illness at the early phase, in which the drugs appear to exhibit the expected therapeutic benefits.WHY DO RESEARCH TRIALS FAIL?The uncertainties and dilemmas regarding COVID-19 and its treatment can be attributed to the fact that everything we know about this disease is still insufficient.", [["illness", "DISEASE", 120, 127], ["COVID-19", "CHEMICAL", 288, 296], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["further studies", "TEST", 11, 26], ["the tested medicaments", "TREATMENT", 64, 86], ["COVID", "TEST", 111, 116], ["COVID", "TEST", 288, 293], ["this disease", "PROBLEM", 375, 387], ["early phase", "OBSERVATION_MODIFIER", 135, 146]]], ["There is no other way to prove the veracity of scientific findings without the replication of facts and experiences.", [["no other", "UNCERTAINTY", 9, 17]]], ["Clinical trials in humans must be guided by the practice standards, norms, and rules established in the International Conference on Harmonization / Good Clinical Practices (ICH/GCP), while following the ethical principles of the Helsinki Declaration, proclaimed in June 1964 (http://www.wma.net), and the Hippocratic Oath, the origin of the modern medical ethics.", [["ICH", "DISEASE", 173, 176], ["humans", "ORGANISM", 19, 25], ["humans", "SPECIES", 19, 25], ["humans", "SPECIES", 19, 25], ["ICH/GCP", "PROBLEM", 173, 180], ["origin", "ANATOMY_MODIFIER", 327, 333]]], ["To develop evidence-based effective public health strategies, all clinical protocols must be based on evidence, which is defined as the link between excellent scientific research and good clinical practices.", [["all clinical protocols", "TREATMENT", 62, 84], ["effective", "OBSERVATION_MODIFIER", 26, 35]]], ["Although scientists are widely trusted and feted for their discoveries, they are repeatedly required to reexamine their findings using new technological strategies and new knowledge.", [["new technological strategies", "TREATMENT", 135, 163]]], ["The randomized clinical study (RCT) is a scientific innovation; a way to draw better conclusions about cause and effect of medications or clinical procedures in matched and paired cohort groups.", [["The randomized clinical study", "TEST", 0, 29], ["medications", "TREATMENT", 123, 134], ["clinical procedures", "TREATMENT", 138, 157]]], ["A double-blind randomized clinical study is another scientific innovation; a way to avoid the interference of patients and investigators on the results.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["blind randomized clinical study", "TEST", 9, 40]]], ["In this context, the effects of the placebo (inert drug) must be tested, and the effectiveness of the drug/vaccine must be higher in the treatment group than that in the placebo group.", [["the placebo (inert drug", "TREATMENT", 32, 55], ["the drug/vaccine", "TREATMENT", 98, 114]]], ["Surrogate markers and secondary endpoints are commonly used in clinical trials to anticipate absolute primary outcomes, which will result in beneficial or adverse effects in the patients.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["Surrogate markers", "TEST", 0, 17], ["secondary endpoints", "PROBLEM", 22, 41]]], ["Equally important are the adoption of new strategies to analyze the data and draw scientific conclusions.", [["new strategies", "TREATMENT", 38, 52], ["the data", "TEST", 64, 72]]], ["Robust statistical methods and well-designed experiments are the fundamental requirements for testing novel treatments and repurposing existing drugs.", [["testing novel treatments", "TREATMENT", 94, 118], ["repurposing existing drugs", "TREATMENT", 123, 149]]], ["The studies in progress\u2014to evaluate the therapeutic effects of BCG and chloroquine in COVID-19\u2014need to continue to answer these important questions and to reinstate peopl\u00e9s trust in science.", [["chloroquine", "CHEMICAL", 71, 82], ["chloroquine", "CHEMICAL", 71, 82], ["BCG", "SIMPLE_CHEMICAL", 63, 66], ["chloroquine", "SIMPLE_CHEMICAL", 71, 82], ["The studies", "TEST", 0, 11], ["BCG", "TREATMENT", 63, 66], ["chloroquine", "TREATMENT", 71, 82], ["COVID", "TREATMENT", 86, 91]]]], "PMC6906185": [["The GRB model provides alternative, biologically plausible long-range targetsA notable example of an SNP involved in long-range regulation of gene expression is a locus obtained by merging two SNPs in LD, with two nearby VRK2 and FANCL genes highlighted as putative targets of these variants.", [["SNP", "CHEMICAL", 101, 104], ["VRK2", "GENE_OR_GENE_PRODUCT", 221, 225], ["FANCL", "GENE_OR_GENE_PRODUCT", 230, 235], ["LD", "DNA", 201, 203], ["VRK2 and FANCL genes", "DNA", 221, 241], ["an SNP", "TREATMENT", 98, 104]]], ["Instead, we propose an alternative target BCL11A: according to the GRB model it is a preferred target for long-range regulation by elements from this entire genomic region, including the LD block spanning these two SNPs.", [["BCL11A", "GENE_OR_GENE_PRODUCT", 42, 48], ["BCL11A", "PROTEIN", 42, 48], ["GRB", "DNA", 67, 70], ["LD block", "DNA", 187, 195], ["long-range regulation", "TREATMENT", 106, 127], ["the LD block", "TREATMENT", 183, 195]]], ["BCL11A is implicated in the aetiology of the schizophrenia [46], and the phenotypes associated to SNPs in the same LD block fit with the role of the BCL11A gene.The GRB model provides alternative, biologically plausible long-range targetsVRK2 encodes a serine/threonine kinase involved in apoptosis and tumour cell growth signalling pathways.", [["tumour cell", "ANATOMY", 303, 314], ["schizophrenia", "DISEASE", 45, 58], ["tumour", "DISEASE", 303, 309], ["serine", "CHEMICAL", 253, 259], ["threonine", "CHEMICAL", 260, 269], ["BCL11A", "GENE_OR_GENE_PRODUCT", 0, 6], ["BCL11A", "GENE_OR_GENE_PRODUCT", 149, 155], ["targetsVRK2", "GENE_OR_GENE_PRODUCT", 231, 242], ["serine", "AMINO_ACID", 253, 259], ["threonine", "AMINO_ACID", 260, 269], ["tumour cell", "CELL", 303, 314], ["BCL11A", "PROTEIN", 0, 6], ["SNPs", "DNA", 98, 102], ["BCL11A gene", "DNA", 149, 160], ["targetsVRK2", "PROTEIN", 231, 242], ["serine/threonine kinase", "PROTEIN", 253, 276], ["the schizophrenia", "PROBLEM", 41, 58], ["the phenotypes", "PROBLEM", 69, 83], ["SNPs", "TREATMENT", 98, 102], ["a serine/threonine kinase", "TREATMENT", 251, 276], ["apoptosis", "PROBLEM", 289, 298], ["tumour cell growth signalling pathways", "PROBLEM", 303, 341], ["schizophrenia", "OBSERVATION", 45, 58], ["BCL11A", "ANATOMY", 149, 155], ["GRB model", "OBSERVATION", 165, 174], ["tumour cell", "OBSERVATION", 303, 314]]], ["A number of SNPs in the region of VRK2 have previously been associated with schizophrenia, implicating it in the development of the disease [47\u201349].", [["schizophrenia", "DISEASE", 76, 89], ["VRK2", "GENE_OR_GENE_PRODUCT", 34, 38], ["VRK2", "DNA", 34, 38], ["SNPs in the region of VRK2", "PROBLEM", 12, 38], ["schizophrenia", "PROBLEM", 76, 89], ["the disease", "PROBLEM", 128, 139], ["number", "OBSERVATION_MODIFIER", 2, 8], ["SNPs", "OBSERVATION", 12, 16], ["region", "ANATOMY_MODIFIER", 24, 30], ["associated with", "UNCERTAINTY", 60, 75], ["schizophrenia", "OBSERVATION", 76, 89], ["disease", "OBSERVATION", 132, 139]]], ["There is also evidence that whole blood VRK2 mRNA levels are lower in schizophrenia patients than healthy controls [48].", [["blood", "ANATOMY", 34, 39], ["schizophrenia", "DISEASE", 70, 83], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["VRK2", "GENE_OR_GENE_PRODUCT", 40, 44], ["patients", "ORGANISM", 84, 92], ["VRK2 mRNA", "RNA", 40, 49], ["patients", "SPECIES", 84, 92], ["whole blood VRK2 mRNA levels", "TEST", 28, 56], ["schizophrenia", "PROBLEM", 70, 83], ["lower", "OBSERVATION_MODIFIER", 61, 66]]], ["FANCL is an ubiquitin ligase, involved in DNA repair.", [["FANCL", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["FANCL", "PROTEIN", 0, 5], ["ubiquitin ligase", "PROTEIN", 12, 28], ["an ubiquitin ligase", "TREATMENT", 9, 28], ["DNA repair", "TREATMENT", 42, 52], ["ubiquitin ligase", "OBSERVATION", 12, 28], ["DNA repair", "OBSERVATION", 42, 52]]], ["BCL11A is, however, implicated in brain development, and the haploinsufficient mice display cognition deficits and impaired social behaviour [50].The GRB model provides alternative, biologically plausible long-range targetsThis locus is spanned by a GRB whose predicted target is BCL11A: a developmental transcription factor essential for cortical development (Fig. 3a).", [["brain", "ANATOMY", 34, 39], ["cortical", "ANATOMY", 339, 347], ["cognition deficits", "DISEASE", 92, 110], ["impaired social behaviour", "DISEASE", 115, 140], ["BCL11A", "GENE_OR_GENE_PRODUCT", 0, 6], ["brain", "ORGAN", 34, 39], ["mice", "ORGANISM", 79, 83], ["locus", "CELLULAR_COMPONENT", 228, 233], ["GRB", "GENE_OR_GENE_PRODUCT", 250, 253], ["BCL11A", "GENE_OR_GENE_PRODUCT", 280, 286], ["cortical", "MULTI-TISSUE_STRUCTURE", 339, 347], ["BCL11A", "PROTEIN", 0, 6], ["GRB", "DNA", 250, 253], ["BCL11A", "PROTEIN", 280, 286], ["developmental transcription factor", "PROTEIN", 290, 324], ["mice", "SPECIES", 79, 83], ["BCL11A", "TEST", 0, 6], ["cognition deficits", "PROBLEM", 92, 110], ["a developmental transcription factor", "PROBLEM", 288, 324], ["brain", "ANATOMY", 34, 39]]], ["In fact, upon further reanalysis of the schizophrenia-associated variation [42], Basak et al. found SNPs in the second intron of the BCL11A gene with significance of association with schizophrenia just missing the genome-wide cut-off at p = 1.52e\u221207 [46].", [["schizophrenia", "DISEASE", 40, 53], ["schizophrenia", "DISEASE", 183, 196], ["BCL11A", "GENE_OR_GENE_PRODUCT", 133, 139], ["BCL11A gene", "DNA", 133, 144], ["the schizophrenia", "PROBLEM", 36, 53], ["SNPs", "PROBLEM", 100, 104], ["schizophrenia", "PROBLEM", 183, 196]]], ["The activity of enhancer elements Enh5\u2013Enh8 are correlated with the expression of VRK2, potentially through short-range regulatory effects, but the dynamic range of the VRK2\u2032s response to enhancer activity is small (shown as the change in median expression values between grey and purple distributions in Fig. 3a).", [["Enh5", "GENE_OR_GENE_PRODUCT", 34, 38], ["Enh8", "GENE_OR_GENE_PRODUCT", 39, 43], ["VRK2", "GENE_OR_GENE_PRODUCT", 82, 86], ["VRK2", "GENE_OR_GENE_PRODUCT", 169, 173], ["enhancer elements", "DNA", 16, 33], ["Enh5", "DNA", 34, 38], ["Enh8", "DNA", 39, 43], ["VRK2", "PROTEIN", 82, 86], ["VRK2", "PROTEIN", 169, 173], ["VRK2", "TEST", 82, 86], ["the change in median expression values", "PROBLEM", 225, 263], ["enhancer activity", "OBSERVATION", 188, 205], ["small", "OBSERVATION_MODIFIER", 209, 214], ["purple", "OBSERVATION_MODIFIER", 281, 287]]], ["However, similar to the example of the obesity linked discussed above [17], there is also a strong positive correlation of elements Enh5\u2013Enh8 with BCL11A transcription (despite a 2.5 Mb separation between the gene and the regulatory elements).", [["obesity", "DISEASE", 39, 46], ["Enh5", "GENE_OR_GENE_PRODUCT", 132, 136], ["Enh8", "GENE_OR_GENE_PRODUCT", 137, 141], ["BCL11A", "GENE_OR_GENE_PRODUCT", 147, 153], ["Enh5", "DNA", 132, 136], ["Enh8", "DNA", 137, 141], ["BCL11A", "DNA", 147, 153], ["regulatory elements", "DNA", 222, 241], ["the obesity", "PROBLEM", 35, 46], ["BCL11A transcription", "TREATMENT", 147, 167], ["a 2.5 Mb separation", "TREATMENT", 177, 196], ["obesity", "OBSERVATION", 39, 46]]], ["Due to the extreme distance between this enhancer cluster and the promoter of the BCL11A gene, this connection will be missed by any of the methods relying on a fixed genomic cut-off for the enhancer\u2013promoter interactions, even in the most generous case presented in the recent schizophrenia TWAS [23, 24] (max. distance of 500 kb), 2 Mb distance by Huo et al. [26] and in a zebrafish phenotype atlas [25].", [["schizophrenia", "DISEASE", 278, 291], ["BCL11A", "GENE_OR_GENE_PRODUCT", 82, 88], ["zebrafish", "ORGANISM", 375, 384], ["enhancer cluster", "DNA", 41, 57], ["promoter", "DNA", 66, 74], ["BCL11A gene", "DNA", 82, 93], ["the extreme distance between this enhancer cluster", "PROBLEM", 7, 57], ["a fixed genomic cut", "TREATMENT", 159, 178], ["the recent schizophrenia TWAS", "PROBLEM", 267, 296], ["Huo et al.", "TEST", 350, 360]]], ["In fact, both TWAS analyses reported FANCL as a significant hit, but failed to further corroborate the link between this locus and the FANCL by the Hi-C data [23], nor the gene list analysis [24].The GRB model provides alternative, biologically plausible long-range targetsWe propose a scenario in which the whole VRK/FANCL region\u2019s chromatin state differs between the two alleles, which can be detectable in TWAS studies and as increased transcriptional activity of the region with two SNPs in the promoter region of the VRK2.", [["chromatin", "ANATOMY", 333, 342], ["FANCL", "GENE_OR_GENE_PRODUCT", 37, 42], ["locus", "CELLULAR_COMPONENT", 121, 126], ["VRK", "GENE_OR_GENE_PRODUCT", 314, 317], ["FANCL", "GENE_OR_GENE_PRODUCT", 318, 323], ["chromatin", "CELLULAR_COMPONENT", 333, 342], ["VRK2", "GENE_OR_GENE_PRODUCT", 522, 526], ["TWAS", "DNA", 14, 18], ["FANCL", "DNA", 37, 42], ["FANCL", "DNA", 135, 140], ["VRK", "DNA", 314, 317], ["FANCL region", "DNA", 318, 330], ["chromatin", "DNA", 333, 342], ["promoter region", "DNA", 499, 514], ["VRK2", "DNA", 522, 526], ["both TWAS analyses", "TEST", 9, 27], ["a significant hit", "PROBLEM", 46, 63], ["the Hi-C data", "TEST", 144, 157], ["the whole VRK/FANCL region", "TREATMENT", 304, 330], ["TWAS studies", "TEST", 409, 421], ["increased", "OBSERVATION_MODIFIER", 429, 438], ["transcriptional activity", "OBSERVATION", 439, 463]]], ["However, both of these genes are ubiquitously expressed across tissues, and have a rather large baseline transcriptional activity: these are hallmarks of GRB bystander genes, which are not dependent on activation via long-range enhancers [16].", [["tissues", "ANATOMY", 63, 70], ["tissues", "TISSUE", 63, 70], ["GRB", "GENE_OR_GENE_PRODUCT", 154, 157], ["GRB bystander genes", "DNA", 154, 173], ["long-range enhancers", "DNA", 217, 237], ["a rather large baseline transcriptional activity", "PROBLEM", 81, 129], ["GRB bystander genes", "PROBLEM", 154, 173], ["large", "OBSERVATION_MODIFIER", 90, 95], ["transcriptional activity", "OBSERVATION", 105, 129], ["GRB bystander genes", "OBSERVATION", 154, 173]]], ["Moreover, the association of another variant in the VRK2 promoter region, rs2312147, with white matter volume in healthy subjects [45], and white matter connectivity in schizophrenia patients [47] implicates this locus in aberrant brain development.", [["white matter", "ANATOMY", 90, 102], ["white matter", "ANATOMY", 140, 152], ["brain", "ANATOMY", 231, 236], ["schizophrenia", "DISEASE", 169, 182], ["VRK2", "GENE_OR_GENE_PRODUCT", 52, 56], ["patients", "ORGANISM", 183, 191], ["brain", "ORGAN", 231, 236], ["VRK2 promoter region", "DNA", 52, 72], ["patients", "SPECIES", 183, 191], ["another variant in the VRK2 promoter region", "PROBLEM", 29, 72], ["white matter volume", "TEST", 90, 109], ["white matter connectivity in schizophrenia patients", "PROBLEM", 140, 191], ["this locus in aberrant brain development", "PROBLEM", 208, 248], ["aberrant brain", "OBSERVATION", 222, 236]]], ["Given BCL11A\u2019s role in the regulation of neuronal migration in the developing cortex, and in agreement with the neural network hypothesis of schizophrenia aetiology [38], we conclude that the evidence points to BCL11A activation by this enhancer as the most likely biological mechanisms responsible for the GWAS hits at this locus.The GRB model provides alternative, biologically plausible long-range targetsIn this example, while there is evidence that VRK2 might play a role in schizophrenia, the variant\u2019s location adjacent to Enh5\u2013Enh8 region suggests that the enhancers in the vicinity of the identified risk variants also regulates BCL11A, with larger effect on its expression level than that of VRK2.", [["neuronal", "ANATOMY", 41, 49], ["cortex", "ANATOMY", 78, 84], ["neural network", "ANATOMY", 112, 126], ["schizophrenia", "DISEASE", 141, 154], ["schizophrenia", "DISEASE", 480, 493], ["BCL11A", "GENE_OR_GENE_PRODUCT", 6, 12], ["neuronal", "CELL", 41, 49], ["cortex", "CANCER", 78, 84], ["BCL11A", "GENE_OR_GENE_PRODUCT", 211, 217], ["locus", "CELLULAR_COMPONENT", 325, 330], ["VRK2", "GENE_OR_GENE_PRODUCT", 454, 458], ["Enh5", "GENE_OR_GENE_PRODUCT", 530, 534], ["BCL11A", "GENE_OR_GENE_PRODUCT", 638, 644], ["VRK2", "GENE_OR_GENE_PRODUCT", 702, 706], ["BCL11A", "PROTEIN", 6, 12], ["BCL11A", "PROTEIN", 211, 217], ["GWAS hits", "DNA", 307, 316], ["VRK2", "PROTEIN", 454, 458], ["Enh5\u2013Enh8 region", "DNA", 530, 546], ["enhancers", "DNA", 565, 574], ["BCL11A", "PROTEIN", 638, 644], ["VRK2", "PROTEIN", 702, 706], ["BCL11A", "TREATMENT", 6, 12], ["neuronal migration", "TREATMENT", 41, 59], ["schizophrenia aetiology", "PROBLEM", 141, 164], ["BCL11A activation", "PROBLEM", 211, 228], ["the GWAS hits", "PROBLEM", 303, 316], ["VRK2", "PROBLEM", 454, 458], ["schizophrenia", "PROBLEM", 480, 493], ["BCL11A", "TEST", 638, 644], ["neuronal migration", "OBSERVATION", 41, 59], ["cortex", "ANATOMY_MODIFIER", 78, 84], ["risk variants", "OBSERVATION", 609, 622], ["larger", "OBSERVATION_MODIFIER", 651, 657], ["effect", "OBSERVATION_MODIFIER", 658, 664]]], ["Therefore, the hypothesis-free annotation of GRB targets has provided a more biologically plausible candidate gene at this locus.The GRB model predicts the potential targets of unannotated SNPsAn advantage of the GRB model is that it provides an unbiased, systematic list of target genes for all non-coding SNPs within the GRB.", [["GRB", "GENE_OR_GENE_PRODUCT", 45, 48], ["locus", "CELLULAR_COMPONENT", 123, 128], ["SNPsAn", "GENE_OR_GENE_PRODUCT", 189, 195], ["GRB", "GENE_OR_GENE_PRODUCT", 323, 326], ["GRB targets", "DNA", 45, 56], ["GRB", "DNA", 133, 136], ["SNPsAn", "DNA", 189, 195], ["target genes", "DNA", 275, 287], ["non-coding SNPs", "DNA", 296, 311], ["GRB", "DNA", 323, 326], ["the hypothesis", "TEST", 11, 25], ["GRB targets", "PROBLEM", 45, 56], ["all non-coding SNPs", "PROBLEM", 292, 311], ["GRB targets", "OBSERVATION", 45, 56], ["GRB model", "OBSERVATION", 133, 142], ["non-coding SNPs", "OBSERVATION", 296, 311]]], ["This is illustrated by the LD block chr2:146416922\u2013146441832 harbouring a chr2_146436222_I insertion located in a gene desert.", [["chr2_146436222_I", "GENE_OR_GENE_PRODUCT", 74, 90], ["LD block chr2:146416922\u2013146441832", "DNA", 27, 60], ["chr2_146436222_I insertion", "DNA", 74, 100], ["a chr2_146436222_I insertion", "TREATMENT", 72, 100]]], ["This GRB spans the ZEB2, GTDC1, ARHGAP15 and KYNU genes, with ARHGAP15 and ZEB2 being the predicted targets of long-range regulation (Fig. 3b).", [["GRB", "GENE_OR_GENE_PRODUCT", 5, 8], ["ZEB2", "GENE_OR_GENE_PRODUCT", 19, 23], ["GTDC1", "GENE_OR_GENE_PRODUCT", 25, 30], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 32, 40], ["KYNU", "GENE_OR_GENE_PRODUCT", 45, 49], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 62, 70], ["ZEB2", "GENE_OR_GENE_PRODUCT", 75, 79], ["GRB", "DNA", 5, 8], ["ZEB2, GTDC1, ARHGAP15 and KYNU genes", "DNA", 19, 55], ["ARHGAP15", "DNA", 62, 70], ["ZEB2", "DNA", 75, 79], ["ARHGAP15", "TREATMENT", 62, 70], ["ZEB2", "TREATMENT", 75, 79]]], ["The expression of both predicted GRB target genes is significantly correlated with the activity of the enhancer overlapping this insertion.", [["GRB", "GENE_OR_GENE_PRODUCT", 33, 36], ["GRB target genes", "DNA", 33, 49], ["enhancer", "DNA", 103, 111], ["this insertion", "TREATMENT", 124, 138], ["both", "OBSERVATION_MODIFIER", 18, 22], ["predicted GRB", "OBSERVATION", 23, 36], ["target genes", "OBSERVATION", 37, 49]]], ["KYNU expression, which is not found to be responsive to long-range regulation in this locus, is also significantly correlated with the activity of the enhancer.", [["KYNU", "GENE_OR_GENE_PRODUCT", 0, 4], ["locus", "CELLULAR_COMPONENT", 86, 91], ["KYNU", "PROTEIN", 0, 4], ["enhancer", "DNA", 151, 159]]], ["Despite this, the directionality index (which indicates the start/end of a TAD [28]) in this region positions KYNU outside of the TAD spanning ARHGAP15, ZEB2 and the LD block with the significantly associated insertion, supporting the GRB model target gene predictions.The GRB model predicts the potential targets of unannotated SNPsZEB2 encodes the zinc finger E-box binding protein and is a key regulator of neurogenic and gliogenic processes [51].", [["zinc", "CHEMICAL", 350, 354], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 143, 151], ["ZEB2", "GENE_OR_GENE_PRODUCT", 153, 157], ["SNPsZEB2", "GENE_OR_GENE_PRODUCT", 329, 337], ["TAD", "PROTEIN", 75, 78], ["TAD", "PROTEIN", 130, 133], ["ARHGAP15", "DNA", 143, 151], ["ZEB2", "PROTEIN", 153, 157], ["LD block", "DNA", 166, 174], ["GRB model target gene", "DNA", 235, 256], ["GRB", "DNA", 273, 276], ["SNPsZEB2", "DNA", 329, 337], ["zinc finger E-box binding protein", "PROTEIN", 350, 383], ["the directionality index", "TEST", 14, 38], ["a TAD", "TREATMENT", 73, 78], ["ZEB2", "TREATMENT", 153, 157], ["the LD block", "TREATMENT", 162, 174], ["neurogenic and gliogenic processes", "PROBLEM", 410, 444], ["neurogenic", "OBSERVATION", 410, 420]]], ["Heterozygous ZEB2 mutations in humans cause Mowat\u2013Wilson syndrome, often associated with structural brain abnormalities and intellectual disability.", [["brain", "ANATOMY", 100, 105], ["Mowat\u2013Wilson syndrome", "DISEASE", 44, 65], ["brain abnormalities", "DISEASE", 100, 119], ["intellectual disability", "DISEASE", 124, 147], ["ZEB2", "GENE_OR_GENE_PRODUCT", 13, 17], ["humans", "ORGANISM", 31, 37], ["brain", "ORGAN", 100, 105], ["ZEB2", "PROTEIN", 13, 17], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37], ["Heterozygous ZEB2 mutations", "PROBLEM", 0, 27], ["Mowat\u2013Wilson syndrome", "PROBLEM", 44, 65], ["structural brain abnormalities", "PROBLEM", 89, 119], ["intellectual disability", "PROBLEM", 124, 147], ["ZEB2 mutations", "OBSERVATION", 13, 27], ["brain", "ANATOMY", 100, 105], ["abnormalities", "OBSERVATION", 106, 119]]], ["Statistically significant GWAS signals have been detected in three smaller studies for the ZEB2 gene: in a 2013 PGC GWAS study predating the dataset analysed here [52], in a Han Chinese population GWAS from 2016 [53] and recently in the GWAS meta-analysis including 40,675 schizophrenia patients that included all the PGC patients, and additional 11,260 cases from the CLOZUK sample [8].", [["schizophrenia", "DISEASE", 273, 286], ["ZEB2", "GENE_OR_GENE_PRODUCT", 91, 95], ["patients", "ORGANISM", 287, 295], ["patients", "ORGANISM", 322, 330], ["ZEB2 gene", "DNA", 91, 100], ["patients", "SPECIES", 287, 295], ["patients", "SPECIES", 322, 330], ["significant GWAS signals", "PROBLEM", 14, 38], ["GWAS study", "TEST", 116, 126], ["schizophrenia", "PROBLEM", 273, 286]]], ["Taken together, the link between ZEB2 and neurological development and phenotypes makes ZEB2 a plausible candidate gene for schizophrenia.", [["neurological", "ANATOMY", 42, 54], ["schizophrenia", "DISEASE", 124, 137], ["ZEB2", "GENE_OR_GENE_PRODUCT", 33, 37], ["ZEB2", "GENE_OR_GENE_PRODUCT", 88, 92], ["ZEB2", "PROTEIN", 33, 37], ["ZEB2", "PROTEIN", 88, 92], ["the link between ZEB2 and neurological development and phenotypes", "PROBLEM", 16, 81], ["schizophrenia", "PROBLEM", 124, 137]]], ["On the other hand, mice mutants for the ARHGAP15 gene showed cognitive deficits due to impaired neuritogenesis in the hippocampus [54], and a de novo synonymous mutation in this gene was found in a patient with sporadic autism [55], followed by a recent report of a chromatin interaction of a schizophrenia GWAS locus with the promoter of the ARHGAP15 gene [8].The GRB model predicts the potential targets of unannotated SNPsIn this example, the GRB model provides us with two novel, testable potential target genes for a schizophrenia-associated variant, which originally had no associated genes, and were confirmed by other GWAS datasets, and subsequently by chromatin conformation data in post-mortem brains.The GRB model identifies mechanistically related SNPsThe next example contains two schizophrenia-associated loci that are both found in the same GRB (chr11:130296827\u2013133970287), and thus most likely affect the same gene.", [["hippocampus", "ANATOMY", 118, 129], ["chromatin", "ANATOMY", 266, 275], ["chromatin", "ANATOMY", 661, 670], ["brains", "ANATOMY", 704, 710], ["cognitive deficits", "DISEASE", 61, 79], ["autism", "DISEASE", 220, 226], ["schizophrenia", "DISEASE", 293, 306], ["schizophrenia", "DISEASE", 522, 535], ["schizophrenia", "DISEASE", 794, 807], ["mice", "ORGANISM", 19, 23], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 40, 48], ["patient", "ORGANISM", 198, 205], ["chromatin", "CELLULAR_COMPONENT", 266, 275], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 343, 351], ["SNPsIn", "GENE_OR_GENE_PRODUCT", 421, 427], ["chromatin", "CELLULAR_COMPONENT", 661, 670], ["brains", "ORGAN", 704, 710], ["ARHGAP15 gene", "DNA", 40, 53], ["chromatin", "DNA", 266, 275], ["schizophrenia GWAS locus", "DNA", 293, 317], ["promoter", "DNA", 327, 335], ["ARHGAP15 gene", "DNA", 343, 356], ["GRB", "DNA", 365, 368], ["SNPsIn", "DNA", 421, 427], ["GRB", "DNA", 446, 449], ["target genes", "DNA", 503, 515], ["GWAS datasets", "DNA", 626, 639], ["chromatin", "DNA", 661, 670], ["GRB", "DNA", 715, 718], ["SNPs", "DNA", 760, 764], ["schizophrenia-associated loci", "DNA", 794, 823], ["GRB", "DNA", 856, 859], ["mice", "SPECIES", 19, 23], ["patient", "SPECIES", 198, 205], ["mice", "SPECIES", 19, 23], ["the ARHGAP15 gene", "TEST", 36, 53], ["cognitive deficits", "PROBLEM", 61, 79], ["impaired neuritogenesis in the hippocampus", "PROBLEM", 87, 129], ["a de novo synonymous mutation", "PROBLEM", 140, 169], ["sporadic autism", "PROBLEM", 211, 226], ["a schizophrenia GWAS locus", "PROBLEM", 291, 317], ["the GRB model", "TEST", 442, 455], ["a schizophrenia-associated variant", "PROBLEM", 520, 554], ["mechanistically related SNPs", "PROBLEM", 736, 764], ["two schizophrenia", "PROBLEM", 790, 807], ["associated loci", "PROBLEM", 808, 823], ["impaired", "OBSERVATION_MODIFIER", 87, 95], ["neuritogenesis", "OBSERVATION", 96, 110], ["hippocampus", "ANATOMY", 118, 129], ["GRB model", "OBSERVATION", 365, 374], ["schizophrenia", "OBSERVATION", 522, 535], ["GRB model", "OBSERVATION", 715, 724], ["two", "OBSERVATION_MODIFIER", 790, 793], ["schizophrenia", "OBSERVATION", 794, 807], ["loci", "OBSERVATION_MODIFIER", 819, 823], ["GRB", "OBSERVATION", 856, 859], ["most likely", "UNCERTAINTY", 898, 909]]], ["As Fig. 3c shows, this GRB spans six genes, three of which (NTM, OPCML and IGSF9B) are predicted GRB targets.", [["GRB", "GENE_OR_GENE_PRODUCT", 23, 26], ["OPCML", "GENE_OR_GENE_PRODUCT", 65, 70], ["IGSF9B", "GENE_OR_GENE_PRODUCT", 75, 81], ["GRB", "GENE_OR_GENE_PRODUCT", 97, 100], ["GRB", "DNA", 23, 26], ["OPCML", "DNA", 65, 70], ["IGSF9B", "DNA", 75, 81], ["GRB targets", "DNA", 97, 108], ["this GRB spans six genes", "PROBLEM", 18, 42], ["NTM", "TEST", 60, 63]]], ["The PGC study proposes IGSF9B as the putative target of the rs75059851 SNP identified in the original study due to the location of the SNP in the promoter/first intron of two transcript isoforms of the IGSF9B.", [["SNP", "CHEMICAL", 71, 74], ["SNP", "CHEMICAL", 135, 138], ["IGSF9B", "GENE_OR_GENE_PRODUCT", 23, 29], ["rs75059851", "GENE_OR_GENE_PRODUCT", 60, 70], ["IGSF9B", "GENE_OR_GENE_PRODUCT", 202, 208], ["IGSF9B", "DNA", 23, 29], ["rs75059851 SNP", "DNA", 60, 74], ["promoter", "DNA", 146, 154], ["IGSF9B", "PROTEIN", 202, 208], ["The PGC study", "TEST", 0, 13], ["the original study", "TEST", 89, 107], ["the SNP", "TREATMENT", 131, 138]]], ["The expression of all three of the predicted GRB target genes is significantly greater in tissues in which the enhancers are active, Fig. 2c.", [["tissues", "ANATOMY", 90, 97], ["GRB", "GENE_OR_GENE_PRODUCT", 45, 48], ["tissues", "TISSUE", 90, 97], ["GRB target genes", "DNA", 45, 61], ["enhancers", "DNA", 111, 120], ["significantly", "OBSERVATION_MODIFIER", 65, 78], ["greater", "OBSERVATION_MODIFIER", 79, 86], ["active", "OBSERVATION_MODIFIER", 125, 131]]], ["In this case all three predicted target genes are neuronal specific cell adhesion molecules involved in neuronal development and thus likely candidate genes.", [["neuronal", "ANATOMY", 50, 58], ["cell", "ANATOMY", 68, 72], ["neuronal", "ANATOMY", 104, 112], ["neuronal", "CELL", 50, 58], ["cell", "CELL", 68, 72], ["neuronal", "CELL", 104, 112], ["target genes", "DNA", 33, 45], ["neuronal specific cell adhesion molecules", "PROTEIN", 50, 91], ["candidate genes", "DNA", 141, 156], ["neuronal specific cell adhesion molecules", "TREATMENT", 50, 91], ["specific cell", "OBSERVATION", 59, 72], ["adhesion molecules", "OBSERVATION", 73, 91]]], ["Indeed, OPCML has been previously implicated in the development of schizophrenia by multiple studies in European [56] and Thai [57] populations.", [["OPCML", "CHEMICAL", 8, 13], ["schizophrenia", "DISEASE", 67, 80], ["OPCML", "GENE_OR_GENE_PRODUCT", 8, 13], ["OPCML", "PROTEIN", 8, 13], ["schizophrenia", "PROBLEM", 67, 80], ["schizophrenia", "OBSERVATION", 67, 80]]], ["In addition, increased levels of an NTM isoform have recently been detected in the dorsolateral prefrontal cortex of schizophrenia patients [58].", [["dorsolateral prefrontal cortex", "ANATOMY", 83, 113], ["schizophrenia", "DISEASE", 117, 130], ["dorsolateral prefrontal cortex", "CANCER", 83, 113], ["patients", "ORGANISM", 131, 139], ["NTM isoform", "PROTEIN", 36, 47], ["patients", "SPECIES", 131, 139], ["an NTM isoform", "PROBLEM", 33, 47], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["levels", "OBSERVATION_MODIFIER", 23, 29], ["NTM", "OBSERVATION", 36, 39], ["dorsolateral", "ANATOMY_MODIFIER", 83, 95], ["prefrontal cortex", "ANATOMY", 96, 113], ["schizophrenia", "OBSERVATION", 117, 130]]], ["More importantly, the concordance of putative enhancers in both schizophrenia-associated loci with genes across the entire GRB (Fig. 3c), including SNX19, supports the idea that variants rs10791097 (found just downstream of, and originally thought to be a bystander locus to SNX19 [42]) and rs75059851 share some mechanistic aspects in the aetiology of the disease, and calls for testing for effects of their interaction despite the large genomic distance between them.", [["schizophrenia", "DISEASE", 64, 77], ["GRB", "GENE_OR_GENE_PRODUCT", 123, 126], ["Fig. 3c", "GENE_OR_GENE_PRODUCT", 128, 135], ["SNX19", "GENE_OR_GENE_PRODUCT", 148, 153], ["rs10791097", "GENE_OR_GENE_PRODUCT", 187, 197], ["SNX19 [42]", "GENE_OR_GENE_PRODUCT", 275, 285], ["rs75059851", "GENE_OR_GENE_PRODUCT", 291, 301], ["putative enhancers", "DNA", 37, 55], ["schizophrenia-associated loci", "DNA", 64, 93], ["GRB", "DNA", 123, 126], ["SNX19", "DNA", 148, 153], ["SNX19", "DNA", 275, 280], ["rs75059851", "DNA", 291, 301], ["putative enhancers", "PROBLEM", 37, 55], ["the disease", "PROBLEM", 353, 364], ["testing", "TEST", 380, 387], ["putative enhancers", "OBSERVATION", 37, 55], ["both", "OBSERVATION_MODIFIER", 59, 63], ["schizophrenia", "OBSERVATION", 64, 77], ["entire", "OBSERVATION_MODIFIER", 116, 122], ["GRB", "OBSERVATION", 123, 126], ["disease", "OBSERVATION", 357, 364], ["large", "OBSERVATION_MODIFIER", 433, 438]]], ["This example highlights how the GRBs can serve as functional units in which the effects of multiple SNPs can be considered as potentially interacting.The unbiased prediction of GRB target genes identifies potentially overlooked candidate genes at well-studied lociThe final example is a locus that overlaps the gene for the dopamine D2 receptor (DRD2)\u2014the target of all licensed antipsychotic therapy drugs [59].", [["dopamine", "CHEMICAL", 324, 332], ["dopamine", "CHEMICAL", 324, 332], ["GRBs", "GENE_OR_GENE_PRODUCT", 32, 36], ["GRB", "GENE_OR_GENE_PRODUCT", 177, 180], ["dopamine D2 receptor", "GENE_OR_GENE_PRODUCT", 324, 344], ["DRD2", "GENE_OR_GENE_PRODUCT", 346, 350], ["GRBs", "DNA", 32, 36], ["GRB target genes", "DNA", 177, 193], ["candidate genes", "DNA", 228, 243], ["dopamine D2 receptor", "PROTEIN", 324, 344], ["DRD2", "PROTEIN", 346, 350], ["functional units", "TREATMENT", 50, 66], ["multiple SNPs", "TREATMENT", 91, 104], ["the dopamine D2 receptor (DRD2)", "TREATMENT", 320, 351], ["all licensed antipsychotic therapy drugs", "TREATMENT", 366, 406], ["GRB target", "OBSERVATION", 177, 187]]], ["The unpredictability of a patient\u2019s response to antipsychotic therapy, and alternative roles of this locus have been under recent scrutiny [60].", [["patient", "ORGANISM", 26, 33], ["locus", "CELLULAR_COMPONENT", 101, 106], ["patient", "SPECIES", 26, 33], ["antipsychotic therapy", "TREATMENT", 48, 69]]], ["This locus overlaps a GRB containing both DRD2 and a neural cell adhesion molecule gene, NCAM1, shown in Fig. 3d.", [["neural cell", "ANATOMY", 53, 64], ["locus", "CELLULAR_COMPONENT", 5, 10], ["GRB", "GENE_OR_GENE_PRODUCT", 22, 25], ["DRD2", "GENE_OR_GENE_PRODUCT", 42, 46], ["neural cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 53, 82], ["NCAM1", "GENE_OR_GENE_PRODUCT", 89, 94], ["GRB", "DNA", 22, 25], ["DRD2", "DNA", 42, 46], ["neural cell adhesion molecule gene", "DNA", 53, 87], ["NCAM1", "DNA", 89, 94], ["a GRB containing both DRD2", "PROBLEM", 20, 46], ["a neural cell adhesion molecule gene", "TREATMENT", 51, 87], ["GRB", "OBSERVATION", 22, 25], ["both DRD2", "OBSERVATION", 37, 46], ["neural cell", "OBSERVATION", 53, 64], ["adhesion molecule", "OBSERVATION", 65, 82]]], ["NCAM1 has previously been implicated in a number of neuropsychiatric disorders, including schizophrenia [61], and our analysis identifies NCAM1 as another plausible target, despite not being categorized as a GRB target (it\u2019s predictive value is just below the threshold, see Supplementary information).", [["NCAM1", "CHEMICAL", 0, 5], ["neuropsychiatric disorders", "DISEASE", 52, 78], ["schizophrenia", "DISEASE", 90, 103], ["NCAM1", "GENE_OR_GENE_PRODUCT", 0, 5], ["NCAM1", "GENE_OR_GENE_PRODUCT", 138, 143], ["NCAM1", "PROTEIN", 0, 5], ["NCAM1", "PROTEIN", 138, 143], ["GRB target", "DNA", 208, 218], ["neuropsychiatric disorders", "PROBLEM", 52, 78], ["schizophrenia", "PROBLEM", 90, 103], ["our analysis", "TEST", 114, 126]]], ["When active, the predicted enhancer element in the schizophrenia-associated locus affects transcription of both DRD2 and NCAM1, with a more prominent effect on the transcription of the NCAM1 gene (Supplementary Fig. 1).", [["schizophrenia", "DISEASE", 51, 64], ["locus", "CELLULAR_COMPONENT", 76, 81], ["DRD2", "GENE_OR_GENE_PRODUCT", 112, 116], ["NCAM1", "GENE_OR_GENE_PRODUCT", 121, 126], ["NCAM1", "GENE_OR_GENE_PRODUCT", 185, 190], ["enhancer element", "DNA", 27, 43], ["schizophrenia-associated locus", "DNA", 51, 81], ["DRD2", "DNA", 112, 116], ["NCAM1", "DNA", 121, 126], ["NCAM1 gene", "DNA", 185, 195], ["the predicted enhancer element", "PROBLEM", 13, 43], ["the schizophrenia", "PROBLEM", 47, 64], ["NCAM1", "TREATMENT", 121, 126], ["the NCAM1 gene", "TREATMENT", 181, 195], ["active", "OBSERVATION_MODIFIER", 5, 11], ["schizophrenia", "OBSERVATION", 51, 64], ["more prominent", "OBSERVATION_MODIFIER", 135, 149]]], ["This locus illustrates the risk of hypothesis-driven target gene search: once a gene, e.g. DRD2, expected to play a role in disease aetiology is identified, other putative targets in its vicinity may be overlooked.Lessons learned from application of the GRB model to disease-associated genomic lociRecent approaches to identifying pathways through which non-coding variants lead to neuropsychiatric disorders such as schizophrenia suffer from three major conceptual oversimplifications.", [["neuropsychiatric disorders", "DISEASE", 382, 408], ["schizophrenia", "DISEASE", 417, 430], ["DRD2", "GENE_OR_GENE_PRODUCT", 91, 95], ["DRD2", "DNA", 91, 95], ["hypothesis", "PROBLEM", 35, 45], ["disease aetiology", "PROBLEM", 124, 141], ["the GRB model to disease", "PROBLEM", 250, 274], ["genomic lociRecent approaches", "TREATMENT", 286, 315], ["neuropsychiatric disorders", "PROBLEM", 382, 408], ["schizophrenia", "PROBLEM", 417, 430]]], ["First and foremost, despite the wealth of the literature published on complex modes of regulation [17, 62], the practice of assigning non-coding variants to nearby genes is still prevalent.", [["nearby genes", "DNA", 157, 169]]], ["The GRB model allows for the expansion of the search for a target beyond adjacent genes and provides boundaries as to which genes should be included and which should not, but only in the cases where GWAS loci occur in the region of the genome implicated in the long-range regulation.", [["GRB", "DNA", 4, 7], ["GWAS loci", "DNA", 199, 208], ["GWAS loci", "PROBLEM", 199, 208], ["GRB model", "OBSERVATION", 4, 13], ["genome", "OBSERVATION", 236, 242]]], ["Further, automated GRB target gene prediction provides a shortlist of genes most likely to be under the control of long-range regulation.Lessons learned from application of the GRB model to disease-associated genomic lociNext, epistatic effects between variants have been reported for a range of human complex traits, however systematic approaches to identify pairs of variants displaying epistatic effects suffers from multidimensionality problems and low reproducibility due to high false positive rates (for a review see [63]).", [["GRB", "GENE_OR_GENE_PRODUCT", 19, 22], ["human", "ORGANISM", 296, 301], ["GRB target gene", "DNA", 19, 34], ["human", "SPECIES", 296, 301], ["human", "SPECIES", 296, 301], ["long-range regulation", "TREATMENT", 115, 136], ["the GRB model to disease", "PROBLEM", 173, 197], ["genomic lociNext", "TREATMENT", 209, 225], ["epistatic effects between variants", "PROBLEM", 227, 261], ["systematic approaches", "TREATMENT", 326, 347], ["epistatic effects", "PROBLEM", 389, 406], ["multidimensionality problems", "PROBLEM", 420, 448], ["low reproducibility", "PROBLEM", 453, 472], ["high false positive rates", "PROBLEM", 480, 505], ["genomic lociNext", "OBSERVATION", 209, 225]]], ["GRBs as functional regulatory units may allow us to identify epistatic effects of non-coding variants that fall within the same GRBs (as in the NTM/OPCML/IGSF9B example in the Fig. 3c), as this effectively reduces the number of statistical tests required potentially allowing for the detection of modest epistatic effects.Lessons learned from application of the GRB model to disease-associated genomic lociFinally, identification of target genes linked to a given locus is often biased towards genes with functions and pathways previously associated with the trait or disease under investigation, potentially overlooking plausible alternative hypotheses.", [["GRBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GRBs", "GENE_OR_GENE_PRODUCT", 128, 132], ["Fig. 3c", "GENE_OR_GENE_PRODUCT", 176, 183], ["locus", "CELLULAR_COMPONENT", 464, 469], ["GRBs", "PROTEIN", 0, 4], ["GRBs", "DNA", 128, 132], ["OPCML", "DNA", 148, 153], ["target genes", "DNA", 433, 445], ["epistatic effects of non-coding variants", "PROBLEM", 61, 101], ["the NTM", "TEST", 140, 147], ["statistical tests", "TEST", 228, 245], ["the detection", "TEST", 280, 293], ["modest epistatic effects", "PROBLEM", 297, 321], ["the GRB model to disease", "PROBLEM", 358, 382], ["genomic lociFinally", "PROBLEM", 394, 413], ["the trait", "PROBLEM", 555, 564], ["disease", "PROBLEM", 568, 575]]], ["The evolutionary nature of the GRB model allows for an unbiased approach to identification of potential target genes, potentially identifying novel target genes and new disease mechanisms.", [["target genes", "DNA", 104, 116], ["target genes", "DNA", 148, 160], ["new disease mechanisms", "PROBLEM", 165, 187], ["GRB model", "OBSERVATION", 31, 40], ["new", "OBSERVATION_MODIFIER", 165, 168], ["disease", "OBSERVATION", 169, 176]]], ["Of particular interest is a network of mutually interacting transcription factors involved in neuronal development of cortical layers, predicted as targets in SCZ-GRBs: BCL11B, BCL11A, TBR1, SATB2 and FEZF2 (Supplementary Fig. S2).", [["neuronal", "ANATOMY", 94, 102], ["cortical layers", "ANATOMY", 118, 133], ["neuronal", "CELL", 94, 102], ["cortical layers", "MULTI-TISSUE_STRUCTURE", 118, 133], ["SCZ-GRBs", "GENE_OR_GENE_PRODUCT", 159, 167], ["BCL11B", "GENE_OR_GENE_PRODUCT", 169, 175], ["BCL11A", "GENE_OR_GENE_PRODUCT", 177, 183], ["TBR1", "GENE_OR_GENE_PRODUCT", 185, 189], ["SATB2", "GENE_OR_GENE_PRODUCT", 191, 196], ["FEZF2", "GENE_OR_GENE_PRODUCT", 201, 206], ["transcription factors", "PROTEIN", 60, 81], ["GRBs", "PROTEIN", 163, 167], ["BCL11B", "PROTEIN", 169, 175], ["BCL11A", "PROTEIN", 177, 183], ["TBR1", "DNA", 185, 189], ["SATB2", "DNA", 191, 196], ["FEZF2", "DNA", 201, 206], ["S2", "PROTEIN", 227, 229], ["cortical layers", "PROBLEM", 118, 133], ["SCZ", "TEST", 159, 162], ["BCL11B", "TEST", 169, 175], ["BCL11A", "TEST", 177, 183], ["TBR1", "TEST", 185, 189], ["SATB2", "TEST", 191, 196], ["FEZF2", "TEST", 201, 206], ["cortical layers", "OBSERVATION", 118, 133], ["BCL11B", "ANATOMY", 169, 175], ["BCL11A", "ANATOMY", 177, 183]]], ["Of these, only BCL11B is listed among targets in the PGC study with remainder not detected based on the assignment of non-coding SNPs to the closest gene.", [["BCL11B", "GENE_OR_GENE_PRODUCT", 15, 21], ["BCL11B", "DNA", 15, 21], ["non-coding SNPs", "DNA", 118, 133], ["the PGC study", "TEST", 49, 62], ["non-coding SNPs", "PROBLEM", 118, 133], ["BCL11B", "OBSERVATION", 15, 21]]], ["GRBs often target genes involved in development, which require complex regulation [16].", [["GRBs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GRBs", "PROTEIN", 0, 4]]], ["Our finding that the non-coding genetic loci associated with schizophrenia and autism, but not bipolar disorder, are significantly more likely to occur in GRBs is thus consistent with other evidence that there is a stronger neurodevelopmental component to these disorders than bipolar [64, 65], and indicates novel potential developmental genes linked to these disorders.Other schizophrenia GWAS datasetsSince the conception of this study, several smaller schizophrenia GWAS datasets have emerged [8, 23, 24, 26, 27], with many signals from the 2014 PGC study replicated, and some new loci discovered.", [["schizophrenia", "DISEASE", 61, 74], ["autism", "DISEASE", 79, 85], ["bipolar disorder", "DISEASE", 95, 111], ["bipolar", "DISEASE", 277, 284], ["schizophrenia", "DISEASE", 377, 390], ["schizophrenia", "DISEASE", 456, 469], ["GRBs", "CANCER", 155, 159], ["non-coding genetic loci", "DNA", 21, 44], ["developmental genes", "DNA", 325, 344], ["the non-coding genetic loci", "PROBLEM", 17, 44], ["schizophrenia", "PROBLEM", 61, 74], ["autism", "PROBLEM", 79, 85], ["bipolar disorder", "PROBLEM", 95, 111], ["a stronger neurodevelopmental component", "PROBLEM", 213, 252], ["these disorders", "PROBLEM", 256, 271], ["these disorders", "PROBLEM", 355, 370], ["Other schizophrenia GWAS datasets", "PROBLEM", 371, 404], ["this study", "TEST", 428, 438], ["several smaller schizophrenia GWAS datasets", "PROBLEM", 440, 483], ["PGC study", "TEST", 550, 559], ["some new loci", "PROBLEM", 576, 589], ["genetic loci", "OBSERVATION", 32, 44], ["schizophrenia", "OBSERVATION", 61, 74], ["consistent with", "UNCERTAINTY", 168, 183], ["schizophrenia", "OBSERVATION", 377, 390], ["smaller", "OBSERVATION_MODIFIER", 448, 455], ["schizophrenia", "OBSERVATION", 456, 469], ["new", "OBSERVATION_MODIFIER", 581, 584]]], ["The most significant change in these is a notable trend towards functional characterisation of SNPs in view of finding regulatory variants using eQTL information [8, 24, 26, 66], chromatin contacts [8, 27] and transcription factor binding profiles [26].", [["chromatin", "ANATOMY", 179, 188], ["chromatin", "CELLULAR_COMPONENT", 179, 188], ["SNPs", "DNA", 95, 99], ["transcription factor", "PROTEIN", 210, 230], ["eQTL information", "TEST", 145, 161], ["transcription factor binding profiles", "TEST", 210, 247], ["most significant", "OBSERVATION_MODIFIER", 4, 20], ["change", "OBSERVATION", 21, 27]]], ["We have analysed the three largest datasets [8, 26, 67] in the same way as the PGC GWAS represented here (Supplementary Fig. S3), and showed that the GRB target gene prediction still implicates many novel long-range contacts not documented in even the most recent published data (Supplementary information and Supplementary Tables S2 andS3).", [["GRB", "GENE_OR_GENE_PRODUCT", 150, 153], ["PGC GWAS", "DNA", 79, 87], ["GRB target gene", "DNA", 150, 165], ["the PGC GWAS", "TEST", 75, 87], ["the GRB target gene prediction", "PROBLEM", 146, 176], ["largest", "OBSERVATION_MODIFIER", 27, 34]]], ["While a greater coverage of high-resolution tissue-specific chromatin contacts, allele-specific gene expression, transcriptome maps and genome-wide binding profiles for a wider range of transcription factors will partially close this gap in the future, the GRB approach will stand as an elegant method of shortlisting (or adding additional evidence for) genes through which regulatory non-coding variants exert their effects on disease emergence.ConclusionsThe last few years have seen a step change in the power of GWAS in neuropsychiatric disorders.", [["tissue", "ANATOMY", 44, 50], ["chromatin", "ANATOMY", 60, 69], ["neuropsychiatric disorders", "DISEASE", 524, 550], ["tissue", "TISSUE", 44, 50], ["chromatin", "CELLULAR_COMPONENT", 60, 69], ["allele", "DNA", 80, 86], ["transcription factors", "PROTEIN", 186, 207], ["regulatory non-coding variants", "DNA", 374, 404], ["transcriptome maps", "TEST", 113, 131], ["transcription factors", "PROBLEM", 186, 207], ["the GRB approach", "TREATMENT", 253, 269], ["genes through which regulatory non-coding variants", "PROBLEM", 354, 404], ["disease emergence", "PROBLEM", 428, 445], ["a step change", "PROBLEM", 486, 499], ["neuropsychiatric disorders", "PROBLEM", 524, 550], ["neuropsychiatric disorders", "OBSERVATION", 524, 550]]], ["This has led to large numbers of novel loci being identified, but raises a new challenge: determining the correct gene(s) linked to these loci.", [["large", "OBSERVATION_MODIFIER", 16, 21], ["numbers", "OBSERVATION_MODIFIER", 22, 29], ["novel loci", "OBSERVATION", 33, 43]]], ["The common practice of assigning non-coding loci identified in GWAS to the nearest is likely to be an oversimplification in a substantial proportion of cases.", [["non-coding loci", "DNA", 33, 48], ["assigning non-coding loci", "PROBLEM", 23, 48], ["common", "OBSERVATION_MODIFIER", 4, 10], ["non-coding loci", "OBSERVATION", 33, 48], ["likely to be", "UNCERTAINTY", 86, 98], ["oversimplification", "OBSERVATION", 102, 120]]], ["In particular, it neglects the topological organisation of the genome, and the possibility that a locus may be in, or linked to, a non-coding element that regulates a distant gene.", [["genome", "CELLULAR_COMPONENT", 63, 69], ["locus", "CELLULAR_COMPONENT", 98, 103], ["non-coding element", "DNA", 131, 149], ["distant gene", "DNA", 167, 179], ["a non-coding element", "PROBLEM", 129, 149]]], ["New understanding on the characteristics of non-coding elements in highly conserved GRBs, and their link to TADs can be used to identify the potential target genes for loci in GRBs.", [["GRBs", "GENE_OR_GENE_PRODUCT", 84, 88], ["TADs", "GENE_OR_GENE_PRODUCT", 108, 112], ["GRBs", "PATHOLOGICAL_FORMATION", 176, 180], ["non-coding elements", "DNA", 44, 63], ["GRBs", "DNA", 84, 88], ["TADs", "DNA", 108, 112], ["target genes", "DNA", 151, 163], ["GRBs", "DNA", 176, 180], ["non-coding elements", "PROBLEM", 44, 63], ["loci in GRBs", "PROBLEM", 168, 180]]], ["We applied this knowledge to the loci from recent GWAS in three neuropsychiatric disorders, to show that for two of them, schizophrenia and autism, there was an excess of loci located in GRBs than would be expected by chance.", [["neuropsychiatric disorders", "DISEASE", 64, 90], ["schizophrenia", "DISEASE", 122, 135], ["autism", "DISEASE", 140, 146], ["GRBs", "GENE_OR_GENE_PRODUCT", 187, 191], ["GRBs", "DNA", 187, 191], ["recent GWAS in three neuropsychiatric disorders", "PROBLEM", 43, 90], ["schizophrenia", "PROBLEM", 122, 135], ["autism", "PROBLEM", 140, 146], ["an excess of loci", "PROBLEM", 158, 175], ["schizophrenia", "OBSERVATION", 122, 135]]], ["Further analysis showed the potential of this approach to identify novel plausible genes for the schizophrenia, such as NTM, ARHGAP15 and ZEB2.", [["schizophrenia", "DISEASE", 97, 110], ["NTM", "DISEASE", 120, 123], ["ARHGAP15", "GENE_OR_GENE_PRODUCT", 125, 133], ["ZEB2", "GENE_OR_GENE_PRODUCT", 138, 142], ["ARHGAP15", "DNA", 125, 133], ["ZEB2", "PROTEIN", 138, 142], ["Further analysis", "TEST", 0, 16], ["this approach", "TREATMENT", 41, 54], ["the schizophrenia", "PROBLEM", 93, 110], ["ARHGAP15", "TREATMENT", 125, 133], ["ZEB2", "TREATMENT", 138, 142], ["schizophrenia", "OBSERVATION", 97, 110]]], ["This illustrates the potential value of the GRB approach and the need to consider the role of non-coding elements to guide the biological analysis of loci identified by GWAS.", [["non-coding elements", "DNA", 94, 113], ["the GRB approach", "TREATMENT", 40, 56], ["the biological analysis", "TEST", 123, 146]]]], "e8bb7ed3959a73cf59a17846be4f39bc12158e16": [["Leuven (campus Brussels), both in Belgium, lecturing amongst others in engineering risk analysis and risk management.Declaration of interest\u2612 The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Declaration of interest\u2610The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:AbstractOur current predicament, the Covid-19 pandemic is first of all a health crisis.", [["risk management", "TREATMENT", 101, 116]]], ["However, social disruption and economic damage are becoming visible some 7 months after the Wuhan City outbreak early December 2019.", [["social disruption", "PROBLEM", 9, 26], ["economic damage", "PROBLEM", 31, 46], ["social disruption", "OBSERVATION", 9, 26]]], ["The authors wondered what could have been done better in prevention and repression of the Covid-19 pandemic from a safety management and risk control point of view.AbstractWithin a case study framework, the authors gathered literature on pandemics, about country response effectiveness, and about human behaviour in the face of danger.", [["human", "ORGANISM", 297, 302], ["human", "SPECIES", 297, 302], ["human", "SPECIES", 297, 302], ["the Covid", "TEST", 86, 95], ["a safety management", "TREATMENT", 113, 132]]], ["The results consist of a safety management oriented narrative about the current pandemic, several critical observations about the current paradigms and shortcomings of preparation, and a number of opportunities for improvements of countermeasures.", [["a safety management", "TREATMENT", 23, 42], ["shortcomings of preparation", "TREATMENT", 152, 179], ["countermeasures", "TREATMENT", 231, 246]]], ["Many of the proverbial animals in the safety zoo, representing typical behaviours, were observed in action.AbstractBased on well proven risk analysis methods -risk management, event tree, scenarios, bowtie -the authors then analyse the generic sequence of events in a pandemic, starting from root causes, through prevention, via the outbreak of a pathogen, through mitigation to long term effects.", [["root", "ANATOMY", 292, 296], ["a pandemic", "PROBLEM", 266, 276], ["a pathogen", "PROBLEM", 345, 355], ["typical", "OBSERVATION_MODIFIER", 63, 70], ["behaviours", "OBSERVATION", 71, 81], ["long term", "OBSERVATION_MODIFIER", 379, 388]]], ["Based on this analysis the authors propose an integrated pandemics barrier model.", [["this analysis", "TEST", 9, 22], ["an integrated pandemics barrier model", "TREATMENT", 43, 80]]], ["In this model the core is a generic pandemic scenario that is distinguishing five risk controllable sequential steps before an outbreak.", [["pandemic", "OBSERVATION", 36, 44]]], ["The authors contend that the prevention of pandemics via safety management based biohazard risk control is both possible and of paramount importance since it can stop pandemic scenarios altogether even before an outbreak.INTRODUCTIONPeople, thinking about safety, use quite a few animals as representations of safety concepts.", [["pandemics", "DISEASE", 43, 52], ["pandemics", "PROBLEM", 43, 52], ["safety management", "TREATMENT", 57, 74], ["biohazard risk control", "TREATMENT", 81, 103]]], ["In addition to Paper tigers (Dekker,2014) , Dinosaurs (Cohen, 2005) , Black swans (Taleb, 2007) , Dragons (Elahi, 2011) and Elephants (Srivatsa, 2018) , Michelle Wucker (2016) introduced Gray rhino's inwhat by now could be called -the 'safety zoo '.", [["Black swans", "SPECIES", 70, 81]]], ["Nathan Jaye (2017) interviews Michele Wucker on October 23, 2017 asking her about 'black swans'.", [["black swans", "SPECIES", 83, 94]]], ["In safety science those stand for the combination of unlikely factors suddenly creating a big problem.", [["a big problem", "PROBLEM", 88, 101]]], ["Jaye and Wucker then engage in a discussion about China and -among other things -about recurring influenza viruses, comparing them with recurring 'gray rhino's'.", [["influenza viruses", "DISEASE", 97, 114], ["recurring influenza viruses", "PROBLEM", 87, 114], ["recurring 'gray rhino's", "PROBLEM", 136, 159]]], ["Not reacting to a charging rhino is the worst thing to do, even when you are frightened, prone to freezing on the spot or are scared to make a wrong choice.", [["frightened", "PROBLEM", 77, 87]]], ["These animal-concepts all address safety problems we do not seem to handle very well.", [["safety problems", "PROBLEM", 34, 49]]], ["But how vulnerable are we, between a hot and violent earth beneath us and cold outer space surrounding us from above?", [["a hot and violent earth beneath us", "PROBLEM", 35, 69]]], ["Another one which manifested itself before, is the extinction of dinosaurs after the successive Yucatan and Shiva asteroid impacts 65 million years ago (Lerbekmo, 2014) .", [["the successive Yucatan and Shiva asteroid impacts", "TREATMENT", 81, 130]]], ["The prevention of such disasters is currently beyond our capabilities.", [["such disasters", "PROBLEM", 18, 32]]], ["Nature may throw earthquakes, volcanic eruptions, enormous firestorms and tsunamis at us in the wake of such impact.", [["earthquakes", "DISEASE", 17, 28], ["eruptions", "DISEASE", 39, 48], ["firestorms", "DISEASE", 59, 69], ["tsunamis", "DISEASE", 74, 82], ["volcanic eruptions", "PROBLEM", 30, 48], ["tsunamis", "TREATMENT", 74, 82], ["volcanic eruptions", "OBSERVATION", 30, 48]]], ["Mitigation would for the most part also be beyond our possibilities.", [["Mitigation", "TREATMENT", 0, 10]]], ["If an asteroid impact were to happen nonetheless, and if part of mankind were to survive, we would certainly need to show resilience.", [["an asteroid impact", "PROBLEM", 3, 21], ["asteroid impact", "OBSERVATION", 6, 21]]], ["Early discovery of a dangerous space-rock could give us some time for preparation and this might help us to recover from the damage and shorten the aftermath.", [["a dangerous space-rock", "TREATMENT", 19, 41], ["the damage", "PROBLEM", 121, 131]]], ["It were grey mouses in local governments that accepted their risks and paper tigers looking away.", [["grey mouses", "OBSERVATION", 8, 19]]], ["In fact they were looking away from a dinosaur in the living room, the WHO, rendered powerless by many years of budget cutting.", [["budget cutting", "TREATMENT", 112, 126]]], ["Many Western countries thought it were black-swans the Far-East was dealing with and -with SARS in mind -decided that it was highly unlikely such a pathogen would ever reach the West.", [["SARS", "DISEASE", 91, 95], ["a pathogen", "PROBLEM", 146, 156]]], ["The response observed in most countries to the emerging pandemic was like not moving out of the way while being in the path of a charging gray rhino.", [["a charging gray rhino", "PROBLEM", 127, 148]]], ["Several other countries did better by taking action immediately however, resulting in exceptionally low death tolls.", [["death", "DISEASE", 104, 109], ["exceptionally low death tolls", "PROBLEM", 86, 115]]], ["The consequences of ineffective responses are exceptionally high death tolls.INTRODUCTIONThese notions raise many questions by many people about what it takes to choose the right strategy for health, safety, vulnerable groups, critical functions, essential services and supplies, society and economy in relation to pandemic risk.", [["death", "DISEASE", 65, 70], ["pandemic", "DISEASE", 315, 323], ["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138], ["ineffective responses", "PROBLEM", 20, 41]]], ["From a safety management point of view the world is confronted with an unwanted event and huge adverse consequences: by June 10, 2020 the growing total death toll in over 190 countries passed 408,000 (WHO, 2020f) while societal disruption and global economic damage continue to develop.PROBLEM DEFINITIONOur current predicament, the Covid-19 pandemic, has an anatomy similar to that of major accidents such as the Bhopal-, Tsjernobyl-and Seveso disasters.", [["death", "DISEASE", 152, 157], ["accidents", "DISEASE", 392, 401], ["a safety management", "TREATMENT", 5, 24], ["societal disruption", "PROBLEM", 219, 238], ["global economic damage", "PROBLEM", 243, 265], ["global", "OBSERVATION_MODIFIER", 243, 249], ["economic damage", "OBSERVATION", 250, 265], ["anatomy", "OBSERVATION", 359, 366]]], ["There are multiple causal factors, important risks to consider, prevention measures to take and -in case all those fail -a well prepared repression system, consisting of preparation, emergency response and mitigation, to put in place.", [["prevention measures", "TREATMENT", 64, 83], ["mitigation", "TREATMENT", 206, 216], ["multiple", "OBSERVATION_MODIFIER", 10, 18]]], ["Since several critical observations can be made originating from this background, we would like to explore in this study, learning from the current Covid-19 pandemic, the possibilities for applying and improving current safety management and risk control concepts to potential future pandemics.", [["this study", "TEST", 110, 120], ["current safety management", "TREATMENT", 212, 237], ["risk control", "TREATMENT", 242, 254]]], ["This study centres on the following question:PROBLEM DEFINITIONWhat could have been done better in prevention and repression of the Covid-19 pandemic from a safety management and risk control perspective?RESEARCH METHODThe overall design of this study follows the case study method (Yin et al., 2006) .", [["This study", "TEST", 0, 10], ["the Covid", "TEST", 128, 137], ["a safety management", "TREATMENT", 155, 174], ["this study", "TEST", 241, 251]]], ["It consists of a sequence of steps to follow in the research process, here simplified from Eisenhardt (1989) to: design, data gathering from literature and observations, analysis and construction of a theoretical model and a critical reflection on the outcome.", [["analysis", "TEST", 170, 178], ["a theoretical model", "TREATMENT", 199, 218]]], ["The latitudinal descriptive case study form we use requires a blue-print to provide a structure for data gathering (Yin et al., 2006) .", [["a blue-print", "TREATMENT", 60, 72]]], ["Table 1 Case study blue-print -structure for data gathering and analysis Several Inclusion and exclusion criteria were used to protect the quality of the sources:-Literature search\uf0b7 Primary peer-reviewed scientific sources from various databases and via reference listings \uf0b7 Secondary sources (Cronin et al., 2008) from government organisations and international institutions. \uf0b7 Tertiary 'Grey' sources (Wessels, 1997) only if particularly relevant to the subjects. \uf0b7 Time period: 2000-2020, with a few exceptions for essential sources from before 2000. \uf0b7 We excluded publications only available in other languages than English and Dutch. \uf0b7 We screened sources found by means of the search terms and the in/exclusion criteria. \uf0b7 Search terms are successively derived from the sources found and different subsets of terms were used for each subject to ensure that important sources were included. \uf0b7 Databases used: Scopus, Medline, Google Scholar, Academia, Research Gate and associated proprietary databases.-Construction of a theoretical modelThe risk management model we use in this study consists of three well proven elements: \uf0b7 a 6 steps risk awareness approach (Oliveira et al., 2017; Enders, 2001; ISO 31000:2009) , \uf0b7 a risk matrix based assessment system (ISO 31000:2009) and \uf0b7 a 'bow-tie' timeline/causality model (L\u00e9ger et al., 2008; Khakzad et al., 2012) .-Construction of a theoretical modelThese elements are generally accepted and widely used risk management techniques, and their combination enables mapping, analysing and comparing the outcomes of safety management and risk control approaches over time.-Construction of a theoretical modelIn support of the theoretical model we analyse the process observed as the current Covid-19 pandemic is unfolding.", [["exclusion criteria", "TEST", 95, 113], ["this study", "TEST", 1080, 1090], ["risk management techniques", "TREATMENT", 1457, 1483], ["safety management", "TREATMENT", 1564, 1581], ["risk control approaches", "TREATMENT", 1586, 1609], ["the current Covid", "TEST", 1727, 1744]]], ["From our literature findings we deduce a series of generic pandemic scenario events, a range of countermeasures and a suite of supporting activities.", [["generic pandemic scenario events", "PROBLEM", 51, 83]]], ["The way we do this follows the steps in a meta-synthesis process (Cronin et al., 2008; Polit & Beck, 2006) .-Critical reflectionComparing our ideals with observed practice is at the roots of every critical reflection no matter which belief, culture or emotion we come from.", [["culture", "TEST", 241, 248]]], ["In practice the method in its simplest form consists of an introduction followed by two stages (Hickson, 2010) : 1) deconstruction of reality and 2) reconstruction towards achieving the ideal outcome.-Limitations, reliability and validityThis study is limited with respect to the number of sources used versus the number of sources available.", [["reconstruction", "TREATMENT", 149, 163], ["This study", "TEST", 238, 248]]], ["The data gathering via literature search started mid-april 2020 and continued up to june 3, 2020.", [["mid-april", "TREATMENT", 49, 58]]], ["By that time it became clear that the internet had grown considerably, reflected by an astounding 5,000,000,000 hits on Google.", [["clear", "OBSERVATION", 23, 28]]], ["This overwhelming quantity of information defies any attempt to get an overview any time soon.-Limitations, reliability and validitySince the exploratory work for this study was conducted by the authors and the danger of subjectivity can therefore not be simply discarded, we contend that the study is repeatable and verifiable.", [["the exploratory work", "TEST", 138, 158], ["this study", "TEST", 163, 173], ["the study", "TEST", 289, 298]]], ["We have chosen the research methodology and the time period for searching as described in the above, to ensure that our findings -learning from the current Covid-19 pandemic -are relevant to the framework of safety management based risk control of pandemics we propose.RESULTSOur findings from literature search, observation, theory and analysis are described in the order of the subjects listed in the case study blue-print (see table 1 ).Literature searchSuccessive literature searches, closely following the blue-print, resulted in 141 sources in total.", [["safety management", "TREATMENT", 208, 225], ["literature search", "TEST", 294, 311], ["theory and analysis", "TEST", 326, 345]]], ["From these sources we compiled a description of our current predicament, a comparison between country responses and their effects over the first 5 months, and a range of human behavioural reactions to danger.Our current predicament: the Covid-19 pandemicThe increasing threat of viral pandemics, such as Spanish Flu (1918) , and several others (Francis et al., 2019; Kain & Fowler, 2019; Jebril, 2020) , has started a sense of urgency in emergency preparedness, especially in intensive care units (ICU) and in elderly homes.", [["viral pandemics", "DISEASE", 279, 294], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["the Covid", "TEST", 233, 242], ["viral pandemics", "PROBLEM", 279, 294], ["urgency", "PROBLEM", 427, 434], ["viral pandemics", "OBSERVATION", 279, 294]]], ["Preparation for a pandemic should include 1-coordinated surveillance in order to spot new viruses, 2-scalable emergency response, 3quickly mass produced vaccines, 4-excellent communication, and 5-pre-approved research plans.", [["spot new viruses", "PROBLEM", 81, 97]]], ["Spotting a virus requires a detection method, testing capability and a warning system (Kain & Fowler, 2019) .", [["a detection method", "TEST", 26, 44], ["virus", "OBSERVATION", 11, 16]]], ["The scalability refers to \"Surge capacity of equipment, physical space, human resources, and system\" (Sheikhbardsiri et al., 2017, p612) .", [["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77]]], ["The later part of the period of some 100 years preceding our current predicament showed a series of multiple and returning H2N2, H1N1 and H3N2 pandemic influenza virus outbreaks (Francis et al., 2019) .", [["H1N1", "DISEASE", 129, 133], ["H3N2", "DISEASE", 138, 142], ["influenza virus outbreaks", "DISEASE", 152, 177], ["H3N2 pandemic influenza virus", "ORGANISM", 138, 167], ["H3N2 pandemic influenza virus", "SPECIES", 138, 167], ["H3N2 pandemic influenza virus", "SPECIES", 138, 167], ["multiple and returning H2N2", "PROBLEM", 100, 127], ["H1N1", "PROBLEM", 129, 133], ["H3N2 pandemic influenza virus outbreaks", "PROBLEM", 138, 177]]], ["By 2013 the WHO had completed guidance on pandemic influenza emergency risk management (WHO, 2013) .", [["influenza", "DISEASE", 51, 60], ["pandemic influenza emergency risk management", "TREATMENT", 42, 86]]], ["Preparing for a next influenza virus pandemic has been subject of WHO studies since.", [["influenza virus pandemic", "DISEASE", 21, 45], ["influenza virus pandemic", "SPECIES", 21, 45], ["a next influenza virus pandemic", "TREATMENT", 14, 45], ["WHO studies", "TEST", 66, 77]]], ["By 2019 the Dutch government finalized the latest National Safety Strategy (NVS, 2019), mentioning a large scale outbreak of an infectious disease, most likely an influenza pandemic.", [["infectious disease", "DISEASE", 128, 146], ["influenza pandemic", "DISEASE", 163, 181], ["an infectious disease", "PROBLEM", 125, 146], ["an influenza pandemic", "PROBLEM", 160, 181], ["large", "OBSERVATION_MODIFIER", 101, 106], ["infectious", "OBSERVATION", 128, 138], ["most likely", "UNCERTAINTY", 148, 159], ["influenza", "OBSERVATION", 163, 172]]], ["These emergency preparedness plans focus on influenza viruses, which are returning and rather well known viruses (Francis et al., 2019) , because of their assumed higher likelihood.", [["influenza viruses", "DISEASE", 44, 61], ["influenza viruses", "ORGANISM", 44, 61], ["influenza viruses", "PROBLEM", 44, 61], ["higher likelihood", "OBSERVATION", 163, 180]]], ["More recent outbreaks from 2014 onwards however, were, unexpectedly, originating from the Ebola virus and the MERS corona virus.", [["Ebola", "DISEASE", 90, 95], ["Ebola virus", "ORGANISM", 90, 101], ["MERS corona virus", "ORGANISM", 110, 127], ["Ebola virus", "SPECIES", 90, 101], ["Ebola virus", "SPECIES", 90, 101], ["MERS corona virus", "SPECIES", 110, 127], ["the Ebola virus", "PROBLEM", 86, 101], ["the MERS corona virus", "PROBLEM", 106, 127], ["outbreaks", "OBSERVATION_MODIFIER", 12, 21], ["Ebola virus", "OBSERVATION", 90, 101]]], ["Our current predicament is the November/December 2019 outbreak of the SARS-CoV-2 virus, causing the \"Coronavirus Disease 2019\", abbreviated to \"Covid-19\".", [["SARS", "DISEASE", 70, 74], ["Coronavirus Disease", "DISEASE", 101, 120], ["SARS-CoV-2 virus", "ORGANISM", 70, 86], ["CoV-2 virus", "SPECIES", 75, 86], ["SARS-CoV-2 virus", "SPECIES", 70, 86], ["the SARS", "PROBLEM", 66, 74], ["CoV-2 virus", "PROBLEM", 75, 86], ["the \"Coronavirus Disease", "PROBLEM", 96, 120], ["Coronavirus Disease", "OBSERVATION", 101, 120]]], ["The outbreak was first detected in December 2019 when several \"clusters of patients with pneumonia of unknown cause that were epidemiologically linked to a seafood and wet animal wholesale market in Wuhan\" were recognized (Zhu et al., 2020, p727; Hua & Shaw, 2020, p2) .", [["pneumonia", "DISEASE", 89, 98], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["pneumonia", "PROBLEM", 89, 98], ["pneumonia", "OBSERVATION", 89, 98], ["Hua", "ANATOMY", 247, 250]]], ["A timeline was established starting from the first reported case -patient 1 -on December 1, 2019 (Yan et al., 2020) .", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73]]], ["Several detailed studies of the onset by Wu et al (2020) , and , did not lead to certainty about how the virus transferred to humans. suggest that airborne transmission is the main culprit.", [["humans", "ORGANISM", 126, 132], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 126, 132], ["main", "OBSERVATION_MODIFIER", 176, 180], ["culprit", "OBSERVATION", 181, 188]]], ["After the declaration by Chinese officials of Covid-19 as the culprit on January 6, 2020, the genome sequence was published on virological.org (Zhang, 2019) a day later.", [["genome sequence", "DNA", 94, 109], ["Covid", "TEST", 46, 51], ["the genome sequence", "TEST", 90, 109]]], ["By January 20, an international group of experts concluded that Covid-19 was similar to the SARS virus of 2002, that evidence was found of human-to-human transmission and that they had developed a diagnostic protocol, being tried out from January 13 onwards, to detect the virus in patients (Corman et al., 2020) .", [["SARS", "DISEASE", 92, 96], ["human", "ORGANISM", 139, 144], ["human", "ORGANISM", 148, 153], ["patients", "ORGANISM", 282, 290], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 148, 153], ["patients", "SPECIES", 282, 290], ["SARS virus", "SPECIES", 92, 102], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 148, 153], ["Covid", "TEST", 64, 69], ["the SARS virus", "PROBLEM", 88, 102], ["a diagnostic protocol", "TEST", 195, 216], ["the virus", "PROBLEM", 269, 278]]], ["The virus particles are some 100 nanometers in size, consist of RNA and proteins, are decomposing above 50 o Celsius, and most likely originate from chrysanthemum bats or pangolin (Jebril, 2020; Zhou et al., 2020) .", [["pangolin", "CHEMICAL", 171, 179], ["chrysanthemum bats", "ORGANISM", 149, 167], ["pangolin", "SIMPLE_CHEMICAL", 171, 179], ["The virus particles", "PROBLEM", 0, 19], ["RNA and proteins", "PROBLEM", 64, 80], ["virus particles", "OBSERVATION", 4, 19], ["some", "OBSERVATION_MODIFIER", 24, 28], ["100 nanometers", "OBSERVATION_MODIFIER", 29, 43], ["size", "OBSERVATION_MODIFIER", 47, 51], ["RNA", "OBSERVATION", 64, 67], ["most likely", "UNCERTAINTY", 122, 133], ["chrysanthemum bats", "OBSERVATION", 149, 167]]], ["Initial average primary reproduction numbers R 0 of 1.5 up to 4.92 were reported (Yan et al., 2020 experiences severe disease and 5% becomes critically ill and of those about one third die from it (WHO, 2020c).", [["critically ill", "DISEASE", 141, 155], ["severe disease", "PROBLEM", 111, 125], ["critically ill", "PROBLEM", 141, 155], ["average", "OBSERVATION_MODIFIER", 8, 15], ["primary", "OBSERVATION_MODIFIER", 16, 23], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["disease", "OBSERVATION", 118, 125]]], ["By May 15, 2020 the estimated economic impact had exceeded the effect of the 2008 financial crisis and large parts of society and economy were \"put on hold\" (WHO, 2020c, p1) .", [["large", "OBSERVATION_MODIFIER", 103, 108]]], ["In many countries the pandemic was still rapidly developing but in a few countries across the globe the impact of the pandemic remained at least a factor 100 less in magnitude.", [["pandemic", "OBSERVATION", 22, 30], ["globe", "ANATOMY", 94, 99]]], ["At the same time, in more remote areas, such as the Solomon Islands in Oceania, thanks to travel restrictions, the virus had not yet arrived after 5 months since the onset of the pandemic beginning of December 2019.", [["the virus", "PROBLEM", 111, 120]]], ["Also the spatial variations within countries seem large, as illustrated by Covid-19 'hot spots', for example in the Milan region in Northern Italy, New York State in the USA and the province Noord-Brabant in the Netherlands.", [["spatial", "OBSERVATION_MODIFIER", 9, 16], ["variations", "OBSERVATION_MODIFIER", 17, 27], ["large", "OBSERVATION_MODIFIER", 50, 55], ["New", "OBSERVATION_MODIFIER", 148, 151]]], ["Although the death count per country heavily depends on the point it has reached in the process following the outbreak (WHO, 2020c), a comparison between countries is indicative when referring to approximately the same point.", [["death", "DISEASE", 13, 18], ["the death count", "TEST", 9, 24]]], ["This provides a first glance at the effect their national strategies have had on the spread of the Covid-19 virus.", [["Covid-19 virus", "ORGANISM", 99, 113], ["Covid-19 virus", "SPECIES", 99, 113], ["the Covid", "TEST", 95, 104]]], ["These other countries are New Zealand, Taiwan, Hong Kong, Finland, Belgium and the Netherlands.", [["New", "OBSERVATION_MODIFIER", 26, 29]]], ["The Dutch National television channel NPO1 reported 5600 officially tested and recorded victims and another 3600 suspected Covid-19 victims on May 15, 2020, bringing the total estimated death toll on 9200.", [["NPO1", "CHEMICAL", 38, 42], ["death", "DISEASE", 186, 191], ["Covid", "TEST", 123, 128]]], ["By June 10, 2020 the official death toll in the Netherlands reached 6031 (WHO, 2020f) leading to an estimated total of 10,000 Dutch Covid-19 victims.", [["death", "DISEASE", 30, 35]]], ["Each country used a different strategy in their approach of the Covid-19 pandemic.", [["a different strategy", "TREATMENT", 18, 38], ["the Covid", "TEST", 60, 69], ["pandemic", "PROBLEM", 73, 81]]], ["Their strategies had different outcomes of death toll versus time.", [["death", "DISEASE", 43, 48]]], ["Figure 1 shows that a quick response with mitigation measures makes all the difference.", [["mitigation measures", "TREATMENT", 42, 61]]], ["Where China, South Korea, New Zealand, Hong Kong and Taiwan managed to reduce spreading from the earliest moment on, leading to the number of local outbreaks and the resulting mortality counts staying low, the other countries showed prolonged and higher growth rates of death tolls Khafaie & Rahim, 2020; WHO, 2020b; Moes, 2020; VPRO-OVT, 2020 .", [["death", "DISEASE", 270, 275], ["Taiwan", "TREATMENT", 53, 59], ["local outbreaks", "PROBLEM", 142, 157], ["the resulting mortality counts", "TEST", 162, 192]]], ["Table 2 shows that the elapsed time between the first Covid-19 related death in China on January 10, 2020, and in the first few of the other countries was some 40 days.", [["death", "DISEASE", 71, 76]]], ["China was the country where it all started (Yan et al., 2020) in Wuhan City in the Hubei region.", [["Hubei", "ANATOMY", 83, 88], ["region", "ANATOMY_MODIFIER", 89, 95]]], ["After a period of increasing awareness of what had happened, the virus got out of control (Jebril, 2020, p5, 10-11) .", [["the virus", "PROBLEM", 61, 70], ["increasing", "OBSERVATION_MODIFIER", 18, 28]]], ["In the spring festival period with many millions gathering and travelling, the virus rapidly spread over China and abroad from Wuhan, a national and international transport hub (Peeri et al., 2020; Chang et al., 2020) .", [["the virus", "PROBLEM", 75, 84], ["many", "OBSERVATION_MODIFIER", 35, 39], ["millions", "OBSERVATION", 40, 48]]], ["China used the 2002-2003 SARS epidemic experience to mitigate the spread (Wang&Wang, 2020).", [["SARS", "DISEASE", 25, 29]]], ["Italy was the first to receive the Covid-19 virus from China in Western Europe, quickly becoming the European 'epi-centre' (Jebril, 2020) .", [["Covid-19 virus", "ORGANISM", 35, 49], ["Covid-19 virus", "SPECIES", 35, 49], ["the Covid-19 virus", "TREATMENT", 31, 49]]], ["Spain was experiencing an increasing case fatality rate (CFR) which was 6.2 % (Khafaie & Rahim, 2020) .", [["Khafaie", "TEST", 79, 86], ["Rahim", "TEST", 89, 94], ["increasing", "OBSERVATION_MODIFIER", 26, 36]]], ["Iran had no early official reporting in place and suddenly became the epi-centre in the Middle-East.", [["Middle", "ANATOMY_MODIFIER", 88, 94]]], ["Germany reported a low death toll among neighbouring European countries and compared to Italy and Iran.", [["death", "DISEASE", 23, 28], ["a low death", "PROBLEM", 17, 28], ["low death", "OBSERVATION_MODIFIER", 19, 28]]], ["France was experiencing an increasing CFR which was 4.2 % (Khafaie & Rahim, 2020) .", [["an increasing CFR", "PROBLEM", 24, 41], ["Khafaie", "TEST", 59, 66], ["increasing", "OBSERVATION_MODIFIER", 27, 37], ["CFR", "OBSERVATION_MODIFIER", 38, 41]]], ["South Korea reported a low death toll by worldwide comparison, most likely related to this country's high volume testing approach, previous experience with SARS, public places disinfection spraying, citizens wearing face masks, smart phone contact tracing and an information campaign (Moes, 2020) .", [["death", "DISEASE", 27, 32], ["SARS", "DISEASE", 156, 160], ["a low death", "PROBLEM", 21, 32], ["high volume testing approach", "TREATMENT", 101, 129], ["SARS", "PROBLEM", 156, 160]]], ["The USA reported the world's highest death toll (WHO, 2020b) .", [["death", "DISEASE", 37, 42]]], ["The country quickly closed its borders and went for a full lockdown, people were told to \"stay within their bubble\" and maintain a safe distance of 2 meters.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75]]], ["Taiwan reactivated the National Health Command Center, created after the SARS epidemic in 2004.", [["SARS", "DISEASE", 73, 77], ["the SARS epidemic", "PROBLEM", 69, 86]]], ["The country chose very early on for a robust quarantine policy, based on backtracking peoples' whereabouts the previous 14 days, and for using the previous SARS epidemic experience.", [["SARS", "DISEASE", 156, 160]]], ["Also with the use of face masks by the general public, disinfection spraying on public places, infrared thermometers at key locations in e.g. transportation hubs, and a risky places information campaign, a lockdown was avoided (Moes, 2020) .", [["face masks", "TREATMENT", 21, 31]]], ["Also here the previous experience with SARS, and citizens wearing face masks were among the measures taken (Moes, 2020) .", [["SARS", "DISEASE", 39, 43], ["SARS", "PROBLEM", 39, 43], ["citizens wearing face masks", "TREATMENT", 49, 76]]], ["Belgium initially reported a relatively modest death toll but then appeared to take over as fastest growing European country.", [["death", "DISEASE", 47, 52]]], ["This data artefact originated from non-tested suspect Covid-19 cases previously not being included in Covid-19 reports but only showing from total death statistics.", [["death", "DISEASE", 147, 152], ["Covid", "TEST", 54, 59], ["total death statistics", "PROBLEM", 141, 163]]], ["Like many other countries The Netherlands had the advantage of seeing the pandemic coming, but did not manage to have all countermeasures, materials and equipment in place before the pathogen had reached the country.", [["equipment", "TREATMENT", 153, 162]]], ["It took until June 1, 2020 before large scale testing facilities became available (NOS, 2020) .", [["large scale testing", "TEST", 34, 53]]], ["Quite the opposite occurred in Finland where a robust emergency preparedness facilitated the immediate introduction of pandemic countermeasures, leading to a low death toll (WHO, 2020f).Human behaviour in the face of exceptional dangerThe animals in the 'safety zoo' represent human conduct towards major safety risks which are not immediately recognized and do not occur very often.", [["death", "DISEASE", 162, 167], ["Human", "ORGANISM", 186, 191], ["human", "ORGANISM", 277, 282], ["Human", "SPECIES", 186, 191], ["human", "SPECIES", 277, 282], ["human", "SPECIES", 277, 282], ["pandemic countermeasures", "TREATMENT", 119, 143], ["opposite", "OBSERVATION_MODIFIER", 10, 18]]], ["As we notice such threats in safety practice:Human behaviour in the face of exceptional danger\uf0b7 We suspect their presence, yet deem them as unknownHuman behaviour in the face of exceptional dangerThe world is a very complex, dynamic and changing place.", [["Human", "ORGANISM", 45, 50], ["Human", "SPECIES", 45, 50]]], ["Part of the world around us is unknown due of lacking awareness of its existence.", [["unknown due of", "UNCERTAINTY", 31, 45]]], ["This requires sufficient risk appetite however (Gjerdrum & Peter, 2011) .Human behaviour in the face of exceptional danger\uf0b7 We are fully aware of them, yet accept their riskHuman behaviour in the face of exceptional dangerIn this probabilistic approach, as the probability gets closer to zero, extremely large consequences may become acceptable even without specific measures being taken.", [["Human", "ORGANISM", 73, 78], ["Human", "SPECIES", 73, 78], ["extremely large consequences", "PROBLEM", 294, 322], ["large", "OBSERVATION", 304, 309]]], ["This implies that a large nationwide disaster scenario could be regarded as acceptable since its risk is properly controlled (HSE, 2001, p43) .", [["a large nationwide disaster scenario", "PROBLEM", 18, 54], ["large", "OBSERVATION_MODIFIER", 20, 25]]], ["The probability may not really be zero though.", [["may not really be", "UNCERTAINTY", 16, 33]]], ["Hence such a disaster is not completely ruled out and it must therefore be considered and accepted as a residual risk.", [["a residual risk", "PROBLEM", 102, 117]]], ["We deem such risks to be unlikely.Human behaviour in the face of exceptional danger\uf0b7 We know about specific safety threats, yet regard them as highly unlikely or impossibleHuman behaviour in the face of exceptional dangerIf we are not fully aware of how identified threats to safety might lead to unwanted events -because they are seen as too complex, interacting, multiple causal, dynamic, entropic (Mol, 2003) or they are depending on conditions -then we might one day suddenly, unexpectedly, be overwhelmed by a black swan (Taleb, 2007; Murphy & Conner, 2012; Ale et al., 2020) .Human behaviour in the face of exceptional danger\uf0b7 Obvious safety risks actually cause damage, yet we do not act on them.Human behaviour in the face of exceptional dangerWe build safety system routines to improve safety, yet we create bureaucracy while doing so.", [["Human", "ORGANISM", 34, 39], ["Human", "ORGANISM", 172, 177], ["Human", "ORGANISM", 582, 587], ["Human", "ORGANISM", 703, 708], ["Human", "SPECIES", 34, 39], ["Human", "SPECIES", 172, 177], ["Human", "SPECIES", 582, 587], ["Human", "SPECIES", 703, 708], ["unwanted events", "PROBLEM", 297, 312], ["damage", "PROBLEM", 669, 675]]], ["Improving on safety management systems in industry and health care may lead to paper tigers (Dekker, 2014) .", [["safety management systems", "TREATMENT", 13, 38]]], ["This makes safety management focus on going through the required administrative motions rather than keep awareness high to spot safety threats.Human behaviour in the face of exceptional danger\uf0b7 Everyone sees a known and feasible opportunity to improve, yet we pretend it doesn't exist A paradoxical observation, done by Cohen (1998; 2005) , in a wider more general area than only safety management, shows that managers pretend known and major improvement potential, not to exist even though means to realize them are available.", [["Human", "ORGANISM", 143, 148], ["Human", "SPECIES", 143, 148], ["safety management", "TREATMENT", 11, 28], ["safety management", "TREATMENT", 380, 397]]], ["He coined this looking away from the \"dinosaur in the living room\", the obvious next thing to do in order to make a leap forward.Human behaviour in the face of exceptional danger\uf0b7 We recognize big and emerging threats to our safety but we still don't act Pandemic risks are an example of a huge threat, known to have created damage in the past and expected to do so again in the future but is not receiving adequate attention so that prevention activities are in place and mitigation is well prepared.", [["Human", "ORGANISM", 129, 134], ["Human", "SPECIES", 129, 134], ["damage", "OBSERVATION", 325, 331]]], ["When Srivatsa (2018) mentioned the \"Elephant in the Doctors Room\" he was addressing the emerging danger of antibiotic-resistant bacterial infections, said to be capable of killing 10 million people before the year 2050.Human behaviour in the face of exceptional danger\uf0b7 We are watching immediate lethal danger of epic proportion and hesitate to act This means -as if the above was not enough to describe the frighteningly unresponsive human condition -we can even deny and ignore a big rapidly developing global disaster, out to destroy millions of us, closing in on us at high speed, and do not move \"when a gray rhino charges\" (Wucker, 2016, p6) .Human behaviour in the face of exceptional danger\uf0b7 We watch the threat coming at us and freezeHuman behaviour in the face of exceptional dangerPeople believe their eyes more than their ears.", [["eyes", "ANATOMY", 813, 817], ["ears", "ANATOMY", 834, 838], ["bacterial infections", "DISEASE", 128, 148], ["people", "ORGANISM", 191, 197], ["Human", "ORGANISM", 219, 224], ["human", "ORGANISM", 435, 440], ["Human", "ORGANISM", 649, 654], ["People", "ORGANISM", 792, 798], ["eyes", "ORGAN", 813, 817], ["ears", "ORGAN", 834, 838], ["people", "SPECIES", 191, 197], ["Human", "SPECIES", 219, 224], ["human", "SPECIES", 435, 440], ["Human", "SPECIES", 649, 654], ["People", "SPECIES", 792, 798], ["human", "SPECIES", 435, 440], ["antibiotic", "TREATMENT", 107, 117], ["resistant bacterial infections", "PROBLEM", 118, 148], ["the frighteningly unresponsive human condition", "PROBLEM", 404, 450], ["bacterial infections", "OBSERVATION", 128, 148]]], ["An unknown and invisible enemy is initially met with unbelief.", [["enemy", "OBSERVATION", 25, 30]]], ["People sometimes appear to have ostrich bird -like ways to go about sudden threats.Critical observations from a safety management point of viewAlthough disaster risk management, preparation and response were mentioned in the WHO plans for the next pandemic (WHO, 2013; , the approaches presented by the many countries following their guidance showed a range of problems.\uf0b7 Prepared for influenzaWe have all been preparing more for the next influenza virus outbreak rather than for a next new unknown virus pandemic outbreak.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["a safety management", "TREATMENT", 110, 129], ["disaster risk management", "TREATMENT", 152, 176], ["influenzaWe", "TREATMENT", 385, 396], ["the next influenza virus outbreak", "PROBLEM", 430, 463], ["a next new unknown virus pandemic outbreak", "PROBLEM", 480, 522]]], ["The majority of activities deployed for an influenza outbreak are valid for any virus outbreak (Kain & Fowler, 2019; Madhav et al., 2017) .", [["influenza", "DISEASE", 43, 52], ["an influenza outbreak", "PROBLEM", 40, 61], ["any virus outbreak", "PROBLEM", 76, 94]]], ["However, the Covid-19 virus differs from an influenza virus.", [["influenza virus", "DISEASE", 44, 59], ["Covid-19 virus", "ORGANISM", 13, 27], ["influenza virus", "ORGANISM", 44, 59], ["influenza virus", "SPECIES", 44, 59], ["Covid-19 virus", "SPECIES", 13, 27], ["the Covid-19 virus", "PROBLEM", 9, 27], ["an influenza virus", "PROBLEM", 41, 59], ["influenza virus", "OBSERVATION", 44, 59]]], ["Assumptions made in the emergency preparedness protocols may therefore not always be applicable, render some of the influenza specific preparation activities unusable and slow down the response since new measures need to be developed on the spot with limited knowledge about the pathogen.", [["the emergency preparedness protocols", "TREATMENT", 20, 56], ["the influenza specific preparation activities", "PROBLEM", 112, 157], ["the pathogen", "PROBLEM", 275, 287]]], ["Recently, the WHO priority for research and development was placed at \"medical countermeasures, including vaccines, therapeutics, and diagnostics\" to cover this gap (WHO, 2020c, p15) .", [["vaccines", "TREATMENT", 106, 114]]], ["Preparation for any virus might have brought us in a better position on e.g. detection method, pre-approved vaccine research, vaccine development, required hospital space, testing commodities, ICU staff and ventilator equipment (Kain & Fowler, 2019) .", [["any virus", "PROBLEM", 16, 25], ["ventilator equipment", "TREATMENT", 207, 227]]], ["Case fatality rates (CFR) of e.g. influenza-A, are between 0.011% (Dawood, 2012) and 0.1% (Anderson et al., 2020) .", [["influenza", "PROBLEM", 34, 43]]], ["Other viruses may have significantly higher CFR's such as Covid-19 (2%), SARS (9.6 %) and MERS (35%) (Yan et al., 2020; Peeri et al., 2020; Khafaie & Rahim, 2020) .", [["SARS", "DISEASE", 73, 77], ["Other viruses", "PROBLEM", 0, 13], ["significantly higher CFR's", "PROBLEM", 23, 49], ["Covid", "TEST", 58, 63], ["SARS", "TEST", 73, 77], ["MERS", "TEST", 90, 94], ["Khafaie", "TEST", 140, 147], ["viruses", "OBSERVATION", 6, 13]]], ["Also the initially observed primary reproduction number R 0 of the Covid-19 virus (R 0 =~5) indicates it spreads between 2 and 3 times faster than influenza viruses (R 0 =~1.5) (Khafaie & Rahim, 2020; Jebril, 2020; Anderson et al., 2020) .", [["influenza viruses", "DISEASE", 147, 164], ["Covid-19 virus", "ORGANISM", 67, 81], ["Covid-19 virus", "SPECIES", 67, 81], ["the Covid", "TEST", 63, 72], ["influenza viruses", "PROBLEM", 147, 164]]], ["As CFR is clearly higher and bats (and perhaps pangolin) in the South-East Asian region are a reservoir of SARS-like Corona viruses (Li, 2005) , the preparation for a pandemic of any virus would have been more substantial, and most likely this would have made us be more cautious, more keen to act and preparing more robust measures.", [["SARS", "DISEASE", 107, 111], ["pangolin", "GENE_OR_GENE_PRODUCT", 47, 55], ["SARS-like Corona viruses", "ORGANISM", 107, 131], ["SARS", "PROBLEM", 107, 111], ["Corona viruses", "PROBLEM", 117, 131], ["any virus", "PROBLEM", 179, 188], ["higher", "OBSERVATION_MODIFIER", 18, 24], ["Corona", "ANATOMY_MODIFIER", 117, 123]]], ["In fact many animals are reservoirs of many pathogens (Han et al., 2015) .\uf0b7 Confusion about the onsetWe also argue that along these lines there is still much to investigate about the causal tree preceding the first confirmed case of patient-1 (Yan et al., 2020) .", [["Confusion", "DISEASE", 76, 85], ["patient", "ORGANISM", 233, 240], ["patient", "SPECIES", 233, 240], ["Confusion", "PROBLEM", 76, 85], ["many", "OBSERVATION_MODIFIER", 8, 12], ["animals", "OBSERVATION", 13, 20], ["reservoirs", "OBSERVATION_MODIFIER", 25, 35], ["many", "OBSERVATION_MODIFIER", 39, 43], ["pathogens", "OBSERVATION_MODIFIER", 44, 53]]], ["Also a better understanding of how containment of the new virus was handled between December 31, 2019 and the January 18, 2020 record breaking Wuhan New Year celebration (Kynge et al., 2020) is needed.", [["the new virus", "PROBLEM", 50, 63]]], ["At that time the term 'prevention', as it was used by , was applied to stopping further infections in an ongoing pandemic.", [["infections", "DISEASE", 88, 98], ["further infections", "PROBLEM", 80, 98], ["infections", "OBSERVATION", 88, 98]]], ["The word 'prevention' as used in safety management refers to all that is being done to avoid a first outbreak.\uf0b7 Lack of education and involvement of citizens and workersEducation would make a difference.", [["safety management", "TREATMENT", 33, 50]]], ["More acceptance of and better adherence to social distancing measures during the repression of a pandemic would be achieved.", [["social distancing measures", "TREATMENT", 43, 69]]], ["For example Chang et al. (2020) mention a home quarantine strategy which -if explained, adopted and implemented correctly -could help to reduce spreading the virus to other members of a household.", [["a home quarantine strategy", "TREATMENT", 40, 66]]], ["An example of a successful approach is found with the -in fact still ongoing -pandemic of the HIV/AIDS virus.", [["HIV/AIDS", "DISEASE", 94, 102], ["HIV/AIDS virus", "ORGANISM", 94, 108], ["HIV", "SPECIES", 94, 97], ["HIV/AIDS virus", "SPECIES", 94, 108], ["a successful approach", "TREATMENT", 14, 35], ["the HIV/AIDS virus", "PROBLEM", 90, 108]]], ["A worldwide information program, comprising education and empowerment of the population groups most involved with the onset of this pandemic, and other groups affected later (Chin, 1990) , was started some 4 years after the onset (Mann & Kay, 1991) by the WHO (1987) , based on the knowledge acquired about the particular relevance of gender, sexual behaviour and education of citizens for the prevention of further spread of the disease (Chin, 1990; Dowsett et al., 1998; Gupta, 2000) .", [["pandemic", "DISEASE", 132, 140], ["citizens", "TREATMENT", 377, 385], ["the disease", "PROBLEM", 426, 437], ["Chin", "ANATOMY", 439, 443]]], ["Also in agricultural biosafety and biosecurity systems there is an acknowledged need for education and training among workers (Heckert et al., 2011) .", [["agricultural", "OBSERVATION_MODIFIER", 8, 20], ["biosafety", "OBSERVATION", 21, 30]]], ["Hence: there is a need for education, training and empowerment.\uf0b7 Treating a continuous threat as a single eventIf pandemics are to occur increasingly more often (WEF, 2019; Kain & Fowler, 2019; Madhav et al., 2017) they will become part of our daily lives even more as HIV/AIDS and influenza are today.", [["HIV/AIDS", "DISEASE", 269, 277], ["influenza", "DISEASE", 282, 291], ["HIV", "SPECIES", 269, 272], ["HIV", "SPECIES", 269, 272], ["pandemics", "PROBLEM", 114, 123], ["HIV/AIDS", "PROBLEM", 269, 277], ["influenza", "PROBLEM", 282, 291]]], ["Irrespective of the specific pathogen potentially causing a pandemic, several generic countermeasures could already be taken.", [["the specific pathogen", "PROBLEM", 16, 37], ["a pandemic", "PROBLEM", 58, 68]]], ["Identifiable areas in the world having a spark-risk, i.e. where onset is more likely (Madhav et al., 2017) both preventive and repressive measures are necessary.", [["repressive measures", "TREATMENT", 127, 146], ["more likely", "UNCERTAINTY", 73, 84]]], ["Here, prevention would include e.g. preventive prophylaxis and spatial-and temporal segregation.", [["preventive prophylaxis", "TREATMENT", 36, 58], ["spatial-and temporal segregation", "PROBLEM", 63, 95], ["temporal segregation", "OBSERVATION", 75, 95]]], ["The repressive measures required to quickly contain an outbreak in such areas could include investing in existing public health methods such as routine health monitoring, regular vaccination, detection activities, and emergency drills, but also new measures.", [["an outbreak in such areas", "PROBLEM", 52, 77], ["routine health monitoring", "TEST", 144, 169], ["regular vaccination", "TREATMENT", 171, 190], ["emergency drills", "TREATMENT", 218, 234], ["outbreak", "OBSERVATION", 55, 63]]], ["This continuous presence of routine pandemic prevention activities creates attention, awareness and caution among the general public and health care providers , especially in regions susceptible for spark-risk the onset of an epidemic or pandemic (Madhav et al., 2017) .", [["routine pandemic prevention activities", "TREATMENT", 28, 66]]], ["This compares to earthquake shelter-, fire evacuation-and cruise ship safety drills.", [["fire evacuation", "TREATMENT", 38, 53]]], ["An involved, educated and trained citizen can become partner in both the prevention and the repression of pandemics.", [["pandemics", "PROBLEM", 106, 115]]], ["This would have a profound impact on both long term global economic development and on social wellbeing and social stability in many countries affected.", [["profound", "OBSERVATION_MODIFIER", 18, 26], ["impact", "OBSERVATION_MODIFIER", 27, 33], ["both", "OBSERVATION_MODIFIER", 37, 41], ["long term", "OBSERVATION_MODIFIER", 42, 51], ["global", "OBSERVATION_MODIFIER", 52, 58], ["economic", "OBSERVATION_MODIFIER", 59, 67]]], ["Businesses, buildings, schools, public space and transportation systems are not designed to accommodate for \". . . a sustainable, steady state [time period] of lowlevel or no transmission . . . in the absence of a safe and effective vaccine\" (WHO, 2020c, p10).", [["p10", "GENE_OR_GENE_PRODUCT", 255, 258], ["lowlevel", "PROBLEM", 160, 168], ["sustainable", "OBSERVATION_MODIFIER", 117, 128]]], ["If pandemics are recurrent, recovery periods in between are also.", [["pandemics", "PROBLEM", 3, 12], ["recurrent", "PROBLEM", 17, 26]]], ["An agreed, prepared and detailed societal, economical and ethical post-pandemic recovery plan and practical preparation for resilience are missing.", [["ethical post-pandemic recovery plan", "TREATMENT", 58, 93], ["practical preparation", "TREATMENT", 98, 119]]], ["Before the Covid-19 pandemic, earlier economic, financial and political considerations have put priorities elsewhere in societies, leading to a slow response, to major logistical problems and little socio-economic resilience.\uf0b7 Poor national proceduresConsensus between neighbouring countries is lacking.", [["a slow response", "PROBLEM", 142, 157], ["Poor national procedures", "TREATMENT", 227, 251]]], ["This is leading to local, regional and country level differences, most noticeable in social distancing measures and emergency preparedness.", [["local, regional and country level differences", "PROBLEM", 19, 64], ["leading to", "UNCERTAINTY", 8, 18], ["local", "OBSERVATION_MODIFIER", 19, 24], ["regional", "OBSERVATION_MODIFIER", 26, 34]]], ["When it comes to risk identification this is achieved via an Integrated Risk Analysis on National Safety, which is -in line with the WHO (2013; 2018) -focusing on an \"influenza pandemic\" (ANV, 2019, p25).", [["influenza pandemic", "DISEASE", 167, 185], ["p25", "GENE_OR_GENE_PRODUCT", 199, 202], ["p25", "PROTEIN", 199, 202], ["an \"influenza pandemic", "PROBLEM", 163, 185]]], ["The word 'prevention' is used as a label on the protection of vulnerable groups and on individual citizen behaviour as to prevent further spreading of the influenza virus.", [["influenza", "DISEASE", 155, 164], ["influenza virus", "ORGANISM", 155, 170], ["the influenza virus", "PROBLEM", 151, 170], ["influenza virus", "OBSERVATION", 155, 170]]], ["The NVS, ANV and CDC19 are not aiming at avoiding a pandemic altogether and therefore do not deal with 'prevention' in the safety management sense.", [["CDC19", "GENE_OR_GENE_PRODUCT", 17, 22], ["NVS, ANV and CDC19", "DNA", 4, 22], ["ANV", "SPECIES", 9, 12], ["The NVS", "TEST", 0, 7]]], ["Preparation is detailed in a range of organisational measures in the CDC19 and response consists of a description of patient treatment from first detection, via home care, hospital care up to ICU care.", [["patient", "ORGANISM", 117, 124], ["CDC19", "DNA", 69, 74], ["patient", "SPECIES", 117, 124], ["patient treatment", "TREATMENT", 117, 134]]], ["Aftercare is not described and therefore -by default -assumed to be arranged via regular care.\uf0b7 Poor national procedures\uf0b7 Not building up an emergency stockpile and scalable local production capacity\uf0b7 Poor national proceduresAt the end of April 2020, the measures applied in practice in The Netherlands consisted of personal hygiene, hospital staff wearing personal protective equipment and the public applying social distancing.", [["Poor national procedures", "TREATMENT", 201, 225], ["the measures", "TREATMENT", 251, 263], ["personal protective equipment", "TREATMENT", 357, 386]]], ["Health care-and infection case contacts tracing staff were a constraining factor.", [["infection", "DISEASE", 16, 25]]], ["Scarcity of material and equipment supplies, led to criticality of hospital and ICU capacity, jeopardised the timely distribution of personal protection equipment in care institutions, and testing among the general public.", [["Scarcity of material", "PROBLEM", 0, 20]]], ["Mainly due to privacy concerns, no \"contactless temperature monitoring\" and \"contacts tracing phone-APP\" were introduced in many countries, such as The Netherlands, in direct response to the \"test, test, test\" instruction coming from the WHO director-general Ghebreyesus (2020) and of the \"detect, test, isolate, care, quarantine contacts\" strategy (WHO, 2020c, p8-10).", [["APP", "PROTEIN", 100, 103]]], ["International press and digital media had shown the presence of antispreading measures in several countries already very shortly after the onset of the pandemic, e.g. face masks, infrared temperature sensors, drive through virus testing booths, disinfection spraying of public places and smart phone based contacts tracing methods.\uf0b7 Poor national proceduresIn countries not having built-up an emergency supplies stockpile and not having production capacity locally available, the supply problems were paramount, including in China .", [["pandemic", "DISEASE", 152, 160], ["antispreading measures", "TREATMENT", 64, 86], ["the pandemic", "PROBLEM", 148, 160], ["face masks", "TREATMENT", 167, 177], ["infrared temperature sensors", "PROBLEM", 179, 207], ["virus testing booths", "TREATMENT", 223, 243], ["Poor national procedures", "TREATMENT", 333, 357], ["production capacity", "PROBLEM", 437, 456]]], ["These logistic problems have led to health professionals working without adequate personal protection and to the general public not contributing to reducing the R 0 below 1.0 as much as would have been possible.", [["These logistic problems", "PROBLEM", 0, 23]]], ["These problems explain much of the death toll differences observed in figure 1.\uf0b7 No guidance for being responsive to needs of vulnerable groupsVulnerable groups, whether due to age, other physical or mental diseases, to unhealthy or overcrowded living conditions e.g. in facilities for asylum seekers and prisons, or due to social isolation in health care facilities, to poverty or to low socio-economic status, all need special attention (WHO, 2020c, p11).", [["death", "DISEASE", 35, 40], ["p11", "GENE_OR_GENE_PRODUCT", 452, 455], ["p11", "PROTEIN", 452, 455], ["the death", "PROBLEM", 31, 40], ["mental diseases", "PROBLEM", 200, 215]]], ["No specific guidance was available with suitable well proven solutions and best practices derived from previous epidemics.", [["previous epidemics", "PROBLEM", 103, 121]]], ["During previous epidemics the overwhelmed health-care system creates yet another vulnerable group: those in need of postponed treatment.", [["postponed treatment", "TREATMENT", 116, 135]]], ["Due to this, higher death rates were observed for other causes (Anderson et al., 2020) .", [["death", "DISEASE", 20, 25], ["higher death rates", "PROBLEM", 13, 31]]], ["This underlines the need for preparedness for these groups.\uf0b7 Case history not recorded in detailAt first statistical data about the different health stages which persons with a diagnosed pathogen infection go through (Zhong, 2017) are highly uncertain, most so immediately after the onset.", [["pathogen infection", "DISEASE", 187, 205], ["persons", "ORGANISM", 162, 169], ["persons", "SPECIES", 162, 169], ["preparedness for these groups", "TREATMENT", 29, 58], ["a diagnosed pathogen infection", "PROBLEM", 175, 205], ["infection", "OBSERVATION", 196, 205]]], ["Such records would gradually shed more light on the success rates of treatment options used in various countries.", [["treatment options", "TREATMENT", 69, 86]]], ["Accurately kept records also allow detailed analysis on vulnerability of specific social groups (Weiss, 2020) .", [["detailed analysis", "TEST", 35, 52]]], ["Some countries did not keep records.\uf0b7 Early SWOT analysisWang & Wang (2020) published an early systematic analysis of strengths, weaknesses, opportunities and threats (SWOT) of the \"Covid-19 epidemic prevention and control strategy\" by the end of March, 2020.", [["epidemic prevention", "TREATMENT", 191, 210]]], ["Of the four highest priority improvements they identify, three are about emergency response and one is about strengthening the economic structure.", [["highest", "OBSERVATION_MODIFIER", 12, 19]]], ["Furthermore, various aspects of social security, psychological issues, economical damage and opportunities for education in relation to emergencies with infectious diseases were mentioned.", [["infectious diseases", "DISEASE", 153, 172], ["psychological issues", "PROBLEM", 49, 69], ["economical damage", "PROBLEM", 71, 88], ["education", "TREATMENT", 111, 120], ["infectious diseases", "PROBLEM", 153, 172]]], ["Wang & Wang (2020, p8,11,12) do mention \"prevention of public health emergencies\" and describe such emergencies as a \"threat to all human beings\".", [["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137]]], ["Although it is early days for a holistic SWOT analysis on the Covid-19 pandemic, we underline the necessity of further evaluation.\uf0b7 Criticality of leadershipTransactional leadership \"aimed at an exchange of rewards for fulfilling expectations\" (Grote, 2019, p.60) seems necessary.", [["a holistic SWOT analysis", "TEST", 30, 54], ["the Covid", "TEST", 58, 67], ["further evaluation", "TEST", 111, 129]]], ["Switching between fixed and flexible attitudes, and between different safety management modes of operation (Pari\u00e8s et al., 2019) are needed to restore society and economy after a disaster.", [["Switching between fixed and flexible attitudes", "TREATMENT", 0, 46], ["operation", "TREATMENT", 97, 106]]], ["We contend that speed and quality of action and of communication determined success rather than gender of the leaders.\uf0b7 Lacking resilienceWiig and Fahlbruch (2019,p.1) mention the range of related fields, the many definitions of resilience, and several challenges, a.o. the many theories and the lack of empirical evidence in several areas.", [["several", "OBSERVATION_MODIFIER", 326, 333]]], ["Moser et al. (2019, p.21,26,27 ) point out that resilience as a concept gradually evolved from the \"ability to bounce back\", via \"coping mechanism\", via \"capacity to adapt to impacts\" and \"prevention strategy\" towards \"system change\" and \"radical transformation\".", [["radical transformation\"", "PROBLEM", 239, 262], ["radical transformation", "OBSERVATION", 239, 261]]], ["The magnitude of disruption caused by an unwanted event determines the effort to neutralize the adverse effects, leading to resilience types, kinds, scales or levels (Macrae & Wiig, 2019, p.126 ) (Pettersen & Schulman, 2019, p.460,461) .", [["the adverse effects", "PROBLEM", 92, 111], ["levels", "TEST", 159, 165], ["Macrae", "TEST", 167, 173], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["disruption", "OBSERVATION", 17, 27]]], ["Woods (2015) describes resilience is as \"sustainable adaptability\".Tiernan et al. (2019) suggest a nuanced exploration of the concept of adaptive resilience.", [["a nuanced exploration", "TEST", 97, 118], ["adaptive resilience", "TREATMENT", 137, 156]]], ["Woods (2015) defines this as: \"a network architectures that can sustain the ability to adapt to future surprises as conditions evolve\".\uf0b7 Ethical concernsThe relatively short medical emergency phase after the pandemic onset is followed by a long mitigation phase, lasting until an effective vaccine becomes available.", [["pandemic", "DISEASE", 208, 216], ["Ethical concerns", "PROBLEM", 137, 153], ["an effective vaccine", "TREATMENT", 277, 297], ["relatively", "OBSERVATION_MODIFIER", 157, 167], ["short", "OBSERVATION_MODIFIER", 168, 173]]], ["The behaviour of individuals not respecting temporary distancing and hygiene measures and individuals engaging in criminal activities such as providing sub-standard medical supplies or selling fake medicines, may require specific temporary legislation to allow adequate law enforcement.", [["temporary distancing", "TREATMENT", 44, 64], ["hygiene measures", "TREATMENT", 69, 85], ["sub-standard medical supplies", "TREATMENT", 152, 181], ["selling fake medicines", "TREATMENT", 185, 207], ["specific temporary legislation", "TREATMENT", 221, 251]]], ["Governments could be tempted to hastily introduce new legislation without respecting democratic decision-making procedures, to introduce election driven aspects into implementation practice and not ensure a timely end to its being in force (Smits & Van Duijn, 2020; Jones, 2020) .\uf0b7 Ethical concernsMajor ethical concerns emerge, not only with criteria to be used during triage when health professionals are suddenly facing limited health care capacity and medical supplies (Berlinger et al., 2020; WHO, 2007; but also with the constraints of fundamental rights, with a lack of democratic debate on proportionality of fines or imprisonment, with uncertainty about which precise behaviour causes the pathogen to spread, and about treating all citizens equal when taking away their livelihood, curtail exertion of democratic rights and limit access to health care.", [["the pathogen", "PROBLEM", 694, 706]]], ["Health ethics aims to contribute to wellbeing, avoidance of damage, respecting autonomy and seeks justice in an inclusive way (Beauchamp & Childress, 2012) .Opportunities for improved or new preventive and repressive barriersAn inquisitive approach of prevention may lead to the discovery of new preventive barriers placed well before the onset of pandemics.", [["damage", "PROBLEM", 60, 66], ["repressive barriers", "TREATMENT", 206, 225], ["An inquisitive approach", "TREATMENT", 225, 248], ["new preventive barriers", "TREATMENT", 292, 315], ["pandemics", "PROBLEM", 348, 357], ["new", "OBSERVATION_MODIFIER", 187, 190], ["new", "OBSERVATION_MODIFIER", 292, 295], ["pandemics", "OBSERVATION", 348, 357]]], ["Since within 4 months' time a fully-fledged global Covid-19 pandemic emerged, we contend that practice has underlined that also opportunities for new repressive barriers, to be placed shortly after the onset, need further investigation.", [["new repressive barriers", "TREATMENT", 146, 169], ["further investigation", "TEST", 214, 235]]], ["As the impact of a pandemic is large, we contend that continuous searching for new barriers, both preventive and repressive is justified.", [["new barriers", "TREATMENT", 79, 91], ["large", "OBSERVATION_MODIFIER", 31, 36]]], ["We have found several lines of thinking opening up possibilities for development of new barrier types.\uf0b7 Embrace the safety management paradigmOn February 8, 2020, WHO Director-General Ghebreyesus (2020) mentioned 216 health threat signals had the attention of the WHO of which Covid-19 was just one.", [["new barrier types", "PROBLEM", 84, 101], ["Covid", "TEST", 277, 282], ["several", "OBSERVATION_MODIFIER", 14, 21], ["lines", "OBSERVATION", 22, 27], ["new", "OBSERVATION_MODIFIER", 84, 87], ["barrier types", "OBSERVATION", 88, 101]]], ["Seeing pandemics as a \"given\" (Madhav et al., 2017) or as a \"a continuum of pandemic phases\" (WHO, 2013) distracts the attention away from the introduction of preventive countermeasures.", [["preventive countermeasures", "TREATMENT", 159, 185]]], ["Treating pandemics as a \"medical emergency\" (WHO, 2020c), may stimulate emergency preparedness and mitigation, but leaves prevention -in the safety management sense -out of scope.\uf0b7 Embrace the safety management paradigmPlacing the focus of attention on repression implies looking less at what caused an event.", [["pandemics", "DISEASE", 9, 18], ["mitigation", "TREATMENT", 99, 109], ["the safety management", "TREATMENT", 189, 210]]], ["Evidently these lines of thinking will result in avoidable repeats of the unwanted event.", [["lines", "OBSERVATION", 16, 21]]], ["Only working on the repression aspect of pandemics implies that the great value of prevention is for a part ignored.", [["pandemics", "PROBLEM", 41, 50]]], ["As a consequence of that, education and training of people working with animals remain underutilized as a preventive means.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["Moreover, nobody in their right mind would knowingly want to accidentally start a global pandemic.", [["a global pandemic", "PROBLEM", 80, 97], ["right", "ANATOMY_MODIFIER", 26, 31]]], ["The current line of thinking does not prepare society for dealing with the social disruption and the huge effort needed for socio-economic recovery (WEF, 2019).", [["the social disruption", "PROBLEM", 71, 92]]], ["We contend that safety management would be a better paradigm for dealing with pandemic risk.\uf0b7 SegregationWith the Australian mathematical model ACEMod, analysts managed to predict that school closures are not contributing much to the social distancing strategy, assuming compliance levels are above 70%.", [["pandemic", "DISEASE", 78, 86], ["safety management", "TREATMENT", 16, 33], ["compliance levels", "TEST", 271, 288]]], ["Also the ACEMod analysis results are pointing at a minimum requirement of 80% to 90% adherence to social distancing measures in order to effectively control the pandemic (Chang et al., 2020) .", [["the ACEMod analysis", "TEST", 5, 24], ["social distancing measures", "TREATMENT", 98, 124]]], ["With allowing the lower grade schools to re-open on May 11, 2020 the Dutch government took the first step on the path towards bringing society back on its feet.", [["feet", "ORGANISM_SUBDIVISION", 155, 159], ["feet", "ANATOMY", 155, 159]]], ["Another strategy would be to quickly compartmentalize society in case of emergency, limit traffic between compartments and introduce robust surveillance.", [["robust surveillance", "TEST", 133, 152]]], ["This would qualify as spatial segregation.", [["spatial segregation", "PROBLEM", 22, 41], ["spatial segregation", "OBSERVATION", 22, 41]]], ["One of the questions here is whether spreading of the Covid-19 virus could also be slowed down at intermediate distances, somewhere in between social distancing with short distances -3 feet (WHO, 2020e), 1.5 meter (RIVM, 2020), 6 feet (CDC, 2020) or 2 meters (Jebril, 2020) -and closed borders with neighbouring countries at long distances, say 300 kilometres.", [["Covid-19 virus", "ORGANISM", 54, 68], ["Covid-19 virus", "SPECIES", 54, 68], ["the Covid-19 virus", "PROBLEM", 50, 68]]], ["Such intermediate distances would be on the scale of a city or region.", [["intermediate distances", "OBSERVATION", 5, 27]]], ["An in depth investigation of the effects of closing the perimeter around e.g. Wuhan City, Singapore and Hong Kong in the first months of 2020 could offer sufficient proof of the potential of such measures.\uf0b7 Embrace biosecurity and biosafety practicesEmployers having workers in close contact with animals should comply with safe work legislation in all countries.", [["such measures", "TREATMENT", 191, 204]]], ["The current guidance from the ILO (2001; does not touch upon epidemic or pandemic risk or upon the principles of biosafety and biosecurity however.", [["pandemic", "DISEASE", 73, 81], ["biosafety and biosecurity", "TREATMENT", 113, 138]]], ["Barker (2015, p16) describes a case where \"10 infected animals crossed paths with 24,500 other animals\" underway in the livestock trade in the UK during the 2001 Foot and Mouth Disease epidemic (Law, 2006) .", [["p16", "GENE_OR_GENE_PRODUCT", 14, 17], ["Mouth Disease epidemic", "PROBLEM", 171, 193], ["Foot", "ANATOMY", 162, 166], ["Mouth", "ANATOMY", 171, 176], ["Disease", "OBSERVATION", 177, 184]]], ["This example indicates that also animal-to-animal (A2A) transfer needs to be minimized during livestock production and transport.\uf0b7 Embrace biosecurity and biosafety practicesIn fact the adoption of biosecurity and biosafety principles will be essential for successful prevention of pandemics in all countries.", [["A2A", "SIMPLE_CHEMICAL", 51, 54], ["Embrace biosecurity", "TREATMENT", 131, 150], ["biosafety practices", "TREATMENT", 155, 174], ["biosecurity and biosafety principles", "TREATMENT", 198, 234], ["pandemics", "PROBLEM", 282, 291]]], ["This is most necessary in 'spark' prone regions in development countries (Madhav et al., 2017) where the international community can invest in long term biosecurity programmes.", [["most necessary", "UNCERTAINTY", 8, 22]]], ["The cost of such programmes is dwarfed by the damage caused by a global pandemic.", [["the damage", "PROBLEM", 42, 52], ["a global pandemic", "PROBLEM", 63, 80], ["global", "OBSERVATION_MODIFIER", 65, 71], ["pandemic", "OBSERVATION", 72, 80]]], ["These programmes could set up biosecurity plans for small producers, assess risks, implement bio-safe working methods and put in place a monitoring and warning system, using veterinary control on animal isolation, sanitation and transport (Conan et al., 2012; Alhaj, 2011; Kimman et al., 2008; Barker, 2015; Cardona, 2008; Zhou et al., 2019; Gonzalez, 2015) .\uf0b7 Prepare for all known dangerIt is known where the danger comes from: the biggest threats are the so called \"select agents\", and they are of \"viral, bacterial, fungal, prions . . . [and other] origins\" (Gonzalez, 2015 (Gonzalez, , p1015-1016 Selectagents.gov, 2020) .", [["small producers", "TREATMENT", 52, 67], ["a monitoring", "TEST", 135, 147], ["veterinary control", "TREATMENT", 174, 192], ["animal isolation", "TREATMENT", 196, 212]]], ["Pre-approved research plans (Kain & Fowler, 2019) and even intensified continuous research on these known sources of pandemic risk are appropriate and justified when considering the magnitude of damage caused by the global pandemic.", [["pandemic", "DISEASE", 117, 125], ["pandemic risk", "PROBLEM", 117, 130], ["damage", "PROBLEM", 195, 201], ["the global pandemic", "PROBLEM", 212, 231], ["damage", "OBSERVATION", 195, 201], ["global", "OBSERVATION_MODIFIER", 216, 222], ["pandemic", "OBSERVATION", 223, 231]]], ["Instead of preparing for influenza pandemic, the WHO could initiate worldwide cooperation in order to extend the scope of pandemics preparation activities to several other threats from the select agents list (Selectagents.gov, 2020) .\uf0b7 Use of safety system failure indicatorsPandemic prevention, consisting of a chain of several preventive measures connected in series, can be assisted by listening to weak signals (Delatour et al., 2013) and early warning signals (Paltrinieri et al., 2019) .", [["influenza pandemic", "DISEASE", 25, 43], ["pandemics", "DISEASE", 122, 131], ["influenza", "PROBLEM", 25, 34], ["safety system failure indicators", "PROBLEM", 243, 275], ["Pandemic prevention", "TREATMENT", 275, 294], ["several preventive measures", "TREATMENT", 321, 348]]], ["Such signals indicate that the likelihood of an outbreak may have increased and that attention or action is needed.", [["an outbreak", "PROBLEM", 45, 56], ["increased", "OBSERVATION_MODIFIER", 66, 75]]], ["Ideally, if a procedural or technical measure in the chain fails, this would be detected and corrective action would be triggered immediately.", [["a procedural", "TEST", 12, 24]]], ["While the other measures in the chain still prevent the onset of a pandemic, the failing measure could be reinstated.", [["a pandemic", "PROBLEM", 65, 75], ["pandemic", "OBSERVATION", 67, 75]]], ["Detection of such a system failure could be done by direct detection of the pathogen on contaminated personal protection equipment.", [["a system failure", "PROBLEM", 18, 34], ["the pathogen", "PROBLEM", 72, 84], ["contaminated personal protection equipment", "TREATMENT", 88, 130]]], ["Indirect detection e.g. by detection of infected people having symptoms, e.g. elevated temperature, has become a proven alternative.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["Indirect detection", "TEST", 0, 18], ["symptoms", "PROBLEM", 63, 71], ["elevated temperature", "PROBLEM", 78, 98], ["infected", "OBSERVATION_MODIFIER", 40, 48]]], ["The Covid-19 virus was found in waste water (Jebril, 2020) , so could bio-sampling sewers be a way to detect and localize a zoonosis before an outbreak?", [["zoonosis", "DISEASE", 124, 132], ["Covid-19 virus", "ORGANISM", 4, 18], ["Covid-19 virus", "SPECIES", 4, 18], ["The Covid", "TEST", 0, 9], ["virus", "PROBLEM", 13, 18], ["a zoonosis", "PROBLEM", 122, 132]]], ["Sniffer dogs can be trained to smell even intentionally hidden and well wrapped illegal substances (Barker, 2015) .", [["dogs", "ORGANISM", 8, 12], ["dogs", "SPECIES", 8, 12]]], ["So could dogs, less vulnerable to the virus as they seem to be be trained as reliable Covid-19 sniffers?\uf0b7 Use of safety system failure indicatorsThe Nosais trial in France and in and other countries may provide the answer (Roe, 2020) .", [["dogs", "ORGANISM", 9, 13], ["dogs", "SPECIES", 9, 13], ["safety system failure indicators", "PROBLEM", 113, 145]]], ["The development of a reliable detection method for a new pathogen takes time however (Corman et al., 2020) .", [["a new pathogen", "PROBLEM", 51, 65]]], ["Hence, failure detection earlier in the prevention part of the chain of events is needed.", [["failure detection", "PROBLEM", 7, 24], ["failure", "OBSERVATION", 7, 14]]], ["In practice that could be done by detection of 'failures to perform' of the successive measures lined up in the chain.", [["'failures", "PROBLEM", 47, 56], ["the successive measures", "TREATMENT", 72, 95], ["chain", "ANATOMY_MODIFIER", 112, 117]]], ["As we have learned from man-made disasters with nuclear power plants and high-risk chemical plants, also our ways to go about handling animals could be made safer with extra layers of preventive and repressive measures (Vadimovna & Sergeevich, 2017) .", [["man", "ORGANISM", 24, 27], ["man", "SPECIES", 24, 27], ["nuclear power plants", "TREATMENT", 48, 68], ["preventive and repressive measures", "TREATMENT", 184, 218]]], ["As this is a proven way to control risks with an unacceptably large potential impact, it may also be useful as a tool to control pandemic risk.", [["pandemic", "DISEASE", 129, 137]]], ["If the primary containment fails, there is a secondary containment protecting people and environment.", [["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84], ["secondary containment", "OBSERVATION", 45, 66]]], ["This approach is used around many industrial high risk locations, and often combined with an emergency shut down (ESD) provision (Markowski & Siuta, 2017) .", [["This approach", "TREATMENT", 0, 13], ["high risk", "OBSERVATION_MODIFIER", 45, 54]]], ["Such failure detection and ESD can even be working automatically if suitable equipment is installed.", [["Such failure detection", "PROBLEM", 0, 22], ["ESD", "TEST", 27, 30]]], ["This leads to the concept of a quarantine delay circle around a bio facility as a secondary containment measure.Analysis and construction of a theoretical modelA pandemic is characterized by a sequence of events leading to adverse effects, disruption, socioeconomic damage and a considerable death toll.", [["death", "DISEASE", 292, 297], ["a secondary containment measure", "TREATMENT", 80, 111], ["Analysis", "TEST", 112, 120], ["a theoretical modelA pandemic", "PROBLEM", 141, 170], ["adverse effects", "PROBLEM", 223, 238], ["disruption", "PROBLEM", 240, 250], ["socioeconomic damage", "PROBLEM", 252, 272], ["a considerable death toll", "PROBLEM", 277, 302], ["secondary containment", "OBSERVATION", 82, 103]]], ["We construct a theoretical model against the background of safety management methods and techniques such as scenario's, fault-trees, feed-back and learning loops, safety barriers and systems in support of such barriers.", [["safety management methods", "TREATMENT", 59, 84], ["learning loops", "TREATMENT", 147, 161], ["safety barriers", "TREATMENT", 163, 178]]], ["We use the recent experiences of the Covid-19 pandemic.Safety management and risk control methodsThe risk management model we construct in this study is based on three well proven elements:Safety management and risk control methodsFirstly, risk management distinguishes several successive time phases associated with increasing awareness and moving towards action.", [["the Covid", "TEST", 33, 42], ["pandemic", "PROBLEM", 46, 54], ["Safety management", "TREATMENT", 55, 72], ["risk control methods", "TREATMENT", 77, 97], ["this study", "TEST", 139, 149], ["Safety management", "TREATMENT", 189, 206], ["risk control methods", "TREATMENT", 211, 231], ["risk management", "TREATMENT", 240, 255], ["increasing awareness", "PROBLEM", 317, 337]]], ["In this study we use 6 generally applicable risk awareness steps: 1-discovering a danger, 2-acknowledge it, 3-investigate and understand its nature, 4-assess its effect magnitude and evaluate the risk, 5-take appropriate preventive and repressive countermeasures and 6-evaluate incidents in support of learning and improvement.Safety management and risk control methodsSecondly, risk management can be done in different ways, depending on the probability and effects of an unwanted event.", [["repressive countermeasures", "TREATMENT", 236, 262], ["Safety management", "TREATMENT", 327, 344], ["risk control methods", "TREATMENT", 349, 369], ["risk management", "TREATMENT", 379, 394], ["an unwanted event", "PROBLEM", 470, 487]]], ["This approach shows 'risk', the interrelation between likelihood and adverse effect.", [["'risk'", "PROBLEM", 20, 26], ["adverse effect", "PROBLEM", 69, 83]]], ["To this end such an event can be plotted in an extended risk matrix (figure 2).Figure 2 Extended risk matrixIf the probability of an unwanted event is close to 100%, we avoid it by taking specific, strong and effective measures such as using other methods, prohibition by law or allowing prescribed safety measures only, often referred to as the 'precautionary principle'.", [["risk matrix", "OBSERVATION_MODIFIER", 97, 108]]], ["Are potential effects (very) large and uncertainties are large as well, then the 'cautionary principle' applies (Aven, 2019) .", [["potential effects (very) large and uncertainties", "PROBLEM", 4, 52], ["large", "OBSERVATION_MODIFIER", 29, 34], ["large", "OBSERVATION_MODIFIER", 57, 62]]], ["These two constitute the deterministic approach to safety: making the unwanted event impossible.Figure 2 Extended risk matrixIf the event has a smaller probability we often use the risk matrix, a square with an effect scale versus a probability scale.", [["the risk matrix", "TREATMENT", 177, 192], ["an effect scale", "TREATMENT", 208, 223], ["a probability scale", "TEST", 231, 250], ["risk matrix", "OBSERVATION_MODIFIER", 114, 125], ["smaller", "OBSERVATION_MODIFIER", 144, 151]]], ["Within the framework of a safety management system, the 'tiled' centre area of this risk matrix can be used to show which effect and probability combinations are acceptable, which need risk reduction measures and which are not acceptable.", [["matrix", "CELLULAR_COMPONENT", 89, 95], ["a safety management system", "TREATMENT", 24, 50], ["the 'tiled' centre area", "TREATMENT", 52, 75], ["this risk matrix", "PROBLEM", 79, 95], ["risk reduction measures", "TREATMENT", 185, 208]]], ["At the left and top of the deterministic and probabilistic areas in figure 2 is a zone where probability and/or effect are zero so nothing will happen here.", [["left", "ANATOMY", 7, 11], ["left", "ANATOMY_MODIFIER", 7, 11], ["top", "OBSERVATION_MODIFIER", 16, 19], ["areas", "OBSERVATION_MODIFIER", 59, 64], ["zone", "OBSERVATION_MODIFIER", 82, 86]]], ["At the lower right is a zone which we consider as not realistic.", [["lower", "ANATOMY_MODIFIER", 7, 12], ["right", "ANATOMY_MODIFIER", 13, 18], ["zone", "OBSERVATION_MODIFIER", 24, 28]]], ["At the lower left we situate the possible yet unlikely extreme events.", [["extreme events", "PROBLEM", 55, 69], ["lower", "ANATOMY_MODIFIER", 7, 12], ["left", "ANATOMY_MODIFIER", 13, 17]]], ["Risk management can be applied, yet there is rather little we actually do in this corner.", [["Risk management", "TREATMENT", 0, 15]]], ["The term 'repression' is used for minimizing all the negative effects which occur after the event.", [["The term 'repression", "TREATMENT", 0, 20]]], ["Such central events normally have both multiple possible causes and multiple possible effects.", [["Such central events", "PROBLEM", 0, 19], ["multiple", "OBSERVATION_MODIFIER", 39, 47], ["possible", "UNCERTAINTY", 48, 56], ["multiple", "OBSERVATION_MODIFIER", 68, 76]]], ["An unwanted central event is therefore preceded by a causal tree and followed by a consequences tree, usually referred to as a 'bow-tie' because of its shape, see figure 3 .", [["An unwanted central event", "PROBLEM", 0, 25], ["central event", "OBSERVATION", 12, 25]]], ["Thus far, as far as we can see, bowtie models have been introduced to manage Covid-19 risks for health and safety from a worker perspective (Wajidi, 2020; Manton, Johnson, Miles, Scanlon & Cowley, 2020) and from an organisation perspective (Protecht, 2020) , but not from a global pandemic risk management perspective.Figure 3 Bow-tie model and the safety hierarchyIn this model, the unwanted central event, in fault-tree terminology also referred to as 'top-event', either happens or does not happen, depending on whether preventive barriers in the causal tree stop one or more causal factors from contributing to a pandemic scenario unfolding in time.", [["Figure", "TEST", 318, 324], ["the unwanted central event", "PROBLEM", 380, 406]]], ["In case the central event happens, repressive barriers are put in place to stop, mitigate and minimize the adverse effects.", [["the adverse effects", "PROBLEM", 103, 122], ["central", "OBSERVATION_MODIFIER", 12, 19]]], ["Preventive and repressive barriers can be classified in several types: behavioural, human-hardware, hardware-human, active hardware, passive hardware and they are kept in place by supporting delivery systems -resources -within a safety management system context, such as leadership, communication, education, training, monitoring, inspection, maintenance and a right attitude of people towards safety.", [["human", "ORGANISM", 84, 89], ["human", "ORGANISM", 109, 114], ["people", "ORGANISM", 379, 385], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 109, 114], ["people", "SPECIES", 379, 385], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 109, 114], ["Preventive and repressive barriers", "TREATMENT", 0, 34], ["human-hardware", "TREATMENT", 84, 98], ["hardware-human, active hardware", "TREATMENT", 100, 131], ["passive hardware", "TREATMENT", 133, 149], ["monitoring", "TEST", 319, 329], ["inspection", "TEST", 331, 341], ["hardware", "OBSERVATION", 90, 98], ["hardware", "OBSERVATION", 100, 108], ["active", "OBSERVATION_MODIFIER", 116, 122], ["hardware", "OBSERVATION", 123, 131], ["passive hardware", "OBSERVATION", 133, 149], ["right", "ANATOMY_MODIFIER", 361, 366]]], ["A feedback loop ensures that learning from unwanted events leads to system improvements via education and renewed risk assessment .", [["A feedback loop", "TREATMENT", 0, 15], ["renewed risk assessment", "TEST", 106, 129], ["feedback loop", "OBSERVATION", 2, 15]]], ["Since prevention is not always perfect, and the central event can happen, 'preparation' is needed for foreseeable events.", [["foreseeable events", "PROBLEM", 102, 120]]], ["Thereto repressive barriers are put in place to prepare for emergency response,EVALUATION EDUCATIONFEED-BACK mitigation and avoidance of long term effects.", [["EVALUATION", "TEST", 79, 89], ["BACK mitigation", "TREATMENT", 104, 119], ["long term effects", "PROBLEM", 137, 154], ["long term", "OBSERVATION_MODIFIER", 137, 146]]], ["If a risk is not identified there will be neither preparation of specific countermeasures, nor any prevention activities.", [["specific countermeasures", "TREATMENT", 65, 89]]], ["Analyses of the root causes of previous incidents feed improvement of preventive barriers.", [["root", "ANATOMY", 16, 20], ["preventive barriers", "TREATMENT", 70, 89], ["root", "ANATOMY", 16, 20], ["improvement", "OBSERVATION_MODIFIER", 55, 66]]], ["Evaluation of the aftermath of an event feeds the improvement of the effectiveness of all barriers, including the repressive ones.", [["Evaluation", "TEST", 0, 10], ["an event feeds", "TREATMENT", 31, 45], ["all barriers", "TREATMENT", 86, 98], ["the repressive ones", "TREATMENT", 110, 129]]], ["This socio-technical modelling technique is used in industrial major accident hazard risk control practice and enables safety analysts to graphically display causality, scenario's, barriers and timelines in an integrated way (L\u00e9ger et al., 2008) .", [["technical modelling technique", "TREATMENT", 11, 40]]], ["In this framework further analysis is possible using static probability data on events and barriers in the causality tree.", [["further analysis", "TEST", 18, 34], ["static probability data", "TEST", 53, 76]]], ["Such analysis can also be made dynamic by replacing the static data by model analysis using real time measurements of process parameters as inputs (Khakzad et al., 2012) .", [["the static data", "TEST", 52, 67], ["model analysis", "TEST", 71, 85]]], ["For the purpose of mapping and analysing the effects of barriers against any pandemic while it is unfolding, combinations with Bayesian networks and agent based spreading models (Chang et al., 2020) may become powerful tools.", [["mapping", "TEST", 19, 26], ["barriers", "TREATMENT", 56, 64], ["any pandemic", "PROBLEM", 73, 85], ["Bayesian networks", "TREATMENT", 127, 144], ["agent", "TREATMENT", 149, 154]]], ["Data about the pathogen properties could be included as they are becoming available in such a model, predicting the outcome of mitigation strategies.Generic pandemic scenarioIf not prevented, a pathogen coming from an animal may infect a human.", [["human", "ORGANISM", 238, 243], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 238, 243], ["mitigation strategies", "TREATMENT", 127, 148], ["Generic pandemic scenarioIf", "PROBLEM", 149, 176], ["a pathogen", "PROBLEM", 192, 202], ["pandemic", "OBSERVATION", 157, 165]]], ["In this way one person may get a zoonosis.", [["zoonosis", "DISEASE", 33, 41], ["person", "ORGANISM", 16, 22], ["person", "SPECIES", 16, 22]]], ["This single case may lead to human-to-human (H2H) transfer.", [["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 38, 43], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 38, 43]]], ["More persons may become infected.", [["persons", "ORGANISM", 5, 12], ["persons", "SPECIES", 5, 12], ["infected", "PROBLEM", 24, 32], ["infected", "OBSERVATION", 24, 32]]], ["If not contained this case can become an outbreak.", [["outbreak", "OBSERVATION", 41, 49]]], ["If not quickly stopped it may reach the stage of a local epidemic.", [["a local epidemic", "PROBLEM", 49, 65], ["local", "OBSERVATION_MODIFIER", 51, 56], ["epidemic", "OBSERVATION", 57, 65]]], ["If not mitigated sufficiently the pathogen may cross country borders and become a global pandemic.", [["the pathogen", "PROBLEM", 30, 42], ["a global pandemic", "PROBLEM", 80, 97], ["global", "OBSERVATION_MODIFIER", 82, 88], ["pandemic", "OBSERVATION", 89, 97]]], ["All these events together constitute a pandemic scenario, unfolding over time.", [["a pandemic scenario", "PROBLEM", 37, 56]]], ["We designed a generic pandemic scenario to be used in our model.", [["a generic pandemic scenario", "TREATMENT", 12, 39]]], ["It is built-up in line with the sequence of events unfolding in the current Covid-19 pandemic.", [["events unfolding", "PROBLEM", 44, 60], ["the current Covid", "TEST", 64, 81], ["pandemic", "PROBLEM", 85, 93]]], ["The generic scenario starts from root causes as identified from literature.", [["root", "ANATOMY", 33, 37], ["root", "ORGAN", 33, 37], ["root causes", "PROBLEM", 33, 44], ["scenario", "OBSERVATION", 12, 20], ["root causes", "OBSERVATION", 33, 44]]], ["Even though root causes may for a part reside in political, cultural, religious, traditional and economical realms, certainly all of them are worth a closer look from risk management point of view.", [["root", "ANATOMY", 12, 16]]], ["Important trends contributing to pandemic risk are population-growth, more deforestation, more living in cities, now 55% and in 2050 some 68%, and more travelling across the globe (WEF, 2019; Kain & Fowler, 2019) .Barriers and support systemsLimiting animal-to-human (A2H) contact transfer risk is an important preventive measure (Chang et al., 2020; WHO (2020b) .", [["pandemic", "DISEASE", 33, 41], ["human", "ORGANISM", 261, 266], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 261, 266], ["pandemic risk", "PROBLEM", 33, 46], ["globe", "ANATOMY", 174, 179]]], ["If human-to-human transfer (H2H) occurs, the risk of epidemic or even pandemic spreading becomes manifest, necessitating \"increased epidemiologic surveillance and monitoring\" (Peeri et al., 2020, p8) .", [["human", "ORGANISM", 3, 8], ["human", "ORGANISM", 12, 17], ["p8", "GENE_OR_GENE_PRODUCT", 196, 198], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 12, 17], ["epidemic", "PROBLEM", 53, 61]]], ["Infection can continue with human-to-animal (H2A) transfer, like the recent case at two Dutch mink farms LNV (2020) where minks, cats and a dog were infected.", [["human", "ORGANISM", 28, 33], ["cats", "ORGANISM", 129, 133], ["dog", "ORGANISM", 140, 143], ["human", "SPECIES", 28, 33], ["mink", "SPECIES", 94, 98], ["cats", "SPECIES", 129, 133], ["dog", "SPECIES", 140, 143], ["human", "SPECIES", 28, 33], ["dog", "SPECIES", 140, 143], ["Infection", "PROBLEM", 0, 9]]], ["On May, 20, 2020 the Dutch news media reported a case of A2H transfer back from the minks to a human, demonstrating the risk of creating new pathogen reservoirs in animals.", [["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["new", "OBSERVATION_MODIFIER", 137, 140], ["pathogen", "OBSERVATION", 141, 149]]], ["On June 3, 2020 the Dutch Government started to destruct all minks at infected farms.", [["infected farms", "OBSERVATION", 70, 84]]], ["This vulnerability of several domesticated animals was discovered recently (Shi et al., 2020, p3) .", [["several", "OBSERVATION_MODIFIER", 22, 29], ["domesticated", "OBSERVATION_MODIFIER", 30, 42], ["animals", "OBSERVATION", 43, 50]]], ["The risk of infection could even involve plants (Heckert et al., 2011) .", [["infection", "DISEASE", 12, 21], ["infection", "PROBLEM", 12, 21], ["infection", "OBSERVATION", 12, 21]]], ["The Covid-19 virus has already been detected in waste water (Jebril, 2020) .", [["Covid-19 virus", "CHEMICAL", 4, 18], ["Covid-19 virus", "ORGANISM", 4, 18], ["Covid-19 virus", "SPECIES", 4, 18], ["The Covid", "TEST", 0, 9]]], ["It would seem that distancing and other spread reducing measures should be applied to animal-human contacts too.", [["human", "ORGANISM", 93, 98], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["spread reducing measures", "TREATMENT", 40, 64]]], ["Jebril (2020, p5, 10-11) lists repressive measures on four geographical levels: Global: travel restrictions; National: government border control, keep vulnerable population safe from infection, reduce transmission; Local: quarantine Covid-19 cases (14 , 18 or 21 days), in hospital: isolate Covid-19 cases , safe Covid-19 case burial practice, safe Covid-19 contaminated waste disposal; Personal : hand washing, safe coughing/sneezing, wearing face mask in public, keep 2 m distance, keep away from Covid-19 cases (infected people).", [["hand", "ANATOMY", 398, 402], ["infection", "DISEASE", 183, 192], ["hand", "ORGANISM_SUBDIVISION", 398, 402], ["people", "ORGANISM", 524, 530], ["people", "SPECIES", 524, 530], ["Jebril", "TEST", 0, 6], ["infection", "PROBLEM", 183, 192], ["safe Covid", "TREATMENT", 308, 318], ["burial practice", "TREATMENT", 327, 342], ["safe Covid", "TREATMENT", 344, 354], ["hand washing", "TREATMENT", 398, 410], ["coughing", "PROBLEM", 417, 425], ["sneezing", "PROBLEM", 426, 434], ["face mask", "TREATMENT", 444, 453], ["Covid", "TEST", 499, 504], ["infection", "OBSERVATION", 183, 192]]], ["Di Gennaro et al. (2020) list several more personal measures: refrain from touching eyes, nose, and mouth, in case of symptoms seek medical care early, and follow advice given by your healthcare provider.", [["eyes", "ANATOMY", 84, 88], ["nose", "ANATOMY", 90, 94], ["mouth", "ANATOMY", 100, 105], ["eyes", "ORGAN", 84, 88], ["nose", "ORGANISM_SUBDIVISION", 90, 94], ["mouth", "ORGANISM_SUBDIVISION", 100, 105], ["symptoms", "PROBLEM", 118, 126], ["nose", "ANATOMY", 90, 94], ["mouth", "ANATOMY", 100, 105]]], ["Turning back part of the transfer reduction measures during mitigation too early may trigger an uncontrolled second wave of infection cases (WHO, 2020c) .", [["infection", "DISEASE", 124, 133], ["the transfer reduction measures", "TREATMENT", 21, 52], ["an uncontrolled second wave of infection cases", "PROBLEM", 93, 139], ["infection", "OBSERVATION", 124, 133]]], ["We extracted 204 text fragments from the literature sources used in this study.", [["text fragments", "PROBLEM", 17, 31], ["this study", "TEST", 68, 78], ["204 text", "OBSERVATION_MODIFIER", 13, 21], ["fragments", "OBSERVATION_MODIFIER", 22, 31]]], ["These fragments are describing conditions, events, required knowledge, listing emergency preparedness activities and needs and mitigation issues concerning our current predicament, the Covid-19 pandemic.", [["fragments", "ANATOMY", 6, 15], ["These fragments", "PROBLEM", 0, 15], ["mitigation issues", "TREATMENT", 127, 144], ["pandemic", "PROBLEM", 194, 202], ["fragments", "OBSERVATION", 6, 15]]], ["Thematic analysis according to the meta-synthesis process (Cronin et al., 2008; Polit & Beck, 2006) was then used to identify supporting systems, unwanted events in a generic pandemic scenario and barriers capable of stopping the scenario at a particular point from progressing any further.Integrated pandemic barrier modelThe combination of these three model elements and the meta-synthesis into the integrated pandemic barrier model we constructed is shown in figure 4 .", [["Thematic analysis", "TEST", 0, 17], ["Integrated pandemic barrier model", "TREATMENT", 290, 323], ["the integrated pandemic barrier model", "TREATMENT", 397, 434]]], ["The horizontal time scale is composed of the 6 steps and the bow-tie time scale.", [["The horizontal time scale", "TREATMENT", 0, 25]]], ["The model is integrated because we merge three safety models and use the sequence of events observed during the Covid-19 pandemic as it unfolded starting from December 1, 2019.", [["the Covid", "TEST", 108, 117]]], ["This model provides an overview of what may happen between root causes and long term effects from a safety management and risk control point of view.", [["root", "ANATOMY", 59, 63], ["long term effects", "PROBLEM", 75, 92], ["a safety management", "TREATMENT", 98, 117], ["long term", "OBSERVATION_MODIFIER", 75, 84]]], ["The pandemic scenario in figure 4 is starting from the position of the country having the first outbreak.", [["pandemic", "OBSERVATION_MODIFIER", 4, 12], ["scenario", "OBSERVATION", 13, 21]]], ["This country is the origin of the pandemic.", [["the pandemic", "PROBLEM", 30, 42], ["pandemic", "OBSERVATION", 34, 42]]], ["The scenario is -though inspired by the current Covid-19 pandemic events -not limited to a specific pathogen.", [["19 pandemic events", "PROBLEM", 54, 72], ["a specific pathogen", "PROBLEM", 89, 108]]], ["This is the point in the pandemic process where an infection may either come from a local outbreak in the country of origin as shown, or from an infected person arriving from another country.", [["infection", "DISEASE", 51, 60], ["person", "SPECIES", 154, 160], ["the pandemic process", "PROBLEM", 21, 41], ["an infection", "PROBLEM", 48, 60], ["pandemic", "OBSERVATION", 25, 33], ["infection", "OBSERVATION", 51, 60], ["local", "OBSERVATION_MODIFIER", 84, 89], ["outbreak", "OBSERVATION", 90, 98], ["infected", "OBSERVATION", 145, 153]]], ["The model structure can be used for any outbreak of any pathogen.Integrated pandemic barrier modelOur approach is complementary to the mathematical modelling of geographical infectious disease spreading over time, such as ACEMod (Chang et al., 2020) , based on analysis of complex human behaviour in space and time and calibration with epidemiological case data (Schoenberg et al., 2019) .", [["infectious disease", "DISEASE", 174, 192], ["human", "ORGANISM", 281, 286], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 281, 286], ["any pathogen", "PROBLEM", 52, 64], ["Integrated pandemic barrier model", "TREATMENT", 65, 98], ["geographical infectious disease", "PROBLEM", 161, 192], ["geographical", "OBSERVATION_MODIFIER", 161, 173], ["infectious", "OBSERVATION", 174, 184]]], ["Recursive patterns (Gouyet, 1996) are observed both in pathogen spreading (Hohl et al., 2016) and in the complex human behaviour in society (Vazquez-Prokopec et al., 2013) .", [["human", "ORGANISM", 113, 118], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118]]], ["Prediction and evaluation of mitigation strategies requires sophisticated mathematical models (AlSharawi et al., 2012; Chang et al., 2020) .", [["evaluation", "TEST", 15, 25], ["mitigation strategies", "TREATMENT", 29, 50]]], ["Such mathematical models show their strengths starting from detection of an outbreak onwards to mitigation and emergence of a pandemic (Siettos & Russo, 2013; Zamba et al., 2013) The integrated pandemic model, as developed in this study (see figure 4) , provides an overview of all possible barriers in the pandemic scenario and shows the causal tree and its opportunities for prevention.", [["this study", "TEST", 226, 236], ["pandemic model", "OBSERVATION", 194, 208]]], ["Pathogen spreading goes on during the mitigation of a pandemic.", [["Pathogen spreading", "PROBLEM", 0, 18], ["a pandemic", "PROBLEM", 52, 62]]], ["This may cause 'flares', i.e. local outbreaks which may develop into a second wave and even multiple waves.", [["'flares'", "PROBLEM", 15, 23], ["flares", "OBSERVATION", 16, 22], ["multiple", "OBSERVATION_MODIFIER", 92, 100], ["waves", "OBSERVATION_MODIFIER", 101, 106]]], ["Each new infection case, e.g. a first case in a country travelling in from abroad, comes in as 'Patient-1' and brings the scenario at the unwanted central event of the pandemic scenario.PREVENTION EDUCATIONSevere cases 8-Emergency preparedness and safety drills 9-Resources stockpile and logistics management 10-Outbreak detection and alarm systems 11-Emergency response team organisation 12-Contamination testing methods and equipmentCritical reflectionIn the model proposed by (Hickson, 2010 ) the text in the previous sections in this study is the introduction to the two stages below.Critical reflectionStage 1-Deconstruction -understanding how an event came about, its elements, what happened and why.", [["sections", "ANATOMY", 521, 529], ["infection", "DISEASE", 9, 18], ["Patient", "SPECIES", 96, 103], ["Each new infection case", "PROBLEM", 0, 23], ["safety drills", "TREATMENT", 248, 261], ["logistics management", "TREATMENT", 288, 308], ["alarm systems", "TEST", 335, 348], ["this study", "TEST", 533, 543], ["new", "OBSERVATION_MODIFIER", 5, 8], ["infection", "OBSERVATION", 9, 18], ["reflection", "OBSERVATION_MODIFIER", 444, 454]]], ["Any pandemic will come about via the generic pandemic scenario shown in figure 4.", [["Any pandemic", "PROBLEM", 0, 12]]], ["Our current predicament, the Covid-19 pandemic, here used as an example, is the resulting effect of barriers failing in a series of 5 consecutive events: 1-Root causes: local traditions, unawareness of biohazard risks, travelling across the globe, pathogen reservoirs in animals.", [["local traditions", "PROBLEM", 169, 185], ["unawareness of biohazard risks", "PROBLEM", 187, 217], ["globe", "ANATOMY", 241, 246], ["pathogen reservoirs", "OBSERVATION", 248, 267]]], ["These lead to : 2-Causal factors: people close to animals, food and hygiene habits, people close to people.", [["people", "ORGANISM", 34, 40], ["people", "ORGANISM", 100, 106], ["people", "SPECIES", 34, 40], ["people", "SPECIES", 84, 90], ["people", "SPECIES", 100, 106]]], ["These lead to : 3-Transfer from/via animal to a human: A2A, A2H, single case zoonosis.", [["zoonosis", "DISEASE", 77, 85], ["human", "ORGANISM", 48, 53], ["A2A", "GENE_OR_GENE_PRODUCT", 55, 58], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53]]], ["This leads to : Transfer between humans: H2H, local outbreak.", [["humans", "ORGANISM", 33, 39], ["H2H", "GENE_OR_GENE_PRODUCT", 41, 44], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39]]], ["This leads to : 4-Epidemic: infected people, pathogen transfer.", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["infected", "OBSERVATION", 28, 36]]], ["This leads to : 5-Pandemic: treatment, quarantine, unnoticed spreading, epidemic reaching other countries.", [["treatment", "TREATMENT", 28, 37], ["quarantine", "TREATMENT", 39, 49], ["unnoticed spreading", "PROBLEM", 51, 70], ["spreading", "OBSERVATION_MODIFIER", 61, 70]]], ["Vaccine induced immunity is not observed, since no vaccine is available.", [["Vaccine", "TREATMENT", 0, 7], ["vaccine", "TREATMENT", 51, 58]]], ["A second wave is not (yet) observed, although there were several new local outbreaks (status per May, 11, 2020) .Critical reflectionStage 2-Reconstruction -building the event up from altered elements and compare the outcome to reality.", [["Reconstruction", "TREATMENT", 140, 154], ["altered elements", "PROBLEM", 183, 199], ["several", "OBSERVATION_MODIFIER", 57, 64], ["new", "OBSERVATION_MODIFIER", 65, 68], ["local", "OBSERVATION_MODIFIER", 69, 74], ["outbreaks", "OBSERVATION", 75, 84]]], ["If this scenario would be subject of robust risk-control all successive scenario events have barriers:Critical reflection\uf0b7 Biosafety education of people working with animals would create awareness about biohazard risks and about safe behaviour. \uf0b7 Biosecurity controlled wild animal markets, using animal-human distancing, personal protection and hygiene measures when working with animals at farms.", [["people", "ORGANISM", 146, 152], ["human", "ORGANISM", 304, 309], ["people", "SPECIES", 146, 152], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 304, 309], ["robust risk", "PROBLEM", 37, 48], ["animal-human distancing", "TREATMENT", 297, 320], ["personal protection", "TREATMENT", 322, 341], ["hygiene measures", "TREATMENT", 346, 362]]], ["Routine animal disease control, if applied systematically at all times, would prevent animal-to-human transfer.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["Routine animal disease control", "TREATMENT", 0, 30], ["disease", "OBSERVATION", 15, 22]]], ["A quarantine delay circle around bio-facilities would prevent escaping pathogen e.g. via workers daily commute and logistic activities. \uf0b7 Fast detection, quarantine and health alert when a single zoonosis case occurs, would prevent human-to-human transfer of the pathogen.", [["zoonosis", "DISEASE", 196, 204], ["human", "ORGANISM", 232, 237], ["human", "ORGANISM", 241, 246], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 241, 246], ["A quarantine delay circle around bio-facilities", "TREATMENT", 0, 47], ["Fast detection", "TEST", 138, 152], ["the pathogen", "PROBLEM", 259, 271]]], ["A quarantine delay circle would allow immediate containment of a zoonosis by closing off a bio-facility from the outside world. \uf0b7 Preventive prophylaxis/vaccination, safety distancing, frequent health checks and hygiene measures such as disinfection spraying would prevent a local outbreak. \uf0b7 Fast response to contain a local outbreak would be possible via routine detection (using sensors, sniffers, IR-thermometers, swab-tests), immediate alert and direct quarantine.", [["zoonosis", "DISEASE", 65, 73], ["A quarantine delay circle", "TREATMENT", 0, 25], ["Preventive prophylaxis", "TREATMENT", 130, 152], ["vaccination", "TREATMENT", 153, 164], ["safety distancing", "TREATMENT", 166, 183], ["frequent health checks", "TEST", 185, 207], ["hygiene measures", "TREATMENT", 212, 228], ["disinfection spraying", "TREATMENT", 237, 258], ["a local outbreak", "PROBLEM", 273, 289], ["a local outbreak", "PROBLEM", 318, 334], ["routine detection", "TEST", 357, 374], ["swab-tests", "TEST", 418, 428]]], ["Suspect infection cases must be quarantined.", [["infection", "DISEASE", 8, 17], ["infection cases", "PROBLEM", 8, 23], ["infection", "OBSERVATION", 8, 17]]], ["Safe waste and waste water disposal methods must be in place.", [["Safe waste", "TREATMENT", 0, 10], ["waste water disposal methods", "TREATMENT", 15, 43]]], ["Local hubs for long distance travelling must be subjected to emergency biosecurity detection.Critical reflectionComparison between Deconstruction and Reconstruction Pillay (2017, p.129) argues that \"The gap between work as imagined and work as performed is an important aspect.\"", [["long distance travelling", "PROBLEM", 15, 39], ["emergency biosecurity detection", "TEST", 61, 92]]], ["Comparison between Deconstruction and Reconstruction shows such a gap.", [["Reconstruction", "TREATMENT", 38, 52], ["such a gap", "PROBLEM", 59, 69]]], ["Even if each of these 5 barrier groups only reaches 80% effectivity the remaining probability of a pandemic will be reduced by more than a factor 3000.", [["these 5 barrier groups", "TREATMENT", 16, 38], ["a pandemic", "PROBLEM", 97, 107]]], ["(If a barrier is 80% effective the probability the scenario passes the barrier is p 1 =0,2.", [["a barrier", "TREATMENT", 4, 13]]], ["The inverse is the reduction factor of 3125).", [["reduction", "OBSERVATION_MODIFIER", 19, 28]]], ["This means that 5 preventive barrier groups, connected in series, can effectively stop a pandemic before the first outbreak.", [["5 preventive barrier groups", "TREATMENT", 16, 43]]], ["The performances in practice of countries with biosecurity interventions (Wang, Artois, et al. 2020) , whether it is a fast emergency response, implementation of robust travelling restrictions, automated contacts tracing, a stockpile of emergency supplies or a full lockdown, all illustrate the feasibility of taking effective measures.CONCLUSIONThe Covid-19 pandemic has shown that in many countries, from a safety management perspective, both prevention and repression have failed.", [["biosecurity interventions", "TREATMENT", 47, 72], ["emergency supplies", "TREATMENT", 237, 255], ["Covid", "TEST", 350, 355], ["pandemic", "PROBLEM", 359, 367], ["a safety management perspective", "TREATMENT", 407, 438]]], ["Two paradigms, the acceptance of pandemic risk as a 'given' and -if it happens -deal with it as a 'medical emergency', have not led to effective pandemic risk control.", [["pandemic", "DISEASE", 33, 41], ["effective pandemic risk control", "TREATMENT", 135, 166]]], ["It would seem that considering pro-active prevention of pandemic risk received too little attention.", [["pandemic", "DISEASE", 56, 64], ["pandemic risk", "PROBLEM", 56, 69]]], ["As ignorance, lacking biosafety and biosecurity measures and limited protective means when people are close to animals, were among the causal factors, there are many opportunities for improvement.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["biosecurity measures", "TREATMENT", 36, 56]]], ["A trade-off between investment in effective country biosecurity programmes and prevention systems and the social and economic damage caused by a global pandemic will very likely be in favour of prevention.", [["investment", "TREATMENT", 20, 30], ["biosecurity programmes", "TREATMENT", 52, 74], ["prevention systems", "TREATMENT", 79, 97], ["economic damage", "PROBLEM", 117, 132], ["a global pandemic", "PROBLEM", 143, 160]]], ["Education in biosafety and biosecurity management systems supports sustainability of effective pandemic prevention barriers.", [["biosecurity management systems", "TREATMENT", 27, 57], ["effective pandemic prevention barriers", "TREATMENT", 85, 123]]], ["These would as a minimum comprise human-animal distancing, personal protection and routine monitoring and testing.", [["human", "ORGANISM", 34, 39], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["personal protection", "TREATMENT", 59, 78], ["routine monitoring", "TEST", 83, 101], ["testing", "TEST", 106, 113]]], ["Pro-active preparation for an outbreak of any new pathogen requires continuous research for detection methods and vaccines so that no time is lost after the onset of a pandemic due to failure of preventive measures.", [["Pro-active preparation", "TREATMENT", 0, 22], ["any new pathogen", "PROBLEM", 42, 58], ["detection methods", "TREATMENT", 92, 109], ["vaccines", "TREATMENT", 114, 122], ["a pandemic", "PROBLEM", 166, 176], ["preventive measures", "TREATMENT", 195, 214]]], ["Repression of the Covid-19 pandemic was taken up in force, after undue delay, but spreading of the virus beyond the Wuhan region could not be stopped.", [["Covid-19", "ORGANISM", 18, 26], ["the Covid", "TEST", 14, 23], ["undue delay", "PROBLEM", 65, 76], ["the virus", "PROBLEM", 95, 104], ["virus", "OBSERVATION", 99, 104]]], ["The global death toll by June, 10, 2020 exceeds 400,000 and is still increasing.", [["death", "DISEASE", 11, 16], ["global", "OBSERVATION_MODIFIER", 4, 10], ["death", "OBSERVATION", 11, 16], ["increasing", "OBSERVATION_MODIFIER", 69, 79]]], ["In many Western countries a slow response, initially unrestrained travelling, preparation for influenza viruses rather than SARS like viruses and major logistical problems with materials, equipment and facilities played a main role.", [["influenza viruses", "DISEASE", 94, 111], ["SARS", "DISEASE", 124, 128], ["a slow response", "PROBLEM", 26, 41], ["influenza viruses", "PROBLEM", 94, 111], ["SARS like viruses", "PROBLEM", 124, 141]]], ["The huge socio-economic aftermath was not addressed in advance or even foreseen.", [["huge", "OBSERVATION_MODIFIER", 4, 8]]], ["Specific preparation activities and barriers to avoid or minimize the socio-economic damage were not in place.", [["barriers", "TREATMENT", 36, 44], ["economic damage", "PROBLEM", 76, 91]]], ["New ways are needed to protect businesses, institutions and individuals against the sudden loss of income due to large scale enforced closure.", [["the sudden loss", "PROBLEM", 80, 95], ["large scale enforced closure", "TREATMENT", 113, 141], ["closure", "OBSERVATION", 134, 141]]], ["New solutions are needed to accommodate for social distancing in public spaces, for incapacitated public transport, for the alleviation of the social deprivation caused by unsuitable buildings, and for a wide variety of services bringing people in close proximity of each other.", [["people", "ORGANISM", 238, 244], ["people", "SPECIES", 238, 244], ["New solutions", "TREATMENT", 0, 13]]], ["Of course this daunting effort will not be required if all of us would take up prevention of the pandemic risk more seriously.", [["pandemic", "DISEASE", 97, 105], ["the pandemic risk", "PROBLEM", 93, 110]]]], "PMC2203979": [["BackgroundWell-known, as well as previously uncharacterized infections continue to (re)emerge around the globe.", [["infections", "DISEASE", 60, 70], ["previously uncharacterized infections", "PROBLEM", 33, 70], ["infections", "OBSERVATION", 60, 70], ["globe", "ANATOMY", 105, 110]]], ["To avoid casualties from outbreaks of these infections and from the potential criminal uses of bioagents, surveillance systems are needed that have the capacity to identify such outbreaks accurately and rapidly.", [["infections", "DISEASE", 44, 54], ["these infections", "PROBLEM", 38, 54], ["bioagents", "TREATMENT", 95, 104], ["surveillance systems", "TEST", 106, 126], ["infections", "OBSERVATION", 44, 54]]], ["The accuracy and timeliness of biosurveillance systems rests on the ability to model the uncertainty, severity, and aberrancy of clinical symptoms that are likely to portend disease outbreaks as expressed through the data monitoring system.", [["biosurveillance systems", "TREATMENT", 31, 54], ["severity", "PROBLEM", 102, 110], ["aberrancy of clinical symptoms", "PROBLEM", 116, 146], ["portend disease outbreaks", "PROBLEM", 166, 191], ["the data monitoring system", "TEST", 213, 239]]], ["Shmueli [1] summarizes the problems that biosurveillance systems, in general, pose to traditional statistical monitoring: (a) biosurveillance data may not be independent or stationary; (b) non-traditional data are assumed to contain earlier signature of an outbreak but this signal is weaker compared to actual diagnosis data; (c) since there are no data that contain bioterrorist outbreaks, outbreak patterns particularly as they would manifest in non-traditional data streams are unknown; (d) biosurveillance data are assumed to have no bioterrorist outbreaks, but the natural outbreaks add up to the background noise.", [["Shmueli", "CHEMICAL", 0, 7], ["an outbreak", "PROBLEM", 254, 265], ["bioterrorist outbreaks", "PROBLEM", 539, 561]]], ["The key issue at hand is to design statistical modeling and detection methods that can address these problems.BackgroundAmong children, respiratory symptoms are an attractive target for surveillance.", [["respiratory", "ANATOMY", 136, 147], ["respiratory symptoms", "DISEASE", 136, 156], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["these problems", "PROBLEM", 95, 109], ["respiratory symptoms", "PROBLEM", 136, 156], ["surveillance", "TEST", 186, 198]]], ["These are a prominent feature of many childhood epidemics and an early presentation of diseases like avian influenza, severe acute respiratory syndrome (SARS), and inhalational anthrax that have recently come to the public's attention.", [["avian influenza", "DISEASE", 101, 116], ["acute respiratory syndrome", "DISEASE", 125, 151], ["SARS", "DISEASE", 153, 157], ["anthrax", "DISEASE", 177, 184], ["avian influenza", "ORGANISM", 101, 116], ["avian influenza", "SPECIES", 101, 116], ["many childhood epidemics", "PROBLEM", 33, 57], ["diseases", "PROBLEM", 87, 95], ["avian influenza", "PROBLEM", 101, 116], ["severe acute respiratory syndrome", "PROBLEM", 118, 151], ["inhalational anthrax", "PROBLEM", 164, 184], ["prominent", "OBSERVATION_MODIFIER", 12, 21], ["many", "OBSERVATION_MODIFIER", 33, 37], ["childhood", "OBSERVATION_MODIFIER", 38, 47], ["epidemics", "OBSERVATION", 48, 57], ["early", "OBSERVATION_MODIFIER", 65, 70], ["diseases", "OBSERVATION", 87, 95], ["influenza", "OBSERVATION", 107, 116], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory syndrome", "OBSERVATION", 131, 151]]], ["Unfortunately, respiratory complaints are also a feature of many common childhood illnesses, reducing the ability of biosurveillance systems to detect epidemics of greater public health concern.", [["respiratory", "ANATOMY", 15, 26], ["respiratory complaints", "DISEASE", 15, 37], ["respiratory complaints", "PROBLEM", 15, 37], ["many common childhood illnesses", "PROBLEM", 60, 91]]], ["What is needed, therefore, is clinical information that is readily accessible and pre-processed in a manner that reflects the severity and aberrancy of respiratory symptoms.", [["respiratory", "ANATOMY", 152, 163], ["respiratory symptoms", "DISEASE", 152, 172], ["the severity", "PROBLEM", 122, 134], ["respiratory symptoms", "PROBLEM", 152, 172], ["respiratory symptoms", "OBSERVATION", 152, 172]]], ["Using such data, discrimination between common childhood diseases and more serious respiratory epidemics would be possible.BackgroundChest radiographs (X-rays), because they are readily available and are generally ordered by clinicians to evaluate respiratory complaints that are atypical or severe, have the potential to act as such a bio-monitoring and validation tool.", [["respiratory", "ANATOMY", 248, 259], ["respiratory complaints", "DISEASE", 248, 270], ["such data", "TEST", 6, 15], ["common childhood diseases", "PROBLEM", 40, 65], ["more serious respiratory epidemics", "PROBLEM", 70, 104], ["BackgroundChest radiographs", "TEST", 123, 150], ["X-rays", "TEST", 152, 158], ["respiratory complaints", "PROBLEM", 248, 270], ["a bio-monitoring and validation tool", "TEST", 334, 370]]], ["In addition, detection based on models of radiograph ordering can indicate when in-depth follow-up is needed, as may occur when ordering of radiographs by clinicians is excessive for a given time of the year.", [["radiograph", "TEST", 42, 52], ["radiographs", "TEST", 140, 151]]], ["Such in-depth review of radiographs may confirm clinical suspicions of an emerging epidemic or signal the need to perform a targeted review of medical charts to identify anomalous findings or groupings of aberrant findings that might herald the early stages of a respiratory-related outbreak.BackgroundIn this article we consider time series methods for the modeling and detection of respiratory-related outbreak signatures based on chest radiograph ordering patterns from a number of pediatric emergency departments (EDs) located in the Midwestern region of the United States.", [["respiratory", "ANATOMY", 263, 274], ["chest", "ANATOMY", 433, 438], ["radiographs", "TEST", 24, 35], ["anomalous findings", "PROBLEM", 170, 188], ["aberrant findings", "PROBLEM", 205, 222], ["a respiratory-related outbreak", "PROBLEM", 261, 291], ["the modeling", "TEST", 354, 366], ["respiratory-related outbreak signatures", "PROBLEM", 384, 423], ["chest radiograph", "TEST", 433, 449], ["respiratory", "ANATOMY", 263, 274], ["chest", "ANATOMY", 433, 438]]], ["These models include ambient temperature records collected in each city, as a covariate.", [["ambient temperature records", "TREATMENT", 21, 48]]], ["We use the temperature series as a surrogate measure of the annual influenza season.", [["influenza", "DISEASE", 67, 76], ["the temperature series", "TREATMENT", 7, 29]]], ["Also, a patient visit count series is included in the models to account for variations between-EDs (like ED sizes) and within-EDs (day-of-week, for example).", [["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["a patient visit count series", "TEST", 6, 34]]], ["Addressing the fact that the underlying process is neither \"independent or stationary\", our interest is to model the underlying \"respiratory-complaint background\", using the available covariates and significant temporal dependencies present in the data.", [["significant temporal dependencies", "PROBLEM", 199, 232]]], ["Without modeling the spatial dependence directly, we investigate whether or not there is evidence of spatial homogeneity in the statistical models across cities.", [["spatial homogeneity", "PROBLEM", 101, 120], ["spatial dependence", "OBSERVATION", 21, 39], ["evidence of", "UNCERTAINTY", 89, 100], ["spatial homogeneity", "OBSERVATION", 101, 120]]], ["We use filter-based prediction methods to indicate evidence of respiratory-related outbreaks (e.g., due to anthrax attack) using chest radiograph data.", [["anthrax", "DISEASE", 107, 114], ["filter", "TREATMENT", 7, 13], ["respiratory-related outbreaks", "PROBLEM", 63, 92], ["chest radiograph data", "TEST", 129, 150], ["respiratory", "ANATOMY", 63, 74], ["chest", "ANATOMY", 129, 134]]], ["We describe the form and function of various filters that are commonly used to detect outbreak signatures.", [["various filters", "TREATMENT", 37, 52]]], ["Using a stochastic model for an anthrax attack, we assess the performance of these methods.", [["anthrax", "DISEASE", 32, 39], ["a stochastic model", "TREATMENT", 6, 24], ["an anthrax attack", "TREATMENT", 29, 46], ["these methods", "TREATMENT", 77, 90]]], ["Since there are no data that contain outbreak patterns, the use of a model is key to providing realistic outbreak patterns that can accurately be used to evaluate these statistical detection methods.BackgroundReis, Mandl, and others use time series methods to detect evidence of disease outbreaks at Boston Children's Hospital [2-4], modeling specific clinical complaints as deterministic trend and seasonalities plus a stationary autoregressive moving average (ARMA) process.", [["Children", "SPECIES", 307, 315], ["disease outbreaks", "PROBLEM", 279, 296], ["modeling specific clinical complaints", "PROBLEM", 334, 371], ["no", "UNCERTAINTY", 16, 18]]], ["They repeat this process for the visit counts instead of considering a joint modeling procedure.", [["the visit counts", "TEST", 29, 45], ["a joint modeling procedure", "TREATMENT", 69, 95], ["joint", "ANATOMY", 71, 76]]], ["The detection algorithm filters one-step-ahead prediction errors [5], and looks for values in this residual process that exceed a predetermined threshold.", [["The detection algorithm filters", "TEST", 0, 31], ["this residual process", "PROBLEM", 94, 115]]], ["Ivanov, et al. [6] use the Exponentially Weighted Moving Average smoother to measure timeliness, sensitivity, and specificity of free-text chief complaints (information describing patient's status on the ED visit).", [["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187], ["sensitivity", "TEST", 97, 108]]], ["They indicate that the methods are good for detecting relatively large seasonal outbreaks, but not for small outbreaks.", [["relatively large seasonal outbreaks", "PROBLEM", 54, 89], ["small outbreaks", "PROBLEM", 103, 118], ["large", "OBSERVATION_MODIFIER", 65, 70], ["seasonal", "OBSERVATION_MODIFIER", 71, 79], ["outbreaks", "OBSERVATION", 80, 89], ["small", "OBSERVATION_MODIFIER", 103, 108], ["outbreaks", "OBSERVATION", 109, 118]]], ["There are also a number of wavelet-based and smoothing-based methods that can be used to monitor and detect abnormalities of unknown form, occurring over different time scales [1,8,9].", [["abnormalities", "PROBLEM", 108, 121]]], ["The use of scan statistics [10-12] has also gained popularity in recent years.", [["scan statistics", "TEST", 11, 26]]], ["Many of the methods based on scan statistics use fixed-effect models for biosurveillance (also see, e.g., [13] and [14] for other methods based on fixed-effect models).BackgroundOur manuscript is organized as follows: we start by summarizing the data of interest, and propose a statistical model for the ED data in each city.", [["the methods", "TEST", 8, 19], ["scan", "TEST", 29, 33], ["other methods", "TREATMENT", 124, 137]]], ["Using the growing literature on the subject, we outline a stochastic model for an anthrax outbreak along with a healthcare utilization model for simulating people entering the ED.", [["anthrax", "DISEASE", 82, 89], ["people", "ORGANISM", 156, 162], ["people", "SPECIES", 156, 162]]], ["We then describe the methodology and theory for detecting unexpected outbreak signatures in time series sources using filters.", [["filters", "TREATMENT", 118, 125]]], ["We examine the form and function of the filters used for detection.", [["the filters", "TREATMENT", 36, 47]]], ["In the results section, we explore the time series models obtained for each Midwest ED included in our study.", [["our study", "TEST", 99, 108]]], ["We assess these detection methods using a simulated anthrax attack, and we end with a discussion.A chest radiograph model for respiratory-complaints ::: MethodsThe data of interest consist of daily counts of ED visits and chest radiographs taken between January 1st, 2003 and September 9th, 2004, in five metropolitan children's hospitals in the Midwest of the USA (Minneapolis/St. Paul, Milwaukee, Chicago, Akron, and Columbus), supplemented with time series of daily average temperature, obtained from the Average Daily Temperature Archive at The University of Dayton [15].", [["chest", "ANATOMY", 99, 104], ["respiratory", "ANATOMY", 126, 137], ["chest", "ANATOMY", 222, 227], ["anthrax", "DISEASE", 52, 59], ["respiratory-complaints", "DISEASE", 126, 148], ["children", "ORGANISM", 318, 326], ["children", "SPECIES", 318, 326], ["A chest radiograph model", "TEST", 97, 121], ["Methods", "TREATMENT", 153, 160], ["chest radiographs", "TEST", 222, 239], ["chest", "ANATOMY", 99, 104], ["chest", "ANATOMY", 222, 227]]], ["These series are shown in Figure 1.", [["These series", "TEST", 0, 12]]], ["There seems to be strong seasonal component in the chest radiograph and visit series, for all the cities, which is negatively correlated with temperature.", [["chest", "ANATOMY", 51, 56], ["chest", "ORGANISM_SUBDIVISION", 51, 56], ["strong seasonal component", "PROBLEM", 18, 43], ["the chest radiograph", "TEST", 47, 67], ["seems to be", "UNCERTAINTY", 6, 17], ["strong", "OBSERVATION_MODIFIER", 18, 24], ["seasonal", "OBSERVATION_MODIFIER", 25, 33], ["component", "OBSERVATION_MODIFIER", 34, 43], ["chest", "ANATOMY", 51, 56]]], ["Although it could be argued that we do not have enough years of data to prove this empirically, it is expected that a higher number of respiratory complaints is associated with colder temperatures.A chest radiograph model for respiratory-complaints ::: MethodsWe now discuss two aspects of the statistical model for these daily chest radiograph counts: distribution and scale.", [["chest", "ANATOMY", 199, 204], ["respiratory", "ANATOMY", 226, 237], ["chest", "ANATOMY", 328, 333], ["respiratory complaints", "DISEASE", 135, 157], ["respiratory-complaints", "DISEASE", 226, 248], ["respiratory complaints", "PROBLEM", 135, 157], ["colder temperatures", "PROBLEM", 177, 196], ["A chest radiograph model", "TEST", 197, 221], ["these daily chest radiograph counts", "TEST", 316, 351], ["higher", "OBSERVATION_MODIFIER", 118, 124], ["number", "OBSERVATION_MODIFIER", 125, 131], ["chest", "ANATOMY", 199, 204], ["chest", "ANATOMY", 328, 333]]], ["The reasons are: (i) A normal approximation to the Poisson random variable is reasonable when the mean number of radiograph counts is large, as in this study; (ii) Gaussian time series models are easier to fit, diagnose, and interpret; (iii) The theory for filter-based methods commonly used for detecting the outbreak signature in such data is well developed for Gaussian processes.", [["radiograph counts", "TEST", 113, 130], ["this study", "TEST", 147, 157], ["filter-based methods", "TREATMENT", 257, 277], ["normal", "OBSERVATION", 23, 29], ["large", "OBSERVATION_MODIFIER", 134, 139]]], ["In some applications, count data are transformed when Gaussian models are used.", [["count data", "TEST", 22, 32], ["Gaussian models", "TEST", 54, 69]]], ["We use the original scale instead of transforming the data, like other researchers in the area, for ease of interpretation.", [["the original scale", "TREATMENT", 7, 25], ["transforming the data", "TEST", 37, 58]]], ["For the same reason, we do not model the number of chest radiographs per daily ED visits (i.e., the proportion of radiographs).", [["chest", "ANATOMY", 51, 56], ["chest radiographs", "TEST", 51, 68], ["radiographs", "TEST", 114, 125], ["chest", "ANATOMY", 51, 56]]], ["The filter-based theory, allows us to directly assess the effect of additive stochastic outbreaks signatures upon the radiograph series.A chest radiograph model for respiratory-complaints ::: MethodsIn our study, the first ten months of data (Jan to Oct, 2003) were used as the training set, while the remaining ten months (Nov, 2003 to Sep, 2004) were used, as a test dataset, to evaluate the model and detection methods.A chest radiograph model for respiratory-complaints ::: MethodsSince the goal is to predict the number of chest radiographs, for each city we fit a linear time series regression model, using the number of chest radiographs as the response, and the number of visits and temperature as predictor variables.", [["chest", "ANATOMY", 138, 143], ["respiratory", "ANATOMY", 165, 176], ["chest", "ANATOMY", 424, 429], ["respiratory", "ANATOMY", 451, 462], ["chest", "ANATOMY", 528, 533], ["chest", "ANATOMY", 627, 632], ["respiratory-complaints", "DISEASE", 165, 187], ["respiratory-complaints", "DISEASE", 451, 473], ["The filter", "TREATMENT", 0, 10], ["additive stochastic outbreaks signatures", "PROBLEM", 68, 108], ["the radiograph series", "TEST", 114, 135], ["A chest radiograph model", "TEST", 136, 160], ["Methods", "TREATMENT", 192, 199], ["our study", "TEST", 202, 211], ["a test dataset", "TEST", 362, 376], ["A chest radiograph model", "TEST", 422, 446], ["chest radiographs", "TEST", 528, 545], ["chest radiographs", "TEST", 627, 644], ["filter", "OBSERVATION", 4, 10], ["chest", "ANATOMY", 138, 143], ["chest", "ANATOMY", 424, 429], ["chest", "ANATOMY", 528, 533], ["chest", "ANATOMY", 627, 632]]], ["We smooth the temperature series, because we believe that long-range temporal trends are more predictive of chest radiograph counts.", [["chest", "ANATOMY", 108, 113], ["the temperature series", "TEST", 10, 32], ["chest radiograph counts", "TEST", 108, 131], ["chest", "ANATOMY", 108, 113]]], ["Let {Rk,t} denote the number of chest radiographs for the ED in city k (k = 1, 2, ..., 5) on day t and letA chest radiograph model for respiratory-complaints ::: MethodsRk,t = \u03b20,k + \u03b2V,k Vk,t + \u03b2T,kTk,t + Xk,t.A chest radiograph model for respiratory-complaints ::: MethodsHere {Vk,t} are the visit counts for city k and {Tk,t} is the smoothed time series of temperatures for city k, filtered by taking a thirty day moving average to remove intra-month variation.", [["chest", "ANATOMY", 213, 218], ["respiratory", "ANATOMY", 240, 251], ["respiratory-complaints", "DISEASE", 135, 157], ["respiratory-complaints", "DISEASE", 240, 262], ["Let {Rk", "GENE_OR_GENE_PRODUCT", 0, 7], ["t + Xk", "SIMPLE_CHEMICAL", 202, 208], ["chest radiographs", "TEST", 32, 49], ["k", "TEST", 72, 73], ["A chest radiograph model", "TEST", 106, 130], ["MethodsRk", "TEST", 162, 171], ["t", "TEST", 172, 173], ["k", "TEST", 179, 180], ["V", "TEST", 184, 185], ["k Vk", "TEST", 186, 190], ["t", "TEST", 191, 192], ["T", "TEST", 196, 197], ["Tk", "TEST", 199, 201], ["t", "TEST", 202, 203], ["A chest radiograph model", "TEST", 211, 235], ["Methods", "TREATMENT", 267, 274], ["city k", "TEST", 311, 317], ["Tk", "TEST", 323, 325], ["temperatures", "TEST", 360, 372], ["city k", "TEST", 377, 383], ["chest", "ANATOMY", 32, 37], ["chest", "ANATOMY", 108, 113], ["chest", "ANATOMY", 213, 218]]], ["The SARIMA model (defined in the Appendix) allows for simultaneous modeling of dependencies on both the day as well as the weekly seasonal scales.", [["The SARIMA model", "TEST", 0, 16], ["simultaneous modeling of dependencies", "PROBLEM", 54, 91], ["Appendix", "ANATOMY", 33, 41]]], ["To aid in the comparison of the dependencies across cities, the order of the time series model, as determined by choosing the autoregressive (pk and Pk) and moving average orders (qk and Qk), will be the same for each city k.A stochastic model for an anthrax outbreak ::: MethodsWe now propose a simple stochastic model for an inhalational anthrax outbreak, based on the work of Buckeridge, et al. and Brookmeyer et al. [16,17].", [["anthrax", "DISEASE", 251, 258], ["anthrax", "DISEASE", 340, 347], ["MethodsWe", "TREATMENT", 272, 281], ["a simple stochastic model", "TREATMENT", 294, 319], ["an inhalational anthrax outbreak", "PROBLEM", 324, 356]]], ["As proposed by these authors, our model incorporates two elements:A stochastic model for an anthrax outbreak ::: Methods1.", [["anthrax", "DISEASE", 92, 99], ["Methods1", "TREATMENT", 113, 121]]], ["A stochastic model of infection and progression of the disease.A stochastic model for an anthrax outbreak ::: Methods2.", [["infection", "DISEASE", 22, 31], ["anthrax", "DISEASE", 89, 96], ["A stochastic model of infection", "PROBLEM", 0, 31], ["the disease", "PROBLEM", 51, 62], ["Methods2", "TREATMENT", 110, 118], ["stochastic model", "OBSERVATION_MODIFIER", 2, 18], ["infection", "OBSERVATION", 22, 31], ["progression", "OBSERVATION_MODIFIER", 36, 47], ["disease", "OBSERVATION", 55, 62]]], ["A model of health-care-utilization that, on a day-by-day-basis, tracks the behavior of each infected individual.A stochastic model for an anthrax outbreak ::: MethodsAny inhalational anthrax outbreak starts with the dispersion of the anthrax spores.", [["anthrax", "DISEASE", 138, 145], ["anthrax", "DISEASE", 183, 190], ["anthrax", "DISEASE", 234, 241], ["anthrax", "ORGANISM", 234, 241], ["Methods", "TREATMENT", 159, 166], ["Any inhalational anthrax outbreak", "PROBLEM", 166, 199], ["the anthrax spores", "PROBLEM", 230, 248], ["inhalational", "OBSERVATION_MODIFIER", 170, 182], ["anthrax", "OBSERVATION", 183, 190], ["anthrax", "OBSERVATION", 234, 241]]], ["Once spores are inhaled by a subject, in the incubation stage spores either germinate or are cleared out the lung.", [["spores", "ANATOMY", 5, 11], ["lung", "ANATOMY", 109, 113], ["lung", "ORGAN", 109, 113], ["lung", "ANATOMY", 109, 113]]], ["For the spores that germinate during incubation, the later stages of the disease are the prodromal and fulminant stages, followed by death.", [["spores", "ANATOMY", 8, 14], ["death", "DISEASE", 133, 138], ["the spores", "PROBLEM", 4, 14], ["the disease", "PROBLEM", 69, 80], ["the prodromal and fulminant stages", "PROBLEM", 85, 119], ["disease", "OBSERVATION", 73, 80], ["fulminant", "OBSERVATION_MODIFIER", 103, 112]]], ["Buckeridge, et al. [16] model the spread of spores over a grid covering the Norfolk, Virginia region using a Gaussian plume model.", [["a Gaussian plume model", "TREATMENT", 107, 129]]], ["Their model considers the source and strength of the anthrax attack, along with prevalent wind directions.A stochastic model for an anthrax outbreak ::: MethodsInstead of using the region-based approach of Buckeridge, et al., we use the individual-based infection scheme of Brookmeyer, et al. [17].", [["anthrax", "DISEASE", 53, 60], ["anthrax", "DISEASE", 132, 139], ["infection", "DISEASE", 254, 263], ["the anthrax attack", "PROBLEM", 49, 67], ["infection", "OBSERVATION", 254, 263]]], ["Although it is known that anthrax spores can survive for long periods of time in the environment, we consider a small scale scenario.", [["spores", "ANATOMY", 34, 40], ["anthrax", "DISEASE", 26, 33], ["anthrax spores", "PROBLEM", 26, 40], ["a small scale scenario", "TREATMENT", 110, 132]]], ["Since the population of interest is the individuals attending children's emergency departments, we assume an outbreak that affects a fixed number, N say, of children.", [["children", "ORGANISM", 62, 70], ["children", "ORGANISM", 157, 165], ["children", "SPECIES", 62, 70], ["children", "SPECIES", 157, 165]]], ["Brookmeyer, et al. [17] define the infection probability of an individual exposed to inhalational anthrax using a competing risk model, modeling the dynamics of spore clearance and germination.", [["spore", "ANATOMY", 161, 166], ["infection", "DISEASE", 35, 44], ["anthrax", "DISEASE", 98, 105], ["the infection", "PROBLEM", 31, 44], ["inhalational anthrax", "TREATMENT", 85, 105], ["infection", "OBSERVATION", 35, 44]]], ["Let \u03b8 represent the hazard rate per unit time (days, say) that a spore is cleared from the lung and \u03bb be the rate of germination.", [["lung", "ANATOMY", 91, 95], ["Let \u03b8", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 91, 95], ["\u03b8", "DNA", 4, 5], ["lung", "ANATOMY", 91, 95]]], ["Suppose that each individual inhales a dose of D spores.", [["D spores", "SIMPLE_CHEMICAL", 47, 55], ["D spores", "PROBLEM", 47, 55]]], ["Then, the probability that at least one spore germinates is called the attack rate (AR) and is calculated using a Poisson approximation, asA stochastic model for an anthrax outbreak ::: MethodsAR = 1 - e-D\u03bb/(\u03bb+\u03b8).A stochastic model for an anthrax outbreak ::: MethodsFor a given attack rate, the probability that at least one of the D spores germinates within t days is given byA stochastic model for an anthrax outbreak ::: MethodsF(t) = 1 - (1 - AR)(1-exp(-(\u03bb+\u03b8)t)).A stochastic model for an anthrax outbreak ::: MethodsNote that the limit, limt \u2192 \u221e F(t) = AR.", [["anthrax", "DISEASE", 165, 172], ["anthrax", "DISEASE", 239, 246], ["anthrax", "DISEASE", 404, 411], ["anthrax", "DISEASE", 494, 501], ["1 - e-D\u03bb/(\u03bb+\u03b8", "SIMPLE_CHEMICAL", 198, 211], ["1 - AR", "SIMPLE_CHEMICAL", 444, 450], ["a Poisson approximation", "TREATMENT", 112, 135], ["asA stochastic model", "TREATMENT", 137, 157], ["MethodsAR", "TEST", 186, 195], ["Methods", "TREATMENT", 260, 267], ["an anthrax outbreak", "PROBLEM", 401, 420], ["MethodsF", "TEST", 425, 433]]], ["Based on a statistical analysis of an anthrax outbreak that occurred in Sverdlovsk, Russia, Brookmeyer, et al. [17] estimate hazard rates of between 0.05 and 0.11 for \u03b8 (which is compatible with \u03b8 = 0.07 obtained from animal studies for an AR of 0.5).", [["anthrax", "DISEASE", 38, 45], ["a statistical analysis", "TEST", 9, 31], ["an anthrax outbreak", "PROBLEM", 35, 54], ["estimate hazard rates", "TEST", 116, 137], ["animal studies", "TEST", 218, 232], ["an AR", "TEST", 237, 242], ["anthrax", "OBSERVATION", 38, 45]]], ["The value of \u03bb is not estimated in their data analysis \u2013 based on animal studies they found that the rate \u03bb lies between 5 \u00d7 10-7 and 10-5.", [["\u03bb", "PROTEIN", 13, 14], ["The value", "TEST", 0, 9], ["animal studies", "TEST", 66, 80], ["the rate", "TEST", 97, 105]]], ["Buckeridge, et al. [16] propose log normal models for the duration of the prodromal and fulminant stages, based on the 2001 anthrax attack in the United States.", [["anthrax", "DISEASE", 124, 131], ["the prodromal and fulminant stages", "PROBLEM", 70, 104], ["fulminant", "OBSERVATION_MODIFIER", 88, 97]]], ["The median duration of the prodromal stage was 12.18 days, with a dispersion of 1.41, and the median duration of the fulminant stage was 1.5 days with a dispersion again of 1.41.A stochastic model for an anthrax outbreak ::: MethodsNext, we describe a simplified health-utilization model for people entering the ED, based on ideas discussed in [16].", [["anthrax", "DISEASE", 204, 211], ["people", "ORGANISM", 292, 298], ["people", "SPECIES", 292, 298], ["median", "OBSERVATION_MODIFIER", 4, 10], ["fulminant", "OBSERVATION_MODIFIER", 117, 126]]], ["During the incubation stage, we assume that no infected people enter the ED.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62], ["no", "UNCERTAINTY", 44, 46], ["infected", "OBSERVATION", 47, 55]]], ["Non-infected people that enter the ED for other chest problems are part of the background data.", [["chest", "ANATOMY", 48, 53], ["people", "ORGANISM", 13, 19], ["chest", "ORGANISM_SUBDIVISION", 48, 53], ["people", "SPECIES", 13, 19], ["other chest problems", "PROBLEM", 42, 62], ["the background data", "TEST", 75, 94], ["chest", "ANATOMY", 48, 53]]], ["During the prodromal and fulminant stages we assume a simple Markov model of utilization: each infected subject is a Bernoulli event, independent across days.", [["the prodromal and fulminant stages", "PROBLEM", 7, 41], ["a Bernoulli event", "PROBLEM", 115, 132], ["fulminant", "OBSERVATION_MODIFIER", 25, 34], ["infected", "OBSERVATION", 95, 103], ["Bernoulli event", "OBSERVATION", 117, 132]]], ["At the prodromal stage people enter the ED with probability Pd on a weekday and Pw on weekends.", [["Pd", "CHEMICAL", 60, 62], ["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29]]], ["At the fulminant stage the probability of entering the ED, Pf say, is larger than the probabilities in the prodromal stage.", [["fulminant", "OBSERVATION_MODIFIER", 7, 16], ["stage", "OBSERVATION", 17, 22], ["larger", "OBSERVATION_MODIFIER", 70, 76]]], ["The reason is that at the fulminant stage, the anthrax symptoms are similar to those of a heart attack and therefore people enter the ED with higher probability.", [["heart", "ANATOMY", 90, 95], ["anthrax", "DISEASE", 47, 54], ["heart attack", "DISEASE", 90, 102], ["heart", "ORGAN", 90, 95], ["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123], ["the fulminant stage", "PROBLEM", 22, 41], ["the anthrax symptoms", "PROBLEM", 43, 63], ["a heart attack", "PROBLEM", 88, 102], ["heart", "ANATOMY", 90, 95], ["attack", "OBSERVATION", 96, 102]]], ["We suppose that a small percentage of people in the prodromal or fulminant stages are misdiagnosed and thus need to re-enter the system.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["fulminant stages", "PROBLEM", 65, 81], ["small", "OBSERVATION_MODIFIER", 18, 23], ["percentage", "OBSERVATION_MODIFIER", 24, 34], ["fulminant", "OBSERVATION_MODIFIER", 65, 74]]], ["Also, we assume that people can potentially be misdiagnosed a maximum of two times during the same attack (10% in the first visit and 5% in the second visit).", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27]]], ["The probabilities of entering the ED after being misdiagnosed are increased by an additive factor, C, for every additional entry.", [["increased", "OBSERVATION_MODIFIER", 66, 75]]], ["The health-utilization model could easily be extended to include, e.g., varying probabilities of entering the ED by stage/time, and/or more advanced ways to exit the system.Filter-based outbreak signature detection ::: MethodsThe main idea of filter-based methods is to create a detection process {Dk,t}, for each time point t, which is a weighted average of the diagnostic or syndromic data to be used for the detection of an outbreak signature.", [["Filter", "TEST", 173, 179], ["Methods", "TREATMENT", 219, 226], ["a detection process", "TEST", 277, 296], ["Dk", "PROBLEM", 298, 300], ["syndromic data", "TEST", 377, 391], ["the detection", "TEST", 407, 420], ["an outbreak signature", "PROBLEM", 424, 445], ["main", "OBSERVATION_MODIFIER", 230, 234], ["filter", "OBSERVATION", 243, 249]]], ["The weights that appear in {Dk,t} are defined using the form of the time series model and a filter, {al} say.", [["The weights", "TEST", 0, 11], ["a filter", "TREATMENT", 90, 98]]], ["Extreme positive values of the detection process at a time point indicate a possible outbreak signature.", [["Extreme positive values of the detection process", "PROBLEM", 0, 48], ["outbreak signature", "PROBLEM", 85, 103], ["positive values", "OBSERVATION_MODIFIER", 8, 23], ["possible", "UNCERTAINTY", 76, 84], ["outbreak signature", "OBSERVATION", 85, 103]]], ["Naturally, the form of the filter has an important effect in the detection process.Filter-based outbreak signature detection ::: MethodsA common parametric approach that we follow in this study is to first obtain the residual process by subtracting off the non-stationary part of the model (i.e., the effect of the covariates).", [["the filter", "TREATMENT", 23, 33], ["Filter", "TEST", 83, 89], ["this study", "TEST", 183, 193], ["filter", "OBSERVATION", 27, 33], ["important", "OBSERVATION_MODIFIER", 41, 50], ["effect", "OBSERVATION_MODIFIER", 51, 57]]], ["We then define the filter {ck,j}, that first decorrelates (whitens) this residual process using the one-step-ahead prediction errors and second filters this whitened series using {al} to yield the detection process {Dk,t}.", [["{al}", "CHEMICAL", 179, 183], ["{al}", "SIMPLE_CHEMICAL", 179, 183], ["{al}", "PROTEIN", 179, 183], ["the filter {ck", "TREATMENT", 15, 29], ["this residual process", "PROBLEM", 68, 89], ["filter", "OBSERVATION", 19, 25]]], ["Commonly used examples of the filter {al} include the differencing, moving average, or exponential filter.", [["the filter", "TREATMENT", 26, 36], ["exponential filter", "TREATMENT", 87, 105], ["filter", "OBSERVATION", 30, 36], ["exponential filter", "OBSERVATION", 87, 105]]], ["For a fixed value of \u03b1, let 1 - \u03b1 denote the specificity (the probability of no detection, when there is no actual outbreak signature).", [["let 1 - \u03b1", "GENE_OR_GENE_PRODUCT", 24, 33], ["a fixed value", "TEST", 4, 17]]], ["We declare evidence of an outbreak signature at time t if the detection process at that time point, Dk,t, exceeds a threshold \u03c4k,\u03b1, calculated using the data or the process.", [["an outbreak signature", "PROBLEM", 23, 44], ["evidence of", "UNCERTAINTY", 11, 22]]], ["Further details are given in the Appendix.Filter-based outbreak signature detection ::: MethodsTo understand the detection process {Dk,t} for different choice of filters, {al}, one should consider the filter involved in the calculation of {Dk,t} using the residual series, {Xk,t}.", [["{al}", "SIMPLE_CHEMICAL", 171, 175], ["Filter", "TEST", 42, 48], ["filters", "TREATMENT", 162, 169], ["the filter", "TREATMENT", 197, 207], ["the residual series", "TEST", 252, 271], ["Appendix", "ANATOMY", 33, 41], ["filter", "OBSERVATION", 201, 207]]], ["Using the results from the Appendix, at time point t,Filter-based outbreak signature detection ::: MethodsDk,t=\u2211h=0L\u22121ah\u2211j=0mck,jXk,t\u2212h\u2212j=\u2211l=0m+L\u22121fk,lXk,t\u2212l.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=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@6D11@Filter-based outbreak signature detection ::: MethodsIn this expression, {fk,l} is the filter defined by the convolution of the filters {al} and {ck,l}.", [["{al}", "CHEMICAL", 1123, 1127], ["{fk", "GENE_OR_GENE_PRODUCT", 1060, 1063], ["{fk", "PROTEIN", 1060, 1063], ["{al}", "PROTEIN", 1123, 1127], ["{ck", "PROTEIN", 1132, 1135], ["Methods", "TREATMENT", 1033, 1040], ["the filter", "TREATMENT", 1070, 1080], ["the filters", "TREATMENT", 1111, 1122], ["Appendix", "ANATOMY", 27, 35]]], ["Hence, we conclude that the detection of outbreaks not only depends on the choice of filter, but on the statistical properties of the time series model which defines {ck,l}.", [["{ck", "GENE_OR_GENE_PRODUCT", 166, 169], ["{ck", "PROTEIN", 166, 169], ["outbreaks", "PROBLEM", 41, 50], ["filter", "TREATMENT", 85, 91]]], ["We will now focus on the effect of {al} (we will investigate the effect of changing the time series model in the Simulations section).", [["{al}", "SIMPLE_CHEMICAL", 35, 39], ["the Simulations section", "TREATMENT", 109, 132]]], ["As Reis, et al did [2], we examine four different filters, {al}, each of which is a form of difference filter.", [["{al}", "SIMPLE_CHEMICAL", 59, 63], ["different filters", "TREATMENT", 40, 57], ["difference filter", "TREATMENT", 92, 109], ["difference filter", "OBSERVATION", 92, 109]]], ["Each filter is an average of a number of days close to the time point minus a weighted average of the remaining values in the past:Filter-based outbreak signature detection ::: Methods1.", [["Each filter", "TREATMENT", 0, 11], ["Methods1", "TREATMENT", 177, 185], ["filter", "OBSERVATION", 5, 11], ["average", "OBSERVATION_MODIFIER", 18, 25]]], ["1-day filter: {al} = (1, 0, 0, 0, 0, 0, 0);Filter-based outbreak signature detection ::: Methods2.", [["Filter", "TEST", 43, 49], ["Methods2", "PROBLEM", 89, 97]]], ["7-day filter: {al} = (1, 1, 1, 1, 1, 1, 1)/7;Filter-based outbreak signature detection ::: Methods3.", [["Filter", "TEST", 45, 51], ["Methods3", "PROBLEM", 91, 99]]], ["Linear filter: {al} = (7, 6, 5, 4, 3, 2, 1)/28;Filter-based outbreak signature detection ::: Methods4.", [["Linear filter", "TEST", 0, 13], ["Filter", "TEST", 47, 53], ["Methods4", "TREATMENT", 93, 101], ["filter", "OBSERVATION", 7, 13]]], ["Exponential filter: {al} = (64, 32, 16, 8, 4, 2, 1)/127.Filter-based outbreak signature detection ::: MethodsThe filters {fk,l} for the detection processes vary according to the amount of autocorrelation within each time series.", [["Exponential filter", "TEST", 0, 18], ["Filter", "TEST", 56, 62], ["Methods", "TREATMENT", 102, 109], ["The filters", "TREATMENT", 109, 120], ["filter", "OBSERVATION", 12, 18]]], ["As an illustration, Figure 2 displays the {fk,l} filter obtained when m = 28 for each of the four {al} filters defined above, using a SARIMA model based on the Akron data (details of the SARIMA model are shown in the Results section).Filter-based outbreak signature detection ::: Methods1.", [["a SARIMA model", "TREATMENT", 132, 146], ["the Akron data", "TEST", 156, 170], ["Filter", "TREATMENT", 234, 240], ["outbreak signature", "OBSERVATION", 247, 265]]], ["When {al} is a 1-day filter, the {fk,l} filter consists of the current time point of the process minus a smaller weighted decaying average of the past values.", [["{al}", "CHEMICAL", 5, 9], ["{al}", "PROTEIN", 5, 9], ["{fk", "PROTEIN", 33, 36], ["l} filter", "TREATMENT", 37, 46], ["filter", "OBSERVATION", 40, 46], ["smaller", "OBSERVATION_MODIFIER", 105, 112]]], ["The weekly seasonal terms in the SARIMA model are reflected in this filter.Filter-based outbreak signature detection ::: Methods2.", [["the SARIMA model", "TREATMENT", 29, 45], ["this filter", "TREATMENT", 63, 74], ["Filter", "TREATMENT", 75, 81], ["Methods2", "PROBLEM", 121, 129], ["filter", "OBSERVATION", 68, 74], ["outbreak signature", "OBSERVATION", 88, 106]]], ["When {al} is the 7-day filter, {fk,l} is a weighted average of the last 7 days (with most weight on the current day), minus a weighted decaying average of the remaining past days.", [["{al}", "CHEMICAL", 5, 9], ["{al}", "SIMPLE_CHEMICAL", 5, 9]]], ["The weekly seasonal terms are not as strong, compared to the filter that is the convolution of the 1-day filter.Filter-based outbreak signature detection ::: Methods3.", [["the filter", "TREATMENT", 57, 67], ["the 1-day filter", "TREATMENT", 95, 111], ["Filter", "TREATMENT", 112, 118], ["Methods3", "PROBLEM", 158, 166], ["filter", "OBSERVATION", 61, 67], ["outbreak signature", "OBSERVATION", 125, 143]]], ["When {al} is the linear filter, {fk,l} is an average of 6 days in the past.", [["{al}", "CHEMICAL", 5, 9], ["{al}", "SIMPLE_CHEMICAL", 5, 9], ["{al}", "PROTEIN", 5, 9], ["the linear filter", "TREATMENT", 13, 30]]], ["Most of the weight from the second average comes from around days 8\u201310 in the past.Filter-based outbreak signature detection ::: Methods4.", [["the weight", "TEST", 8, 18], ["Filter", "TREATMENT", 83, 89], ["Methods4", "TREATMENT", 129, 137], ["outbreak signature", "OBSERVATION", 96, 114]]], ["When {al} is the exponential filter, {fk,l} is a combination of the 4 most recent days (mostly the current day, very little by the fourth day).", [["{al}", "CHEMICAL", 5, 9], ["{al}", "SIMPLE_CHEMICAL", 5, 9], ["{al}", "PROTEIN", 5, 9], ["the exponential filter", "TREATMENT", 13, 35]]], ["We subtract an average of the past values (mostly days 6 \u2013 11 in the past).Filter-based outbreak signature detection ::: MethodsIn Figure 2, the numbers within the parentheses at the top of each panel show the value of the threshold \u03c4k,0.03, calculated using the normal approximation used in the Appendix (equation 10), assuming an innovation variance of \u03c3k2MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacqWFdpWCdaqhaaWcbaGaem4AaSgabaGaeGOmaidaaaaa@30F4@ = 1 for the process.", [["Filter", "TEST", 75, 81], ["an innovation variance of \u03c3k2MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacqWFdpWCdaqhaaWcbaGaem4AaSgabaGaeGOmaidaaaaa@30F4@", "TREATMENT", 329, 648], ["average", "OBSERVATION_MODIFIER", 15, 22], ["normal", "OBSERVATION", 263, 269], ["Appendix", "ANATOMY", 296, 304]]], ["We examine the effects upon the sensitivity, specificity, and timeliness to detect anthrax outbreaks in the simulations that we present later.Time series modeling ::: ResultsWe fit the chest radiograph model given by (1) to the first ten months of data for each ED in city k.", [["chest", "ANATOMY", 185, 190], ["anthrax", "DISEASE", 83, 90], ["the sensitivity", "TEST", 28, 43], ["anthrax", "PROBLEM", 83, 90], ["the chest radiograph model", "TEST", 181, 207], ["chest", "ANATOMY", 185, 190]]], ["We selected the order of the SARIMA model for the time series errors, {Xk,t}, as defined by (4) in the Appendix using standard identification techniques based on the sample autocorrelation and partial autocorrelation (e.g., [18]).", [["the SARIMA model", "TREATMENT", 25, 41], ["the sample autocorrelation", "TEST", 162, 188], ["Appendix", "ANATOMY", 103, 111]]], ["The orders pk = 1 and qk = 1, correspond to a single autoregressive and moving average term on the daily scale, equivalent to observing an autoregressive process of first order with measurement error ([19], Exercise 2.9).", [["The orders pk", "TEST", 0, 13], ["the daily scale", "TREATMENT", 95, 110], ["Exercise", "TEST", 207, 215]]], ["With a seasonal period of seven days (s = 7), we set Pk = 1 and Qk = 1, so that the random seasonal component is a combination of an autoregressive and moving average term, each of first order over a period of seven days.", [["Pk", "TEST", 53, 55], ["the random seasonal component", "PROBLEM", 80, 109]]], ["The seasonal component of the time series model corresponds to an evolution of a first order autoregressive process with a measurement error over the weeks.Time series modeling ::: ResultsThe model fit for the data in each city was assessed using diagnostic plots (time series plots, normal quantile plots, autocorrelation and partial autocorrelation plots, and the spectral estimates) of the estimated innovations of the time series component.", [["diagnostic plots", "TEST", 247, 263], ["partial autocorrelation plots", "TEST", 327, 356], ["the spectral estimates", "TEST", 362, 384], ["seasonal", "OBSERVATION_MODIFIER", 4, 12], ["component", "OBSERVATION_MODIFIER", 13, 22]]], ["Figure 3 shows some of these diagnostic plots for the Akron data (the residuals plots for the other cities were similar).", [["the Akron data", "TEST", 50, 64], ["the residuals plots", "PROBLEM", 66, 85]]], ["Except for a few extremely positive values, the estimated time series looks stationary.", [["a few extremely positive values", "PROBLEM", 11, 42], ["positive", "OBSERVATION", 27, 35]]], ["The normal approximation is good, as evidenced by the straight line on the normal quantile plot.", [["normal", "OBSERVATION", 4, 10], ["approximation", "OBSERVATION_MODIFIER", 11, 24], ["good", "OBSERVATION_MODIFIER", 28, 32], ["straight line", "OBSERVATION", 54, 67]]], ["The plots of the sample autocorrelation and partial autocorrelations functions of the time series innovations lie inside the dotted confidence bounds for a white noise process (i.e., are samples of uncorrelated time series errors).Time series modeling ::: ResultsThe parameter estimates for each city are summarized in Table 1.", [["the sample autocorrelation", "TEST", 13, 39], ["a white noise process", "PROBLEM", 154, 175]]], ["We note some homogeneities in the results across the EDs for each city.", [["some homogeneities", "PROBLEM", 8, 26]]], ["The intercept of the model, \u03b2^0,kMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFYoGygaqcamaaBaaaleaacqaIWaamcqGGSaalcqWGRbWAaeqaaaaa@31BD@, is positive for all cities, being largest in magnitude for Columbus, and smallest in magnitude for Chicago.", [["\u03b2^0,kMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFYoGygaqcamaaBaaaleaacqaIWaamcqGGSaalcqWGRbWAaeqaaaaa@31BD@", "SIMPLE_CHEMICAL", 28, 335], ["largest", "OBSERVATION_MODIFIER", 371, 378], ["smallest", "OBSERVATION_MODIFIER", 410, 418]]], ["The parameter estimate, \u03b2^V,kMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFYoGygaqcamaaBaaaleaacqWGwbGvcqGGSaalcqWGRbWAaeqaaaaa@3204@, relating visit counts and the radiograph counts is significantly different from zero, and positive, indicating, as one would expect, that a large number of ED visits are associated with a larger number of radiographs.", [["The parameter estimate", "TEST", 0, 22], ["the radiograph counts", "TEST", 359, 380], ["radiographs", "TEST", 538, 549], ["large", "OBSERVATION_MODIFIER", 473, 478], ["number", "OBSERVATION_MODIFIER", 479, 485]]], ["The parameter estimate, \u03b2^T,kMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFYoGygaqcamaaBaaaleaacqWGubavcqGGSaalcqWGRbWAaeqaaaaa@3200@, relating the smooth temperature and radiograph counts is negative, indicating a significant negative association between these two quantities across all cities.", [["The parameter estimate", "TEST", 0, 22], ["the smooth temperature", "TEST", 342, 364], ["radiograph counts", "TEST", 369, 386], ["significant", "OBSERVATION_MODIFIER", 413, 424], ["negative", "OBSERVATION", 425, 433]]], ["The values of the autoregressive and moving average term on the daily scale (\u03c6^k,1MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFgpGzgaqcamaaBaaaleaacqWGRbWAcqGGSaalcqaIXaqmaeqaaaaa@31D7@ and \u03b8^k,1MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWF4oqCgaqcamaaBaaaleaacqWGRbWAcqGGSaalcqaIXaqmaeqaaaaa@31D4@, respectively) are similar in value across all cities.", [["The values", "TEST", 0, 10], ["the daily scale (\u03c6^k,1MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFgpGzgaqcamaaBaaaleaacqWGRbWAcqGGSaalcqaIXaqmaeqaaaaa@31D7@ and \u03b8^k,1MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWF4oqCgaqcamaaBaaaleaacqWGRbWAcqGGSaalcqaIXaqmaeqaaaaa@31D4@", "TREATMENT", 60, 696]]], ["By looking at the pointwise 95% confidence intervals for these two parameters, we conclude that there is no significant weekly variation in the Chicago series.", [["these two parameters", "TEST", 57, 77], ["no", "UNCERTAINTY", 105, 107], ["significant", "OBSERVATION_MODIFIER", 108, 119]]], ["As expected the values of \u03c3^k2MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFdpWCgaqcamaaDaaaleaacqWGRbWAaeaacqaIYaGmaaaaaa@3104@, the estimated variance of the time series innovations, differ by city.Simulations ::: ResultsIn the simulations described in this section we used the following experimental design.", [["the values", "TEST", 12, 22]]], ["We used the second half of the data from November 1st, 2003 onwards and added outbreak-related counts to test for the detection of an outbreak signature.Simulations ::: ResultsWe simulated an outbreak, as previously described, 500 times on 500 individuals using an attack rate of 0.5.", [["the detection", "TEST", 114, 127], ["an outbreak signature", "PROBLEM", 131, 152], ["an attack rate", "TEST", 262, 276]]], ["The first day of the outbreak was randomly picked from a uniform distribution in the period December 5th, 2003 to June 22nd, 2004.", [["uniform", "OBSERVATION_MODIFIER", 57, 64], ["distribution", "OBSERVATION_MODIFIER", 65, 77]]], ["(Making the earliest date later than November 1st, 2003, guarantees enough data for the filter-based methods to work with a prediction window of m = 28 days).", [["the filter", "TREATMENT", 84, 94]]], ["In the absence of other information (e.g., Buckeridge, et al. [16] do not report their probabilities) we set the ED utilization probabilities to be: Pd = 0.25 (weekday entry probability at the prodromal stage); Pw = 0.4 (weekend entry probability at the prodromal stage) and Pf = 0.80 (entry probability at the fulminant stage).", [["Pd", "CHEMICAL", 149, 151], ["Pd", "TEST", 149, 151], ["Pw", "TEST", 211, 213], ["Pf", "TEST", 275, 277], ["fulminant stage", "OBSERVATION_MODIFIER", 311, 326]]], ["The daily drop-out probability was set at 0.05.", [["The daily drop", "TEST", 0, 14]]], ["We assumed that with probability 0.9, the infected persons that enter the ED for the first time during a given outbreak receive a chest radiograph, i.e., 10% of the infected persons are misdiagnosed at the first visit.", [["chest", "ANATOMY", 130, 135], ["persons", "ORGANISM", 51, 58], ["persons", "ORGANISM", 174, 181], ["persons", "SPECIES", 51, 58], ["persons", "SPECIES", 174, 181], ["a chest radiograph", "TEST", 128, 146], ["infected", "OBSERVATION", 42, 50], ["chest", "ANATOMY", 130, 135]]], ["In a subsequent visit, 5% of the infected persons that re-enter the ED are misdiagnosed.", [["persons", "ORGANISM", 42, 49], ["persons", "SPECIES", 42, 49]]], ["We added the counts from the ED visits and subsequent number of chest radiographs generated from the healthcare utilization model on each day during the outbreak period.", [["chest", "ANATOMY", 64, 69], ["chest radiographs", "TEST", 64, 81], ["chest", "ANATOMY", 64, 69]]], ["Let {Ok,t} denote the number of chest radiographs attributable to the anthrax attack on day t.", [["chest", "ANATOMY", 32, 37], ["anthrax", "DISEASE", 70, 77], ["Let {Ok", "GENE_OR_GENE_PRODUCT", 0, 7], ["chest radiographs", "TEST", 32, 49], ["the anthrax attack", "PROBLEM", 66, 84], ["chest", "ANATOMY", 32, 37]]], ["Figure 4 shows a plot of the 0.025, 0.5 (i.e., median), and 0.975 quantiles calculated over the 500 simulated realizations for each day t.", [["a plot", "TEST", 15, 21]]], ["Examining the progression of the quantiles over time allows us to explore the center and tails of the extra radiograph count distribution.", [["the extra radiograph count distribution", "TEST", 98, 137], ["progression", "OBSERVATION_MODIFIER", 14, 25], ["tails", "ANATOMY_MODIFIER", 89, 94]]], ["The counts increase rapidly in the first week, then stay fairly constant (except for the spikes), for a week and then slowly drop to zero after the second week.", [["The counts", "TEST", 0, 10], ["counts", "OBSERVATION_MODIFIER", 4, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["rapidly", "OBSERVATION_MODIFIER", 20, 27]]], ["The small spikes are due to the different probabilities of entry in the prodromal stage.", [["The small spikes", "PROBLEM", 0, 16], ["small", "OBSERVATION_MODIFIER", 4, 9], ["spikes", "OBSERVATION", 10, 16], ["entry", "OBSERVATION_MODIFIER", 59, 64]]], ["Although the shapes at each quantile are similar, the magnitude and duration of the extra radiographs counts differ.", [["the extra radiographs counts", "TEST", 80, 108], ["shapes", "OBSERVATION_MODIFIER", 13, 19], ["similar", "OBSERVATION_MODIFIER", 41, 48]]], ["The counts drop to zero at different time points for the different quantiles.", [["The counts", "TEST", 0, 10], ["counts", "OBSERVATION_MODIFIER", 4, 10], ["drop", "OBSERVATION_MODIFIER", 11, 15]]], ["These patterns in the observed time-varying distribution of the outbreak signature are a strong motivation to not use deterministic outbreak patterns, as used by some authors, since deterministic outbreak patterns do not give a realistic assessment of detection methods.Simulations ::: ResultsWe declare that there is evidence of an outbreak signature in the radiograph data at time t if the outbreak process Dk,t, defined by (2), exceeds a given threshold, \u03c4k,\u03b1.", [["a realistic assessment", "TEST", 226, 248], ["an outbreak signature", "PROBLEM", 330, 351], ["the radiograph data", "TEST", 355, 374], ["varying", "OBSERVATION_MODIFIER", 36, 43], ["distribution", "OBSERVATION_MODIFIER", 44, 56], ["evidence of", "UNCERTAINTY", 318, 329]]], ["Suppose that {Yk,t} is the process defined as the sum of {Ok,t}, the extra radiograph counts attributable to the outbreak, and the radiograph process {Rk,t} that follows model (1).", [["the extra radiograph counts", "TEST", 65, 92], ["the outbreak", "PROBLEM", 109, 121], ["the radiograph process", "TEST", 127, 149]]], ["Removing the non-stationary part due to the estimated effect of the covariates yieldsSimulations ::: ResultsWk,t\u2261Yk,t\u2212(\u03b2V,kVk,t+\u03b2^T,kTk,t)\u2248Ok,t+Xk,t.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGxbWvdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabggMi6kabdMfaznaaBaaaleaacqWGRbWAcqGGSaalcqWG0baDaeqaaOGaeyOeI0IaeiikaGccciGaf8NSdiMbaKaadaWgaaWcbaGaeGimaaJaeiilaWIaem4AaSgabeaakiabgUcaRiqb=j7aIzaajaWaaSbaaSqaaiabdAfawjabcYcaSiabdUgaRbqabaGccqWGwbGvdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabgUcaRiqb=j7aIzaajaWaaSbaaSqaaiabdsfaujabcYcaSiabdUgaRbqabaGccqWGubavdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabcMcaPiabgIKi7kabd+eapnaaBaaaleaacqWGRbWAcqGGSaalcqWG0baDaeqaaOGaey4kaSIaemiwaG1aaSbaaSqaaiabdUgaRjabcYcaSiabdsha0bqabaGccqGGUaGlaaa@64AE@Simulations ::: ResultsBy applying the filter to this series we obtain the detection process that we would observe in the presence of extra counts attributable to an outbreak:Simulations ::: Results\u2211l=0m+L\u22121fk,lWk,t\u2212l\u2248\u2211l=0m+L\u22121fk,lOk,t\u2212l+\u2211l=0m+L\u22121fk,lXk,t\u2212l.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=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@7644@Simulations ::: ResultsTo examine the effect of the filter upon the outbreak signature we examine the standardized quantitySimulations ::: Resultsgk,t=\u2211l=0m+L\u22121fk,lOk,t\u2212l/\u03c4k,\u03b1MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGNbWzdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabg2da9maaqahabaGaemOzay2aaSbaaSqaaiabdUgaRjabcYcaSiabdYgaSbqabaGccqWGpbWtdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqNaeyOeI0IaemiBaWgabeaakiabc+caVGGaciab=r8a0naaBaaaleaacqWGRbWAcqGGSaalcqWFXoqyaeqaaaqaaiabdYgaSjabg2da9iabicdaWaqaaiabd2gaTjabgUcaRiabdYeamjabgkHiTiabigdaXaqdcqGHris5aaaa@50FB@Simulations ::: Resultsfor the filters that we defined previously.", [["lWk", "GENE_OR_GENE_PRODUCT", 1140, 1143], ["t\u2212l\u2248\u2211l=0m+L\u22121fk", "GENE_OR_GENE_PRODUCT", 1144, 1159], ["lWk", "PROTEIN", 1140, 1143], ["t\u2212l\u2248\u2211l=0m+L\u22121fk", "PROTEIN", 1144, 1159], ["Simulations", "TEST", 85, 96], ["ResultsWk", "TEST", 101, 110], ["V", "TEST", 120, 121], ["Vk", "TEST", 123, 125], ["t", "TEST", 126, 127], ["T", "TEST", 130, 131], ["Tk", "TEST", 133, 135], ["t", "TEST", 136, 137], ["the filter", "TREATMENT", 965, 975], ["extra counts", "PROBLEM", 1064, 1076], ["Results\u2211l=", "TEST", 1121, 1131], ["the filter", "TREATMENT", 2129, 2139], ["the filters", "TREATMENT", 2853, 2864], ["filter", "OBSERVATION", 2133, 2139]]], ["Then, as shown in the Appendix, the threshold, \u03c4k,\u03b1, is chosen by solving P(Dk,t > \u03c4k,\u03b1) = \u03b1 for \u03c4k,\u03b1.", [["\u03c4k", "PROTEIN", 97, 99], ["Dk", "TEST", 76, 78], ["t", "TEST", 79, 80], ["Appendix", "ANATOMY", 22, 30]]], ["There were some differences between the values of \u03c4k,\u03b1 for the two methods in the simulations we studied.", [["some", "OBSERVATION_MODIFIER", 11, 15], ["differences", "OBSERVATION_MODIFIER", 16, 27]]], ["Scaling gk,t by \u03c4k,0.03 and using the same simulated radiograph realizations due to the outbreak, allow us to compare the filtered signals consistently across filters.Simulations ::: ResultsThe filtered series will be different for each simulated outbreak pattern realization.", [["the same simulated radiograph realizations", "TEST", 34, 76]]], ["Just as in Figure 4 with the radiograph series, we calculate the 0.025, 0.5 (median), and 0.975 quantiles of the filtered radiograph series on each day t, based on the model fit to the Akron ED series.", [["the radiograph series", "TEST", 25, 46], ["the filtered radiograph series", "TEST", 109, 139]]], ["Figure 5 shows the time-varying quantiles for each of the four filters.", [["the four filters", "TREATMENT", 54, 70]]], ["Relative to the no-outbreak situation, positive values denote those time points for which there would be a greater chance of setting off a detection.", [["positive values", "PROBLEM", 39, 54]]], ["Except for the 0.975 quantile of the 1-day filter, each quantile of the filtered signal drops below zero for a period, and stabilizes at zero after that.Simulations ::: ResultsThere are some similarities in the shapes of the three quantiles presented in Figures 4 and 5.", [["the 1-day filter", "TREATMENT", 33, 49], ["shapes", "OBSERVATION_MODIFIER", 211, 217]]], ["Namely, the filtered signals increase over the first week, and then slowly decrease.", [["increase", "OBSERVATION_MODIFIER", 29, 37]]], ["The spikes in the distributions of the original signal are preserved for the 1-day filter, smoothed out for the 7-day filter, and partial smoothed over for the linear and exponential filters.", [["The spikes", "PROBLEM", 0, 10], ["the 1-day filter", "TREATMENT", 73, 89], ["the 7-day filter", "TREATMENT", 108, 124], ["the linear and exponential filters", "TREATMENT", 156, 190], ["spikes", "OBSERVATION_MODIFIER", 4, 10], ["partial", "OBSERVATION_MODIFIER", 130, 137], ["smoothed", "OBSERVATION_MODIFIER", 138, 146], ["exponential filters", "OBSERVATION", 171, 190]]], ["Smoothing out the spikes tends to lead more sustained peaks (i.e., wider periods of higher sensitivity).", [["Smoothing out the spikes", "PROBLEM", 0, 24], ["spikes", "OBSERVATION_MODIFIER", 18, 24], ["peaks", "OBSERVATION_MODIFIER", 54, 59]]], ["The power of detection is smaller for the 1-day and 7-day than the linear and the exponential (as witnessed by smaller maximum heights in each of these stwo curves).", [["these stwo curves", "TEST", 146, 163], ["power", "OBSERVATION_MODIFIER", 4, 9], ["smaller", "OBSERVATION_MODIFIER", 26, 33], ["linear", "OBSERVATION_MODIFIER", 67, 73], ["exponential", "OBSERVATION_MODIFIER", 82, 93], ["smaller", "OBSERVATION_MODIFIER", 111, 118], ["maximum", "OBSERVATION_MODIFIER", 119, 126], ["heights", "OBSERVATION_MODIFIER", 127, 134]]], ["For all filters, a drop below zero occurs immediately after the peaks; the counts go slowly back to zero.", [["all filters", "TREATMENT", 4, 15], ["the peaks", "PROBLEM", 60, 69], ["the counts", "TEST", 71, 81], ["filters", "OBSERVATION", 8, 15]]], ["Periods for which the filtered signals are below zero inhibit detection and thus can mislead the prediction of the end of the outbreak signature.Simulations ::: ResultsWe calculated the proportion of true non-detects in the absence of an outbreak signature, based on the test data (the specificity), as well as the proportion of true detects during the outbreak (the sensitivity) averaging over the 500 simulated anthrax outbreaks, for each filter and city.", [["anthrax", "DISEASE", 413, 420], ["an outbreak signature", "PROBLEM", 235, 256], ["the test data", "TEST", 267, 280], ["each filter", "TREATMENT", 436, 447]]], ["We calculated the actual specificity and sensitivity using the test data, for values of \u03b1, in the range 0.01 to 0.10 in steps of 0.005.", [["the test data", "TEST", 59, 72], ["values", "TEST", 78, 84]]], ["Figure 6 displays the difference of actual specificity (calculated using the training data) and the nominal specificity (predetermined 1 - \u03b1) for different values of \u03b1.", [["the training data", "TEST", 73, 90], ["the nominal specificity", "TEST", 96, 119]]], ["Curves above or below the horizontal dotted line at zero, indicate departures from the nominal \u03b1.", [["Curves", "TEST", 0, 6]]], ["The Chicago series preserves the nominal value of the specificity (curves are clustered around the zero line).", [["zero line", "OBSERVATION", 99, 108]]], ["For the Minneapolis-St.Paul series the actual specificity is biased downwards, and for the other cities, the departure from the nominal value changes as \u03b1 increases.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 153, 154], ["\u03b1", "PROTEIN", 153, 154], ["downwards", "OBSERVATION_MODIFIER", 68, 77]]], ["The choice of filter affected the calibration.", [["filter", "TREATMENT", 14, 20], ["the calibration", "TREATMENT", 30, 45], ["filter", "OBSERVATION", 14, 20]]], ["To understand the tradeoff between the specificity and the sensitivity we show the receiver operator characteristic (ROC) curves, for each city, in Figure 7.", [["the sensitivity", "TEST", 55, 70]]], ["For all cities, the 1-day filter has the poorest sensitivity.", [["the 1-day filter", "TREATMENT", 16, 32]]], ["Except for Milwaukee, the 7-day filter tends to have higher sensitivities compared to the other filters, but also tends to have the poorest specificity.", [["the 7-day filter", "TREATMENT", 22, 38], ["higher sensitivities", "PROBLEM", 53, 73]]], ["The exponential filter balances the specificity-sensitivity tradeoff.Simulations ::: ResultsTables 2 and 3 display, respectively, the median and maximum detection times for each filter and city for our model.", [["The exponential filter", "TREATMENT", 0, 22], ["each filter", "TREATMENT", 173, 184], ["exponential", "OBSERVATION_MODIFIER", 4, 15], ["filter", "OBSERVATION", 16, 22]]], ["The 1-day filter performed poorly.", [["The 1-day filter", "TREATMENT", 0, 16]]], ["The other filters are more comparable.", [["The other filters", "TREATMENT", 0, 17], ["filters", "OBSERVATION", 10, 17], ["more comparable", "OBSERVATION_MODIFIER", 22, 37]]], ["We observed (results not shown) that the time to detection increases if the attack rate is reduced and also if the probabilities of entering the ED is delayed.Simulations ::: ResultsWe now compare the performance of our model, as defined by equation (1), with three other models, in order to investigate the effect of different covariates and time series components upon outbreak signature detection.", [["the attack rate", "TEST", 72, 87], ["outbreak signature detection", "TEST", 371, 399]]], ["Remember {Rk,t} are the number of chest radiographs for the ED in city k on day t, {Vk,t} are the ED visit counts, and {Tk,t} are the thirty day smoothed time series of temperature.", [["chest radiographs", "TEST", 34, 51], ["the ED visit counts", "TEST", 94, 113], ["chest", "ANATOMY", 34, 39]]], ["Our covariates plus SARIMA errors model: Rk,t = \u03b20,k + \u03b2V,kVk,t + \u03b2T,kTk,t + Xk,t, where {Xk,t} is the SARIMA model used in the Results section.Simulations ::: Results2.", [["Our covariates", "TEST", 0, 14], ["model", "TEST", 34, 39], ["k", "TEST", 51, 52], ["V", "TEST", 56, 57], ["k", "TEST", 58, 59], ["Vk", "TEST", 59, 61], ["t", "TEST", 62, 63], ["T", "TEST", 67, 68], ["Tk", "TEST", 70, 72], ["t", "TEST", 73, 74], ["Xk", "TEST", 77, 79], ["t", "TEST", 80, 81], ["Xk", "TEST", 90, 92], ["the SARIMA model", "TEST", 99, 115], ["Tk", "ANATOMY", 70, 72]]], ["Covariates (with seasonality) with autoregressive moving average (ARMA) errors model: Rk,t=\u03b20,k+\u03b2V,tVk,t+\u03b2T,kTk,t+\u2211d=16\u03b2D,d,kDd,t+Xk,tMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGsbGudaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabg2da9GGaciab=j7aInaaBaaaleaacqaIWaamcqGGSaalcqWGRbWAaeqaaOGaey4kaSIae8NSdi2aaSbaaSqaaiabdAfawjabcYcaSiabdsha0bqabaGccqWGwbGvdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabgUcaRiab=j7aInaaBaaaleaacqWGubavcqGGSaalcqWGRbWAaeqaaOGaemivaq1aaSbaaSqaaiabdUgaRjabcYcaSiabdsha0bqabaGccqGHRaWkdaaeWaqaaiab=j7aInaaBaaaleaacqWGebarcqGGSaalcqWGKbazcqGGSaalcqWGRbWAaeqaaOGaemiraq0aaSbaaSqaaiabdsgaKjabcYcaSiabdsha0bqabaaabaGaemizaqMaeyypa0JaeGymaedabaGaeGOnaydaniabggHiLdGccqGHRaWkcqWGybawdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaaaaa@67AD@, where {Xk,t} is an ARMA model (equation (4), without the \u03a6k and \u0398k terms) with orders pk = 1 and qk = 1.", [["tVk", "PROTEIN", 99, 102], ["\u03a6k", "PROTEIN", 1002, 1004], ["model", "TEST", 79, 84], ["Rk", "TEST", 86, 88], ["k", "TEST", 94, 95], ["V", "TEST", 97, 98], ["tVk", "TEST", 99, 102], ["T", "TEST", 106, 107], ["kTk", "TEST", 108, 111], ["t", "TEST", 112, 113], ["\u2211d", "TEST", 114, 116], ["D", "TEST", 120, 121], ["d", "TEST", 122, 123], ["Dd", "TEST", 125, 127], ["an ARMA model", "TEST", 961, 974], ["pk", "TEST", 1031, 1033]]], ["Instead of modeling the weekly effect using a random seasonal component we use day-of-the week as a fixed effect (covariate).Simulations ::: Results3.", [["a fixed effect (covariate)", "TREATMENT", 98, 124]]], ["Covariates and no time series errors: Rk,t=\u03b20,k+\u03b2V,tVk,t+\u03b2T,kTk,t+\u2211d=16\u03b2D,d,kDd,t+Xk,tMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGsbGudaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabg2da9GGaciab=j7aInaaBaaaleaacqaIWaamcqGGSaalcqWGRbWAaeqaaOGaey4kaSIae8NSdi2aaSbaaSqaaiabdAfawjabcYcaSiabdsha0bqabaGccqWGwbGvdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabgUcaRiab=j7aInaaBaaaleaacqWGubavcqGGSaalcqWGRbWAaeqaaOGaemivaq1aaSbaaSqaaiabdUgaRjabcYcaSiabdsha0bqabaGccqGHRaWkdaaeWaqaaiab=j7aInaaBaaaleaacqWGebarcqGGSaalcqWGKbazcqGGSaalcqWGRbWAaeqaaOGaemiraq0aaSbaaSqaaiabdsgaKjabcYcaSiabdsha0bqabaaabaGaemizaqMaeyypa0JaeGymaedabaGaeGOnaydaniabggHiLdGccqGHRaWkcqWGybawdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaaaaa@67AD@, where {Xk,t} is a mean zero white noise process with innovation variance \u03c3k2MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacqWFdpWCdaqhaaWcbaGaem4AaSgabaGaeGOmaidaaaaa@30F4@.Simulations ::: Results4.", [["Results4", "PROTEIN", 1280, 1288], ["errors", "TEST", 30, 36], ["Rk", "TEST", 38, 40], ["t", "TEST", 41, 42], ["k", "TEST", 46, 47], ["V", "TEST", 49, 50], ["tVk", "TEST", 51, 54], ["t", "TEST", 55, 56], ["T", "TEST", 58, 59], ["kTk", "TEST", 60, 63], ["t", "TEST", 64, 65], ["\u2211d", "TEST", 66, 68], ["D", "TEST", 72, 73], ["d", "TEST", 74, 75], ["Dd", "TEST", 77, 79], ["a mean zero white noise process", "PROBLEM", 913, 944], ["no", "UNCERTAINTY", 15, 17]]], ["No covariates and ARMA errors: Rk,t = \u03b20,k + Xk,t, where {Xk,t} is the same ARMA model as in Model 2.Simulations ::: ResultsFigure 8 displays the difference of actual specificity (calculated using the training data) and the nominal specificity (the predetermined 1 - \u03b1) for different values of \u03b1 for these four models.", [["covariates", "PROBLEM", 3, 13], ["ARMA errors", "TEST", 18, 29], ["Rk", "TEST", 31, 33], ["t", "TEST", 34, 35], ["k", "TEST", 41, 42], ["Xk", "TEST", 45, 47], ["t", "TEST", 48, 49], ["Xk", "TEST", 58, 60], ["the training data", "TEST", 197, 214], ["the nominal specificity", "TEST", 220, 243], ["ARMA errors", "OBSERVATION", 18, 29]]], ["For illustration we use the linear filter, which represents a compromise between the actual specificity and sensitivity (Across all four models, the 1-day filter always had specificities closest to nominal and the 7-day filter had specificities furthest away).", [["the linear filter", "TREATMENT", 24, 41], ["compromise", "OBSERVATION", 62, 72]]], ["Except in Chicago, Model 4 had the largest magnitude of bias.Simulations ::: ResultsFigure 9 compares the receiver operator characteristic (ROC) curves for the four models across the five EDs using the linear filter (Across all models, the sensitivity for the 1-day filter was the lowest while the 7-day and linear filters tended to have the highest sensitivity).", [["the linear filter", "TREATMENT", 198, 215], ["the 1-day filter", "TREATMENT", 256, 272], ["linear filters", "TREATMENT", 308, 322], ["largest", "OBSERVATION_MODIFIER", 35, 42], ["bias", "OBSERVATION", 56, 60], ["linear", "OBSERVATION_MODIFIER", 202, 208], ["filter", "OBSERVATION", 209, 215]]], ["Except for Akron and Minneapolis/St. Paul, the random weekly and daily time series components in Model 1 yield higher sensitivities, compared to including a day-of-week covariate plus ARMA errors in Model 2, and day-of-week covariate plus no ARMA errors in Model 3.", [["ARMA errors", "PROBLEM", 184, 195], ["ARMA errors in Model", "PROBLEM", 242, 262], ["no", "UNCERTAINTY", 239, 241], ["ARMA errors", "OBSERVATION", 242, 253]]], ["This is due to the insignificance of the day-of-week fixed effect in Models 2 and 3.", [["fixed effect in Models", "PROBLEM", 53, 75]]], ["In Akron, Model 3 has higher sensitivities than Model 1, suggesting that the time series errors are less relevant in outbreak signature detection for the test data.", [["the test data", "TEST", 150, 163]]], ["Across all cities either Model 2 or Model 4 had the lowest sensivities, indicating that these models are less reliable for outbreak signature detection.Simulations ::: ResultsIn terms of sensitivity, except for Chicago, Model 3 tended to outperform Model 2 for all filters in the cities we studied.", [["sensitivity", "TEST", 187, 198], ["all filters", "TREATMENT", 261, 272], ["filters", "OBSERVATION", 265, 272]]], ["For each ED, a smaller AIC denotes a model that better fits the data.", [["a smaller AIC", "PROBLEM", 13, 26]]], ["Using the AIC we find Model 1 fits best to the training data, even though it does not always yield the highest sensitivity.DiscussionOur intention in this study was to find a flexible set of statistical models that could be applied across a number of emergency departments.", [["the AIC", "TREATMENT", 6, 13], ["the training data", "TEST", 43, 60], ["this study", "TEST", 150, 160]]], ["We employ time series models that include covariates, such as patient visit counts and ambient temperature, as well as random seasonal terms.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69]]], ["We use chest-radiograph ordering data from emergency departments of five regional Midwest children's hospitals to detect signatures of respiratory outbreaks.", [["respiratory", "ANATOMY", 135, 146], ["respiratory outbreaks", "DISEASE", 135, 156], ["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98], ["chest-radiograph", "TEST", 7, 23], ["respiratory outbreaks", "PROBLEM", 135, 156], ["chest", "ANATOMY", 7, 12], ["respiratory outbreaks", "OBSERVATION", 135, 156]]], ["We include visit counts series as a covariate in the chest radiograph model to account for variations due to, for example, ED sizes, changes of staff within the ED, and even some seasonalities across the time period of interest.", [["chest", "ANATOMY", 53, 58], ["visit counts series", "TEST", 11, 30], ["the chest radiograph model", "TEST", 49, 75], ["chest", "ANATOMY", 53, 58], ["sizes", "OBSERVATION_MODIFIER", 126, 131]]], ["We use the temperature series as a surrogate measure of the influenza season \u2013 the colder months in the western hemisphere.", [["the temperature series", "TEST", 7, 29]]], ["This is a more accurate measure of the influenza season than using a fixed covariate such as a sinusoid.", [["influenza", "DISEASE", 39, 48], ["the influenza season", "PROBLEM", 35, 55], ["a fixed covariate", "TREATMENT", 67, 84]]], ["To reflect uncertainty in the variation of the influenza background over seasons, these models allow for randomness in the seasonal components.", [["influenza", "DISEASE", 47, 56], ["the influenza background", "PROBLEM", 43, 67], ["randomness in the seasonal components", "PROBLEM", 105, 142], ["uncertainty", "OBSERVATION_MODIFIER", 11, 22], ["influenza", "OBSERVATION", 47, 56]]], ["The use of random seasonal components is an advantage over traditional fixed effect models, since temporal patterns are not assumed to repeat precisely the same way.", [["random seasonal components", "TREATMENT", 11, 37], ["traditional fixed effect models", "TREATMENT", 59, 90]]], ["Thus, signature detection capabilities are improved for the majority of EDs \u2013 sensitivity is higher.", [["signature detection capabilities", "TEST", 6, 38], ["higher", "OBSERVATION_MODIFIER", 93, 99]]], ["For increased accuracy and timeliness, the use of our model for the data analysis should represent one component of an integrated detection system.", [["increased accuracy", "PROBLEM", 4, 22], ["the data analysis", "TEST", 64, 81], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["accuracy", "OBSERVATION_MODIFIER", 14, 22]]], ["Once a signal is triggered by any of our models, we recommend the use of clinical follow-up to corroborate or refute the emergence of a bona fide epidemic.", [["epidemic", "OBSERVATION", 146, 154]]], ["For example, radiographs and medical charts will need to be reviewed to identify highly anomalous findings or groupings of aberrant findings that would be expected to be present at early stages of outbreaks.", [["radiographs", "TEST", 13, 24], ["aberrant findings", "PROBLEM", 123, 140]]], ["We believe that the approach utilized in this work will aid in this process and is more appropriate than models using fixed periodicities that do not have the ability to capture the underlying variabilities across seasons.DiscussionOf note, our study shows that there are similarities in the chest radiographs series from different EDs that can, for the most part, be modeled by similar time series models.", [["chest", "ANATOMY", 292, 297], ["our study", "TEST", 241, 250], ["the chest radiographs series", "TEST", 288, 316], ["chest", "ANATOMY", 292, 297]]], ["Similarities of the time series model across EDs have a number of ramifications for detection of outbreak signatures.", [["outbreak signatures", "PROBLEM", 97, 116]]], ["First, by borrowing information across the different EDs we can build more complicated multivariate time series models, possibly involving the joint modeling of chest radiograph and visit counts across locations.", [["chest", "ANATOMY", 161, 166], ["chest radiograph", "TEST", 161, 177], ["joint", "ANATOMY", 143, 148], ["chest", "ANATOMY", 161, 166]]], ["Second, we could use these models to jointly detect outbreak signatures across large spatial regions.", [["large", "OBSERVATION_MODIFIER", 79, 84], ["spatial", "OBSERVATION_MODIFIER", 85, 92]]], ["In this context, Diggle et al. [20] use spatio-temporal Cox models to identify anomalies (real and artificial outbreaks) in the space-time distribution of gastrointestinal infections.", [["gastrointestinal", "ANATOMY", 155, 171], ["gastrointestinal infections", "DISEASE", 155, 182], ["gastrointestinal", "ORGANISM_SUBDIVISION", 155, 171], ["temporal Cox models", "PROBLEM", 47, 66], ["anomalies (real and artificial outbreaks", "PROBLEM", 79, 119], ["gastrointestinal infections", "PROBLEM", 155, 182], ["anomalies", "OBSERVATION", 79, 88], ["gastrointestinal", "ANATOMY", 155, 171], ["infections", "OBSERVATION", 172, 182]]], ["For localized outbreaks, there is still some utility in building models that borrow strength across EDs, even if the joint detection of outbreak signatures is not meaningful.", [["the joint detection", "TEST", 113, 132], ["outbreaks", "OBSERVATION", 14, 23], ["joint", "ANATOMY", 117, 122]]], ["In terms of these localized outbreaks, a geographically close site could act as a benchmark to judge detections at other sites.", [["these localized outbreaks", "PROBLEM", 12, 37], ["a geographically close site", "PROBLEM", 39, 66], ["localized", "OBSERVATION_MODIFIER", 18, 27], ["outbreaks", "OBSERVATION", 28, 37]]], ["For example, under certain circumstances an epidemic detection signal triggered in Columbus, but not in Akron, could imply that some unusual event had occurred in Columbus.", [["an epidemic detection signal", "PROBLEM", 41, 69]]], ["It should be noted, however, that even though there are similarities in the time series models, our simulations demonstrate that the sensitivity and timeliness to detect outbreak signatures using chest radiograph counts were different across EDs.", [["chest", "ANATOMY", 196, 201], ["the sensitivity", "TEST", 129, 144], ["outbreak signatures", "TEST", 170, 189], ["chest radiograph counts", "TEST", 196, 219], ["chest", "ANATOMY", 196, 201]]], ["These differences may limit the utility of our models in comparing signals across different EDs.DiscussionOur study has a number of limitations.", [["DiscussionOur study", "TEST", 96, 115]]], ["We assume that the resulting series {Xk,t}, after accounting for these covariates, is stationary.", [["Xk", "GENE_OR_GENE_PRODUCT", 37, 39]]], ["Furthermore, these data do not contain any known anthrax outbreaks.", [["anthrax", "DISEASE", 49, 56], ["these data", "TEST", 13, 23], ["any known anthrax outbreaks", "PROBLEM", 39, 66], ["anthrax", "OBSERVATION", 49, 56]]], ["Instead, outbreak patterns are simulated using a simple stochastic model.", [["a simple stochastic model", "TREATMENT", 47, 72]]], ["Although more care needs to be taken when summarizing simulation results, we agree with Buckeridge, et al. [16] and Brookmeyer, et al. [17] that stochastic outbreaks are more realistic than deterministic ones.", [["stochastic outbreaks", "PROBLEM", 145, 165]]], ["Other results (not presented here) indicate that the results are different (and possibly misleading) with a smooth deterministic outbreak rather than a stochastic one.", [["a smooth deterministic outbreak", "PROBLEM", 106, 137], ["smooth", "OBSERVATION_MODIFIER", 108, 114]]], ["We utilize the four filters used by Reis, et al. [2].", [["the four filters", "TREATMENT", 11, 27]]], ["Although filter design is an active area of research, especially in engineering, we decided to only study these four simple and fairly easy to understand filters.", [["filter", "OBSERVATION", 9, 15], ["active", "OBSERVATION_MODIFIER", 29, 35], ["area", "OBSERVATION_MODIFIER", 36, 40]]], ["In the future we could extend our analysis to different choices of filter.", [["our analysis", "TEST", 30, 42], ["filter", "TREATMENT", 67, 73], ["filter", "OBSERVATION", 67, 73]]], ["We view wavelet-based biosurveillance methods [1,8] as extensions of this idea to different linear time-invariant filters.", [["based biosurveillance methods", "TREATMENT", 16, 45], ["invariant filters", "TREATMENT", 104, 121], ["invariant filters", "OBSERVATION", 104, 121]]], ["An important issue in filter-based-prediction methods is the choice of covariates and the correlation structure for the time series model.", [["filter", "OBSERVATION", 22, 28]]], ["In this case, the choice of window length is critical as it represents a compromise between the efficiency to estimate the model parameters, and the sensitivity and specificity of detection.", [["a compromise between the efficiency", "PROBLEM", 71, 106], ["the sensitivity", "TEST", 145, 160], ["detection", "TEST", 180, 189], ["compromise", "OBSERVATION", 73, 83]]], ["Other issues to be taken into account include negative singularities (as defined by [8]) that can cause a drop in the sensitivity.", [["a drop in the sensitivity", "PROBLEM", 104, 129], ["drop", "OBSERVATION_MODIFIER", 106, 110]]], ["Abnormal points (like holidays or severe weather) can cause \"false alarms\".", [["Abnormal points", "PROBLEM", 0, 15], ["false alarms\"", "PROBLEM", 61, 74], ["false alarms", "OBSERVATION", 61, 73]]], ["Our solution to this problem is to jointly model chest radiograph and visit counts.", [["chest", "ANATOMY", 49, 54], ["model chest radiograph", "TEST", 43, 65], ["chest", "ANATOMY", 49, 54]]], ["So far, we have assumed that the visit counts are observed without error.", [["the visit counts", "TEST", 29, 45]]], ["Related to these issues, we are investigating methods that can be used to incorporate the uncertainty in parameter estimation upon the detection procedure.ConclusionWe present in this paper a stochastic model of chest radiograph ordering patterns and temperature as an adjunct to a biosurveillance system for detecting emerging respiratory-related epidemics, focusing on a potentially high-impact public health hazard such as inhalational anthrax.", [["respiratory", "ANATOMY", 328, 339], ["anthrax", "DISEASE", 439, 446], ["the detection procedure", "TREATMENT", 131, 154], ["chest radiograph", "TEST", 212, 228], ["a biosurveillance system", "TEST", 280, 304], ["emerging respiratory-related epidemics", "PROBLEM", 319, 357], ["chest", "ANATOMY", 212, 217]]], ["We also demonstrate the importance in assessing the sensitivity and specificity of these methods, of utilizing more realistic stochastic, rather than deterministic, models for outbreaks patterns.", [["the sensitivity", "TEST", 48, 63], ["these methods", "TEST", 83, 96]]], ["We demonstrate spatial homogeneity in chest radiograph data across EDs and suggest ways in which these observations may be used to improve regional biosurveillance for (re)emergent infections.ConclusionRegardless of the choice of filter, our simulations demonstrate that the specificity calculated using the training data varied across the five EDs studied (Figure 6).", [["infections", "DISEASE", 181, 191], ["chest radiograph data", "TEST", 38, 59], ["emergent infections", "PROBLEM", 172, 191], ["filter", "TREATMENT", 230, 236], ["the specificity", "TEST", 271, 286], ["the training data", "TEST", 304, 321], ["spatial", "OBSERVATION_MODIFIER", 15, 22], ["homogeneity", "OBSERVATION_MODIFIER", 23, 34], ["chest", "ANATOMY", 38, 43], ["infections", "OBSERVATION", 181, 191], ["filter", "OBSERVATION", 230, 236]]], ["The tradeoff between specificity and sensitivity also varied by the ED (Figures 6 and 7).", [["sensitivity", "TEST", 37, 48], ["Figures", "TEST", 72, 79]]], ["The 1-day filter, while closely matching the nominal specificity, performed poorly in terms of maximizing the sensitivity to detect an outbreak signature.", [["The 1-day filter", "TREATMENT", 0, 16], ["the sensitivity", "TEST", 106, 121], ["an outbreak signature", "PROBLEM", 132, 153]]], ["The 7-day filter, by smoothing over the outbreak signature (Figure 5), maximized the sensitivity, but at a compromise to the actual specificity obtained (Figures 6 and 7).", [["The 7-day filter", "TREATMENT", 0, 16], ["the sensitivity", "TEST", 81, 96], ["the actual specificity", "TEST", 121, 143], ["Figures", "TEST", 154, 161], ["7-day filter", "OBSERVATION_MODIFIER", 4, 16]]], ["The linear and exponential filters provided a balance between the specificity and sensitivity.", [["The linear and exponential filters", "TREATMENT", 0, 34], ["the specificity", "TEST", 62, 77], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["exponential", "OBSERVATION_MODIFIER", 15, 26], ["filters", "OBSERVATION", 27, 34]]], ["Detection using our covariate-based seasonal time series model performed well across all EDs compared with fixed-effects regression models or time series models that omitted seasonal terms and/or covariates (Figures 8 and 9).Competing interestsThe author(s) declare that they have no competing interests.Authors' contributionsDr.", [["our covariate", "TEST", 16, 29], ["Figures", "TEST", 208, 215]]], ["Under supervision, N. Kim developed the preliminary simulation model for an anthrax attack.", [["anthrax", "DISEASE", 76, 83], ["an anthrax attack", "PROBLEM", 73, 90], ["anthrax", "OBSERVATION", 76, 83]]], ["All authors jointly edited this work.The SARIMA model ::: AppendixIn city k, we define a SARIMA (pk, 0, qk) \u00d7 (Pk, 0, Qk) with period of seasonality s for the time series {Xk,t} using the notation of Section 6.5 of Brockwell and Davis [19].", [["a SARIMA (pk", "TEST", 87, 99], ["Pk", "TEST", 111, 113], ["seasonality s", "PROBLEM", 137, 150], ["the time series", "TEST", 155, 170]]], ["Letting B denote the backshift operator defined by BrZk,t = Br-1 Zk,t-1 for r > 0, with B0 Zk,t = Zk,t, we define Xk,t byThe SARIMA model ::: Appendix\u03c6k(B)\u03a6k(Bs)Xk,t = \u03b8k(B)\u0398k(Bs)Zk,t.The SARIMA model ::: AppendixIn this model the parameter s denotes the period of the seasonality.", [["Appendix\u03c6k(B)\u03a6k(Bs)Xk", "CHEMICAL", 142, 163], ["BrZk", "SIMPLE_CHEMICAL", 51, 55], ["B0 Zk", "SIMPLE_CHEMICAL", 88, 93], ["BrZk", "PROTEIN", 51, 55], ["Zk", "TEST", 65, 67], ["Appendix\u03c6k", "TEST", 142, 152], ["Bs", "TEST", 158, 160], ["Xk", "TEST", 161, 163], ["t", "TEST", 164, 165], ["Zk", "TEST", 179, 181]]], ["The characteristic polynomials for the SARIMA model areThe SARIMA model ::: Appendix\u03c6k(z)=1\u2212\u03c6k,1z\u2212\u2026\u2212\u03c6k,pkzpk;\u03a6k(z)=1\u2212\u03a6k,1z\u2212\u2026\u2212\u03a6k,PKzPK;\u03b8k(z)=1+\u03b8k,1z+\u2026+\u03b8k,qKzqK;\u0398k(z)=1+\u0398k,1z+\u2026+\u0398k,QKzQK.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaafaqadeabdaaaaeaaiiGacqWFgpGzdaWgaaWcbaGaem4AaSgabeaakiabcIcaOiabdQha6jabcMcaPaqaaiabg2da9aqaaiabigdaXiabgkHiTiab=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@A787@The SARIMA model ::: AppendixThe terms \u03c6k(z) and \u03b8k(z) define an autoregressive moving average process on the unit time scale, whereas the terms \u03a6k(z) and \u0398k(z) define an autoregressive moving average process on a time scale of s units.", [["Appendix\u03c6k(z)=1\u2212\u03c6k,1z\u2212\u2026\u2212\u03c6k,", "CHEMICAL", 76, 103], ["pkzpk;\u03a6k(z)=1\u2212\u03a6k,1z\u2212\u2026\u2212\u03a6k,PKzPK;\u03b8k(z)=1+\u03b8k,1z+\u2026+\u03b8k,qKzqK;\u0398k(z)=1+\u0398k,1z+\u2026+\u0398k,QKzQK.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaafaqadeabdaaaaeaaiiGacqWFgpGzdaWgaaWcbaGaem4AaSgabeaakiabcIcaOiabdQha6jabcMcaPaqaaiabg2da9aqaaiabigdaXiabgkHiTiab=z8aMnaaBaaaleaacqWGRbWAcqGGSaalcqaIXaqmaeqaaOGaemOEaONaeyOeI0IaeSOjGSKaeyOeI0Iae8NXdy2aaSbaaSqaaiabdUgaRjabcYcaSiabdchaWnaaBaaameaacqWGRbWAaeqaaaWcbeaakiabdQha6naaCaaaleqabaGaemiCaa3aaSbaaWqaaiabdUgaRbqabaaaaOGaei4oaSdabaGaeuOPdy0aaSbaaSqaaiabdUgaRbqabaGccqGGOaakcqWG6bGEcqGGPaqkaeaacqGH9aqpaeaacqaIXaqmcqGHsislcqqHMoGrdaWgaaWcbaGaem4AaSMaeiilaWIaeGymaedabeaakiabdQha6jabgkHiTiablAciljabgkHiTiabfA6agnaaBaaaleaacqWGRbWAcqGGSaalcqWGqbaudaWgaaadbaGaem4saSeabeaaaSqabaGccqWG6bGEdaahaaWcbeqaaiabdcfaqnaaBaaameaacqWGlbWsaeqaaaaakiabcUda7aqaaiab=H7aXnaaBaaaleaacqWGRbWAaeqaaOGaeiikaGIaemOEaONaeiykaKcabaGaeyypa0dabaGaeGymaeJaey4kaSIae8hUde3aaSbaaSqaaiabdUgaRjabcYcaSiabigdaXaqabaGccqWG6bGEcqGHRaWkcqWIMaYscqGHRaWkcqWF4oqCdaWgaaWcbaGaem4AaSMaeiilaWIaemyCae3aaSbaaWqaaiabdUealbqabaaaleqaaOGaemOEaO3aaWbaaSqabeaacqWGXbqCdaWgaaadbaGaem4saSeabeaaaaGccqGG7aWoaeaacqqHyoqudaWgaaWcbaGaem4AaSgabeaakiabcIcaOiabdQha6jabcMcaPaqaaiabg2da9aqaaiabigdaXiabgUcaRiabfI5arnaaBaaaleaacqWGRbWAcqGGSaalcqaIXaqmaeqaaOGaemOEaONaey4kaSIaeSOjGSKaey4kaSIaeuiMde1aaSbaaSqaaiabdUgaRjabcYcaSiabdgfarnaaBaaameaacqWGlbWsaeqaaaWcbeaakiabdQha6naaCaaaleqabaGaemyuae1aaSbaaWqaaiabdUealbqabaaaaOGaeiOla4caaaaa@A787@", "CHEMICAL", 103, 1706], ["Appendix\u03c6k(", "TEST", 76, 87], ["z)", "TEST", 87, 89], ["polynomials", "OBSERVATION_MODIFIER", 19, 30]]], ["Thus we can model dependencies simultaneously on two different time scales.", [["dependencies", "OBSERVATION_MODIFIER", 18, 30]]], ["The SARIMA model is causal (i.e., can be represented in terms of a moving average (MA) process of only past events) if \u03c6k(z) \u2260 0 and \u03a6k(z) \u2260 0, for complex valued z such that |z| \u2264 1.The SARIMA model ::: AppendixTo complete the model we assume that {Zk,t} is a mean zero white noise process with innovation variance \u03c3k2MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacqWFdpWCdaqhaaWcbaGaem4AaSgabaGaeGOmaidaaaaa@30F4@.Filtering ::: AppendixA discrete-time filter is a set of coefficients, {fl : l = ..., -2, -1, 0, 1, 2, ...}, where \u2211l|fl| < \u221e.", [["Zk", "TEST", 250, 252], ["a mean zero white noise process", "PROBLEM", 259, 290]]], ["The new time series {Yt} obtained by filtering the time series {Xt} using {fl} is defined by the convolutionFiltering ::: AppendixYt=\u2211l=\u2212\u221e\u221eflXt\u2212l,MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGzbqwdaWgaaWcbaGaemiDaqhabeaakiabg2da9maaqahabaGaemOzay2aaSbaaSqaaiabdYgaSbqabaGccqWGybawdaWgaaWcbaGaemiDaqNaeyOeI0IaemiBaWgabeaaaeaacqWGSbaBcqGH9aqpcqGHsislcqGHEisPaeaacqGHEisPa0GaeyyeIuoakiabcYcaSaaa@41FB@Filtering ::: Appendixfor each t.", [["The new time series", "TEST", 0, 19], ["the time series", "TEST", 47, 62]]], ["The actual operation that a filter carries out upon a time series depends on the values of the filter coefficients.", [["The actual operation", "TREATMENT", 0, 20], ["a filter", "TREATMENT", 26, 34], ["the filter coefficients", "TREATMENT", 91, 114], ["operation", "OBSERVATION", 11, 20], ["filter", "OBSERVATION", 28, 34], ["filter", "OBSERVATION", 95, 101]]], ["Simple examples of a filter include the differencing filter defined byFiltering ::: Appendixfl={1l=0;\u22121l=1;0otherwise,MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGMbGzdaWgaaWcbaGaemiBaWgabeaakiabg2da9maaceqabaqbaeaabmGaaaqaaiabigdaXaqaaiabdYgaSjabg2da9iabicdaWiabcUda7aqaaiabgkHiTiabigdaXaqaaiabdYgaSjabg2da9iabigdaXiabcUda7aqaaiabicdaWaqaaiabb+gaVjabbsha0jabbIgaOjabbwgaLjabbkhaYjabbEha3jabbMgaPjabbohaZjabbwgaLjabcYcaSaaaaiaawUhaaaaa@4B81@Filtering ::: Appendixwhich corresponds to Yt = Xt - Xt-1 for each t, and the simple moving average filter of length 2M + 1 whose filter is defined byFiltering ::: Appendixfl={1/(2M+1)l=\u2212M,...,M;0otherwise.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGMbGzdaWgaaWcbaGaemiBaWgabeaakiabg2da9maaceqabaqbaeaabiGaaaqaaiabigdaXiabc+caViabcIcaOiabikdaYiabd2eanjabgUcaRiabigdaXiabcMcaPaqaaiabdYgaSjabg2da9iabgkHiTiabd2eanjabcYcaSiabc6caUiabc6caUiabc6caUiabcYcaSiabd2eanjabcUda7aqaaiabicdaWaqaaiabb+gaVjabbsha0jabbIgaOjabbwgaLjabbkhaYjabbEha3jabbMgaPjabbohaZjabbwgaLjabc6caUaaaaiaawUhaaaaa@5280@Filtering ::: AppendixThus, Yt=(2M+1)\u22121\u2211l=\u2212MMXt+lMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGzbqwdaWgaaWcbaGaemiDaqhabeaakiabg2da9iabcIcaOiabikdaYiabd2eanjabgUcaRiabigdaXiabcMcaPmaaCaaaleqabaGaeyOeI0IaeGymaedaaOWaaabmaeaacqWGybawdaWgaaWcbaGaemiDaqNaey4kaSIaemiBaWgabeaaaeaacqWGSbaBcqGH9aqpcqGHsislcqWGnbqtaeaacqWGnbqta0GaeyyeIuoaaaa@44EB@, for each t.Filtering ::: AppendixSuppose that the radiograph series {Rk,t} follows a time series model given by (1).", [["Xt", "PROTEIN", 684, 686], ["Xt", "PROTEIN", 689, 691], ["2M", "PROTEIN", 753, 755], ["a filter", "TREATMENT", 19, 27], ["the differencing filter", "TREATMENT", 36, 59], ["Appendixwhich", "TEST", 650, 663], ["Yt", "TEST", 679, 681], ["AppendixThus", "TEST", 1430, 1442], ["the radiograph series", "TEST", 1998, 2019], ["filter", "OBSERVATION", 21, 27], ["differencing filter", "OBSERVATION", 40, 59]]], ["Let \u03b3X,k(\u00b7) denote the autocovariance function of the stationary error component {Xk,t}.", [["Let \u03b3X", "GENE_OR_GENE_PRODUCT", 0, 6], ["\u03b3X", "DNA", 4, 6]]], ["Consider only the last m values of the process Rk,t, {Rk,t-1, ..., Rk,t-m}.", [["t", "TEST", 57, 58]]], ["Given the model parameters, by linearity of the prediction operator, the best linear one-step predictor of Rk,t is given byFiltering ::: AppendixRk,tMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGsbGugaqcamaaBaaaleaacqWGRbWAcqGGSaalcqWG0baDaeqaaOGaeyypa0dcciGae8NSdi2aaSbaaSqaaiabicdaWiabcYcaSiabdsha0bqabaGccqGHRaWkcqWFYoGydaWgaaWcbaGaemOvayLaeiilaWIaem4AaSgabeaakiabdAfawnaaBaaaleaacqWGRbWAcqGGSaalcqWG0baDaeqaaOGaey4kaSIae8NSdi2aaSbaaSqaaiabdsfaujabcYcaSiabdUgaRbqabaGccqWGubavdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabgUcaRiqbdIfayzaajaWaaSbaaSqaaiabdUgaRjabcYcaSiabdsha0bqabaaaaa@5477@Filtering ::: AppendixwhereFiltering ::: AppendixX^k,t=\u2211j=1mbk,jXk,t\u2212j,MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGybawgaqcamaaBaaaleaacqWGRbWAcqGGSaalcqWG0baDaeqaaOGaeyypa0ZaaabCaeaacqWGIbGydaWgaaWcbaGaem4AaSMaeiilaWIaemOAaOgabeaakiabdIfaynaaBaaaleaacqWGRbWAcqGGSaalcqWG0baDcqGHsislcqWGQbGAaeqaaaqaaiabdQgaQjabg2da9iabigdaXaqaaiabd2gaTbqdcqGHris5aOGaeiilaWcaaa@4736@Filtering ::: Appendixdenotes the one-step ahead prediction for the SARIMA process and {bk,1, ..., bk,m} are obtained from the solution of the set of m linear equations:Filtering ::: Appendix\u03b3X,k(h)=\u2211j=1mbk,j\u03b3X,k(h\u2212j),h=1,...,m.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaafaqabeqacaaabaacciGae83SdC2aaSbaaSqaaiabdIfayjabcYcaSiabdUgaRbqabaGccqGGOaakcqWGObaAcqGGPaqkcqGH9aqpdaaeWbqaaiabdkgaInaaBaaaleaacqWGRbWAcqGGSaalcqWGQbGAaeqaaOGae83SdC2aaSbaaSqaaiabdIfayjabcYcaSiabdUgaRbqabaGccqGGOaakcqWGObaAcqGHsislcqWGQbGAcqGGPaqkaSqaaiabdQgaQjabg2da9iabigdaXaqaaiabd2gaTbqdcqGHris5aOGaeiilaWcabaGaemiAaGMaeyypa0JaeGymaeJaeiilaWIaeiOla4IaeiOla4IaeiOla4IaeiilaWIaemyBa0gaaiabc6caUaaa@57CE@Filtering ::: AppendixThe one-step prediction error process, {Ek,t} isFiltering ::: AppendixEk,t=Rk,t\u2212Rk,t=Xk,t\u2212\u2211j=1mbk,jXk,t\u2212j=\u2211j=0mck,jXk,t\u2212j,MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=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@79FC@Filtering ::: Appendixwhere we define ck,0 = 1 and ck,j = -bk,j for j = 1, ..., m.", [["Rk", "SIMPLE_CHEMICAL", 107, 109], ["Rk", "PROTEIN", 107, 109], ["h\u2212j", "PROTEIN", 1561, 1564], ["the SARIMA process", "PROBLEM", 1412, 1430], ["{bk", "TEST", 1435, 1438], ["bk", "TEST", 1447, 1449], ["Appendix\u03b3X", "TEST", 1531, 1541], ["k", "TEST", 1542, 1543], ["Appendix", "PROBLEM", 2232, 2240], ["AppendixEk", "TEST", 2302, 2312], ["Appendixwhere", "TEST", 3345, 3358], ["ck", "TEST", 3369, 3371], ["ck", "TEST", 3382, 3384], ["j", "TEST", 3385, 3386], ["m.", "ANATOMY", 3411, 3413]]], ["The process {Ek,t} is a filtering of {Xk,t} and so if {Xk,t} is stationary, by the linear time invariant filtering result for stationary processes, {Ek,t} is also stationary ([18], Theorem 4.10.1).", [["{Xk", "SIMPLE_CHEMICAL", 37, 40], ["Theorem", "TEST", 181, 188]]], ["Moreover for large enough m, if {Xk,t} is an invertible time series process then we can approximate {Xk,t} by an autoregressive, AR(m) process ([18], Theorem 4.4.3).", [["an autoregressive, AR(m) process", "PROBLEM", 110, 142], ["Theorem", "TEST", 150, 157]]], ["Using this approximation we can argue that {Ek,t} is approximately a mean zero Gaussian independent and identically distributed process with variance gamma \u03b3X,k(0).Filtering ::: AppendixLet {a0, ..., aL-1} denote a pre-specified filter of width L. We define the detection process {Dk,t} by filtering the error process {Ek,t} using this filter.", [["gamma \u03b3X", "GENE_OR_GENE_PRODUCT", 150, 158], ["gamma \u03b3X", "PROTEIN", 150, 158], ["variance gamma \u03b3X", "TEST", 141, 158], ["AppendixLet", "TEST", 178, 189], ["a pre-specified filter of width L.", "TREATMENT", 213, 247], ["the detection process", "TEST", 258, 279], ["Dk", "TEST", 281, 283], ["Ek", "TEST", 319, 321], ["this filter", "TREATMENT", 331, 342], ["filter", "OBSERVATION", 229, 235]]], ["Thus,Filtering ::: AppendixDk,t=\u2211h=0L\u22121ahEk,t\u2212h.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGebardaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabg2da9maaqahabaGaemyyae2aaSbaaSqaaiabdIgaObqabaGccqWGfbqrdaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqNaeyOeI0IaemiAaGgabeaaaeaacqWGObaAcqGH9aqpcqaIWaamaeaacqWGmbatcqGHsislcqaIXaqma0GaeyyeIuoakiabc6caUaaa@4628@Filtering ::: AppendixBy the filtering result for stationary processes, stationarity of {Xk,t} implies that {Dk,t} is also a stationary process.", [["{Dk", "SIMPLE_CHEMICAL", 642, 645], ["stationary processes", "PROBLEM", 584, 604]]], ["For large enough m, since {Ek,t} is approximately a white noise process,{Dk,t} is approximately a moving average process of order L - 1 with coefficients \u03b80 = 1, \u03b8j = aj-1/a0 for j = 1, ..., L - 1, and innovation variance a02\u03b3X,k(0)MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGHbqydaqhaaWcbaGaeGimaadabaGaeGOmaidaaGGacOGae83SdC2aaSbaaSqaaiabdIfayjabcYcaSiabdUgaRbqabaGccqGGOaakcqaIWaamcqGGPaqkaaa@380A@.Filtering ::: AppendixWe declare evidence of an outbreak signature (test positive), at time t if the observed detection value Dk,t is larger than a given threshold.", [["Dk", "GENE_OR_GENE_PRODUCT", 73, 75], ["a white noise process", "PROBLEM", 50, 71], ["L", "TEST", 130, 131], ["coefficients", "TEST", 141, 153], ["\u03b8j", "TEST", 162, 164], ["j", "TEST", 179, 180], ["innovation variance", "TEST", 202, 221], ["an outbreak signature (test positive", "PROBLEM", 643, 679], ["large", "OBSERVATION_MODIFIER", 4, 9], ["enough m", "OBSERVATION_MODIFIER", 10, 18], ["evidence of", "UNCERTAINTY", 631, 642], ["larger", "OBSERVATION_MODIFIER", 732, 738]]], ["For a fixed value of \u03b1, let 1 - \u03b1 denote the specificity (the probability of a true-negative).", [["let 1 - \u03b1", "GENE_OR_GENE_PRODUCT", 24, 33], ["\u03b1", "PROTEIN", 32, 33], ["a fixed value", "TEST", 4, 17]]], ["Similarly, the sensitivity is defined to be the probability of true positive.", [["the sensitivity", "TEST", 11, 26], ["true positive", "PROBLEM", 63, 76], ["positive", "OBSERVATION", 68, 76]]], ["The threshold, \u03c4k,\u03b1, is chosen by solving P (Dk,t > \u03c4k,\u03b1) = \u03b1 for \u03c4k,\u03b1.", [["\u03c4k", "PROTEIN", 66, 68], ["Dk", "TEST", 45, 47], ["t", "TEST", 48, 49], ["\u03c4k", "TEST", 66, 68]]], ["Either we can estimate this value from the data using the 1 - \u03b1 quantile of the {Dk,t} process of non-outbreak-based training data, or if {Xk,t} is Gaussian then for large m,Filtering ::: AppendixP(Dk,t>\u03c4k,\u03b1)\u2248P(Z>\u03c4k,\u03b1\u03b3X,k(0)\u2211h=0L\u22121ah2)=\u03b1,MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGqbaucqGGOaakcqWGebardaWgaaWcbaGaem4AaSMaeiilaWIaemiDaqhabeaakiabg6da+GGaciab=r8a0naaBaaaleaacqWGRbWAcqGGSaalcqWFXoqyaeqaaOGaeiykaKIaeyisISRaemiuaa1aaeWaaeaacqWGAbGwcqGH+aGpdaWcaaqaaiab=r8a0naaBaaaleaacqWGRbWAcqGGSaalcqWFXoqyaeqaaaGcbaWaaOaaaeaacqWFZoWzdaWgaaWcbaGaemiwaGLaeiilaWIaem4AaSgabeaakiabcIcaOiabicdaWiabcMcaPmaaqadabaGaemyyae2aa0baaSqaaiabdIgaObqaaiabikdaYaaaaeaacqWGObaAcqGH9aqpcqaIWaamaeaacqWGmbatcqGHsislcqaIXaqma0GaeyyeIuoaaSqabaaaaaGccaGLOaGaayzkaaGaeyypa0Jae8xSdeMaeiilaWcaaa@5F82@Filtering ::: Appendixwhere Z is a standard normal random variable.", [["AppendixP", "CHEMICAL", 188, 197], ["P(", "CHEMICAL", 209, 211], ["AppendixP", "SIMPLE_CHEMICAL", 188, 197], ["AppendixP", "PROTEIN", 188, 197], ["Dk", "PROTEIN", 198, 200], ["t>\u03c4k", "PROTEIN", 201, 205], ["Z", "PROTEIN", 1002, 1003], ["AppendixP", "TEST", 188, 197], ["Z>\u03c4k", "TEST", 211, 215]]], ["The solution for the threshold under this approximation isFiltering ::: Appendix\u03c4k,\u03b1=(\u03b3X,k(0)\u2211h=0L\u22121ah2)1/2\u03a6\u22121(1\u2212\u03b1),MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacqWFepaDdaWgaaWcbaGaem4AaSMaeiilaWIae8xSdegabeaakiabg2da9maabmaabaGae83SdC2aaSbaaSqaaiabdIfayjabcYcaSiabdUgaRbqabaGccqGGOaakcqaIWaamcqGGPaqkdaaeWbqaaiabdggaHnaaDaaaleaacqWGObaAaeaacqaIYaGmaaaabaGaemiAaGMaeyypa0JaeGimaadabaGaemitaWKaeyOeI0IaeGymaedaniabggHiLdaakiaawIcacaGLPaaadaahaaWcbeqaaiabigdaXiabc+caViabikdaYaaakiabfA6agnaaCaaaleqabaGaeyOeI0IaeGymaedaaOGaeiikaGIaeGymaeJaeyOeI0Iae8xSdeMaeiykaKIaeiilaWcaaa@55EB@Filtering ::: Appendixwhere \u03a6-1(\u00b7) denotes the inverse cumulative distribution function for a standard normal random variable.Filtering ::: AppendixThe filter-based detection method requires knowledge of the \"true\" values of the model parameters.", [["The solution", "TREATMENT", 0, 12], ["Appendix\u03c4k,\u03b1=(\u03b3X,", "TEST", 72, 89], ["k(", "TEST", 89, 91], ["0)\u2211h", "TEST", 91, 95], ["Appendixwhere", "TEST", 786, 799], ["Appendix", "PROBLEM", 912, 920], ["The filter", "TREATMENT", 920, 930], ["filter", "OBSERVATION", 924, 930]]], ["In our work, we replace the parameters with their maximum likelihood estimates.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication history", [["Pre-publication", "DISEASE", 79, 94], ["pre-publication", "DISEASE", 106, 121], ["Pre-publication", "DISEASE", 166, 181]]]]}